METHODS FOR IDENTIFYING GENES WHICH PREDICT DISEASE OUTCOME FOR PATIENTS WITH COLON CANCER

FIELD OF THE INVENTION

The present invention is directed to methods of determining the prognosis of a subject having colon cancer. Collections of genes whose expression levels are informative of colon cancer prognosis are also disclosed.

BACKGROUND OF THE INVENTION

Oncologists are often faced with difficult treatment decisions regarding the use of chemotherapy and adjuvant radiation therapy for various tumors. Patients and oncologists are increasingly looking for prognostic indicators to help them make these difficult decisions. Since these treatments have significant toxicity and inherent dangers, it is critical to have means to help determine prognosis and minimize adverse events as a result of over-treating patients who would have fared well without aggressive treatments.

With the advent of accurate and rapid means to analyze the RNA and DNA found in tumors, diagnostic tests that predict outcome are increasingly utilized in clinical settings to help guide treatment decisions for clinicians. In particular, patients who suffer from breast cancer have recently been able to have their tumors analyzed using molecular genetic techniques to help predict their disease outcome. This initial breast cancer prognostic test consisted of a mutation analysis of a small number of genes including, BRCA1, BRCA2, and BRCA3. Analysis of ErbB2 status has also been helpful in guiding patient treatment with targeted therapies such as Herceptin.

Although these initial analyses provided some useful information for a subset of breast cancer patients, it did not provide useful prognostic information for the vast majority of patients. Therefore, more recent attempts to provide prognostic information for breast cancer tumors have been based on gene expression patterns of multiple genes.

Several recent publications report the use of microarray gene expression analysis to characterize tumors such as breast cancers (Golub et al, “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring,” Science, 286(5439):531-537 (1999); Bhattarcharjee et al, “Classification of Human Lung Carcinomas by mRNA Expression Profiling Reveals Distinct Adenocarcinoma Subclasses,” Proceed. Natl. Acad. Sci. U.S.A., 98(24):13790-13795 (2001); Ramaswamy et al, “Multiclass Cancer Diagnosis Using Tumor Gene Expression Signatures,” Proceed. Natl. Acad. Sci. U.S.A., 98(26):15149-15154 (2001); Martin et al, “Linking Gene Expression Patterns to Therapeutic Groups in Breast Cancer,” Cancer Res., 60(8):2232-2238 (2000); West et al, “Predicting the Clinical Status of Human Breast Cancer by Using Gene Expression Profiles,” Proceed. Natl. Acad. Sci. U.S.A., 98(20):11462-11467 (2001)). These studies have shown gene expression patterns specific to breast cancer tumors that may have prognostic value. (Sorlie et al, “Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications,” Proceed. Natl. Acad. Sci. U.S.A., 98(19):10869-10874 (2001); Yan et al, “Dissecting Complex Epigenetic Alterations in Breast Cancer Using CpG Island Microarrays,” Cancer Res., 61(23):8375-8380 (2001); Van De Vijver et al, “A Gene-Expression Signature as a Predictor of Survival in Breast Cancer,” N. Engl. J. Med., 347(25):1999-2009 (2002)). Using similar techniques, commercial products like Oncotype Dx (Genomic Health, Redwood City, Calif.) have been developed, making breast cancer prognosis widely available.

Similar testing for other cancers, such as colon cancer, are currently not available. This year, over 153,000 new cases of colorectal cancer (CRC) will be diagnosed, and 52,180 patients will die from this disease in the United States. There is an urgent need to improve colorectal cancer prognosis by developing accurate molecular techniques that will complement the clinico-pathology, as well as to identify individuals with early disease.

The present invention is directed to overcoming these and other deficiencies in the art.

SUMMARY OF THE INVENTION

A first aspect of the present invention relates to a method for determining the prognosis of a subject having colon cancer that involves obtaining a biological sample from the subject and detecting expression levels of at least five genes selected from a group of 176 genes informative of colon cancer prognosis. The group of 176 genes informative of colon cancer prognosis includes the following genes: ACSL4, RQCD1, AA058828*, AIP, AKR1A1, AP3D1, ARL2BP, ARL4A, ARL6IP4, OGFOD2, ASNA1, ATP5B, C12orf52, C19orf36, C1GALT1, C1orf144, C5orf23, C6orf15, C7orf10, C8orf70, CALML4, CASP1, CCNA2, CCT2, CDC42BPA, AK023058*, CDR2L, CFB, CHST12, CLN5, CMPK1, CNOT7, CNPY2, COBL, COMMD4, COX5A, CXCL11, CYB561, CYB5B, DAZAP2, DDX23, DENND2A, DENND2D, DHX15, AL359599*, DND1, DOCK9, EGFR, ELP3, ERP29, ETV1, FAM82C, FDFT1, FKBP14, FLJ10357, FRYL, GALNS, GCHFR, GHITM, GLS, GPR177, GRB10, GREM2, GRHPR, GRP, GSR, GSTA1, H2AFZ, HOXB7, IFT88, IL15RA, ISG20, ITGAE, KIAA0746, SERINC2, KIF13B, KLC1, LAMP3, LANCL1, LAP3, LEPREL1, LL22NC03-5H6.5, LOC100131861, SAMM50, LRRC41, LRRC47, MAP4, MAPKAPK5, MCM5, MCRS1, METRN, METTL3, MFHAS1, MMP3, MOSPD1, MRPL46, MTUS1, MYRIP, N4BP2L2, NAB1, NAT1, NDUFC1, NISCH, NUMB, OGT, OSBPL3, PAM, PBK, PDGFA, PEBP1, PGDS, PIGR, PIGT, PRDM2, PRELP, PSMA5, PSMD9, PSPC1, PTHLH, R3HCC1, RP3-377H14.5, RPLP0, RPLP0-like, RPS27L, RTN2, RYK, SAV1, SCAMP1, SERPINA1, SF3B1, SFPQ, SGCD, SLC25A3, SLC39A8, SMG7, SMURF2, SORD, SOX4, SPATA5L1, SQRDL, SRP72, SSNA1, STK3, SYNGR1, TAPBPL, TEGT, TES, TLN1, TMCC1, TMEM106C, TMEM16A, TMEM33, TMEM87A, TNFRSF10B, TNFSF10, TNIK, TRIM36, U2AF2, UBE2L6, UCP2, UNC84A, UQCRFS1, UQCRH, USP12, USP3, VPS41, WARS, WDR1, WDR68, XPO7, YBX1, ZC3H7B, ZMYM2, ZMYM5, ZNF117, and ZNF430. This method further involves comparing the detected expression levels of the at least five genes from the biological sample with the expression levels of the corresponding at least five genes when associated with a good disease prognosis expression profile and when associated with a bad disease prognosis expression profile. Based on that comparison, the prognosis of the subject having colon cancer is determined.

Another aspect of the present invention relates to a method for determining the prognosis of a subject having colon cancer that involves obtaining a biological sample from the subject and detecting the expression level of at least five genes selected from a group of 101 genes informative of colon cancer prognosis. The group of 101 genes informative of colon cancer prognosis includes the following genes: NARS, WDR1, WARS, CCT4, ATP5B, SORD, UBE2L6, PSME2, AIP, RRM2, LRRC41, CCT2, TAF9, HDAC5, SVIL, CCNB2, DBN1, PBX2, RFC5, IDE, MAD2L1, PSMA4, NDUFC1, IVD, PPIH, NEO1, CXCL10, FXN, GABBR1, ARHGAP8, LOC553158, HOXA4, COMMD4, DFFB, KLF12, GLMN, CASP7, PIR, ATP5G3, ACTN1, DDOST, TAPBP, RGL2, CYB561, TUSC3, C3orf63, GRB10, NR2F1, WDR68, CXCL2, CNPY2, CASP1, INDO, PFKM, CXCL11, MCAM, MAP2K5, MRPS11, NOLC1, CD59, CAMSAP1L1, SHANK2, KLC1, EMP1, C1orf95, GMDS, RPLP0, RPLP0-like, PDLIM4, PAM, TM4SF1, BEX4, ADORA1, FAM48A, ITM2B, PREB, CMPK1, LAP3, FAM82C, AACS, RP5-1077B9.4, NUP37, RHBDF1, PBK, TIPIN, TMEM204, ALG6, NPR3, SCD5, FLJ13236, GPATCH4, GREM2, RPL22, KLHL3, C15orf44, USP3, TNS1, ZBTB20, RTN2, FLJ10357, and CALML4. This method further involves comparing the detected expression levels of the at least five genes from the biological sample with the expression levels of the corresponding at least five genes when associated with a good disease prognosis expression profile and when associated with a bad disease prognosis expression profile. Based on that comparison, the prognosis of the subject having colon cancer is determined.

The present invention is also directed to a method of identifying an agent that improves the prognosis of a subject having colon cancer. This method involves administering the agent to the subject having colon cancer and obtaining a first biological sample from the subject before said administering and a second biological sample from the subject after said administering. The method further involves detecting the expression levels of at least five genes selected from the group of 176 genes informative of colon cancer prognosis disclosed supra. Determining increases or decreases in the expression levels of the at least five genes in the second sample compared to the first sample identifies an agent that improves the prognosis of a subject having colon cancer.

Another aspect of the present invention is related to a collection of 101 genes having expression levels informative for predicting a prognosis of a patient having colon cancer. The collection of 101 genes comprises the following genes: AACS, ACTN1, ADORA1, AIP, ALG6, ARHGAP8, L00553158, ATP5B, ATP5G3, BEX4, C15orf44, C1orf95, C3orf63, CALML4, CAMSAP1L1, CASP1, CASP7, CCNB2, CCT2, CCT4, CD59, CMPK1, CNPY2, COMMD4, CXCL10, CXCL11, CXCL2, CYB561, DBN1, DDOST, DFFB, EMP1, FAM48A, FAM82C, FLJ10357, FLJ13236, FXN, GABBR1, GLMN, GMDS, GPATCH4, GRB10, GREM2, HDAC5, HOXA4, IDE, INDO, ITM2B, IVD, KLC1, KLF12, KLHL3, LAP3, LRRC41, MAD2L1, MAP2K5, MCAM, MRPS11, NARS, NDUFC1, NEO1, NOLC1, NPR3, NR2F1, NUP37, PAM, PBK, PBX2, PDLIM4, PFKM, PIR, PPIH, PREB, PSMA4, PSME2, RFC5, RGL2, RHBDF1, RP5-1077B9.4, RPL22, RPLP0, RPLP0-like, RRM2, RTN2, SCD5, SHANK2, SORD, SVIL, TAF9, TAPBP, TIPIN, TM4SF1, TMEM204, TNS1, TUSC3, UBE2L6, USP3, WARS, WDR1, WDR68, and ZBTB20.

The current standard of care for colorectal cancer provides the average treatment for the average tumor, with less than average results. Current cancer care over-treats many patients to help an unknown few, with toxic, relatively ineffective, expensive therapeutics. There is an urgent need to develop a means to predict which patients will respond to standard therapies, which patients do not require therapy in addition to surgery, and which patients are likely not to respond to current therapeutics. For every 100 stage 11 and III colon cancer patients on adjuvant therapy, only about 12 of them will respond favorably, about 50 would survive without therapy, and about 38 will experience a recurrence even when given the current treatments. The current invention seeks to help individuals on both sides of this equation by stratifying the risk of a poor outcome. Thus, individuals with low risk tumors, in consultation with their physicians, may opt to avoid unnecessary and debilitating therapy. On the other hand, individuals with high risk tumors may seek to enroll in clinical trials testing the newest therapies to increase their chance of a better outcome.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a flow chart outlining methods for determining the prognosis of a subject having colon cancer in accordance with the present invention. Tumor tissue RNA is harvested and converted to cDNA using reverse transcription. The cDNA is then hybridized to an expression array to determine gene expression levels. Tumor tissue DNA is analyzed for microsatellite instability, gene promoter methylation, and mutational status. Data from one or more analyses is used to determine a subject's prognosis and develop a personalized treatment plan.

FIG. 2 is a flow chart depicting the steps used to identify the 176 and 71 gene predictor sets of the present invention that are useful for predicting disease outcome in subjects having colon cancer.

FIGS. 3A-3B illustrate how a patient's outcome is determined using the expression levels of the 71, 101, or 176 gene predictor sets of the present invention. FIG. 3A outlines the steps taken to determine, in a sample taken from a patient having colon cancer, the prognosis of that patient based on the expression levels of the genes in the 71-, 101-, or 176 genes sets and FIG. 3B applies the steps outlined in FIG. 3A to three hypothetical samples where the expression levels of six genes were determined.

FIG. 4 is a scatterplot graphing the predicted outcome for 166 stage I-IV primary colon cancer tumor samples based on gene expression levels of the 71-genes in the 71-gene predictor set. The x-axis depicts the percentage of genes for a given tumor sample that had expression values associated with a bad disease outcome. The y-axis depicts the percentage of genes for a given tumor sample that had expression values associated with a good disease outcome. Tumor samples from patients who died of disease (DOD) (n=56) are represented by (▪), while tumor sample from all other patients who survived or died of other causes (non-DOD) (n=110) are represented by (♦). Samples which binned to Group 1 had good prognosis with only 6% being categorized as DOD. Samples which binned to Group 4 had poor prognosis with 70% being categorized as DOD. Groups 2 and 3 had intermediate prognosis levels.

FIGS. 5A-5E are scatterplots graphing the predicted outcomes for the 166 stage I-IV primary colon cancer tumor samples based on gene expression levels of the 71-genes in the 71-gene predictor set stratified into high, intermediate, and low risk groups with the stage and recurrence status of the tumor identified. FIG. 5A is the same plot as shown in FIG. 4 with further stratification. The percentage of DOD patients increases steadily in each subgroup from Group 1 (0%) to Group 2A+2B (14%) to Group 3A+3B (42%) to Group 4 (69%) to Group 5+6 (83%). In FIG. 5B, stage I tumors are identified. Most stage I tumors binned to low risk groups 1 and 2A. One recurrence was identified in this group (i.e. stage I tumor) and is noted on the graph (“R68”). The recurrence was detected after 68 months, and, therefore, it is unclear if it is a recurrence or a new tumor. In FIG. 5C, stage II tumors are identified. Stage II tumor samples are spread evenly through the risk groups. Three recurrences were identified and binned to group 3B and the border of group 2A/2B. In FIG. 5D, the stage III tumors are identified. Surprisingly, a number of stage III tumor samples binned to Group 1 showing that analysis of gene expression of the 71-gene predictor set is not simply recapitulating tumor stage. Recurrences in the stage III population of samples were identified in all risk groups. FIG. 5E shows the stage IV tumor samples. These samples binned as predicted, mostly to groups 4-6 (i.e. high risk).

FIG. 6 is a scatterplot graphing the predicted outcome for the 166 stage I-IV primary colon cancer tumor samples based on gene expression levels of the 1389-genes in the 1389-gene predictor set. The x-axis depicts the percentage of genes for a given tumor sample that had expression values associated with a bad disease outcome. The y-axis depicts the percentage of genes for a given tumor sample that had expression values associated with a good disease outcome. Tumor samples from DOD patients are represented by (▪), while tumor sample from non-DOD patients (n=110) are represented by (♦). The stratification of survival outcome did not improve significantly between the 71 gene set and the 1389 gene set.

FIG. 7 is a scatterplot graphing the predicted outcome for the 166 stage I-IV primary colon cancer tumor samples based on gene expression levels of the 101 genes in the 101-gene predictor set ranked by the odds ratio analysis. The x-axis depicts the percentage of genes for a given tumor sample that had expression values associated with a bad disease outcome. The y-axis depicts the percentage of genes for a given tumor sample that had expression values associated with a good disease outcome. Tumor samples from DOD patients are represented by (▪), while tumor sample from non-DOD patients (n=110) are represented by (♦). The low risk category can be segregated from the intermediate and high risk categories by the lines indicated on the graph.

FIG. 8 is a scatterplot graphing the predicted outcome for the 166 stage I-IV primary colon cancer tumor samples based on gene expression levels of the 101 genes in the 101-gene predictor set ranked by difference scores. The x-axis depicts the percentage of genes for a given tumor sample that had expression values associated with a bad disease outcome. The y-axis depicts the percentage of genes for a given tumor sample that had expression values associated with a good disease outcome. Tumor samples from DOD patients are represented by (▪), while tumor sample from non-DOD patients (n=110) are represented by (♦). The low risk category had 2% of patients who were in the DOD category. The high risk group by contrast had 87% of patients in the DOD category. The intermediate risk had 56% of patients in the DOD category.

FIG. 9 is a scatterplot graphing the predicted outcome for the 166 stage I-IV primary colon cancer tumor samples based on gene expression levels of the 71 genes in the 71-gene predictor set as shown in FIG. 4 with LRAT methylation status of various samples identified (see arrows). Several DOD samples that had binned to group 1 based on gene expression levels had low to no LRAT methylation, which predicts poor prognosis. Removing these samples from group 1 based on LRAT methylation status improved the performance of the prognosis prediction in the low risk category. The low risk category in this analysis only had 3% of patients in the DOD category.

FIG. 10 is a scatterplot graphing the predicted outcome for the 166 stage I-IV primary colon cancer tumor samples based on gene expression levels of the 71 genes in the 71-gene predictor set stratified into high, intermediate, and low risk groups. The LRAT methylation status of various samples is also identified. As in FIG. 9, when LRAT methylation status was included in the analysis, the low risk groups had excellent prediction of good outcome. Group 1 does not contain patients with DOD status while Group 2A+2B only has 6% of patients with DOD status.

FIG. 11 is a scatterplot graphing the predicted outcome for the 166 stage I-IV primary colon cancer tumor samples based on gene expression levels of the 101 genes in the 101-gene predictor set ranked by difference score. The LRAT methylation status of various samples is also identified. The x-axis depicts the percentage of genes for a given tumor sample that had expression values associated with a bad disease outcome. The y-axis depicts the percentage of genes for a given tumor sample that had expression values associated with a good disease outcome. Tumor samples from DOD patients are represented by (▪), while tumor sample from non-DOD patients (n=110) are represented by (♦). Inclusion of LRAT methylation status was useful to reclassify some patient outcomes in this example as well.

FIG. 12 is the overall view of gene expression dysregulation in regions of chromosomal aberrations. Shown are the percentages of samples with copy number gains (top chart), copy number losses (middle chart), and copy neutral-LOH events (bottom chart) in every autosomal chromosome. Each circle represents a gene located in the region of aberration, and whose colon cancer expression is at least 3 standard deviation units above (red) or below (green) the baseline (normal mucosa samples) for at least 10% of the colon cancer samples. As evident in the population of the colored circles, there are more upregulated genes in regions of gains, and more downregulated genes in regions of losses.

FIG. 13 is a numerical representation of FIG. 12. It shows the percentages of genes that have: a) gained copy number and increased expression level (red bar), b) lost copy number and decreased expression level (green bar), c) gained copy number and decreased expression level (gray bar, pointing down), and d) lost copy number and increased expression level (gray bar, pointing up). The percentages are calculated based on the number of unique genes in every chromosome arm. As shown in this chart, chromosome arms 7p, 7q, 8q, 13q, 20p, and 20q have high proportion of upregulated genes. On the other hand, 1p, 4q, 8p, 14q, 15q, 17p, 18p, and 18q have high proportion of downregulated genes.

FIG. 14 shows genes that have dysregulated expression on chromosome 8. In general, genes which are upregulated correlate with regions of copy number gain and genes which are downregulated correlate with regions of copy number loss. The 8q arm, containing numerous regions of gain, includes the genes NCO6AIP (or TGS1), CHD7, DPY19L4, LAPTM4B, PABPC3, SLC25A32, and EIF2C2 which all have elevated expression. The 8p arm, containing numerous regions of loss, includes the highly downregulated genes MTUS1, ADAMEC1, EPHX2, TMEM64, and PPP2CB.

FIG. 15 is a graph summarizing the Kaplan-Meier (KM) survival curve analyses done for the most highly dysregulated genes in the widely recognized aneuploidy regions in colorectal cancer. Shown are the percentages (fractions indicated on each bar) of the most highly dysregulated genes in chromosomes 7, 8p, 13q, 17p, 18, 20p, and 20q where expression levels are concordant (red for the gained and green for the lost arms) or discordant (gray bars) with prognosis.

FIGS. 16A-16J are Kaplan-Meier survival curves for 10 of the 13 most dysregulated genes on chromosomal arm 8p. Included in each graph is the Affymetrix probe identifier, gene name, and chromosome location. In each case, lower expression (shown in red) correlated with worse outcome, consistent with chromosomal loss contributing to bad prognosis. Higher expression is shown in green.

FIGS. 17A-17B show the distribution of the 71 gene set among different autosomal chromosomal arms. FIG. 17A shows chromosomes 1-7, while FIG. 17B shows chromosomes 8-22 and X. In general, the expression pattern of the 71 gene set followed the pattern of chromosomal copy number dysregulation observed in the colon tumors analyzed. The number of dysregulated genes in each chromosomal arm predicting outcome based on expression is indicated. Copy loss (green), gain (red), and copy neutral LOH (yellow) are demonstrated across the chromosomal arms.

FIGS. 18A-18B show the distribution of the 176 gene set among different chromosomal arms. FIG. 18A shows chromosomes 1-7, while FIG. 18B shows chromosomes 8-22 and X. In general, the expression pattern of the 176 gene set followed the pattern of chromosomal copy number dysregulation observed in the colon tumors analyzed. The number of dysregulated genes in each chromosomal arm predicting outcome based on expression is indicated. Copy loss (green), gain (red), and copy neutral LOH (yellow) are demonstrated across the chromosomal arms.

FIG. 19 is the Kaplan-Meier survival curve for Caspase 1, one of the genes of the 71 gene predictor set. The red line indicates survival for patients having tumors where the expression of Caspase 1 is in the top third of average tumor expression. The green line indicates survival for patients having tumors where the expression of Caspase 1 is in the middle third of average tumor expression. The blue line indicates survival for patients having tumors where the expression of Caspase 1 is in the bottom third of average tumor expression. When the expression level of Caspase 1 is in the top third of average tumor expression a favorable prognosis is predicted and when the expression level is in the bottom third of average tumor expression an unfavorable prognosis is predicted.

FIG. 20 is a Kaplan-Meier survival curve for the TMEM106C gene showing a skewed distribution. When TMEM106C gene expression is in the lower third, relative to the average tumor expression level, a bad prognosis is predicted as indicated by the low percentage of survival in the KM curve (blue line). The percent survival was the same for tumors having average (middle third, green line) and above average (top third, red line) TMEM106C expression. Based on this analysis, this transmembrane protein is believed to have an important role in tumor progression.

FIG. 21 is a schematic diagram of enzymes and protein factors involved in retinol metabolism.

FIGS. 22A-22B show the LRAT methylation status for 69 samples that were classified as having microsatellite instability by either the three marker criteria (FIG. 22A) or the NCI criteria (FIG. 22B).

FIG. 23 shows the disease specific Kaplan-Meier survival analysis for LRAT methylation status. Only CRC tumor samples of all four clinical stages which were MSS (Microsatellite stable) were included in the survival analysis. The log-rank test shows a chi-square=4.73 and p-value=0.0296.

FIG. 24 shows the disease specific Kaplan-Meier survival analysis for LRAT methylation status. CRC tumor samples of all four clinical stages were included in the survival analysis. The log-rank test shows a chi-square=4.73 and p-value=0.0296.

FIG. 25 shows the disease specific Kaplan-Meier survival analysis for LRAT methylation status and retinoic acid receptor-β(RAR-β) methylation status. CRC tumor samples of all four clinical stages were included in the survival analysis.

FIG. 26 is a scatterplot graphing the predicted outcome for 22 additional primary colon tumor samples from patients that were not included in the original analysis of the 166 tumor set. There was excellent correlation between the predicted outcome and survival for samples in Group 1 as illustrated by the lack of samples from patients who DOD binning to Group 1.

FIG. 27 is a scatterplot graphing the predicted outcome for 36 liver metastases specimens generated using the 71 gene predictor set of the present invention. This analysis was performed to validate the 71 gene set on more advanced tumor samples. As shown, the vast majority of these specimens which included many that had DOD status binned to Group 4.

FIG. 28 is a scatterplot graphing the predicted outcome for 19 lung metastases specimens generated using the 71 gene predictor set of the present invention. This analysis was done to validate the 71 gene set on more advanced tumor samples. As shown, the vast majority of these specimens which included many that had DOD status binned to Group 4.

FIG. 29 is a scatterplot graphing the predicted outcome for 46 large primary adenoma specimens generated using the 71 gene predictor set of the present invention. The adenoma expression profiles in general predicted a low risk as most samples binned to Group 1. The few samples that did have DOD status also have either a synchronous primary tumor or synchronous metastases. It is important to note that the gene expression profiles of the primary colon tumors or metastatic tumors, in general predicted a poor outcome for survival as seen in the previous figures.

FIG. 30 is a scatterplot graphing the predicted outcome for 48 mucosa samples taken adjacent to a primary tumor sample. There are some mucosal samples, in which the results of this analysis may predict a poor outcome as a result of a field effect for genes that are dysregulated in the mucosa prior to the onset of a primary colon carcinoma.

FIG. 31 is a scatterplot graphing the predicted outcome for both normal mucosa and matched adjacent primary colon tumors. In this figure each matched pair is labeled with the same letter. The normal mucosa is marked in green and the tumor samples are marked in red. In general, the normal mucosa samples predict a better outcome in each case than the matched tumors. Also some tumors show greater changes in their expression profiles than others. This distribution may be a result of a combination of genes predisposing to the development of tumors, as well as, genes that contribute to poor outcome once a primary tumor has become aggressive and metastatic.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates generally to methods of determining the prognosis of a subject having colon cancer. In a first aspect of the present invention, the method for determining the prognosis of a subject having colon cancer involves obtaining a biological sample from the subject and detecting expression levels of at least five genes selected from the group of 176 genes informative of colon cancer prognosis. The group of 176 genes informative of colon cancer prognosis includes the following genes: ACSL4, RQCD1, AA058828*, AIP, AKR1A1, AP3D1, ARL2BP, ARL4A, ARL6IP4, OGFOD2, ASNA1, ATP5B, C12orf52, C19orf36, C1GALT1, C1orf144, C5orf23, C6orf15, C7orf10, C8orf70, CALML4, CASP1, CCNA2, CCT2, CDC42BPA, AK023058*, CDR2L, CFB, CHST12, CLN5, CMPK1, CNOT7, CNPY2, COBL, COMMD4, COX5A, CXCL11, CYB561, CYB5B, DAZAP2, DDX23, DENND2A, DENND2D, DHX15, AL359599*, DND1, DOCK9, EGFR, ELP3, ERP29, ETV1, FAM82C, FDFT1, FKBP14, FLJ10357, FRYL, GALNS, GCHFR, GHITM, GLS, GPR177, GRB10, GREM2, GRHPR, GRP, GSR, GSTA1, H2AFZ, HOXB7, IFT88, IL15RA, ISG20, ITGAE, KIAA0746, SERINC2, KIF13B, KLC1, LAMP3, LANCL1, LAP3, LEPREL1, LL22NC03-5H6.5, LOC100131861, SAMM50, LRRC41, LRRC47, MAP4, MAPKAPK5, MCM5, MCRS1, METRN, METTL3, MFHAS1, MMP3, MOSPD1, MRPL46, MTUS1, MYRIP, N4BP2L2, NAB1, NAT1, NDUFC1, NISCH, NUMB, OGT, OSBPL3, PAM, PBK, PDGFA, PEBP1, PGDS, PIGR, PIGT, PRDM2, PRELP, PSMA5, PSMD9, PSPC1, PTHLH, R3HCC1, RP3-377H14.5, RPLP0, RPLP0-like, RPS27L, RTN2, RYK, SAV1, SCAMP1, SERPINA1, SF3B1, SFPQ, SGCD, SLC25A3, SLC39A8, SMG7, SMURF2, SORD, SOX4, SPATA5L1, SQRDL, SRP72, SSNA1, STK3, SYNGR1, TAPBPL, TEGT, TES, TLN1, TMCC1, TMEM106C, TMEM16A, TMEM33, TMEM87A, TNFRSF10B, TNFSF10, TNIK, TRIM36, U2AF2, UBE2L6, UCP2, UNC84A, UQCRFS1, UQCRH, USP12, USP3, VPS41, WARS, WDR1, WDR68, XPO7, YBX1, ZC3H7B, ZMYM2, ZMYM5, ZNF117, and ZNF430. This method further involves comparing the detected expression levels of the at least five genes from the biological sample with the expression levels of the corresponding at least five genes when associated with a good disease prognosis expression profile and when associated with a bad disease prognosis expression profile. Based on that comparison, the prognosis of the subject having colon cancer is determined.

In a preferred embodiment of this aspect of the present invention, the at least five genes are selected from a group of 71 genes informative of colon cancer prognosis. This group of 71 genes is a subset of the 176 genes informative of colon cancer prognosis and includes the following genes, SLC25A3, DAZAP2, TEGT, ERP29, PSMA5, DDX23, LOC100131861, SAMM50, SFPQ, NISCH, CYB5B, TMEM106C, EGFR, MCRS1, SERPINA1, CCNA2, NDUFC1, COX5A, GCHFR, ITGAE, PRDM2, PDGFA, GSR, GRP, COMMD4, XPO7, YBX1, SRP72, UCP2, SLC39A8, NAB1, WDR68, CXCL11, RECQL, CASP1, PTHLH, UNC84A, MTUS1, KIAA0746, SERINC2, DOCKS, FRYL, MAPKAPK5, LRRC47, RQCD1, TNIK, RPLP0, RPLP0-like, CLN5, NAT1, CDC42BPA, GSTA1, ZMYM5, RYK, PIGT, CMPK1, SQRDL, FAM82C, CNOT7, LL22NC03-5H6.5, PSPC1, TAPBPL, METRN, PBK, MRPL46, FKBP14, C1GALT1, GREM2, GPR177, DND1, and PRELP.

As described in greater detail in the Examples below, the 176- and 71-genes, whose expression levels are informative for predicting colon cancer outcome were derived from a larger pool of 383 genes. Kaplan-Meier (KM) survival curves were generated for the 383-genes and genes having p-values of >0.02 were removed from further analysis. The remaining group of 176 genes was further narrowed to 71 genes by removing genes having p-values associated with the KM curves of >0.0125 (See FIG. 2). Although a preferred embodiment of the invention, involves determining the prognosis of a subject having colon cancer by detecting the expression levels of at least five genes selected from the group of 176 or 71 genes, the expression levels of any five of the 383 genes also provides valuable prognostic information. The 383 genes, including the 176- and 71-genes whose expression levels are informative for the prediction of colon cancer are listed in Table 1, by gene symbol, alternative gene name(s), and Genbank Accession Number. The nucleotide sequences of the Affymetrix probes used to identify and quantify gene expression levels are also provided.

TABLE 1

383 Genes Informative of Colon Cancer Prognosis

Gene

Accession #

Probe Set
Symbol

(Entrez Gene

ID
(*identifier)
AKA
Gene Title
ID)
Probe Sequence(s)

222033_s_at
AA058828*

TAACAAAGAACGAGCACTTCCTTTC (SEQ ID NO: 1)

GCACTTCCTTTCAGAGTTTCTGAGA (SEQ ID NO: 2)

GGAACAGTCTGGGTGGAATGGGGCT (SEQ ID NO: 3)

GGGGCTGAAACCATGTGCAAGTCTG (SEQ ID NO: 4)

GAGATGTTAATTTTAGGGACCCGTG (SEQ ID NO: 5)

TGTTTCCTAGCCCACAAGAATGCAA (SEQ ID NO: 6)

AACAGATACTCGCTAGCCTCATTTA (SEQ ID NO: 7)

AAAGGAGGAGTGCATCTTTGGCCGA (SEQ ID NO: 8)

GCATCTTTGGCCGACAGTGGTGTAA (SEQ ID NO: 9)

GGTTTGGTCCTATATTTCTAGTCAT (SEQ ID NO: 10)

GTATTTTGTATACCATCTTCATATA (SEQ ID NO: 11)

63825_at
ABHD2
HS1-2, LABH2,
abhydrolase domain
11057
TGAAGTGCAACTGAAAGCTGCTAGT (SEQ ID NO: 12)

MGC111112,
containing 2

ACTGAAAGCTGCTAGTGATGATCTG (SEQ ID NO: 13)

MGC26249,

CTGAAAGCTGCTAGTGATGATCTGG (SEQ ID NO: 14)

PHPS1-2

GTAATATACAATTTGTCCAGTAGCC (SEQ ID NO: 15)

AATATACAATTTGTCCAGTAGCCAG (SEQ ID NO: 16)

AATTTGTCCAGTAGCCAGTTTGTTT (SEQ ID NO: 17)

AATGGTCACCGCAGGCCATACTACC (SEQ ID NO: 18)

TCACCGCAGGCCATACTACCAATGA (SEQ ID NO: 19)

CCATACTACCAATGAAATGGTAGGT (SEQ ID NO: 20)

GAAATAGCACTCTGCATGCTTTGCT (SEQ ID NO: 21)

AGCACTCTGCATGCTTTGCTCTACA (SEQ ID NO: 22)

GCACTCTGCATGCTTTGCTCTACAA (SEQ ID NO: 23)

CACTCTGCATGCTTTGCTCTACAAG (SEQ ID NO: 24)

ACTCTGCATGCTTTGCTCTACAAGA (SEQ ID NO: 25)

CTCTGCATGCTTTGCTCTACAAGAT (SEQ ID NO: 26)

TCTGCATGCTTTGCTCTACAAGATG (SEQ ID NO: 27)

202422_s_at
ACSL4
ACS4, FACL4,
acyl-CoA synthetase
2182
ATTTTGATCTCACATTTTTATACCT (SEQ ID NO: 28)

LACS4, MRX63,
long-chain family

AAATTGCTCACAGTTATTACATACA (SEQ ID NO: 29)

MRX68
member 4

ATTACATACACATCAGCCATCAACT (SEQ ID NO: 30)

ACACATCAGCCATCAACTAAAGTTG (SEQ ID NO: 31)

ACTACAATATGTACATTTCTAAGTC (SEQ ID NO: 32)

CTTTTGCTTTAATTCCATGAATGTT (SEQ ID NO: 33)

ATGTTTCTTTGATCATGAATAACTG (SEQ ID NO: 34)

GTAAGTCTTGCCTATATTTTCCTGA (SEQ ID NO: 35)

TATTTTCCTGATAGCATATGACAAA (SEQ ID NO: 36)

TATTCATATTTGTACTTTCTGTTAA (SEQ ID NO: 37)

GTTTTTAAGTTTGCACTCAAATCTT (SEQ ID NO: 38)

201782_s_at
AIP
ARA9, FKBP16,
aryl hydrocarbon
9049
GTGCCACTTATCCACCAGGAGGGCA (SEQ ID NO: 39)

FKBP37,
receptor interacting

AGGAGGCTGCTGCCAAGTACTACGA (SEQ ID NO: 40)

SMTPHN, XAP2
protein

CAAGTACTACGATGCCATTGCCTGC (SEQ ID NO: 41)

CATTGCCTGCCTCAAGAACCTGCAG (SEQ ID NO: 42)

CCTGGGTCCCCTGAATGGATCCAGC (SEQ ID NO: 43)

GAGGAGTACTACGAGGTGCTGGACC (SEQ ID NO: 44)

GTCAAGGCCTACTTCAAGCGGGGCA (SEQ ID NO: 45)

CGGCCGTGTGGAATGCCCAGGAGGC (SEQ ID NO: 46)

GCCTGTGGTGAGCCGAGAGCTGCGG (SEQ ID NO: 47)

CCTGGAGGCACGGATCCGGCAGAAG (SEQ ID NO: 48)

GGGATCTTCTCCCATTGACAGGAGC [(SEQ ID NO: 49)

222159_at
AK023058

CDNA FLJ12996 fis,

TAGGAAATCCAGCAATCCTGGCCCC (SEQ ID NO: 50)

clone

CAGAAGTTCCCCCTAAGAACCACTG (SEQ ID NO: 51)

NT2RP3000235

AAGGGGAGCCTCCTATGAGAATTCC (SEQ ID NO: 52)

ATGAGAATTCCCCTAGTGATTCCCT (SEQ ID NO: 53)

TGATTCCCTGTGGAGGTGGTTCCCA (SEQ ID NO: 54)

AGGCTCATCTGCCCGAGGAGAGAAG (SEQ ID NO: 55)

GAGGAGATTGGCACAGTGGGGTGGC (SEQ ID NO: 56)

ATCAGCATCTAGTCATGGAGCTCCA (SEQ ID NO: 57)

ATAAATCAATCTGTCTTTCTCACTG (SEQ ID NO: 58)

AAGCAACATGGCATTCACGCAGGGC (SEQ ID NO: 59)

GGCATTCACGCAGGGCCTGGTAATG (SEQ ID NO: 60)

201900_s_at
AKR1A1
ALDR1, ALR,
aldo-keto reductase
10327
GCCTGTCCAACTTCAACAGTCGGCA (SEQ ID NO: 61)

ARM, DD3,
family 1, member A1

TGATGACATACTCAGTGTGGCCTCC (SEQ ID NO: 62)

MGC12529,
(aldehyde reductase)

GTAACTGCTTATAGCCCTTTGGGCT (SEQ ID NO: 63)

MGC1380

CGTGCATGGCGTGATCCTGATGAGC (SEQ ID NO: 64)

GAAAAGTATGGCCGATCTCCAGCTC (SEQ ID NO: 65)

AGCGGAAAGTGATCTGCATCCCCAA (SEQ ID NO: 66)

CTCCTTCTCGAATCCTTCAGAACAT (SEQ ID NO: 67)

TTGACTTCACCTTTAGCCCAGAAGA (SEQ ID NO: 68)

ATATTGTGCCTATGCTTACGGTGGA (SEQ ID NO: 69)

TGTACCCCTTTAATGACCCGTACTG (SEQ ID NO: 70)

CAGCTCTGCAGCTAATGAGGTCCTG (SEQ ID NO: 71)

215828_at
AL359599*

MRNA; cDNA

CAATTAAACTTTTCTGCTTGCTCTC (SEQ ID NO: 72)

DKFZp547C126

AATGATCTGGTCTGCTGGAAGGTGG (SEQ ID NO: 73)

(from clone

TGGGCAGTGGGTTGAGCGTGCAGCC (SEQ ID NO: 74)

DKFZp547C126)

GACTTGCACCTTTTCAGCAGTTATC (SEQ ID NO: 75)

CAGCAGTTATCTAGACCTGGCCGCA (SEQ ID NO: 76)

CCGCAGTGGCCTGAGTTGCAGTGAT (SEQ ID NO: 77)

GATTCGTATTCACTCATTCTTTGAT (SEQ ID NO: 78)

AGGGTTTTGTGCGTGTTGTTTCAGC (SEQ ID NO: 79)

TATGACACGTGGCACCAGCTGTACA (SEQ ID NO: 80)

TGCCCTTCTGGTTAGTGTTGTTCTT (SEQ ID NO: 81)

GAAGCATTGATACTGTGGCCACTCA (SEQ ID NO: 82)

222108_at
AMIGO2
ALI1, DEGA
adhesion molecule
347902
TATTCAGCCAAAATTACCGTTTTAG (SEQ ID NO: 83)

with Ig-like domain 2

AATGCCACATCCTATATGGTGTTAT (SEQ ID NO: 84)

GAAAGTACATTTGTTTGCCTGTCTT (SEQ ID NO: 85)

TTCATTTTGTACATTCTTCCCATTC (SEQ ID NO: 86)

AAGTCATCATAATTTGTTGCCATAA (SEQ ID NO: 87)

GAGTAACTTCTTAAATCCCTGTTCT (SEQ ID NO: 88)

AAATCCCTGTTCTAGCAAACTAATA (SEQ ID NO: 89)

ATATTGGTTCATGTGCTTGTGTATA (SEQ ID NO: 90)

AATAGACCCTACTGTACTGTGCTTT (SEQ ID NO: 91)

ACTGTACTGTGCTTTGGACATTTGA (SEQ ID NO: 92)

TCACTGGACCGACGTTTTAACAACG (SEQ ID NO: 93)

220144_s_at
ANKRD5
RP5-839B4.5,
ankyrin repeat
63926
GATACCTTGGGTTGAATACACTTTT (SEQ ID NO: 94)

FLJ21669,
domain 5

GAATACACTTTTAACAGCCCTAGAT (SEQ ID NO: 95)

dJ839B4.6

TAACAGCCCTAGATCGATAGCCCTA (SEQ ID NO: 96)

GCCCTAGCCCTAGATAGATAGCCCT (SEQ ID NO: 97)

AGATAGCCCTAGCCCTAGATAGATA (SEQ ID NO: 98)

GTTTACATAATTTTGGGCCCCAGAT (SEQ ID NO: 99)

GGCCCCAGATGGTTAAGTGCTAAAT (SEQ ID NO: 100)

GGGTAGGCTATCAGGAAGTGCAGGC (SEQ ID NO: 101)

GGCTGGAAACATGCAGGAGCTGTCC (SEQ ID NO: 102)

GTCCACAAGTGGAATTTCTTCTTCA (SEQ ID NO: 103)

GAAACCTCAGTTTTGTTCATACACC (SEQ ID NO: 104)

210974_s_at
AP3D1
ADTD, hBLVR
adaptor-related
8943
CGTGGCCATCCGCGTGAAGGCCATC (SEQ ID NO: 105)

protein complex 3,

TGTCTGCGCTGCTTGACAGTGCACA (SEQ ID NO: 106)

delta 1 subunit

GCAGCACCCAGCGGAACGGGATCTG (SEQ ID NO: 107)

GCGGAACGGGATCTGTGAGGTGCTG (SEQ ID NO: 108)

GGATCTGTGAGGTGCTGTACGCTGC (SEQ ID NO: 109)

CTGCGGGGAGTTCTCAGAGCATCTG (SEQ ID NO: 110)

CAGGCCGTGTATGTGCAGAACGTGG (SEQ ID NO: 111)

CAGAACGTGGTCAAGCTCTACGCCT (SEQ ID NO: 112)

AGTTTGTGCAGAGCGCAGACCTGGA (SEQ ID NO: 113)

GAAGCTTCAGGCCAAGGACGTGCCT (SEQ ID NO: 114)

GGCCAAGGACGTGCCTGTGGCAGAG (SEQ ID NO: 115)

205980_s_at
ARHGAP8
BPGAP1,
Rho GTPase
23779
GCCTGTGTCTTCGGGCTGAATTTGA (SEQ ID NO: 116)

///
FLJ20185,
activating protein 8 ///
553158
GTGTCTTCGGGCTGAATTTGATCTG (SEQ ID NO: 117)

LOC553158
PP610 ///
PRR5-ARHGAP8
55615
TGAATTTGATCTGGCCATCCCAGGG (SEQ ID NO: 118)

/// PRR5
LOC553158;
fusion /// proline rich

AGTCCCCTGATGGCAGCCAGAAGAC (SEQ ID NO: 119)

ARHGAP8 ///
5 (renal)

TGATGGCAGCCAGAAGACGTCTCTA (SEQ ID NO: 120)

ARHGAP8,

GGCAGCCAGAAGACGTCTCTAGTGT (SEQ ID NO: 121)

FLJ20185,

GCCAGAAGACGTCTCTAGTGTTGCG (SEQ ID NO: 122)

PP610,

GAAGACGTCTCTAGTGTTGCGAACA (SEQ ID NO: 123)

PROTOR1

GTCTCTAGTGTTGCGAACACTCTGT (SEQ ID NO: 124)

TGTGCACTTGTATGTTTTGTAAACT (SEQ ID NO: 125)

TTGTAAACTTGGCATCTGTAAAAAT (SEQ ID NO: 126)

202091_at
ARL2BP
BART1
ADP-ribosylation
23568
TTTTCTGCTCTGTAGTCCAAAAACA (SEQ ID NO: 127)

factor-like 2 binding

GCATGTCGAATATGTCACCAGCCAC (SEQ ID NO: 128)

protein

CAGCCACTTCATCCTTATGGTGCTG (SEQ ID NO: 129)

GAAGGCTGCCATGTTGAACTCAGGA (SEQ ID NO: 130)

TCAAACTCCAGGTAGTACTTGTCCA (SEQ ID NO: 131)

AGTACTTGTCCATGAAATTTCTCTG (SEQ ID NO: 132)

TCGTCATCCATGATAATGTCCTCTA (SEQ ID NO: 133)

ATATCCAACCACAGCATCAAATTCT (SEQ ID NO: 134)

GAAAGACAGCGCAAAGCTCTCTCCT (SEQ ID NO: 135)

TTCTAAGGCGTCCATCGCAGTCGCC (SEQ ID NO: 136)

GGTTAAGGCCTCTCAGCCAAGGCCG (SEQ ID NO: 137)

205020_s_at
ARL4A
ARL4
ADP-ribosylation
10124
GGGAGTCCCTGTACTTATAGTTGCT (SEQ ID NO: 138)

factor-like 4A

GAGGAACTCATTGTCACTTTCAGAA (SEQ ID NO: 139)

GGTGAACTGAGCTCATCAACTCCTT (SEQ ID NO: 140)

CAACTCCTTGGCATTTGCAGCCTAC (SEQ ID NO: 141)

TGCAGCCTACCTGTGCAATCATAGG (SEQ ID NO: 142)

GGAGTAGGTTTTCTCTGGTCTGATT (SEQ ID NO: 143)

TCTGCCCTCCTGGATGCTATTAAAG (SEQ ID NO: 144)

GAACAATCAGATGCCCAACTCTGTT (SEQ ID NO: 145)

CCAACTCTGTTGCCTTGTGGAAGAT (SEQ ID NO: 146)

GTGCTTCTTAAAGTGGTCTCTTCTC (SEQ ID NO: 147)

TTGGTACTACCATTTGGGGAAGCCA (SEQ ID NO: 148)

220597_s_at
ARL6IP4 ///
MGC814, SR-
ADP-ribosylation-like
51329
CTTCCTCCAGTGATGGCCGGAAGAA (SEQ ID NO: 149)

OGFOD2
25, SRp25 ///
factor 6 interacting
79676
GTGATGGCCGGAAGAAGCGGGGGAA (SEQ ID NO: 150)

DKFZp686H15154,
protein 4 /// 2-

GAAGCGGGGGAAGTACAAGGACAAG (SEQ ID NO: 151)

FLJ13491,
oxoglutarate and

GGCAAGGAGAAGGCGGAAGCACAGC (SEQ ID NO: 152)

FLJ37501,
iron-dependent

GGGCGCACCAGGCTTATTAAGGGAG (SEQ ID NO: 153)

MGC120434,
oxygenase domain

CGCACCAGGCTTATTAAGGGAGATG (SEQ ID NO: 154)

MGC120436
containing 2

GATGGCGAGGTCCTAGAGGAAATCG (SEQ ID NO: 155)

AGGGTGCCAGTGGGAAGCCTGATGG (SEQ ID NO: 156)

GCCAGTGGGAAGCCTGATGGGTGCT (SEQ ID NO: 157)

GTGGGAAGCCTGATGGGTGCTGGTG (SEQ ID NO: 158)

GGAAGCCTGATGGGTGCTGGTGGCC (SEQ ID NO: 159)

217852_s_at
ARL8B
ARL10C,
ADP-ribosylation
55207
TGAAGCATGTTGCATACTACCCTGG (SEQ ID NO: 160)

FLJ10702, Gie1
factor-like 8B

TAAACTTGCTACTGTTGTTCAACAC (SEQ ID NO: 161)

GAATGTGGCAACTTGCTTGTGCCTA (SEQ ID NO: 162)

GACTCTGTGGGGACTGCATAGGTTT (SEQ ID NO: 163)

TGTGTCTATACATTGCTTTCCGCAT (SEQ ID NO: 164)

TGCTTTCCGCATTTCAAGACATCCA (SEQ ID NO: 165)

AAGACATCCAGACGCTATTACCAAC (SEQ ID NO: 166)

GACGCTATTACCAACATTTTCCTGT (SEQ ID NO: 167)

ACATTTTCCTGTGCATTAACCTCTG (SEQ ID NO: 168)

AGGTGGATGCATTTTTTGTCTGTTT (SEQ ID NO: 169)

TGTCAGAAATCAGATCAGCCCTCAA (SEQ ID NO: 170)

202024_at
ASNA1
ARSA-I, ARSA1,
arsA arsenite
439
CGTCATCCGCTCAGTCAGCGAACAG (SEQ ID NO: 171)

MGC3821
transporter, ATP-

GGACCCTGAGCAGACAACTTTCATC (SEQ ID NO: 172)

binding, homolog 1

GCGTATGCATTGCTGAGTTCCTGTC (SEQ ID NO: 173)

(bacterial)

TATAATTGTCAACCAGCTCGTCTTC (SEQ ID NO: 174)

CCCGAGAAGCCCTGCAAGATGTGTG (SEQ ID NO: 175)

TGAGGCCCGTCACAAGATCCAGGCC (SEQ ID NO: 176)

AGACTTCCACATCGTGAAGCTGCCG (SEQ ID NO: 177)

CCGCTGTTACCCCATGAGGTGCGGG (SEQ ID NO: 178)

CAGACAAGGTCAACACCTTCTCGGC (SEQ ID NO: 179)

GGGCAGAGTTTGCACAAAGTCCCCC (SEQ ID NO: 180)

TGGTGGGGAGCTGTAGTTGCCCCCT (SEQ ID NO: 181)

218857_s_at
ASRGL1
ALP, ALP1,
asparaginase like 1
80150
GACTCACCCTGTTCCACATAGAACA (SEQ ID NO: 182)

FLJ22316

AGAAGAGGCTGCGGACCTATCGTTG (SEQ ID NO: 183)

GTGGCCTCATCGTGGTTAGCAAAAC (SEQ ID NO: 184)

GGGTGGCAAAGTGGACCTCCACCTC (SEQ ID NO: 185)

GGCAAGCTGCACTTCGGAATTGATC (SEQ ID NO: 186)

TGACGATACTACTATCACCGACCTT (SEQ ID NO: 187)

GACCTTCCCTAAGCCGCTGGAAGAT (SEQ ID NO: 188)

GAGGTCAAGTACAGTCTCCTCATGA (SEQ ID NO: 189)

GGAAAAATTGTCCCGTCTGTCACTT (SEQ ID NO: 190)

TGTCACTTGTTTTGTTGCCTTAATA (SEQ ID NO: 191)

GGGGCGGGTTCTGAAGCGATGAGAG (SEQ ID NO: 192)

213036_x_at
ATP2A3
SERCA3
ATPase, Ca++
489
CACGACACCCATGAGCCGAAAGGAT (SEQ ID NO: 193)

transporting,

TAAGGATGGCTGATTCCCCAAGGGC (SEQ ID NO: 194)

ubiquitous

CTCCCTCCCTGCTGGAGGAACACGT (SEQ ID NO: 195)

TTTCTCTTAACTCAGCTTTTGCTAC (SEQ ID NO: 196)

GAAACCTGCACCAAGGATTGTCCCT (SEQ ID NO: 197)

CCCTCCTAGAGCGTGTGCAGACTGA (SEQ ID NO: 198)

TAAATCAAGACTCACATCCCTTTCC (SEQ ID NO: 199)

CAGCCTGCCTTGCAGACCAATGGGC (SEQ ID NO: 200)

AATGGGCTCCATGTTCTGTAGCCCC (SEQ ID NO: 201)

GTCTTAGCAGGAGCGGGCCCTGTAC (SEQ ID NO: 202)

CCTGCTGACCTGCTGTTTGGTAGAG (SEQ ID NO: 203)

201322_at
ATP5B
ATPMB, ATPSB,
ATP synthase, H+
506
TTGGATGCTACCACTGTACTGTCGC (SEQ ID NO: 204)

MGC5231
transporting,

TCGCGTGCCATTGCTGAGCTGGGCA (SEQ ID NO: 205)

mitochondrial F1

AGCTGTGGATCCTCTAGACTCCACC (SEQ ID NO: 206)

complex, beta

GTGAGCATTACGATGTTGCCCGTGG (SEQ ID NO: 207)

polypeptide

TCCTGCAGGACTACAAATCCCTCCA (SEQ ID NO: 208)

GAAGACAAGTTGACCGTGTCCCGTG (SEQ ID NO: 209)

TTGTCTCAGCCATTCCAGGTTGCTG (SEQ ID NO: 210)

GAGGTCTTCACAGGTCATATGGGGA (SEQ ID NO: 211)

GAAGCTGGTACCCCTGAAGGAGACC (SEQ ID NO: 212)

ACAGGCCTTCTATATGGTGGGACCC (SEQ ID NO: 213)

TCGTGAGGGGTCTTTGTCCTCTGTA (SEQ ID NO: 214)

207507_s_at
ATP5G3
MGC125738, P3
ATP synthase, H+
518
CGCGCAGTCCCGAAGAGTGTAAGAT (SEQ ID NO: 215)

transporting,

CCTCTCTGATCCGAGCTGGATCCAG (SEQ ID NO: 216)

mitochondrial F0

GCATACAGACCAATTTCTGCATCAG (SEQ ID NO: 217)

complex, subunit C3

TGCATCAGTGTTATCTCGACCAGAG (SEQ ID NO: 218)

(subunit 9)

ATCTCGACCAGAGGCTAGTAGGACT (SEQ ID NO: 219)

TGGGGCCCAGAATGGTGTGTCTCAG (SEQ ID NO: 220)

GTGTCTCAGCTAATCCAAAGGGAGT (SEQ ID NO: 221)

TTGTTTGATGGTTGCTTTCTTGATT (SEQ ID NO: 222)

ACTGCTTGACATGTTGGCATTCATA (SEQ ID NO: 223)

TGTGTATCTTACTGTGACTCCGAAA (SEQ ID NO: 224)

AAAACTGTAGTATTGGTGTCATGGG (SEQ ID NO: 225)

200818_at
ATP5O
ATPO, OSCP
ATP synthase, H+
539
GAAGGAACCCAAAGTGGCTGCTTCT (SEQ ID NO: 226)

transporting,

GAATCCCTATGTGAAGCGTTCCATT (SEQ ID NO: 227)

mitochondrial F1

CCTCACTACCAACCTGATCAATTTG (SEQ ID NO: 228)

complex, O subunit

CAATACCCAAGGAGTCGTTTCTGCC (SEQ ID NO: 229)

(oligomycin sensitivity

CTACCATGATGAGTGTCCATCGCGG (SEQ ID NO: 230)

conferring protein)

GTGTCCATCGCGGAGAGGTACCTTG (SEQ ID NO: 231)

GAGGTACCTTGCACAGTGACCTCTG (SEQ ID NO: 232)

ATCTCCTTTAGAAGAAGCCACACTC (SEQ ID NO: 233)

AGCCACACTCTCTGAATTAAAAACT (SEQ ID NO: 234)

GGAGGCTAAGACTGATCCGTCAATC (SEQ ID NO: 235)

GACTGATCCGTCAATCTTGGGTGGA (SEQ ID NO: 236)

201089_at
ATP6V1B2
ATP6B1B2,
ATPase, H+
526
CTTTCCTGAGTGTTTGCTTTCGGTT (SEQ ID NO: 237)

ATP6B2, HO57,
transporting,

GCTTTCGGTTTGTTGGTATGCCTGT (SEQ ID NO: 238)

VATB, VPP3,
lysosomal 56/58 kDa,

TCTTTTTGCTCTTTCCTATATAATG (SEQ ID NO: 239)

Vma2
V1 subunit B2

TGGGATTCCTGTGTCTTACAGCTCT (SEQ ID NO: 240)

GCAACTTTTTGCACAGCTGGTATCT (SEQ ID NO: 241)

TCTGGTAGCAGTGAGACCCCTTGTC (SEQ ID NO: 242)

GGTGATCCTTACTGGGTTTCCAAGC (SEQ ID NO: 243)

AAACCTACAGCCTTTCTACATTCTG (SEQ ID NO: 244)

AGAGAGCAGCCTTTGAAAATCCCCA (SEQ ID NO: 245)

GAAAATCCCCAATTTGGTTCTGCTT (SEQ ID NO: 246)

CCTCTCTCTACCTTTTCAGGGTAAT (SEQ ID NO: 247)

215608_at
AU144378*

AAAGTGACTTGCCTGGAATGATACA (SEQ ID NO: 248)

GCCTGGAATGATACAGCCACCGAGC (SEQ ID NO: 249)

CCACCGAGCAGGAGGCAAGGAAAGC (SEQ ID NO: 250)

GCAAGGAAAGCCAGCTCTGTCTAAC (SEQ ID NO: 251)

AAGCCAGCTCTGTCTAACTGCTGCT (SEQ ID NO: 252)

AGCTCTGTCTAACTGCTGCTGAGTA (SEQ ID NO: 253)

GTCTAACTGCTGCTGAGTACTTTGT (SEQ ID NO: 254)

ACTGCTGCTGAGTACTTTGTAAAAG (SEQ ID NO: 255)

ACAAAAAATGTGATCCAGAACTGTG (SEQ ID NO: 256)

TTCGAACCCAGCCTTTACAATGTAA (SEQ ID NO: 257)

TTACAATGTAATGAAACCCTGCCTC (SEQ ID NO: 258)

218580_x_at
AURKAIP1
AIP, AKIP,
aurora kinase A
54998
GGAGCTGGAGGAGATGCTGGTCCCC (SEQ ID NO: 259)

FLJ20608
interacting protein 1

CTGCCCAGACTGGATACCGGGACCG (SEQ ID NO: 260)

TGTCCGCCCAGCCAGATAGGGGAAG (SEQ ID NO: 261)

ATGAAGGCGTCGCGGATGCGCCTCA (SEQ ID NO: 262)

AAAAACGTGCTGAAGATCCGCCGGC (SEQ ID NO: 263)

TGAACCACCACAAGTACCGGAAGCT (SEQ ID NO: 264)

GACGCGGTTCCTGCGGAGGAAGGTC (SEQ ID NO: 265)

GGACGCCTGAGACGCAAGCAGATCA (SEQ ID NO: 266)

ACCTGAGGCGCATCTGGCTGAAGGC (SEQ ID NO: 267)

CCCCCAAGATCTACCTGCGGGGCAA (SEQ ID NO: 268)

CGTTGCTGCTGTGATCCGTAGTAAT (SEQ ID NO: 269)

219326_s_at
B3GNT2
B3GN-T1, B3GN-
UDP-GlcNAc:betaGal
10678
GACGTTTATACTGGAATGTGCCTTC (SEQ ID NO: 270)

T2, B3GNT,
beta-1,3-N-

AATGTGCCTTCAGAAACTCGGCCTC (SEQ ID NO: 271)

B3GNT-2,
acetylglucosaminyltransferase 2

CTCGGCCTCGTTCCAGAGAAACACA (SEQ ID NO: 272)

B3GNT1,

AACATCTGCTCCTATGTAGATCTGA (SEQ ID NO: 273)

BETA3GNT

TGGTCTCAGTTGCAGAGTGCTCATT (SEQ ID NO: 274)

GAGTGATACCCATTTGAGGGCCTCT (SEQ ID NO: 275)

TTGAGGGCCTCTAAACCCTTCAATT (SEQ ID NO: 276)

GTTCTGATCTTACCGGCTAGTGGTC (SEQ ID NO: 277)

TAAAAAACTTGTACCCTCTTATCTG (SEQ ID NO: 278)

GTACCCTCTTATCTGAAATCCTGTT (SEQ ID NO: 279)

CTTCTATAATATTCCTACTTCCCAT (SEQ ID NO: 280)

91920_at
BCAN
RP11-66D17.1,
brevican
63827
AGCCAGCAGCCCAGGAGGAGTCACT (SEQ ID NO: 281)

BEHAB, CSPG7,

AGCCCAGGAGGAGTCACTCTCCCAG (SEQ ID NO: 282)

MGC13038

CAGCAAGGGCAGTCCTGCAGCCTGG (SEQ ID NO: 283)

AGTCCTGCAGCCTGGTGCATCACCA (SEQ ID NO: 284)

AGCCTGGTGCATCACCACTTCCTGA (SEQ ID NO: 285)

GGTGCATCACCACTTCCTGATGGAG (SEQ ID NO: 286)

TTCCTGATGGAGAGTCAGAAGCTTC (SEQ ID NO: 287)

GAGAGTCAGAAGCTTCCAGGCCTCC (SEQ ID NO: 288)

CTTCCAGGCCTCCAAGGGTCCATGG (SEQ ID NO: 289)

TCCAAGGGTCCATGGACCACCTACT (SEQ ID NO: 290)

GTCCATGGACCACCTACTGAGACTC (SEQ ID NO: 291)

GAGAGGAACCTAGCATCCCCATCAC (SEQ ID NO: 292)

CATCACCTTCCACTCTGGTTGAGGC (SEQ ID NO: 293)

CCACTCTGGTTGAGGCAAGAGAGGT (SEQ ID NO: 294)

GAGGCAACTGGTGGTCCTGAGCTAT (SEQ ID NO: 295)

AGCTATCTGGGGTCCCTCGAGGAGA (SEQ ID NO: 296)

213156_at
BG251521*

Homo sapiens, clone

ACACACTTCCTATATGTATCCACAT (SEQ ID NO: 297)

IMAGE: 4214654,

ATCAGATGCTCATTACAAATCCAGA (SEQ ID NO: 298)

mRNA

TTGGACTCTTGCAACAGATCACAAA (SEQ ID NO: 299)

GACTTTGGTCATTTCTGTATGTTCA (SEQ ID NO: 300)

GGGCGAAACCATCTTGATCCGATGC (SEQ ID NO: 301)

GATCCGATGCGAATGCAGTAATGTT (SEQ ID NO: 302)

GTTCTATATACCATTTCATCAGTTA (SEQ ID NO: 303)

GTTATTTCTTTTAGTCATGTTGATT (SEQ ID NO: 304)

ACTACAGTGAAAGCCCTTTTCAGTG (SEQ ID NO: 305)

TGGCCTGACTCAGAACTACCATGTG (SEQ ID NO: 306)

GAAAATCAGTACTCTCTTAATGTTT (SEQ ID NO: 307)

202592_at
BLOC1S1
BLOS1,
biogenesis of
2647
TCCCGCCTCCTAAAAGAACACCAGG (SEQ ID NO: 308)

FLJ39337,
lysosome-related

GGAGGCGAGAGGCTATCACTGCAGC (SEQ ID NO: 309)

FLJ97089,
organelles complex-

CGACCTGCCTGACAGAAGCTTTGGT (SEQ ID NO: 310)

GCN5L1,
1, subunit 1

GGTGTGGCCCAGGCCTACATGAACC (SEQ ID NO: 311)

MGC87455,

TGAAGACCCTACAGGTCCAGGCTGC (SEQ ID NO: 312)

MICoA, RT14

CAGGCTGCCCAATTTGCCAAGCAGA (SEQ ID NO: 313)

GCCAAGCAGACAGGCCAGTGGATCG (SEQ ID NO: 314)

GGTGGAGAACTTCAACCAGGCACTC (SEQ ID NO: 315)

TGTGGAGAACTGGGCTCGGAGCATC (SEQ ID NO: 316)

CACCATTGCCACTGCACTGGAATAT (SEQ ID NO: 317)

CTACCTCACCCGCAGGGGGAAGGAG (SEQ ID NO: 318)

218220_at
C12orf10
MST024,
chromosome 12 open
60314
CACGAGTTGCTCGACTTAATCCTAC (SEQ ID NO: 319)

MSTP024, MYG,
reading frame 10

TCAAGCGTGCAATGGATCTGGTTCA (SEQ ID NO: 320)

MYG1

GATTAGATTTCTACCAACACAGCTG (SEQ ID NO: 321)

CAGCGATTCCAGGTGGACCCAAGTG (SEQ ID NO: 322)

ACTGGCGAAAGGTGCATGTCCCTGG (SEQ ID NO: 323)

ATGTCCCTGGAAGGAGCATCTCTAC (SEQ ID NO: 324)

CATCTCTACCACCTGGAATCTGGGC (SEQ ID NO: 325)

CCATCTTCTTTGTTATCTACACTGA (SEQ ID NO: 326)

GGACCAGGTCAGTGGGATCCCTGGC (SEQ ID NO: 327)

GTCCATGCAAGCGGCTTCATTGGCG (SEQ ID NO: 328)

CCGACCCGAGAGGGTGCCTTGAGCA (SEQ ID NO: 329)

221777_at
C12orf52
FLJ14827
chromosome 12 open
84934
GTTAGCATTTCAGTGCCATCTACCC (SEQ ID NO: 330)

reading frame 52

GCCATCTACCCCACGACGAGGTGGG (SEQ ID NO: 331)

AGCCCCCTTGGAAATGATACTCTTT (SEQ ID NO: 332)

GATACTCTTTCATCAGGGTTGCCTA (SEQ ID NO: 333)

CTATGGGGCCACGGCGACAGGTATG (SEQ ID NO: 334)

ATGGCCCCTTGCCAGGGTAGGAGGA (SEQ ID NO: 335)

TCCCTTTATCCTGACAATCTCTAGT (SEQ ID NO: 336)

AATCTCTAGTCGATTCTTGCCTTTT (SEQ ID NO: 337)

CCTTTTTCTCCCGATTGCGGATTTG (SEQ ID NO: 338)

ATTTGGGGGCCACCTCTAAGATGCC (SEQ ID NO: 339)

AAATTAGTGCCAACCCAGGGGCCTG (SEQ ID NO: 340)

214296_x_at
C19orf36
IMAGE: 4215339
chromosome 19 open
113177
ACGAGGGGTCGTGGATGTGGCCACA (SEQ ID NO: 341)

reading frame 36

GTGGCCACACATAGGACCACACGTC (SEQ ID NO: 342)

ACCACACGTCCCAGCTGGGAGGAGA (SEQ ID NO: 343)

GTGGGGGACATGGAGAGCTGAGGCA (SEQ ID NO: 344)

TCGGCGCAGTGGAAGTCAGCTGTCC (SEQ ID NO: 345)

CTGGTATCGCCAGCCTTAAGGTGTC (SEQ ID NO: 346)

ACTTGGCCAACCTGACCTTGGAAGA (SEQ ID NO: 347)

GGAAGATGCTGCTGAGTGTCTCAAG (SEQ ID NO: 348)

AGCAGCACTGACAGCAGCTGGGCCT (SEQ ID NO: 349)

GGGCGGAGACTCAGCTGGACAGCCC (SEQ ID NO: 350)

GAGGGAGGGAATGGGGGTGGGCTGT (SEQ ID NO: 351)

219439_at
C1GALT1
C1GALT, T-
core 1 synthase,
56913
TCTGACATAGAACACTGGAATCCCA (SEQ ID NO: 352)

synthase
glycoprotein-N-

GGAATCCCAGTGAGGAATTCTAAGT (SEQ ID NO: 353)

acetylgalactosamine

GAACATTCCTTATAGAAACCTTTCA (SEQ ID NO: 354)

3-beta-

AATGGTGGCCAGGTAGAGGAACTAG (SEQ ID NO: 355)

galactosyltransferase, 1

GACCATCTGTGTTATTGTCACTGAG (SEQ ID NO: 355)

ATTTACTAAAACTACACTGCACCAT (SEQ ID NO: 357)

AACTACACTGCACCATGTTAGTAAT (SEQ ID NO: 358)

GAAATATTGTTGCTCAGTGTTGTTA (SEQ ID NO: 359)

TATGCTATAAATGATACCCCCCTAC (SEQ ID NO: 360)

TAATTGGTAGTATTTCTTCCAGAAG (SEQ ID NO: 361)

GACTGGCACTTACCCTGAAGTGCAT (SEQ ID NO: 362)

212005_at
C1orf144
DKFZp566C0424,
chromosome 1 open
26099
TTCCCATGAGCCACTACTCTGATGT (SEQ ID NO: 363)

MGC70432
reading frame 144

TCCCATGAGCCACTACTCTGATGTC (SEQ ID NO: 364)

CCATGAGCCACTACTCTGATGTCAG (SEQ ID NO: 365)

GTCAGCCTATAACCAAAGGAGCTGG (SEQ ID NO: 366)

GCCTATAACCAAAGGAGCTGGGGGG (SEQ ID NO: 367)

TTTCTCAGCCCACTCAATCAGGGTG (SEQ ID NO: 368)

CTCAGCCCACTCAATCAGGGTGCTC (SEQ ID NO: 369)

AGCCTCCCTGGTAAGCAGAGACTCA (SEQ ID NO: 370)

CCTCCCTGGTAAGCAGAGACTCAAG (SEQ ID NO: 371)

GAGACTCAAGAAACCTCTGGGGTCC (SEQ ID NO: 372)

GACTCAAGAAACCTCTGGGGTCCTG (SEQ ID NO: 373)

210652_s_at
C1orf34
C1orf34, DEME-
chromosome 1 open
22996
CACCTGTAAGTCTTTGTCTTCACCT (SEQ ID NO: 374)

6, KIAA0452
reading frame 34

TGTCTTCACCTATTATCATCTGGAG (SEQ ID NO: 375)

GCTTGTGTGACGGAAGGTCCTTCAG (SEQ ID NO: 376)

GAGGACCTGAGGAATGCCTGGGAGA (SEQ ID NO: 377)

AAGCCTCAGGCTTCAATGCTTCTGG (SEQ ID NO: 378)

GCTTCTGGGGTTGGGCATGAGGATG (SEQ ID NO: 379)

TGGAAGAGCTGTGTAGCCCTTTCTA (SEQ ID NO: 380)

GGCAGGAGGAGGTTCTCAGAATCCA (SEQ ID NO: 381)

AGTCTGTATCTTTGCTGTATGCCAA (SEQ ID NO: 382)

TAAAAATCTTCTGTACTTCACTCCA (SEQ ID NO: 383)

ACTTCACTCCAAGGTACATTTGCTT (SEQ ID NO: 384)

222301_at
C1orf61
CROC4;
Chromosome 1 open
10485
CCTATTTAGATCCGTCAGCCCACGG (SEQ ID NO: 385)

FLJ38303; RP11-
reading frame 61

CAAGCAGTCATTCCCTGTTATACAA (SEQ ID NO: 386)

139I14.3

GTCATTCCCTGTTATACAAGCAAGA (SEQ ID NO: 387)

AGACAGCAATGGGGCCTTTAGGCCT (SEQ ID NO: 388)

CAGGCTGCGGCTGGCATATGGAGGT (SEQ ID NO: 389)

ATTGGCTGCCATATTGTACCTCAGA (SEQ ID NO: 390)

GTACCTCAGAGCACTAGCTCCTATC (SEQ ID NO: 391)

CACTAGCTCCTATCTGGATTTTCCC (SEQ ID NO: 392)

GCGGGGTTCCTAGAGGGTGGGAGAT (SEQ ID NO: 393)

GAGATGGGTCTCCAGGGATTTATCC (SEQ ID NO: 394)

CCTTTCCCCTGATATCTATCCAATA (SEQ ID NO: 395)

219054_at
C5orf23
CSGalNAcT-2,
chromosome 5 open
79614
GACAACAATGAAGTAGCCCCTGAAC (SEQ ID NO: 396)

DKFZp686H13226,
reading frame 23

GTAGCCCCTGAACAGCATGGAGTTG (SEQ ID NO: 397)

FLJ43310,

GAGTTGCTGTGAGTTTGTTCGTTGC (SEQ ID NO: 398)

GALNACT-2,

GTTCGTTGCAGACCTTTGTGTTGGG (SEQ ID NO: 399)

GALNACT2,

GGTCCTGGGAATCTGAGCTTTGTTC (SEQ ID NO: 400)

MGC40204,

CTTTGTTCCCTGTGCATGGTGGATA (SEQ ID NO: 401)

PRO0082

GGGATAGACCTTGTGACAGACCAAT (SEQ ID NO: 402)

GACAGACCAATTCTGTGACCCCTGT (SEQ ID NO: 403)

TGACCCCTGTCTTCTGGGTCACATT (SEQ ID NO: 404)

AAATGTGTATGTGTCCTTGTAAATG (SEQ ID NO: 405)

GCAAGAATGCCACGTACTCAGAGTA (SEQ ID NO: 406)

39817_s_at
C6orf108
RCL, RP3-
chromosome 6 open
10591
AGTGACACAGCCATCCTTGGGTGTA (SEQ ID NO: 407)

330M21.3,
reading frame 108

CACAGCCATCCTTGGGTGTAGGCTA (SEQ ID NO: 408)

dJ330M21.3

AGTCTGGCCGCGTGCTTTCGGCCAT (SEQ ID NO: 409)

GTCTGGCCGCGTGCTTTCGGCCATG (SEQ ID NO: 410)

TGGCCGCGTGCTTTCGGCCATGATC (SEQ ID NO: 411)

GGCCGCGTGCTTTCGGCCATGATCC (SEQ ID NO: 412)

TGCTTTCGGCCATGATCCGGGGAGC (SEQ ID NO: 413)

TTTCGGCCATGATCCGGGGAGCAGC (SEQ ID NO: 414)

ATCCGGGGAGCAGCAGATGGCTCTC (SEQ ID NO: 415)

GCAGCAGATGGCTCTCGGTTCCAGG (SEQ ID NO: 416)

CAGCAGATGGCTCTCGGTTCCAGGT (SEQ ID NO: 417)

AGCAGATGGCTCTCGGTTCCAGGTG (SEQ ID NO: 418)

ATACTTCGAGGCTGATCCTCCAGGG (SEQ ID NO: 419)

TTCGAGGCTGATCCTCCAGGGCAGG (SEQ ID NO: 420)

TCGAGGCTGATCCTCCAGGGCAGGT (SEQ ID NO: 421)

ATCCTCCAGGGCAGGTGGCTGCCTC (SEQ ID NO: 422)

221100_at
C6orf15
DADB-141O4.4,
chromosome 6 open
29113
CATCCACAGGGTTCTGCCTGATCAC (SEQ ID NO: 423)

STG
reading frame 15

TGATCACCCCTGGGGTACCCTGAAT (SEQ ID NO: 424)

TACCCTGAATCCCAGTGTGTCCTGG (SEQ ID NO: 425)

TGGTTGGGGAACGAGGCCCATGCCA (SEQ ID NO: 426)

TCAATAATCAACCCCCAGGTACCAG (SEQ ID NO: 427)

CAGGTATCAATAACCCATTTCCTCC (SEQ ID NO: 428)

CTGGCTCTTCTTGGAACATCCCAGC (SEQ ID NO: 429)

CTCCAAGCCCTAGGTTGCAGTGGGG (SEQ ID NO: 430)

TTGGGAGTTAGAGTCCTGCTCCCGC (SEQ ID NO: 431)

CTTGCTGTGTGGGCTCAATCCAGGC (SEQ ID NO: 432)

TCCAGGCCCTGTTAACATGTTTCCA (SEQ ID NO: 433)

219655_at
C7orf10
DERP13,
chromosome 7 open
79783
GCAGAACCTCAGAACGCTGTCTCTG (SEQ ID NO: 434)

FLJ11808,
reading frame 10

GGGTATTACACAATGGCCTCGTTAT (SEQ ID NO: 435)

ORF19

GATGGAGCATCCAACTGTGGGGAAG (SEQ ID NO: 436)

CACACAACGCACATCCTGAAGGAGG (SEQ ID NO: 437)

CGATGACAGGGCCATCGGGGAGCTG (SEQ ID NO: 438)

TGCTCAGCGCTGGAGTGGTGGACCA (SEQ ID NO: 439)

GGAAAAGGGCTCTTCCTCATAACCT (SEQ ID NO: 440)

ACCTCGATCCGAATACACTGGCAAA (SEQ ID NO: 441)

TCCCCAGTTCTGATACCACTAAGAA (SEQ ID NO: 442)

AACTCCAGATTTCTTACATGGCATC (SEQ ID NO: 443)

ACATGGCATCTCCAGAATGGCTCTG (SEQ ID NO: 444)

219060_at
C8orf32
FLJ10204
chromosome 8 open
55093
AAGCTATCCTTTCATCGAGGACAGC (SEQ ID NO: 445)

reading frame 32

ACATTATGGTACAGTTGGCTTGGAA (SEQ ID NO: 446)

GGCTTGGAATTATGTCTTTCTCTTT (SEQ ID NO: 447)

GTGCGTACTTGCTAAGATATTCCTG (SEQ ID NO: 448)

GATATTCCTGTGGCTCATGCGTTAC (SEQ ID NO: 449)

GCGTTACAACACGAGGACTTAAGCC (SEQ ID NO: 450)

AAGCCAGTAATCGTTTTTGTTCAGA (SEQ ID NO: 451)

AGAGGTGTGGAGGTAGAGCCAGCCC (SEQ ID NO: 452)

TGTCTCTCCAGCTACATTGTAAGTT (SEQ ID NO: 453)

AAATGCCCATAAAAGGTGCCCATAA (SEQ ID NO: 454)

AGCCCTCTCAGACTTGAGCGTTAAT (SEQ ID NO: 455)

220038_at
C8orf44 ///
FLJ11267 ///
serum/glucocorticoid
56260
TTTCCCTCTAAGTTTACACTAACAT (SEQ ID NO: 456)

SGK3
CISK,
regulated kinase
23678
GTTTACACTAACATCTACCCAAGAT (SEQ ID NO: 457)

DKFZp781N0293,
family, member 3 ///

ACATCTACCCAAGATAGACTGTTTT (SEQ ID NO: 458)

SGK2, SGKL
chromosome 8 open

ACAGTCAATTTCAGTTCAGCTAACA (SEQ ID NO: 459)

reading frame 44

TTGTAACTCTTTGCTATGGCTTTTG (SEQ ID NO: 460)

GCTATGGCTTTTGTTATCACACCAA (SEQ ID NO: 461)

GTTATCACACCAAAACTATGCAATT (SEQ ID NO: 462)

TATGCAATTGGTACATGGTTGTTTA (SEQ ID NO: 463)

GAAACCGTATTTTTCCATGATAAAT (SEQ ID NO: 464)

GAAATATTTGGTTCATGGTATGATC (SEQ ID NO: 465)

CATAATTAACACATTGGCTGCTAGT (SEQ ID NO: 466)

205308_at
C8orf70
C8orf70, CGI-62
chromosome 8 open
51101
GCAAAACTGTTGTAGGTGTTCCTTC (SEQ ID NO: 467)

reading frame 70

AAGTGTCTTCAAGTAGCAGCTCTTT (SEQ ID NO: 468)

AACAAACTTCAGACCTTGTCTCCCT (SEQ ID NO: 469)

ATAAAGGGATAGCAGCCCCTCATGC (SEQ ID NO: 470)

GCAGGAGCTAATGTCAAACCCCGAA (SEQ ID NO: 471)

GAAATTCCACACCACCTAGTTTGGC (SEQ ID NO: 472)

GCCCCAGGTGTGCTTACAAACAAAA (SEQ ID NO: 473)

GAGAGCTACATAGCCAGGCCAGATG (SEQ ID NO: 474)

AGATGGGGACTGTGCATCTTCCCTT (SEQ ID NO: 475)

GGACATTCACCTGGAAACTTACCAA (SEQ ID NO: 476)

GCTTGGACAGCTAGAGCACATCCTC (SEQ ID NO: 477)

64408_s_at
CALML4
MGC4809, NY-
calmodulin-like 4
91860
GAAAGAAATTCTTCTAGCCATGTTG (SEQ ID NO: 478)

BR-20

ATTCTTCTAGCCATGTTGATGGTGG (SEQ ID NO: 479)

CTTCTAGCCATGTTGATGGTGGACA (SEQ ID NO: 480)

CTAGCCATGTTGATGGTGGACAAGG (SEQ ID NO: 481)

CGGTCAAAACTCACGAGTCTGGGGG (SEQ ID NO: 482)

GGTCAAAACTCACGAGTCTGGGGGA (SEQ ID NO: 483)

GATCACCCTTCCTGGACGGGACTAT (SEQ ID NO: 484)

CACCCTTCCTGGACGGGACTATTGA (SEQ ID NO: 485)

TTCCTGGACGGGACTATTGAAGGAG (SEQ ID NO: 486)

CTCCCCTGGGCCTGAAAACTTGGAG (SEQ ID NO: 487)

CCTGGGCCTGAAAACTTGGAGCAAT (SEQ ID NO: 488)

CTGGGCCTGAAAACTTGGAGCAATT (SEQ ID NO: 489)

AACACAGTGGCAAGACAACATTACC (SEQ ID NO: 490)

AACATTACCCAACTATAGAAGAGAG (SEQ ID NO: 491)

TACCCAACTATAGAAGAGAGGCTAA (SEQ ID NO: 492)

ACCCAACTATAGAAGAGAGGCTAAC (SEQ ID NO: 493)

212710_at
CAMSAP1
RP11-100C15.2,
calmodulin regulated
157922
AACTCTGTTTATCAATGTCTCCTAT (SEQ ID NO: 494)

DKFZp434F195,
spectrin-associated

TCCTATATTCAAAGCCCCTGCAGTG (SEQ ID NO: 495)

DKFZp434G2311,
protein 1

GCAGTGGTATTTGTGTCTCGTTGCA (SEQ ID NO: 496)

FLJ31228,

CAACTTTCGTTGTGTCTCAGAATTC (SEQ ID NO: 497)

MGC163452,

TAAGACAAGCTGCTCTACCCATTTA (SEQ ID NO: 498)

PRO2405,

ACTTGCGTGAGTCCCATTATTTTAC (SEQ ID NO: 499)

bA100C15.1

TGTGCAGATACGTTCTACCCACACG (SEQ ID NO: 500)

GCGTGCACATGGCTGTGTGCGTGCA (SEQ ID NO: 501)

AGATGGACTGCTTTCCATGTGTCCT (SEQ ID NO: 502)

CTCTTAGCAGACTTCAGGCCCAAAC (SEQ ID NO: 503)

TCTAGGTTATACTTTTACCTCCCTG (SEQ ID NO: 504)

212765_at
CAMSAP1L1
RP11-93N17.1,
calmodulin regulated
23271
GAGTTCATTGCTCTCAGTATAAGAT (SEQ ID NO: 505)

KIAA1078,
spectrin-associated

AAGTCTGAGGATTTTCGTCAACCTT (SEQ ID NO: 506)

MGC150680,
protein 1-like 1

CGTCAACCTTACTGAAACACACTGG (SEQ ID NO: 507)

MGC150681

AACACACTGGTGCTTTCATCATCAG (SEQ ID NO: 508)

TTGTCGTGGTTACCAGTGCAGCCTG (SEQ ID NO: 509)

AAATTCTGCTATTTGACACAGCTTT (SEQ ID NO: 510)

ATGGTTTCATGGACACTGTTGAGCA (SEQ ID NO: 511)

AGTGTATGGTGTGCTTACCTGTCCA (SEQ ID NO: 512)

TACCTGTCCACTCTAGAGCATTGCT (SEQ ID NO: 513)

GAGCATTGCTTACAGGTTTTTTGTT (SEQ ID NO: 514)

TGCTATTTCCTGGTACAGTGTAGTT (SEQ ID NO: 515)

209970_x_at
CASP1
ICE, IL1BC, P45
caspase 1,
834
CGAAGGTGATCATCATCCAGGCCTG (SEQ ID NO: 516)

apoptosis-related

ACAGCCCTGGTGTGGTGTGGTTTAA (SEQ ID NO: 517)

cysteine peptidase

GGAAACCTATCTTTACCAACTACAG (SEQ ID NO: 518)

(interleukin 1, beta,

GAAGGATTTTATCGCTTTCTGCTCT (SEQ ID NO: 519)

convertase)

TTTCTGCTCTTCCACACCAGATAAT (SEQ ID NO: 520)

GAGACATCCCACAATGGGCTCTGTT (SEQ ID NO: 521)

GAATATGCCTGTTCCTGTGATGTGG (SEQ ID NO: 522)

TTTCCGCAAGGTTCGATTTTCATTT (SEQ ID NO: 523)

GATGGTAGAGCGCAGATGCCCACCA (SEQ ID NO: 524)

TGACAAGATGTTTCTACCTCTTCCC (SEQ ID NO: 525)

TTCTACCTCTTCCCAGGACATTAAA (SEQ ID NO: 526)

211367_s_at
CASP1
ICE, IL1BC, P45
caspase 1,
834
GAGCTGAGGTTGACATCACAGGCAT (SEQ ID NO: 527)

apoptosis-related

ATCACAGGCATGACAATGCTGCTAC (SEQ ID NO: 528)

cysteine peptidase

GACAATGCTGCTACAAAATCTGGGG (SEQ ID NO: 529)

(interleukin 1, beta,

AAATCTGGGGTACAGCGTAGATGTG (SEQ ID NO: 530)

convertase)

AAAAAAATCTCACTGCTTCGGACAT (SEQ ID NO: 531)

TCATGTCTCATGGTATTCGGGAAGG (SEQ ID NO: 532)

GGTATTCGGGAAGGCATTTGTGGGA (SEQ ID NO: 533)

GAAGAAACACTCTGAGCAAGTCCCA (SEQ ID NO: 534)

ACTACAACTCAATGCAATCTTTAAC (SEQ ID NO: 535)

GTTGAATACCAAGAACTGCCCAAGT (SEQ ID NO: 536)

ACCGAAGGTGATCATCATCCAGGCC (SEQ ID NO: 537)

211368_s_at
CASP1
ICE, IL1BC, P45
caspase 1,
834
AATGTTTCTTGGAGACATCCCACAA (SEQ ID NO: 538)

apoptosis-related

GGAGACATCCCACAATGGGCTCTGT (SEQ ID NO: 539)

cysteine peptidase

GGCTCTGTTTTTATTGGAAGACTCA (SEQ ID NO: 540)

(interleukin 1, beta,

GGAAGACTCATTGAACATATGCAAG (SEQ ID NO: 541)

convertase)

TATGCAAGAATATGCCTGTTCCTGT (SEQ ID NO: 542)

GAGGAAATTTTCCGCAAGGTTCGAT (SEQ ID NO: 543)

AAGGTTCGATTTTCATTTGAGCAGC (SEQ ID NO: 544)

TGAGCAGCCAGATGGTAGAGCGCAG (SEQ ID NO: 545)

GATGGTAGAGCGCAGATGCCCACCA (SEQ ID NO: 546)

GACTTTGACAAGATGTTTCTACCTC (SEQ ID NO: 547)

CTACCTCTTCCCAGGACATTAAAAT (SEQ ID NO: 548)

220466_at
CCDC15
FLJ13215
coiled-coil domain
80071
GGGATTTTCTACCCAGAGACCTGCA (SEQ ID NO: 549)

containing 15

ATGTTCTCTCCAACGACCAGAATAT (SEQ ID NO: 550)

TGTCAGGACCAAGATTTTCTACCAA (SEQ ID NO: 551)

AGAAGACTTTTCTCTGGCAGACTAT (SEQ ID NO: 552)

AAATCAGCAACCTGCATCTTTTATG (SEQ ID NO: 553)

GGAATTGCCTCTGGACTATCATCAA (SEQ ID NO: 554)

GACCAAGACTCCCCTAGAGAACAGA (SEQ ID NO: 555)

AAGCATATCAAACTACCCTCATCTT (SEQ ID NO: 556)

GAGCACTGAATTCCAAGCTCCACTG (SEQ ID NO: 557)

GCTCCACTGGCATTTCAGTCTGACG (SEQ ID NO: 558)

GTACCTGAGACATAGACGACTTTTC (SEQ ID NO: 559)

203418_at
CCNA2
CCN1, CCNA
cyclin A2
890
TACCCAATACTTTCTGCATCAGCAG (SEQ ID NO: 560)

TCTGCATCAGCAGCCTGCAAACTGC (SEQ ID NO: 561)

TGATAGATGCTGACCCATACCTCAA (SEQ ID NO: 562)

CCATCAGTTATTGCTGGAGCTGCCT (SEQ ID NO: 563)

TGGAGCTGCCTTTCATTTAGCACTC (SEQ ID NO: 564)

TTTAGCACTCTACACAGTCACGGGA (SEQ ID NO: 565)

GTCACGGGACAAAGCTGGCCTGAAT (SEQ ID NO: 566)

GGAAAGTCTTAAGCCTTGTCTCATG (SEQ ID NO: 567)

TACCTCAAAGCACCACAGCATGCAC (SEQ ID NO: 568)

AAAGTATCATGGTGTTTCTCTCCTC (SEQ ID NO: 569)

AAAGACTGCCTTTGTTTTCTAAGAT (SEQ ID NO: 570)

201947_s_at
CCT2
99D8.1, CCT-
chaperonin
10576
GAAGCTGTTGCAATGGAGTCTTATG (SEQ ID NO: 571)

beta, CCTB,
containing TCP1,

ATGTTGCCAACCATCATAGCTGACA (SEQ ID NO: 572)

MGC142074,
subunit 2 (beta)

GCTATGACAGTGCAGACCTGGTGGC (SEQ ID NO: 573)

MGC142076,

GCTCAGGGCTGCTCACAGTGAAGGC (SEQ ID NO: 574)

PRO1633, TCP-

GAAGGCAATACCACTGCTGGATTGG (SEQ ID NO: 575)

1-beta

AGATATGGCTATCCTGGGTATAACA (SEQ ID NO: 576)

AGGTGATTCTGCGTGTGGACAACAT (SEQ ID NO: 577)

GGACAACATCATCAAAGCGGCACCC (SEQ ID NO: 578)

ACGTGCTGTCGATCTTTGGACCAGT (SEQ ID NO: 579)

GACCAGTTTCTAGCAAAGTTGTGTT (SEQ ID NO: 580)

ATTTAGCTGACCTTCGCTTTAACAT (SEQ ID NO: 581)

214464_at
CDC42BPA
MRCK; MRCKA;
CDC42 binding
8476
ATTCGGAACTGTGAAGCACCTTATA (SEQ ID NO: 582)

PK428;
protein kinase alpha

GTTAGTAGCCCAACAGATACATCGA (SEQ ID NO: 583)

FLJ23347;
(DMPK-like)

GCCACCATCTGCCATTTGTTGGTTT (SEQ ID NO: 584)

KIAA0451;

GTAGCTGTGTACTTTCTGATCGGAG (SEQ ID NO: 585)

DKFZp686L1738;

GTACTTTCTGATCGGAGCTGTTTAA (SEQ ID NO: 586)

DKFZp686P1738

TGTTTAAGAGTTACGGCTGGTCCCA (SEQ ID NO: 587)

TCCCACCTCACTGGATCTTGATGTT (SEQ ID NO: 588)

GAGGACTCTAGACAACAACTTAGCA (SEQ ID NO: 589)

AACACAGACTGTCCAAGCTCTGCAG (SEQ ID NO: 590)

AGCTCTGCAGTATTCAACTGTTGAT (SEQ ID NO: 591)

GATGGTCCACTAACAGCAAGCAAAG (SEQ ID NO: 592)

221520_s_at
CDCA8
BOR,
cell division cycle
55143
TGGGACTTAGGGATCTTTCACCTGC (SEQ ID NO: 593)

BOREALIN,
associated 8

CCTGCTGTGCCCAGTAGTTCTGAAG (SEQ ID NO: 594)

FLJ10468,

GTTTATCCCTGTTTACTGAAGACCA (SEQ ID NO: 595)

FLJ12042

GAGACAACTTCCATGTCTTGCTCTT (SEQ ID NO: 596)

TCTTCTACCTCCCTAGTTAGTGGAA (SEQ ID NO: 597)

AGGGAACTGTAGGGCCCAGATTCTG (SEQ ID NO: 598)

AACTGTCTCTAAGCTATCCATGGTC (SEQ ID NO: 599)

AGCAGTGAGGTCCTCATTCTCCAGC (SEQ ID NO: 600)

CTGCCCTGGAGAATCATGTGCTATG (SEQ ID NO: 601)

TTGAGAACTAGAGTCCTCATCCCCA (SEQ ID NO: 602)

TTCTCATGTAGGGCTCTCTGTGGTA (SEQ ID NO: 603)

213230_at
CDR2L
HUMPPA
cerebellar
30850
GCTGCGTCAGGAGTTTTGCTTCAAG (SEQ ID NO: 604)

degeneration-related

AGTTCAGCTAAGAGACACCCAGGTC (SEQ ID NO: 605)

protein 2-like

GCCCTTCCTGAGACCTTAGAAACCA (SEQ ID NO: 606)

GAAACCAGAAGAGCCATACAGTCAG (SEQ ID NO: 607)

TACAGTCAGTGGAAGGCGGGGGGGC (SEQ ID NO: 608)

GGATCCCAGTGGGAACCTTCATGCC (SEQ ID NO: 609)

ATGGGAGCTGGTGGCGACTGAGTCC (SEQ ID NO: 610)

AGTCCTTCTGTACGTGCAACTGGGA (SEQ ID NO: 611)

TTGTCCTTTGAGGCTAGGCAGCTCC (SEQ ID NO: 612)

TCCGTGTGTGTCTGTTATCTGGGGG (SEQ ID NO: 613)

CAGACCAGCGTCACCTTTGAAGTAT (SEQ ID NO: 614)

207719_x_at
CEP170
FAM68A, KAB,
centrosomal protein
9859
GTAACTCTATACACTTCAAGACTTT (SEQ ID NO: 615)

KIAA0470
170 kDa

TAATGGATCTCCTATTTTTCTTTAA (SEQ ID NO: 616)

AATGAACTATTCTCCTTGTAAAGCT (SEQ ID NO: 617)

TAAAGCTAAATTCCCCATTCTGTCT (SEQ ID NO: 618)

AATAATCAGCATTGCTCCCTCTTTT (SEQ ID NO: 619)

ATTGCTCCCTCTTTTATTTAATATT (SEQ ID NO: 620)

GGGTACTGATTATATCCACATGGAA (SEQ ID NO: 621)

AATCTACTCTGCTTACATTCTTGTT (SEQ ID NO: 622)

GTGTTTACACAGTTTGGTTCAATTA (SEQ ID NO: 623)

CATTTGGCCTTTTACTATGTTATTT (SEQ ID NO: 624)

ACATTATCCTCCTTATTTATTTTTG (SEQ ID NO: 625)

207209_at
CETN1
CEN1, CETN
centrin, EF-hand
1068
CTAAAGTGACTCTCTGGGTTGCCTG (SEQ ID NO: 626)

protein, 1

TAGAGGACAGCGGCTGCCTGTCCCT (SEQ ID NO: 627)

CTCACCCCCATAATTTGTCTAGATC (SEQ ID NO: 628)

GGCCCTGAAGTTTGAGTGCGCCCTC (SEQ ID NO: 629)

GGACAGCTTCTGGGACACACAAAAA (SEQ ID NO: 630)

TCCCTTTGTCACTTCTTTGGTGGTC (SEQ ID NO: 631)

TCTTGCTTCATATATCATTCCTTAA (SEQ ID NO: 632)

AAATTCCAGTCATTGTTCCAGCATA (SEQ ID NO: 633)

GCCAGTAGATTTGCCTAGCCTGTCC (SEQ ID NO: 634)

TAGCCTGTCCACTTAGCTGAATACC (SEQ ID NO: 635)

GTGGCCACTTACAAACTTACGGAGC (SEQ ID NO: 636)

202357_s_at
CFB
DADB-122G4.5,
complement factor B
629
CAGACTATCAGGCCCATTTGTCTCC (SEQ ID NO: 637)

BF, BFD, CFAB,

TCCCCTGCACCGAGGGAACAACTCG (SEQ ID NO: 638)

FB, FBI12, GBG,

GAACAACTCGAGCTTTGAGGCTTCC (SEQ ID NO: 639)

H2-Bf, PBF2

CAACTACCACTTGCCAGCAACAAAA (SEQ ID NO: 640)

CCCTGCACAGGATATCAAAGCTCTG (SEQ ID NO: 641)

GCTCTGTTTGTGTCTGAGGAGGAGA (SEQ ID NO: 642)

ACTCGGAAGGAGGTCTACATCAAGA (SEQ ID NO: 643)

GAAGTCGTTTCATTCAAGTTGGTGT (SEQ ID NO: 644)

AAGTTGGTGTAATCAGCTGGGGAGT (SEQ ID NO: 645)

GCTGGGGAGTAGTGGATGTCTGCAA (SEQ ID NO: 646)

ACTTTCACATCAACCTCTTTCAAGT (SEQ ID NO: 647)

218927_s_at
CHST12
C4S-2, C4ST-2,
carbohydrate
55501
GACCCGCACACGGAGAAGCTGGCGC (SEQ ID NO: 648)

C4ST2
(chondroitin 4)

CACTGGCGGCAGGTGTACCGCCTCT (SEQ ID NO: 649)

sulfotransferase 12

GCCAGATCGACTACGACTTCGTGGG (SEQ ID NO: 650)

GCTGGAGACTCTGGACGAGGACGCC (SEQ ID NO: 651)

GGAGGAGGACTGGTTCGCCAAGATC (SEQ ID NO: 652)

TAAACTCTACGAGGCCGACTTTGTT (SEQ ID NO: 653)

GAAAACCTCCTCCGAGACTGAAAGC (SEQ ID NO: 654)

AAAGCTTTCGCGTTGCTTTTTCTCG (SEQ ID NO: 655)

GCGTGCCTGGAACCTGACGCACGCG (SEQ ID NO: 656)

TTTGCAATCTGGGCTTCTTGTTCAC (SEQ ID NO: 657)

TCCACTGCCTCTATCCATTGAGTAC (SEQ ID NO: 658)

209666_s_at
CHUK
IKBKA, IKK-
conserved helix-loop-
1147
CAATCTTTCATGTCTTGTCATACAA (SEQ ID NO: 659)

alpha, IKK1,
helix ubiquitous

ACAAATTTATAAAGGTCTGCACTCC (SEQ ID NO: 660)

IKKA, NFKBIKA,
kinase

TCTGCACTCCTTTATCTGTAATTGT (SEQ ID NO: 661)

TCF16

AAGGTTTCCATAAGCTTGGTGACAA (SEQ ID NO: 662)

ATTTGCTTGCAATCTAATCTGAACT (SEQ ID NO: 663)

AATCTGAACTGACCTTGAATCTTTT (SEQ ID NO: 664)

TATCCCATTTAGTGTGAATATTCCT (SEQ ID NO: 665)

TGTGAATATTCCTTTATTTTGCTGC (SEQ ID NO: 666)

CCACAGACTGTGGTGAGGGCTGGTT (SEQ ID NO: 667)

GAGGGCTGGTTAATGTAGTATGGTA (SEQ ID NO: 668)

ATATGCACAAAACTACTTTTCTAAA (SEQ ID NO: 669)

214252_s_at
CLN5
FLJ90628, NCL
ceroid-lipofuscinosis,
1203
TATGCATGATGCCATTGGATTCAGA (SEQ ID NO: 670)

neuronal 5

GGATTCAGAAGTACATTAACTGGCA (SEQ ID NO: 671)

TAACTGGCAAGAACTACACAATGGA (SEQ ID NO: 672)

TGGTATGAACTTTTCCAACTTGGCA (SEQ ID NO: 673)

ACTTGGCAACTGTACATTTCCCCAT (SEQ ID NO: 674)

ATCTCCGACCTGAAATGGATGCCCC (SEQ ID NO: 675)

ACCTGAAATGGATGCCCCTTTCTGG (SEQ ID NO: 676)

ATGCCCCTTTCTGGTGTAATCAAGG (SEQ ID NO: 677)

TTCTGGTGTAATCAAGGCGCTGCCT (SEQ ID NO: 678)

TGCTTTTTTGAGGGAATTGATGATG (SEQ ID NO: 679)

AATGGGACATTAGTTCAAGTAGCAA (SEQ ID NO: 680)

204050_s_at
CLTA
CLTA2,
clathrin, light chain
1211
GGAACGCTTGGAAGCCCTTGATGCC (SEQ ID NO: 681)

MGC140767
(Lca)

ACGCTTGGAAGCCCTTGATGCCAAT (SEQ ID NO: 682)

TTGGAAGCCCTTGATGCCAATTCTC (SEQ ID NO: 683)

CCCTTGATGCCAATTCTCGGAAGCA (SEQ ID NO: 684)

GCCAATTCTCGGAAGCAAGAAGCAG (SEQ ID NO: 685)

GAATGGTATGCAAGACAGGACGAGC (SEQ ID NO: 686)

GCAAGACAGGACGAGCAGCTACAGA (SEQ ID NO: 687)

GACAGGACGAGCAGCTACAGAAAAC (SEQ ID NO: 688)

GGAAGCTTCCCAAGAGTAGCCTCAA (SEQ ID NO: 689)

CTTCCCAAGAGTAGCCTCAACCTGT (SEQ ID NO: 690)

CAAGAGTAGCCTCAACCTGTGCTTC (SEQ ID NO: 691)

217870_s_at
CMPK1
CMK; UMK;
cytidine
51727
GGAATGAGTTCTTATCTAGTGTTGC (SEQ ID NO: 692)

CMPK; UMPK;
monophosphate

TCTTATCTAGTGTTGCAGGCCAGCA (SEQ ID NO: 693)

UMP-CMPK1;
(UMP-CMP) kinase

GGTTTCGAGAGCATTCCTACTCACA (SEQ ID NO: 694)

RP11-511I2.1
1, cytosolic

GAGCATTCCTACTCACATAAGTGAA (SEQ ID NO: 695)

TGAGACTAGGTGCTTTGCTTCCTTT (SEQ ID NO: 696)

GCTTCCTTTCATCAGGTATCTTTCT (SEQ ID NO: 697)

AGGTATCTTTCTGTGGCATTTGAGA (SEQ ID NO: 698)

TTACTAAATTATGAGGCTTTGCTTT (SEQ ID NO: 699)

TAACTAGTTTTGTCATTCCATTTGT (SEQ ID NO: 700)

GATACAGTCACCAAGAATGTTTTGA (SEQ ID NO: 701)

AGACCCCAATTTAAGCCTTGCTTAT (SEQ ID NO: 702)

218250_s_at
CNOT7
CAF1, hCAF-1
CCR4-NOT
29883
GGTTACGACTTTGGCTACTTAATCA (SEQ ID NO: 703)

transcription

TCCTAACCAACTCTAACTTGCCTGA (SEQ ID NO: 704)

complex, subunit 7

AGGACCACAACATCAGGCAGGATCT (SEQ ID NO: 705)

GGCAGGATCTGATTCATTGCTCACA (SEQ ID NO: 706)

TGCTCACAGGAATGGCCTTTTTCAA (SEQ ID NO: 707)

GTGGTCATTTGTATGGCCTTGGTTC (SEQ ID NO: 708)

CCTTGGTTCTGGTTCATCCTATGTA (SEQ ID NO: 709)

ATTTCGAGCTACACACATGCTTGTA (SEQ ID NO: 710)

GTTTTATCTCTGGTTGAATCCCTCG (SEQ ID NO: 711)

GAATCCCTCGAACAATAGACAGTAC (SEQ ID NO: 712)

CATGGCCCATTTTATTGTCTGCCTT (SEQ ID NO: 713)

209796_s_at
CNPY2
MGC156825,
canopy 2 homolog
10330
TGGAGCGACCCCATTACGCTAAAGA (SEQ ID NO: 714)

Tmem4
(zebrafish)

GAGCGACCCCATTACGCTAAAGATG (SEQ ID NO: 715)

GACCCCATTACGCTAAAGATGAAAG (SEQ ID NO: 716)

GAGCCAGGATCTCCACTGTGGAGCA (SEQ ID NO: 717)

GAATGGGAAATTGCCCAGGTGGACC (SEQ ID NO: 718)

ACCCCAAGAAGACCATTCAGATGGG (SEQ ID NO: 719)

GACCATTCAGATGGGATCTTTCCGG (SEQ ID NO: 720)

GATGGGATCTTTCCGGATCAATCCA (SEQ ID NO: 721)

GGATCTTTCCGGATCAATCCAGATG (SEQ ID NO: 722)

TTTCCGGATCAATCCAGATGGCAGC (SEQ ID NO: 723)

TCCAGATGGCAGCCAGTCAGTGGTG (SEQ ID NO: 724)

213050_at
COBL
DKFZp686G13227,
cordon-bleu homolog
23242
GCCATTCCCCAGGCTATGAAGTGAC (SEQ ID NO: 725)

KIAA0633,
(mouse)

GCCTGTGTACGGAGCCTGATGACTT (SEQ ID NO: 726)

MGC131893

TCACTGGGAGCCTTCTGGAATCCTG (SEQ ID NO: 727)

CAGGGATGTTGGATGCCCACCTGTC (SEQ ID NO: 728)

AATTTTGGTTCAGCCTTGACGCGTT (SEQ ID NO: 729)

TTGACGCGTTTGTCCAACAGCTCAT (SEQ ID NO: 730)

TTGGCTCCCTTTGTATGATATCGTG (SEQ ID NO: 731)

AATGTTTCACAGCGATCTCAGATCT (SEQ ID NO: 732)

TGGAAGCTGTTCTGCATTCACTGAT (SEQ ID NO: 733)

GAGCTACCAGCCAATTGCTCTTCAT (SEQ ID NO: 734)

AGCTATCTGTCTTTTAGTGCCACAA (SEQ ID NO: 735)

206441_s_at
COMMD4
FLJ20452
COMM domain
54939
GGAGCTGCTGGGACAGGGGATTGAT (SEQ ID NO: 736)

containing 4

AGCTCACGGCTGACGCCAAGTTTGA (SEQ ID NO: 737)

TCCAGTGCGGCCAAGCACAGTGTCG (SEQ ID NO: 738)

AGTGTCGATGGCGAATCCTTGTCCA (SEQ ID NO: 739)

TCCTTGTCCAGTGAACTGCAGCAGC (SEQ ID NO: 740)

AGCTGGGGCTGCCCAAAGAGCACGC (SEQ ID NO: 741)

CCAGCCTGTGCCGCTGTTATGAGGA (SEQ ID NO: 742)

CAAAGCCCCTTGCAGAAGCACTTGC (SEQ ID NO: 743)

TGAACTGCTCTTCGGGAGGCAGCCC (SEQ ID NO: 744)

GCCCTGGTTCTAGGATGCTGAGGCC (SEQ ID NO: 745)

GCCTCACTTCTCTCTTGAGAACTTG (SEQ ID NO: 746)

202078_at
COPS3
SGN3
COP9 constitutive
8533
GACCTTTTTAACTCTATCATTACAA (SEQ ID NO: 747)

photomorphogenic

ATGGCAAGTCGTGTGCAGTTGTCTG (SEQ ID NO: 748)

homolog subunit 3

TGTGCAGTTGTCTGGACCTCAGGAG (SEQ ID NO: 749)

(Arabidopsis)

TGGTCAGTTTCCATGATAACCCTGA (SEQ ID NO: 750)

ATAACCCAGCCATGCTTCATAACAT (SEQ ID NO: 751)

GGAGATCACAGTGAACCCTCAGTTT (SEQ ID NO: 752)

GAAACAAACCATCCAGTTATTCTTG (SEQ ID NO: 753)

AAGAGAAACTACCATCTTGGCCAGT (SEQ ID NO: 754)

GTGACAAGTGTTCGGAGGGCAGCAG (SEQ ID NO: 755)

CAGAGAGGACCAAGCCTGTGTCACC (SEQ ID NO: 756)

TTGACATCTTCAGTCCTGTGTGCTT (SEQ ID NO: 757)

218328_at
COQ4
OSTLU_119511
coenzyme Q4
51117
AAGTGCTGGTCTCGGAGTTGATCCC (SEQ ID NO: 758)

homolog (S. cerevisiae)

GTTGATCCCATGGGCCGTTCAGAAC (SEQ ID NO: 759)

AACGGGCGCAGAGCCCATTGTGTCC (SEQ ID NO: 760)

CAACCTGTACTATGAGCGGCGCTGG (SEQ ID NO: 761)

AGGAGCTGGGCATTACAGCACCACC (SEQ ID NO: 762)

TCTTCTTTGAACACTGACCCTTGGA (SEQ ID NO: 763)

CTGAGTGGCCTTGAGGACGAACCCC (SEQ ID NO: 764)

GCAAGCAGTACAGTGGCATTCCCAG (SEQ ID NO: 765)

GAACAGTATCAGTCGTCTGGGCTCA (SEQ ID NO: 766)

ATTGTGCAGTGCTCCTGTTGCAACT (SEQ ID NO: 767)

GGAGTGAGGGCTACACCCAATTCCA (SEQ ID NO: 768)

203663_s_at
COX5A
COX, COX-VA,
cytochrome c oxidase
9377
GTTTGATGCTCGCTGGGTAACATAC (SEQ ID NO: 769)

VA
subunit Va

TGCTCGCTGGGTAACATACTTCAAC (SEQ ID NO: 770)

AACACACTTGTTACCTATGATATGG (SEQ ID NO: 771)

CCTATGATATGGTTCCAGAGCCCAA (SEQ ID NO: 772)

CGGAGGAACTGGGCCTTGACAAAGT (SEQ ID NO: 773)

GGGCCTTGACAAAGTGTAAACCGCA (SEQ ID NO: 774)

GTAAACCGCATGGATGGGCTTCCCC (SEQ ID NO: 775)

GGCTTCCCCAAGGATTTATTGACAT (SEQ ID NO: 776)

TTGCTACTTGAGTGTGAACAGTTAC (SEQ ID NO: 777)

GAACAGTTACCTGGAAATACTGATG (SEQ ID NO: 778)

CCTTTATTGAGTACCAAGCCATGTA (SEQ ID NO: 779)

218871_x_at
CSGALNACT2
CSGalNAcT-2,
chondroitin sulfate N-
55454
AAAATCATTACTCTTTTTCTCAGTA (SEQ ID NO: 780)

DKFZp686H13226,
acetylgalactosaminyltransferase 2

AATATTACAATAACTCTTACCTAAT (SEQ ID NO: 781)

FLJ43310,

TAACTCTTACCTAATTATTCTTACA (SEQ ID NO: 782)

GALNACT-2,

AGATGTGTGAAATGTTCTCTGCAAA (SEQ ID NO: 783)

GALNACT2,

AATAATTCAGGCCACTGTCTCCTTT (SEQ ID NO: 784)

MGC40204,

GCCACTGTCTCCTTTTATATATTAT (SEQ ID NO: 785)

PRO0082

GAAGACCAGTGAATTACGATATTTA (SEQ ID NO: 786)

GGTAAGTTACAGCTTGTTTTTTGAG (SEQ ID NO: 787)

ATGAGTTTACTTTTGTTCCTGTTGT (SEQ ID NO: 788)

TGTTCCTGTTGTTTTTAACTAGCTT (SEQ ID NO: 789)

ATGGAAATGCTATACGTTTTTGACA (SEQ ID NO: 790)

222235_s_at
CSGALNACT2
CSGalNAcT-2,
chondroitin sulfate N-
55454
ATATTCAGATAGGACTGCACTACAT (SEQ ID NO: 791)

DKFZp686H13226,
acetylgalactosaminyltransferase 2

CAGATAGGACTGCACTACATTATTT (SEQ ID NO: 792)

FLJ43310,

ATCTGTTACCATCAGGTCAATTCCT (SEQ ID NO: 793)

GALNACT-2,

GTTACCATCAGGTCAATTCCTAGTA (SEQ ID NO: 794)

GALNACT2,

AGGTCAATTCCTAGTATGCATAAAT (SEQ ID NO: 795)

MGC40204,

GAGACCTATGTTGAAAACCCCTGAA (SEQ ID NO: 796)

PRO0082

TTTTTCTCAGTAAATCATATCATCT (SEQ ID NO: 797)

ATTTCTAGGTGCTATATTAATTCAA (SEQ ID NO: 798)

TGTGAAATGTTCTCTGCAAAATAAT (SEQ ID NO: 799)

GCAAAATAATTCAGGCCACTGTCTC (SEQ ID NO: 800)

TTTGCAAAGGTAAGTTACAGCTTGT (SEQ ID NO: 801)

202156_s_at
CUGBP2
BRUNOL3, ETR-
CUG triplet repeat,
10659
ATTTCTAAGACCATTTCATTCTGAA (SEQ ID NO: 802)

3, NAPOR
RNA binding protein 2

TCTGAAACTTCTTATCAATTACCTA (SEQ ID NO: 803)

TTTCTTCTTCACAAGTCACCAAGAG (SEQ ID NO: 804)

TTCTCCAAAAAATAACCTTCCACAG (SEQ ID NO: 805)

AGAGACAAACTGTCCTTCTATCCAC (SEQ ID NO: 806)

CTTCTATCCACTTTTATCTTTTAAT (SEQ ID NO: 807)

GCAAGGGTGCAAAGGGCCTGTGCCA (SEQ ID NO: 808)

GATACAATGGCAGTCCTCAAAGGCG (SEQ ID NO: 809)

AAGGCGTAACGAGTTCATCTTTCTT (SEQ ID NO: 810)

TCATCTTTCTTTCACCATAGGGGTT (SEQ ID NO: 811)

ATAGTTGGCTTGTGCTACTCTGGAA (SEQ ID NO: 812)

204533_at
CXCL10
C7, IFI10, INP10,
chemokine (C—X—C
3627
TAACTCTACCCTGGCACTATAATGT (SEQ ID NO: 813)

IP-10, SCYB10,
motif) ligand 10

GCTCTACTGAGGTGCTATGTTCTTA (SEQ ID NO: 814)

crg-2, gIP-10,

TCTTAGTGGATGTTCTGACCCTGCT (SEQ ID NO: 815)

mob-1

TCTGACCCTGCTTCAAATATTTCCC (SEQ ID NO: 816)

GGTACTAAGGAATCTTTCTGCTTTG (SEQ ID NO: 817)

GCTTTGGGGTTTATCAGAATTCTCA (SEQ ID NO: 818)

AATGCTCTTTACTTCATGGACTTCC (SEQ ID NO: 819)

TTACTTCATGGACTTCCACTGCCAT (SEQ ID NO: 820)

ATTCTTTCAGTGGCTACCTACATAC (SEQ ID NO: 821)

GCTACCTACATACAATTCCAAACAC (SEQ ID NO: 822)

AATGAGGTACTCTCCTGGAAATATT (SEQ ID NO: 823)

210163_at
CXCL11
H174, I-TAC, IP-
chemokine (C—X—C
6373
TTCTTTCCCCAAATATCATGTAGCA (SEQ ID NO: 824)

9, IP9,
motif) ligand 11

GAAACATTCTTATGCATCATTTGGT (SEQ ID NO: 825)

MGC102770,

TACGCTATGGGATACTGGCAACAGT (SEQ ID NO: 826)

SCYB11,

GCAACAGTGCACATATTTCATAACC (SEQ ID NO: 827)

SCYB9B, b-R1

TTCATAACCAAATTAGCAGCACCGG (SEQ ID NO: 828)

GCAGCACCGGTCTTAATTTGATGTT (SEQ ID NO: 829)

GGATATGTGTGTTTACTGTACTTTT (SEQ ID NO: 830)

TTTGTTTTGATCCGTTTGTATAAAT (SEQ ID NO: 831)

GATAGCAATATCTTGGACACATTTG (SEQ ID NO: 832)

ATACCTAGCAATCACTTTTACTTTT (SEQ ID NO: 833)

TTTTACTTTTTGTAATTCTGTCTCT (SEQ ID NO: 834)

211122_s_at
CXCL11
H174, I-TAC, IP-
chemokine (C—X—C
6373
GAGACTTTTCTATGGTTTTGTGACT (SEQ ID NO: 835)

9, IP9,
motif) ligand 11

GTGACTTTCAACTTTTGTACAGTTA (SEQ ID NO: 836)

MGC102770,

GACAATCAGAATTCCACTGCCCAAA (SEQ ID NO: 837)

SCYB11,

GGCTGGTTACCATCGGAGTTTACAA (SEQ ID NO: 838)

SCYB9B, b-R1

TGCTTTCACGTTCTTACTTGTTGTA (SEQ ID NO: 839)

TACATTCATGCATTTCTAGGCTAGA (SEQ ID NO: 840)

AGAGAACCTTCTAGATTTGATGCTT (SEQ ID NO: 841)

GTCTCTAGAAGTTATCTGTCTGTAT (SEQ ID NO: 842)

CTGTCTGTATTGATCTTTATGCTAT (SEQ ID NO: 843)

GCTATATTACTATCTGTGGTTACAG (SEQ ID NO: 844)

TACTGGAGTCAAGCCCTTATAAGTC (SEQ ID NO: 845)

209774_x_at
CXCL2
CINC-2a, GROb,
chemokine (C—X—C
2920
AGAGAGACACAGCTGCAGAGGCCAC (SEQ ID NO: 846)

Gro2, MIP-2,
motif) ligand 2

ACCTGGATTGCGCCTAATGTGTTTG (SEQ ID NO: 847)

MIP-2a, Mgsa-b,

TGATTGAATCTACTTGCACACTCTC (SEQ ID NO: 848)

Mip2, Scyb,

GCACACTCTCCCATTATATTTATTG (SEQ ID NO: 849)

Scyb2

AACCCAAGTTAGTTCAATCCTGATT (SEQ ID NO: 850)

GAAGGTTTGCAGATATTCTCTAGTC (SEQ ID NO: 851)

GACATATCACATGTCAGCCACTGTG (SEQ ID NO: 852)

ATGGCCAGTAAGATCAATGTGACGG (SEQ ID NO: 853)

TGTGACGGCAGGGAAATGTATGTGT (SEQ ID NO: 854)

CAGTGTGTGGTCAACATTTCTCATG (SEQ ID NO: 855)

ATGTTAATTATGCAGTGTTTCCCTC (SEQ ID NO: 856)

217200_x_at
CYB561
FRRS2
cytochrome b-561
1534
CTGCTGCCTCTGTTCTGGAGGACGA (SEQ ID NO: 857)

TTCTGGAGGACGAGCCTTCTCCTTA (SEQ ID NO: 858)

GCTGCCCATCTTTCCAGGAAGTCAG (SEQ ID NO: 859)

AGTCAGACAACTAACGATCATCCCC (SEQ ID NO: 860)

ACATCACTCCAGCCCCATAAAGAGT (SEQ ID NO: 861)

GTGTCATGTTAGCTGAGTCACCATT (SEQ ID NO: 862)

TCACCATTTGGCTTCGGCCTGGAAA (SEQ ID NO: 863)

ACACTGATCGTGTGCGAGGCCAGGA (SEQ ID NO: 864)

AAGACCATCCTGACTAACAAACACA (SEQ ID NO: 865)

GTCTCTACGGAATTCCCTGTATTAG (SEQ ID NO: 866)

GGATGCCTTTTCTGTGATTGGGTGG (SEQ ID NO: 867)

201634_s_at
CYB5B
CYB5-M,
cytochrome b5 type B
80777
GTGGTGCCGGACAAAAAACTACATG (SEQ ID NO: 868)

CYPB5M,
(outer mitochondrial

CAAAAAACTACATGGCCCTTTCGTG (SEQ ID NO: 869)

DKFZp686M0619,
membrane)

GGGAGGGATGAATTGGGGTGATAGA (SEQ ID NO: 870)

OMB5

GGTGATAGAACCCTGGTGAATTCAG (SEQ ID NO: 871)

GTGAATTCAGAGTAATCTTTCTTTA (SEQ ID NO: 872)

GATAGGAGTTTAGAGAAGGCACCAA (SEQ ID NO: 873)

GAAGGCACCAAAGCTTTCACTTTGG (SEQ ID NO: 874)

CAAAGCTTTCACTTTGGTTTGGCAC (SEQ ID NO: 875)

CCTAGCTATCTTTTATTGGTAAAAT (SEQ ID NO: 876)

TGTATAATTATGTTTGTAGAGCTTT (SEQ ID NO: 877)

GTTTGTAGAGCTTTACCAAGGAGTT (SEQ ID NO: 878)

200794_x_at
DAZAP2
KIAA0058,
DAZ associated
9802
ATAGGTTGTCTCTGCATACACGAAC (SEQ ID NO: 879)

MGC14319,
protein 2

TACACGAACCTAACCCAAATTTGCT (SEQ ID NO: 880)

MGC766

GATGTCGTGCAAACTGTACTGTGAA (SEQ ID NO: 881)

GAGGAGGATGCATTTCAAAAGCTTG (SEQ ID NO: 882)

GGTTACCATTTTTTGTCAGAGTGTC (SEQ ID NO: 883)

AGAGTGTCTGATGCGGCCACTCATT (SEQ ID NO: 884)

GGCTCCCCAGAATTCCTAGACTGGG (SEQ ID NO: 885)

AATGACTTGAGTCCAGTGAAATCTC (SEQ ID NO: 886)

GTTTGACTGTACCATTGACTGTTAT (SEQ ID NO: 887)

AAGTTCAGCGTTGTATGTCTCTCTC (SEQ ID NO: 888)

CTCTCTCTACACTGTGGTGCACTTA (SEQ ID NO: 889)

208675_s_at
DDOST
AGE-R1,
dolichyl-
1650
CATCGTGATCCAGCAGCTCTCAAAT (SEQ ID NO: 890)

KIAA0115,
diphosphooligosaccharide-

CTCAAATGGCAAATGGGTCCCCTTT (SEQ ID NO: 891)

MGC2191,
protein

GGTCCCCTTTGATGGCGATGACATT (SEQ ID NO: 892)

OK/SW-cl.45,
glycosyltransferase

GGAGTTTGTCCGCATTGATCCTTTT (SEQ ID NO: 893)

OST, OST48,

GATCCTTTTGTGAGGACCTTCCTGA (SEQ ID NO: 894)

WBP1

ACAGTGTTCAGTTCAAGTTGCCCGA (SEQ ID NO: 895)

GTTGCCCGACGTGTATGGTGTATTC (SEQ ID NO: 896)

GATTACAACCGGCTAGGCTACACAC (SEQ ID NO: 897)

CCTGTACTCTTCCACTCAGGTATCC (SEQ ID NO: 898)

CACACGCAGTATGAGCGCTTCATCC (SEQ ID NO: 899)

ATGGCACAACTTTACCTCTGTGGGA (SEQ ID NO: 900)

201440_at
DDX23
MGC8416,
DEAD (Asp-Glu-Ala-
9416
AGGACGACGCTGTCGGAGGCAGGGA (SEQ ID NO: 901)

PRPF28, U5-
Asp) box polypeptide

GAGAGCAAATTACCACAGCTTCTTG (SEQ ID NO: 902)

100K, U5-100KD,
23

TTTGGGATTGCACTGGGCCATCAGC (SEQ ID NO: 903)

prp28

CCATCAGCTCATGCCAGGCTATGGG (SEQ ID NO: 904)

TGGGGGCAGCCAGTTGGCATTGCTC (SEQ ID NO: 905)

CATTGCTCCCCAGACTGAACAGAAA (SEQ ID NO: 906)

ACTGCAGTAGCATCATTGCCCTAGA (SEQ ID NO: 907)

GTCATCTGGACAGCTGTTTTCCTGT (SEQ ID NO: 908)

AGAGTCTTTAGACCTGTGCACAGCC (SEQ ID NO: 909)

CCAAGGGGTGCTGTATGCTCTAGGC (SEQ ID NO: 910)

TGAACTGGCTGTGTCCATCTTTGTC (SEQ ID NO: 911)

221885_at
DENND2A
FAM31D,
DENN/MADD domain
27147
TTGTGGGACACTACTCTTTGTTCCT (SEQ ID NO: 912)

KIAA1277
containing 2A

CCTGACGTCGGGCGAGCGTGAGGAG (SEQ ID NO: 913)

GCGTGAGGAGAGAACCCTGCAGCGG (SEQ ID NO: 914)

TGGAGACTCAGATGTTTCGGGGCTT (SEQ ID NO: 915)

TCTGTTTGAGGTCCGAGCCCAAGAG (SEQ ID NO: 916)

AACACTCCCCAGTGGAGAGCACAGC (SEQ ID NO: 917)

AAGGGAAAACTTCCTCCTAGTGCAG (SEQ ID NO: 918)

CCTTTCTGAAAGGCTGGGTCCCAGG (SEQ ID NO: 919)

TCCCAGGTTGTCACGGTGCGGAACT (SEQ ID NO: 920)

AGAAAGGGAGCCCGAGACCAGGCGT (SEQ ID NO: 921)

GTGTCGCCGACATGCAAATGGGTTG (SEQ ID NO: 922)

53991_at
DENND2A
FAM31D,
DENN/MADD domain
27147
TTTGTTCCTGACGTCGGGCGAGCGT (SEQ ID NO: 923)

KIAA1277
containing 2A

GAGGCCTTCCGCAAAGCTGTCTCCT (SEQ ID NO: 924)

TGGAGACTCAGATGTTTCGGGGCTT (SEQ ID NO: 925)

GGTCCGAGCCCAAGAGTATCTGGAA (SEQ ID NO: 926)

GAGCACAGCGGTGTCAATAAGTTCC (SEQ ID NO: 927)

GTCAATAAGTTCCTGAAGGGACTAG (SEQ ID NO: 928)

TTCCTGAAGGGACTAGGCAATAAAA (SEQ ID NO: 929)

CAAGAAATAACTCTCAGCCTCAAGG (SEQ ID NO: 930)

TAACTCTCAGCCTCAAGGGAAAACT (SEQ ID NO: 931)

GGAAAACTTCCTCCTAGTGCAGCCC (SEQ ID NO: 932)

GTCCCAGGTTGTCACGGTGCGGAAC (SEQ ID NO: 933)

TCCCAGGTTGTCACGGTGCGGAACT (SEQ ID NO: 934)

TCTGGCCGAGGCTGGGCTCTTCCCT (SEQ ID NO: 935)

GGGCTCTTCCCTGGATGAGGACCTG (SEQ ID NO: 936)

CGTGTCGCCGACATGCAAATGGGTT (SEQ ID NO: 937)

GCCGACATGCAAATGGGTTGTTTTG (SEQ ID NO: 938)

221081_s_at
DENND2D
FLJ22457, RP5-
DENN/MADD domain
79961
TTCTCACTTTTCATCCAGGAAGCCG (SEQ ID NO: 939)

1180E21.2
containing 2D

AAGAGCAAGAATCCTCCTGCAGGCT (SEQ ID NO: 940)

GAGCTACACACCATTTCTGGACTTC (SEQ ID NO: 941)

GGATCAGCAAAACTGTCAGCTCCCA (SEQ ID NO: 942)

ATCCTCACTCTGAGTCTTGGTATCC (SEQ ID NO: 943)

GGTGTCTGAGATTTGGATCCCTGGT (SEQ ID NO: 944)

GACACCATGCTCACAGAACTGGGCT (SEQ ID NO: 945)

GGCTCAGAGCTCCATTTTTTGCAGA (SEQ ID NO: 946)

TGGTTAGAAGCTGCTGCAACTGCCC (SEQ ID NO: 947)

TTTGTGGTCGAAAGGCTCAGCCTCT (SEQ ID NO: 948)

GCTCAGCCTCTCTACATGAAGTCTG (SEQ ID NO: 949)

218021_at
DHRS4 ///
NRDR;
dehydrogenase/reductase
10901
CAGGATGCTCTGGATGGACAAGGAA (SEQ ID NO: 950)

DHRS4L2
DHRS4L2; SDR-
(SDR family)
317749
GCGGATAAGAAGGTTAGGCGAGCCA (SEQ ID NO: 951)

SRL; humNRDR;
member 4 ///

TTAGGCGAGCCAGAGGATTGTGCTG (SEQ ID NO: 952)

FLJ11008;
dehydrogenase/reductase

GTCTTTCCTGTGCTCTGAAGATGCC (SEQ ID NO: 953)

SCAD-SRL ///
(SDR family)

GAAGATGCCAGCTACATCACTGGGG (SEQ ID NO: 954)

MGC905
member 4 like 2

GTCCCGCCTCTGAGGACCGGGAGAC (SEQ ID NO: 955)

CCTTACTGTTCACCTCATCAAATCA (SEQ ID NO: 956)

CCTCATCAAATCAGTTCTGCCCTGT (SEQ ID NO: 957)

CTGCCGTCAAGGTGGCGTCTTACTC (SEQ ID NO: 958)

TGTTGTGGCCTTGGGTAAAGGCCTC (SEQ ID NO: 959)

CCTCCCCTGAGAACACAGGACAGGC (SEQ ID NO: 960)

201385_at
DHX15
DBP1, DDX15,
DEAH (Asp-Glu-Ala-
1665
AAGTTCGAGTTGTGCTCTTCACGTT (SEQ ID NO: 961)

HRH2, PRP43,
His) box polypeptide

TGTGCTCTTCACGTTGGTTCGATAA (SEQ ID NO: 962)

PRPF43,
15

CACGTTGGTTCGATAATGGCCTTTA (SEQ ID NO: 963)

PrPp43p

GTAAATATTCCATTCTGATTTCATA (SEQ ID NO: 964)

ATTAAACATTTATGCCTCCCTTTTG (SEQ ID NO: 965)

CCTCCCTTTTGTGTTGACACTGTAG (SEQ ID NO: 966)

GTTGACACTGTAGCTCATACTGGAA (SEQ ID NO: 967)

GTGATTATCGACCATGGTATGCATG (SEQ ID NO: 968)

GGTATGCATGATCGTTGTAATTGTT (SEQ ID NO: 969)

TTTTTTGTTTCAGTACCAGAGGCAC (SEQ ID NO: 970)

GTACCAGAGGCACTGACTTCAATAA (SEQ ID NO: 971)

201386_s_at
DHX15
DBP1, DDX15,
DEAH (Asp-Glu-Ala-
1665
GGAGATCATCTGACACTGCTGAACG (SEQ ID NO: 972)

HRH2, PRP43,
His) box polypeptide

TGCTGAACGTCTACCATGCTTTTAA (SEQ ID NO: 973)

PRPF43,
15

CAACTTCATTAACTACAGGTCCCTG (SEQ ID NO: 974)

PrPp43p

GTACGCCAGCAGCTATCTCGAATTA (SEQ ID NO: 975)

GATTTAATTTGCCTCGTCGAAGTAC (SEQ ID NO: 976)

GCAGGTGGCACATTTAGAACGAACA (SEQ ID NO: 977)

AACCAGGTGGTTCAGTTGCATCCCT (SEQ ID NO: 978)

CCTCTACTGTTCTTGACCACAAACC (SEQ ID NO: 979)

GGTTGGTGAAAATTGCCCCTCAATA (SEQ ID NO: 980)

ATGACATGAGCAATTTCCCACAGTG (SEQ ID NO: 981)

GAGACAGTTGGACCGCATCATTGCC (SEQ ID NO: 982)

210469_at
DLG5
RP13-39P12.4,
discs, large homolog
9231
AGAGGCTTCCTAAGGCTGTTTTCTT (SEQ ID NO: 983)

KIAA0583, LP-
5 (Drosophila)

TTTCTTAGCCGTGGAGAAGCCCGCA (SEQ ID NO: 984)

DLG, P-DLG5,

CTACATGCTCCCAAGTGCTGTCATG (SEQ ID NO: 985)

PDLG

CATGAGCACGTTCCTGACAAGTCAG (SEQ ID NO: 986)

AGTCAGGTGTTCAGATTGCAGTCCC (SEQ ID NO: 987)

GGCCAACGTCAGGATTCTTACAGGT (SEQ ID NO: 988)

GAATGTTAAGCTCACCGATCTTGGC (SEQ ID NO: 989)

TGCCTGCTCATTTTCACACGTGCAG (SEQ ID NO: 990)

GCAGTGGTGGGTCTGTCTCATAGCA (SEQ ID NO: 991)

GTGGGCAGCGGAGGCTAGGGGCCCA (SEQ ID NO: 992)

GGCAGTCCCGTTTTGCAGCGGGATT (SEQ ID NO: 993)

203301_s_at
DMTF1
DMP1, DMTF,
cyclin D binding myb-
9988
GTAACAAAACCCACCAGAATCTAAG (SEQ ID NO: 994)

FLJ41265,
like transcription

CAGAATCTAAGCAGTTTTCACCCCC (SEQ ID NO: 995)

hDMP1
factor 1

CCCCCTCAGAAACCACTGTCATTAG (SEQ ID NO: 996)

AGTAATGTTACCTATCCTTGATACC (SEQ ID NO: 997)

CTATCCTTGATACCATGACCATTTA (SEQ ID NO: 998)

GAATAGTTTGTCATCCACTTAGTGT (SEQ ID NO: 999)

CTTAGTGTGTTAGCTGGTGGGGTAC (SEQ ID NO: 1000)

GGGGTACAATATAACCTCTCATCTC (SEQ ID NO: 1001)

CTAAGAATCATTCCTGTACTACAGA (SEQ ID NO: 1002)

GATCTTCACAAAGTTGTCTTTTCAC (SEQ ID NO: 1003)

CACTGTGTTTTGTCAACGTGAAATT (SEQ ID NO: 1004)

222070_at
DND1
RBMS4;
dead end homolog 1
373863
TGCTGGGACAGGGACCTATGGCACC (SEQ ID NO: 1005)

MGC34750
(zebrafish)

GGCAGCTTAGGTTTGGGTTAAGTTG (SEQ ID NO: 1006)

TAAGTTGTGGTGAGGGGCCTTGCCC (SEQ ID NO: 1007)

GGGTCCAACCTGACCCAGTGATCTT (SEQ ID NO: 1008)

TTCTTTATTGTCCTGATTTGTCCTC (SEQ ID NO: 1009)

TGATTTGTCCTCTTTGTTGGTTTTT (SEQ ID NO: 1010)

GAAGGGCAGCTGAGCCAAAGGGGTC (SEQ ID NO: 1011)

GGGTCAGAAATTCTGCCCTTTGCCT (SEQ ID NO: 1012)

CCTCCACCACATGGCATTCTGGTTT (SEQ ID NO: 1013)

CATGGCATTCTGGTTTTGGTTTCTG (SEQ ID NO: 1014)

GGTCTTTCTATGCTGGTTGTATTTA (SEQ ID NO: 1015)

57739_at
DND1
RBMS4;
dead end homolog 1
373863
TCAGCCTCCCTGCTGGGACAGGGAC (SEQ ID NO: 1016)

MGC34750
(zebrafish)

CCCTGCTGGGACAGGGACCTATGGC (SEQ ID NO: 1017)

AGCTTAGCATGAATCTTCTTTATTG (SEQ ID NO: 1018)

GCTTAGCATGAATCTTCTTTATTGT (SEQ ID NO: 1019)

AGCATGAATCTTCTTTATTGTCCTG (SEQ ID NO: 1020)

GCATGAATCTTCTTTATTGTCCTGA (SEQ ID NO: 1021)

GCAGCTGAGCCAAAGGGGTCAGAAA (SEQ ID NO: 1022)

GGGTCAGAAATTCTGCCCTTTGCCT (SEQ ID NO: 1023)

GGTCAGAAATTCTGCCCTTTGCCTC (SEQ ID NO: 1024)

CCACCACATGGCATTCTGGTTTTGG (SEQ ID NO: 1025)

CACCACATGGCATTCTGGTTTTGGT (SEQ ID NO: 1026)

ACCACATGGCATTCTGGTTTTGGTT (SEQ ID NO: 1027)

CCACATGGCATTCTGGTTTTGGTTT (SEQ ID NO: 1028)

CACATGGCATTCTGGTTTTGGTTTC (SEQ ID NO: 1029)

ACATGGCATTCTGGTTTTGGTTTCT (SEQ ID NO: 1030)

CATGGCATTCTGGTTTTGGTTTCTG (SEQ ID NO: 1031)

212538_at
DOCK9
RP11-155N3.2,
dedicator of
23348
GTGAACCAGGAGATTTAGTGCTTTT (SEQ ID NO: 1032)

DKFZp686C11110,
cytokinesis 9

AAGCAGTTTAGAACCAAAGGCCTAT (SEQ ID NO: 1033)

DKFZp686D2047,

AAGGCCTATATTAATAACCGCAACT (SEQ ID NO: 1034)

DKFZp686N04132,

TAACCGCAACTATGCTGAAAAGTAC (SEQ ID NO: 1035)

FLJ11949,

ATCATTGTTAATACAGTCCTGGCAT (SEQ ID NO: 1036)

FLJ16744,

AGTCCTGGCATTCTGTACATATATG (SEQ ID NO: 1037)

FLJ44528,

AATACTCACATGGGCTTATGCATTA (SEQ ID NO: 1038)

FLJ45282,

TGTGCTGTTCCAGTATATGCAATAC (SEQ ID NO: 1039)

FLJ45601,

GGAGATGTATACAGTCTTTACTATA (SEQ ID NO: 1040)

KIAA1058,

AATCCTGTGGTGAATGGTGGTGTAC (SEQ ID NO: 1041)

KIAA1085, ZIZ1,

AGCTGTCACCATGTTATATTTTCTT (SEQ ID NO: 1042)

ZIZIMIN1

205595_at
DSG3
CDHF6,
desmoglein 3
1830
CCATCCCATAGAAGTCCAGCAGACA (SEQ ID NO: 1043)

DKFZp686P23184,
(pemphigus vulgaris

AGTCAAGGAGCTTCTGCTTTGTCCG (SEQ ID NO: 1044)

PVA
antigen)

CTGACCCTCTGCAGCATGGTAACTA (SEQ ID NO: 1045)

AGTAACGGAGACTTACTCGGCTTCT (SEQ ID NO: 1046)

AGAAAGGGTGATCTGTCCCATTTCC (SEQ ID NO: 1047)

CCATTTCCAGTGTTCCTGGCAACCT (SEQ ID NO: 1048)

GCCCAACGCAGCTACGAGGGTCACA (SEQ ID NO: 1049)

GAGGGTCACATACTATGCTCTGTAC (SEQ ID NO: 1050)

CCTTGCTCCCGTCTAATATGACCAG (SEQ ID NO: 1051)

TGAGCTGGAATACCACACTGACCAA (SEQ ID NO: 1052)

GTTGTCACTCCTAATTCTCAAGTAC (SEQ ID NO: 1053)

201323_at
EBNA1BP2
EBP2, NOBP,
EBNA1 binding
10969
TGGATTTCCTTGAGGGAGATCAGAA (SEQ ID NO: 1054)

P40
protein 2

AAACCTCTGGCACAGCGCAAGAAGG (SEQ ID NO: 1055)

GGAGCCAAAGGCCAGCAGATGAGGA (SEQ ID NO: 1056)

GGCTCAAAGTGGAACACTCGGGAGA (SEQ ID NO: 1057)

CTTCCGGGCCAAGACAGCTCATGGC (SEQ ID NO: 1058)

GACAGCTCATGGCAGAGGCCTCAAG (SEQ ID NO: 1059)

GCCTCAAGAGGCCTGGCAAGAAAGG (SEQ ID NO: 1060)

GACTCGCAATTTCACGACACACTTT (SEQ ID NO: 1061)

ACACTTTGATCCCTTCTGTTGGTGT (SEQ ID NO: 1062)

GAAGTTACTTTCCATTGCTATCTAT (SEQ ID NO: 1063)

AGACATTGAGTTCAAATTGCCTTCA (SEQ ID NO: 1064)

200789_at
ECH1
HPXEL
enoyl Coenzyme A
1891
ATGTAGGAACACTGGAGCGCCTGCC (SEQ ID NO: 1065)

hydratase 1,

AGGTCATCGGGAACCAGAGCCTGGT (SEQ ID NO: 1066)

peroxisomal

CCAGAGCCTGGTCAACGAGCTGGCC (SEQ ID NO: 1067)

CCTTCACCGCCCACAAGATGATGGC (SEQ ID NO: 1068)

GCTGACGAGGCCCTGGACAGTGGGC (SEQ ID NO: 1069)

TCAGCCGGGTGTTCCCAGACAAAGA (SEQ ID NO: 1070)

GACCACCGTGTTGGTGCAGAGCACC (SEQ ID NO: 1071)

GCAGAGCACCAAGGTCAACCTGCTG (SEQ ID NO: 1072)

GAACATGAGCATGCTGCAGACCCAA (SEQ ID NO: 1073)

GTCCAGCCCACGACTGAGAACAAGG (SEQ ID NO: 1074)

GATGACAGTTGTTTCTATGCCTTCT (SEQ ID NO: 1075)

218973_at
EFTUD1
FAM42A,
elongation factor Tu
79631
CTGCAAGTGAAACCTCAGCGCCTGA (SEQ ID NO: 1076)

FLJ13119,
GTP binding domain

AGCGCCTGATGGCAGCTATGTACAC (SEQ ID NO: 1077)

HsT19294, RIA1
containing 1

ACTGGTGATGTTCTCGGTCGAGTCT (SEQ ID NO: 1078)

GTCGAGTCTATGCTGTCTTGTCAAA (SEQ ID NO: 1079)

GACATGTTCATCATCAAGGCTGTGC (SEQ ID NO: 1080)

GCCAGCCCACAACTAGTATTCAGCC (SEQ ID NO: 1081)

TGGGAGATCATTCCCAGTGACCCCT (SEQ ID NO: 1082)

CCCTTCTGGGTGCCAACTACTGAGG (SEQ ID NO: 1083)

TGACTCTGAGAACCAAGCCCGGAAG (SEQ ID NO: 1084)

AGCTACCTACTACTGGTGGATTCTT (SEQ ID NO: 1085)

GCCACATTATCTCTGTTTATTCACT (SEQ ID NO: 1086)

201984_s_at
EGFR
Dmel_CG10079,
epidermal growth
1956
CTCAAAGAGTATATGTTCCCTCCAG (SEQ ID NO: 1087)

C-erb, CG10079,
factor receptor

CCTCCTTACGCTTTGTCACACAAAA (SEQ ID NO: 1088)

D-EGFR, D-Egf,
(erythroblastic

AAAGTGTCTCTGCCTTGAGTCATCT (SEQ ID NO: 1089)

DER, DER flb,
leukemia viral (v-erb-

GAGTCATCTATTCAAGCACTTACAG (SEQ ID NO: 1090)

DER/EGFR,
b) oncogene

GCCACAACAGGGCATTTTACAGGTG (SEQ ID NO: 1091)

DER/faint little
homolog, avian)

GTGCCCTGTAACCTGACTGGTTAAC (SEQ ID NO: 1092)

ball, DER/top,

GGTTAACAGCAGTCCTTTGTAAACA (SEQ ID NO: 1093)

DER/torpedo,

TAAACTCTCCTAGTCAATATCCACC (SEQ ID NO: 1094)

Degfr, DmHD-33,

ATCCACCCCATCCAATTTATCAAGG (SEQ ID NO: 1095)

EFG-R, EGF-R,

TCAGCCTACAGTTATGTTCAGTCAC (SEQ ID NO: 1096)

EK2-6, Egf, El,

TGACTCCCAGATCAGTCAGAGCCCC (SEQ ID NO: 1097)

Elp, Elp-1, Elp-

B1, Elp-B1RB1,

HD-33,

Torpedo/DER,

Torpedo/Egfr, c-

erbB, d-egf-r,

dEGFR1, flb,

I(2)05351,

I(2)09261,

I(2)57DEFa,

I(2)57EFa,

I(2)57Ea, pnt,

top, top/DER,

top/flb

200595_s_at
EIF3A
EIF-3A
eukaryotic translation
8661
GAAGACCCTTTAAAGCAGTGAATCT (SEQ ID NO: 1098)

initiation factor 3,

GAAACAATTTTCACACCCTTAAGTG (SEQ ID NO: 1099)

subunit A

GTGGTTGATACGTACCTATTTTAGG (SEQ ID NO: 1100)

ATTACTGCGCAAGTGTGAATCCAAA (SEQ ID NO: 1101)

ATTATCGCTGAGTTTTTTTCTGTTG (SEQ ID NO: 1102)

ATAGCAAACTGCTTTTCCATTAATG (SEQ ID NO: 1103)

AATGGAGAATTCATGCCTTTCAAGC (SEQ ID NO: 1104)

GTAATGACTGTGTTGACTTCAATTT (SEQ ID NO: 1105)

GACTTCAATTTTGGAGCGCAGTAGC (SEQ ID NO: 1106)

TGAACTATTTGGTCTCATTGAAGCC (SEQ ID NO: 1107)

GGTCTCATTGAAGCCAACACAGAAC (SEQ ID NO: 1108)

221094_s_at
ELP3
FLJ10422, KAT9
elongation protein 3
55140
GGTGGCTGGGAAACATTCTTGTCAT (SEQ ID NO: 1109)

homolog (S. cerevisiae)

CAAGACATTTTGATTGGCCTCCTAC (SEQ ID NO: 1110)

GGCCTCCTACGATTACGCAAGTGTT (SEQ ID NO: 1111)

ATGGGTCTGGGAAAATCGCTGTGAT (SEQ ID NO: 1112)

GATATCAGGGGTCGGCACCAGGAAT (SEQ ID NO: 1113)

TCGGCTACAGATTACAAGGCCCGTA (SEQ ID NO: 1114)

AGATGCTGAAATAATGGCCACACCA (SEQ ID NO: 1115)

ATCCTCCCTGGCAGAACACGGAGAA (SEQ ID NO: 1116)

AGAGCAAATGGGGGGCTTCACCCTC (SEQ ID NO: 1117)

GAGACTGGAAACTGCCTTCAAGGCC (SEQ ID NO: 1118)

AAATCACTTGCGTTTTTGAGGCTTA (SEQ ID NO: 1119)

213895_at
EMP1
CL-20, EMP-1,
epithelial membrane
2012
AAGGACTGGTATCTTTCTGTGAGCA (SEQ ID NO: 1120)

TMP
protein 1

GATAAAGACTGCATATCCTTGTGTC (SEQ ID NO: 1121)

ATTGCATTGATTCTTGATGCTTTCT (SEQ ID NO: 1122)

GATGCTTTCTTAGAGGCCTACATGA (SEQ ID NO: 1123)

GATTTCTTAGATTGCTCTGATAAAC (SEQ ID NO: 1124)

AGAGGGAACTTTTGTCAGACTCTGC (SEQ ID NO: 1125)

CAGACTCTGCAACAAACTCCTAGCT (SEQ ID NO: 1126)

AACTCCTAGCTCTATCCAGAGTGTC (SEQ ID NO: 1127)

TCCAGAGTGTCCTCTGCTGCTAAGA (SEQ ID NO: 1128)

GTATCTTTCTCCTCAAAAGCCTGGA (SEQ ID NO: 1129)

GGGGGTGCATTAGTCAGAATTCTCC (SEQ ID NO: 1130)

214053_at
ERBB4
HER4,
v-erb-a erythroblastic
2066
ATTGGCCTGTGATTGTTTCTTTTTT (SEQ ID NO: 1131)

MGC138404,
leukemia viral

GTGATTCTGTGTTCAGCACTATTGT (SEQ ID NO: 1132)

p180erbB4
oncogene homolog 4

TGTGATGTGTTCAACCTCTGCACTC (SEQ ID NO: 1133)

(avian)

TTTTAGTATACTTTCTCTTATTCTT (SEQ ID NO: 1134)

TAGGCTTTTCCGTTAGTTCTCAAGG (SEQ ID NO: 1135)

TCAAGGATCCTCTTTTGGCTCTTGG (SEQ ID NO: 1136)

TAGAATGCGAACTGCTTTGCCTCAT (SEQ ID NO: 1137)

TTGCCTCATTCCATACTGATCATCC (SEQ ID NO: 1138)

TACTGATCATCCCAGCTGAACAATT (SEQ ID NO: 1139)

ATTTGAAAACTGTTCTGCCTTTTTG (SEQ ID NO: 1140)

TCTGCCTTTTTGTTACATGAATCTG (SEQ ID NO: 1141)

201216_at
ERP29
C12orf8, ERp28,
endoplasmic
10961
GACTTTGAGAACCCAGTCCCATACA (SEQ ID NO: 1142)

ERp31, PDI-DB
reticulum protein 29

TTAAGGTTGGAGCCATCCAGCGCTG (SEQ ID NO: 1143)

TACCTAGGTATGCCTGGTTGCCTGC (SEQ ID NO: 1144)

TGGCCGGGGAGTTCATCAGGGCCTC (SEQ ID NO: 1145)

GTGGGCCGAGCAATACCTGAAGATC (SEQ ID NO: 1146)

GACACGGATCGCCAGGCTGATTGAG (SEQ ID NO: 1147)

AAGAGCTTAAACATCCTGACTGCCT (SEQ ID NO: 1148)

AAGGCTGTCTGTGATTTTCCAGGGT (SEQ ID NO: 1149)

GAGGGGAGAGTTAACCTGCTGGCTG (SEQ ID NO: 1150)

CTGGCTGTGAGTCCCTTGTGGAATA (SEQ ID NO: 1151)

TGGTACTAACCCACGATTCTGAGCC (SEQ ID NO: 1152)

221911_at
ETV1
DKFZp781L0674,
ets variant gene 1
2115
TAATATTCTCTTTCATGCTGAATTT (SEQ ID NO: 1153)

ER81,

TGCTGAATTTACTATGACCATTTAT (SEQ ID NO: 1154)

MGC104699,

TAAGCAGTGCAGTTAACTACAGATA (SEQ ID NO: 1155)

MGC120533,

AACTACAGATAGCATTTCAGGACAA (SEQ ID NO: 1156)

MGC120534

AGCTTACGCCATGCTATGCTATAAG (SEQ ID NO: 1157)

GAATATGAGGAAGTTGCTGTATGAC (SEQ ID NO: 1158)

GCTGTATGACATAGTGCTGGCACTG (SEQ ID NO: 1159)

GTGCTGGCACTGATATTATCCATCA (SEQ ID NO: 1160)

CTGATATTATCCATCATCTCTTTTT (SEQ ID NO: 1161)

GGGTATGTTGTTTCATTCACCTTGA (SEQ ID NO: 1162)

TAGAATCTCTGAATAGCTCGCTAAA (SEQ ID NO: 1163)

215947_s_at
FAM136A
FLJ14668
family with sequence
84908
AGAGAAGGGGGTTTTGATTGTGATA (SEQ ID NO: 1164)

similarity 136,

GAGCAGTTGGCTACTTGATTACAAC (SEQ ID NO: 1165)

member A

TTGGGCTAGGATGAGCTGACTCCCT (SEQ ID NO: 1166)

ATGAGCTGACTCCCTTAGAGCAAAG (SEQ ID NO: 1167)

GCAAAGGAGAGACAGCCCCCATTAC (SEQ ID NO: 1168)

AAATACCATTTTTGCCTGGGGCTTG (SEQ ID NO: 1169)

CCAGCATGGCACCTTATTGTTTTGA (SEQ ID NO: 1170)

AGCAACTTCGTTGAATTTTCACCAA (SEQ ID NO: 1171)

GAATTTTCACCAACTTATTACTTGA (SEQ ID NO: 1172)

TATAATATAGCCTGTCCGTTTGCTG (SEQ ID NO: 1173)

GCTGTGATATATTTTCCTAGTGGTT (SEQ ID NO: 1174)

221774_x_at
FAM48A
RGD1307812
family with sequence
55578
ATACTTCAAGTCTCAGGCCCTTAAA (SEQ ID NO: 1175)

similarity 48, member A

CTTAAATCTACTCCAGCTTCCAGGT (SEQ ID NO: 1176)

TATTTTTAACACTCTGCAGCAGCAG (SEQ ID NO: 1177)

GTAGTCCTCAACAGCCAGGGGAGCA (SEQ ID NO: 1178)

CAAGAACAGGCCTTATCTGCTCAGC (SEQ ID NO: 1179)

CAGTCACAGGCAGCTGCAGTTGCGA (SEQ ID NO: 1180)

GCAGTTGCGATTCTTGCAGCATCAA (SEQ ID NO: 1181)

GCAGCAGCAGCACAAACAGCTCAGC (SEQ ID NO: 1182)

AGCTCAGCTACATCATCATCGGCAT (SEQ ID NO: 1183)

TCATCGGCATACAGGCAGCCAGTCA (SEQ ID NO: 1184)

GTCTTGCATTACTTTTTGTTCCTTT (SEQ ID NO: 1185)

218126_at
FAM82C
RMD3;
family with sequence
55177
CTTTTTTCCTTAGACCTTGCTGAGA (SEQ ID NO: 1186)

FAM82A2;
similarity 82, member C

ACCACACAAATCTGTCTCCTGGGTC (SEQ ID NO: 1187)

FAM82C; hRMD-

TACCACTCCCCATTAGTTAATTTAT (SEQ ID NO: 1188)

3; ptpip51;

GTTGTTCTCTCCCTTGAGTAATCTC (SEQ ID NO: 1189)

FLJ10579

ACCTGCCCCAGGATTACACATGGGT (SEQ ID NO: 1190)

GGTAGAGCCTGCAAGACCTGAGACC (SEQ ID NO: 1191)

GACCTGAGACCTTCCAATTGCTGGT (SEQ ID NO: 1192)

CAGAGTGGCCCACAGACATTGCTTT (SEQ ID NO: 1193)

GAATTCTACCTGTATTCCAGGGCTG (SEQ ID NO: 1194)

AGGGCTGGACCACTTGATAACTTCC (SEQ ID NO: 1195)

AACTTCCAGTGTCCTGGCAGCTTTT (SEQ ID NO: 1196)

210950_s_at
FDFT1
DGPT, ERG9,
farnesyl-diphosphate
2222
GAACTTATAACCAATGCACTGCACC (SEQ ID NO: 1197)

SQS, SS
farnesyltransferase 1

TGCACCACATCCCAGATGTCATCAC (SEQ ID NO: 1198)

TCACCTACCTTTCGAGACTCAGAAA (SEQ ID NO: 1199)

TTCCACAGGTGATGGCCATTGCCAC (SEQ ID NO: 1200)

TTGCCACTTTGGCTGCCTGTTATAA (SEQ ID NO: 1201)

GATGGATGCCACCAATATGCCAGCT (SEQ ID NO: 1202)

TTATCATAGAATCCCCGACTCAGAC (SEQ ID NO: 1203)

CTCAGACCCATCTTCTAGCAAAACA (SEQ ID NO: 1204)

AACTGTCAGCTGATTTCCCGAAGCC (SEQ ID NO: 1205)

ACCTGTCGTTTGTCATGCTTTTGGC (SEQ ID NO: 1206)

TTGTCCATAGCTGAAGTCCACCATA (SEQ ID NO: 1207)

217518_at
FER1L3
RP11-624L12.2,
fer-1-like 3, myoferlin
26509
GGGTGGGTGCTAATGAGCAGGGCCC (SEQ ID NO: 1208)

FLJ36571,
(C. elegans)

AGAGCCCTCTTGCATGAGTTTCGGC (SEQ ID NO: 1209)

FLJ90777, MYOF

GTTACGTGACTGCCACATTGGGGCT (SEQ ID NO: 1210)

CATTGGGGCTTGGAGGCATCTGGCA (SEQ ID NO: 1211)

GAATGGGCTGGCACCACACTAATTA (SEQ ID NO: 1212)

AGGCCACGATGATCCAGTTTGACTC (SEQ ID NO: 1213)

GACAAGCGACTGAGCTAGGCACGGC (SEQ ID NO: 1214)

CTAGGCACGGCTGACTAGCTCTGAG (SEQ ID NO: 1215)

AGCTCTGAGCTTTCTGTTCATGTTT (SEQ ID NO: 1216)

ATTCTTCATTCAATTTTCAGCCTGT (SEQ ID NO: 1217)

TTCAGCCTGTAGTGTCCTCAAGCAG (SEQ ID NO: 1218)

206404_at
FGF9
GAF, HBFG-9,
fibroblast growth
2254
GTGGGTTCTTATTGATTCGCTGTGT (SEQ ID NO: 1219)

MGC119914,
factor 9 (glia-

CTCCACTGTTGCCAAACTTTGTCGC (SEQ ID NO: 1220)

MGC119915
activating factor)

AGGGCCACTTGCTTGATTTATCATG (SEQ ID NO: 1221)

GAGACTGAGCGCTAGGAGTGTGTGT (SEQ ID NO: 1222)

CTGCGGCCTGATGCATGCTGGAAAA (SEQ ID NO: 1223)

GACACGCTTTTCATTTCTGATCAGT (SEQ ID NO: 1224)

TTCATCCTATATCAGCACAGCTGCC (SEQ ID NO: 1225)

CAGCTGCCATACTTCGACTTATCAG (SEQ ID NO: 1226)

ATCAGGATTCTGGCTGGTGGCCTGC (SEQ ID NO: 1227)

TGCGCGAGGGTGCAGTCTTACTTAA (SEQ ID NO: 1228)

GTTAATTCTCACTGGTATCATCGCA (SEQ ID NO: 1229)

219390_at
FKBP14
FKBP22;
FK506 binding
55033
CATTGAGACATGCTACCTAGGACTT (SEQ ID NO: 1230)

FLJ20731
protein 14, 22 kDa

GCTACCTAGGACTTAAGCTGATGAA (SEQ ID NO: 1231)

AGCTGATGAAGCTTGGCTCCTAGTG (SEQ ID NO: 1232)

TTGGCTCCTAGTGATTGGTGGCCTA (SEQ ID NO: 1233)

GTGATTGGTGGCCTATTATGATAAA (SEQ ID NO: 1234)

AATATTTACTTCTTAAGGCTAGCGG (SEQ ID NO: 1235)

AGGCTAGCGGAATATCCTTCCTGGT (SEQ ID NO: 1236)

TATCCTTCCTGGTTCTTTAATGGGT (SEQ ID NO: 1237)

GGTTCTTTAATGGGTAGTCTATAGT (SEQ ID NO: 1238)

GTAAACCAGTCTACATTTTCCCATT (SEQ ID NO: 1239)

CTGTCTCATCAAAAACTGAAGTTAG (SEQ ID NO: 1240)

58780_s_at
FLJ10357
SOLO
hypothetical protein
55701
CTGGAGTCCCTGGTGACTCCATTCT (SEQ ID NO: 1241)

FLJ10357

GAGTCCCTGGTGACTCCATTCTGAG (SEQ ID NO: 1242)

GTCCCTGGTGACTCCATTCTGAGGT (SEQ ID NO: 1243)

TCCCTGGTGACTCCATTCTGAGGTG (SEQ ID NO: 1244)

CTGGTGACTCCATTCTGAGGTGTCA (SEQ ID NO: 1245)

GGTGACTCCATTCTGAGGTGTCACA (SEQ ID NO: 1246)

GACTCCATTCTGAGGTGTCACAAGC (SEQ ID NO: 1247)

CTCCATTCTGAGGTGTCACAAGCAA (SEQ ID NO: 1248)

TCCATTCTGAGGTGTCACAAGCAAT (SEQ ID NO: 1249)

ATTCTGAGGTGTCACAAGCAATGAA (SEQ ID NO: 1250)

TTCTGAGGTGTCACAAGCAATGAAG (SEQ ID NO: 1251)

TCTGAGGTGTCACAAGCAATGAAGC (SEQ ID NO: 1252)

TGAGGTGTCACAAGCAATGAAGCTA (SEQ ID NO: 1253)

AGGTGTCACAAGCAATGAAGCTATG (SEQ ID NO: 1254)

GTGTGACAGGGGAACCGTAGACTTT (SEQ ID NO: 1255)

TGTGACAGGGGAACCGTAGACTTTA (SEQ ID NO: 1256)

220912_at
FLJ11827
FLJ11827
hypothetical protein
80163
CCACCCAAATGTCCTTCAAGGGGCG (SEQ ID NO: 1257)

FLJ11827

GTGATACATCCATACCATAGACTAC (SEQ ID NO: 1258)

CATAGACTACTCCCCAGCAATAAAA (SEQ ID NO: 1259)

AAATCATTCGTGCAACAACTTGGAT (SEQ ID NO: 1260)

TGCTGAGTGAAAAACACCAATCCTA (SEQ ID NO: 1261)

GGGCAACACAAGGGTTCCTTATAGT (SEQ ID NO: 1262)

GTGCCTTGACTGTGGCGATGATTAC (SEQ ID NO: 1263)

GAACTACCACACAATCAAAGGACTG (SEQ ID NO: 1264)

AGTGGATGACATCTATCTGAATATC (SEQ ID NO: 1265)

ATATCCTGGTTGTGACATTGTGGTA (SEQ ID NO: 1266)

GTAAGGGGTACACGGGATAATTCTG (SEQ ID NO: 1267)

219182_at
FLJ22167
ALYE870,
hypothetical protein
79583
TTACCCTCGTGGCTAAGCAAGTGTC (SEQ ID NO: 1268)

PRO1886
FLJ22167

GCACACGGAAGATGGCTTGTTCAGC (SEQ ID NO: 1269)

ACCTCCTGAGGATGTGGGCAGTCTC (SEQ ID NO: 1270)

GCAGTCTCCTCCAAGAACACATGGA (SEQ ID NO: 1271)

ATCCCAAGCAGGTCATTGCCACTGG (SEQ ID NO: 1272)

TGCCACTGGAAGGACATGGCCCCGG (SEQ ID NO: 1273)

GAAACACACCCCTCAGTGTGTGCCT (SEQ ID NO: 1274)

GTGCCTCAGTTTACTTTGGAGATCA (SEQ ID NO: 1275)

GATCAGTTGTCGTTTTTAGTGCTCC (SEQ ID NO: 1276)

TTTTAGTGCTCCTTTAGGCTTACTA (SEQ ID NO: 1277)

GCAGAGGAATTCCCTAACACTGACC (SEQ ID NO: 1278)

212546_s_at
FRYL
FLJ16177;
FRY-like
285527
AGACCTGCAAAGCTGCTTGGATTTC (SEQ ID NO: 1279)

KIAA0826;

TGAAAACCTAACCTGCAATTGATGC (SEQ ID NO: 1280)

DKFZp686E205

GATGCTTAATCATCCATCCACATGA (SEQ ID NO: 1281)

CATGAACATGCAGTCAGCTATACGC (SEQ ID NO: 1282)

GCTATACGCATCAAGACTCGTTTGC (SEQ ID NO: 1283)

GGTGATAACGTCTCAGAGCATGCCT (SEQ ID NO: 1284)

GAGCATGCCTAAAAGAGCACTGCAA (SEQ ID NO: 1285)

TTGGAATGCTGCTCAGTTCTCTGAT (SEQ ID NO: 1286)

TTCTCTGATCAGTGCTTATGTTATG (SEQ ID NO: 1287)

TAACCAAAGTAGATGCCTGCAGAGA (SEQ ID NO: 1288)

GTATGCTGCCTGTCAGCTATTCTCA (SEQ ID NO: 1289)

219683_at
FZD3
Fz-3, hFz3
frizzled homolog 3
7976
AATCCTAAATGTGTGGTGACTGCTT (SEQ ID NO: 1290)

(Drosophila)

GTGACTGCTTTGTAGTGAACTTTCA (SEQ ID NO: 1291)

AACATTCTGGTAGCTCAGTTAATAA (SEQ ID NO: 1292)

TTCTATGCAAGGTTTACTTCTCAGA (SEQ ID NO: 1293)

GAACAGTAGGACTTTGTAGTTTTAT (SEQ ID NO: 1294)

GAAAGGTTCTCTTAAAATTCTATCG (SEQ ID NO: 1295)

GATATTCAGGGTTTGGATTAGCAGT (SEQ ID NO: 1296)

AGAGATGGGCATTGTTTCCCCTATA (SEQ ID NO: 1297)

GTTTCCCCTATAATTGTGCTGTTTT (SEQ ID NO: 1298)

TTCTGGCTGTGTTTTTATAACTTAT (SEQ ID NO: 1299)

TTAATTTGTAGCCATCTTTTCCCAT (SEQ ID NO: 1300)

206335_at
GALNS
FLJ17434,
galactosamine (N-
2588
CAGGGGGACTGCACAATTCCACCTG (SEQ ID NO: 1301)

FLJ42844,
acetyl)-6-sulfate

GTGAACCCCAAATATCTGAGACCAG (SEQ ID NO: 1302)

FLJ98217,
sulfatase (Morquio

GAGACCAGTCTCAGTTTATTTTGCC (SEQ ID NO: 1303)

GALNAC6S,
syndrome,

TAAGGATGCACCTGTGACAGCCTCA (SEQ ID NO: 1304)

GAS, MPS4A
mucopolysaccharidosis

TACATTGGTTCAGTCAGCCTTCCAC (SEQ ID NO: 1305)

type IVA)

AATACACGATTGAGTCTGGCCCAGT (SEQ ID NO: 1306)

GCCCAGTGAATCCGCATTTTTATGT (SEQ ID NO: 1307)

CAGAGGGATGACTTCCAGTTCCGTC (SEQ ID NO: 1308)

CCGTCTGTCCTTTGTCCACAAGGAA (SEQ ID NO: 1309)

GAATTTCCCTGGGCGCTAATTATGA (SEQ ID NO: 1310)

GAGGCGTGTAGCTTCTTATCATTGT (SEQ ID NO: 1311)

214718_at
GATAD1
tcag7.279,
GATA zinc finger
57798
GCTGGGCAATGGAGTCAGATTCTCT (SEQ ID NO: 1312)

FLJ22489,
domain containing 1

GGAGTCAGATTCTCTTTCTTAAAAA (SEQ ID NO: 1313)

FLJ40695,

ACTGGATTTCCAGTTCTCTAATATT (SEQ ID NO: 1314)

ODAG,

GTTCTCTAATATTCTTAGTACCACA (SEQ ID NO: 1315)

RG083M05.2

TTAGTACCACAAGATATGTCATAGG (SEQ ID NO: 1316)

GAAATTCTTAGCTGGAAAAGTGACT (SEQ ID NO: 1317)

TTTTTCTCCTGCTACCTAGTAATAA (SEQ ID NO: 1318)

TCTCCTGCTACCTAGTAATAAACAA (SEQ ID NO: 1319)

GTTTATTACTGGTCACTTAGAAAAT (SEQ ID NO: 1320)

ACCTGAGGTCGGGAAGTGGATCGCC (SEQ ID NO: 1321)

AGGTCGGGAAGTGGATCGCCTGAGG (SEQ ID NO: 1322)

204867_at
GCHFR
GFRP,
GTP cyclohydrolase I
2644
TGGGCCCCACTATGGTGGGCGATGA (SEQ ID NO: 1323)

HsT16933,
feedback regulator

GAACAGTCGGATCCAGAGCTGATGC (SEQ ID NO: 1324)

MGC138467,

ATGAATACTACGTCGATGACCCTCC (SEQ ID NO: 1325)

MGC138469,

TCCCCGCATAGTCCTGGACAAGCTG (SEQ ID NO: 1326)

P35

CAAGCTGGAACGCAGGGGCTTCCGT (SEQ ID NO: 1327)

TGCTGAGCATGACGGGGGTGGGCCA (SEQ ID NO: 1328)

GCCAGACGCTGGTGTGGTGTCTGCA (SEQ ID NO: 1329)

GGTGTCTGCACAAGGAGTGACCTTC (SEQ ID NO: 1330)

GACCTTCTCATGCTGATTTGCAGAC (SEQ ID NO: 1331)

GGCAGTGAATGGCCTTCTCTGAAAC (SEQ ID NO: 1332)

TTCTCTGAAACCCTGCGTCAAGCAG (SEQ ID NO: 1333)

209248_at
GHITM
DERP2; MICS1;
growth hormone
27069
AATTTAGTAGGTTCACTGAGTAACT (SEQ ID NO: 1334)

My021; PTD010;
inducible

GAAGGAGTCACCTGCAGTCTTTTGT (SEQ ID NO: 1335)

TMBIM5;
transmembrane

AATACTTAGAACTTAGCACTTGTGT (SEQ ID NO: 1336)

HSPC282;
protein

GTTATTGATTAGTGAGGAGCCAGTA (SEQ ID NO: 1337)

FLJ26584;

GAAACATCTGGGTATTTGGAAACAA (SEQ ID NO: 1338)

DKFZp566C0746

GTGGTCATTGTTACATTCATCTGCT (SEQ ID NO: 1339)

TCATCTGCTGAACTTAACAAAACTG (SEQ ID NO: 1340)

ACAGGCACAGGTGATGCATTCTCCT (SEQ ID NO: 1341)

ACAGGTGATGCATTCTCCTGCTGTC (SEQ ID NO: 1342)

CTCAGTGCTCTCTTTCCAATATAGA (SEQ ID NO: 1343)

ATGTGGTCATGTTTGACTTGTACAG (SEQ ID NO: 1344)

215243_s_at
GJB3
CX31, DFNA2,
gap junction protein,
2707
CACTGCTAGCAGGGCTTCAACCAGG (SEQ ID NO: 1345)

EKV, FLJ22486,
beta 3, 31 kDa

GGAGAGGCTTCCCTGAGGACATAAT (SEQ ID NO: 1346)

MGC102938

AGGTGAGAAGTGCTCCCAAGCAGAC (SEQ ID NO: 1347)

CCAAGCAGACACAACAGCAGCACAG (SEQ ID NO: 1348)

AGCAGCACAGAGGTCTGGAGGCCAC (SEQ ID NO: 1349)

ACACAAAAAGTGATGCTCGCCCTGG (SEQ ID NO: 1350)

GGCTAGCCTCAGCAGACCTAAGGCA (SEQ ID NO: 1351)

AGCAGACCTAAGGCATCTCTACTCC (SEQ ID NO: 1352)

TCTGGAGATACCCAGAGGTCCCCCA (SEQ ID NO: 1353)

CCAGGTCATCACTTGGCTCAGTGGA (SEQ ID NO: 1354)

ACTTGGCTCAGTGGAAGCCCTCTTT (SEQ ID NO: 1355)

209092_s_at
GLOD4
C17orf25, CGI-
glyoxalase domain
51031
AAATCCAATCATGAGTCCAGGTAGA (SEQ ID NO: 1356)

150, HC71
containing 4

AGGTAGAGAACGCCTGCTGTAATCT (SEQ ID NO: 1357)

GACTGCGCATTCTGTATATAACTGT (SEQ ID NO: 1358)

TCCAGACTAGGACAGCGGCATGAAC (SEQ ID NO: 1359)

ATGACTTTGGTTGGGATTGCGGATA (SEQ ID NO: 1360)

GATTGCGGATAGTTAGGGTTACCTC (SEQ ID NO: 1361)

GGGTTACCTCTGAATCGTGTAGCTT (SEQ ID NO: 1362)

GAATCCACATTAATGCCTTGTCGTG (SEQ ID NO: 1363)

CCTGACGATACGCTCTTCTATTGTC (SEQ ID NO: 1364)

GCTCTTCTATTGTCTTATTCTGGCA (SEQ ID NO: 1365)

TGTGCGAGCTTCTTTCTGTGTATAT (SEQ ID NO: 1366)

221510_s_at
GLS
AAD20,
glutaminase
2744
GAAGATTTAGTTTTCATATCGTATA (SEQ ID NO: 1367)

DKFZp686O15119,

AATTTGTGTCACTTACTATTTTTGT (SEQ ID NO: 1368)

FLJ10358,

GTACTGTTATCTAAGCTACTGTGTT (SEQ ID NO: 1369)

GLS1, KIAA0838

AGATACTGCGAATAGGCCCTCAAAC (SEQ ID NO: 1370)

TTTGCCAGTTTTAAGGACATATTTT (SEQ ID NO: 1371)

CACTATTATTGGGTTTGTTTTATGC (SEQ ID NO: 1372)

ATGCCATTATTGATTCTTGATATTC (SEQ ID NO: 1373)

ACAATGTAGCATATTTGATTTTCTT (SEQ ID NO: 1374)

TTGTGTTGTTTAGCTTTCATTTGCT (SEQ ID NO: 1375)

ATGTACCTTTATTTTCCAGTATGCC (SEQ ID NO: 1376)

TTTCCAGTATGCCTACATTTTGTAT (SEQ ID NO: 1377)

201180_s_at
GNAI3
RP23-89M15.4,
guanine nucleotide
2773
TATCCTGCTCAAAGTACCATTATGG (SEQ ID NO: 1378)

AI158965,
binding protein (G

TAAGATTCTAGTTCTCTCTTTTCTT (SEQ ID NO: 1379)

AW537698,
protein), alpha

CAGCTTCTTGGATACAGACACACCC (SEQ ID NO: 1380)

Galphai3, Gnai-3
inhibiting activity

GAACCAGTGACTTTGCTGCTACATA (SEQ ID NO: 1381)

polypeptide 3

TTGACCACTTTGATTCTTGCTTGTT (SEQ ID NO: 1382)

CTTGCTTGTTTGTCTCAGTTATAGG (SEQ ID NO: 1383)

TTTGTACATGGTGCCTCTTGTTTTC (SEQ ID NO: 1384)

AAATGTGGTGCCAAATCCCTGTTTG (SEQ ID NO: 1385)

TTGCCATCGTTTTTACTGTACCGAT (SEQ ID NO: 1386)

GTAATCCTTAGCCAGTATGTTCTTT (SEQ ID NO: 1387)

GAAACTGTTGCATTTTGGGACTTTT (SEQ ID NO: 1388)

221958_s_at
GPR177
EVI; MRP; WLS;
G protein-coupled
79971
GGCTTCACCAAGGTGTGGTTTGCCA (SEQ ID NO: 1389)

C1orf139;
receptor 177

TAGATTTTAACATCCTTTGCGGTCC (SEQ ID NO: 1390)

FLJ23091;

CGGTCCCAGTCCAAGGTAGGCTGGT (SEQ ID NO: 1391)

MGC14878;

CAAGGTAGGCTGGTGTCATAGTCTT (SEQ ID NO: 1392)

MGC131760

TAATCCATGACCACTGTTTTTTTCC (SEQ ID NO: 1393)

TTCCTATTTATATCACCAGGTAGCC (SEQ ID NO: 1394)

GTCAATAGATAAGTGTCCCTGTTTT (SEQ ID NO: 1395)

TGAGAAGATTTATTCCACCAGGGGT (SEQ ID NO: 1396)

TCCACCAGGGGTATTTCAGCTTTGA (SEQ ID NO: 1397)

GAAACCAAATCTGTGTATCTAATAC (SEQ ID NO: 1398)

ATGTTTGCTAAACTACCCAAGTAAG (SEQ ID NO: 1399)

209409_at
GRB10
GRB-IR, Grb-10,
growth factor
2887
TGTATCTCTGCCTGTGATTTTCTTT (SEQ ID NO: 1400)

IRBP, KIAA0207,
receptor-bound

GAAACTCCATGTAGCAACCAGGACG (SEQ ID NO: 1401)

MEG1, RSS
protein 10

TGTGCCTCAGCCTAGATGTTTTGTC (SEQ ID NO: 1402)

TTCTCTTTTCTGCACTTAATACCTG (SEQ ID NO: 1403)

TGACAGTATGACCGATCTCTGCGCC (SEQ ID NO: 1404)

CGCCTTTCTGGGGGCGGGCAAGCTG (SEQ ID NO: 1405)

GCTGGCGGTAGATTTGTGATGTCAC (SEQ ID NO: 1406)

AACCTTTATTCCATGTGCTTTGCTT (SEQ ID NO: 1407)

CTTCATTCTGTACATAGCTCTTTGG (SEQ ID NO: 1408)

AGCTCTTTGGCTCGTGAACCTAATT (SEQ ID NO: 1409)

AGGGACTGATGTTCTGTTTCTTGTA (SEQ ID NO: 1410)

220794_at
GREM2
PRDC; DAND3;
gremlin 2, cysteine
64388
CGCCCCCTATTTGTGGACTAAAGAT (SEQ ID NO: 1411)

CKTSF1B2
knot superfamily,

GATGAACTCTGGTGTGCATGCTATT (SEQ ID NO: 1412)

homolog (Xenopus

AAGGTCTCTATATTAACGCTGGTTT (SEQ ID NO: 1413)

laevis)

TCACATGTTTTGACTCTGGCTTGCA (SEQ ID NO: 1414)

TGGCTTGCAGCACCATTCGGAGTAA (SEQ ID NO: 1415)

GGAGTAAGGATGACAGCAGGCCCAG (SEQ ID NO: 1416)

AGCAGGCCCAGAAGGTGTTTTACTC (SEQ ID NO: 1417)

CAGCAATTCACTGTCATGCACCTAT (SEQ ID NO: 1418)

TTCACTGACGTTACTAAGCATTGCA (SEQ ID NO: 1419)

AAACCGTATACTACTTTCACTGCCA (SEQ ID NO: 1420)

CTACTTTCACTGCCATGACACTAGG (SEQ ID NO: 1421)

216308_x_at
GRHPR
RP11-397D12.2,
glyoxylate
9380
CAATCTGATTTCATCGTCGTGGCCT (SEQ ID NO: 1422)

GLXR, PH2
reductase/hydroxypyruvate

TAACACCTGCAACCGAGGGACTCTG (SEQ ID NO: 1423)

reductase

GACTCTGCAACAAGGACTTCTTCCA (SEQ ID NO: 1424)

CAACATCAGCAGGGGCGACGTCGTA (SEQ ID NO: 1425)

CCTGTACCAGGCCTTGGCCAGTGGT (SEQ ID NO: 1426)

GATTCTGCCCCACATTGGCAGTGCC (SEQ ID NO: 1427)

CACCATGTCCTTGTTGGCAGCTAAC (SEQ ID NO: 1428)

ACAACTTGCTGGCTGGCCTGAGAGG (SEQ ID NO: 1429)

ACAGTACAGGTGGAGGGCCGGGAAG (SEQ ID NO: 1430)

GCAAACCGTGCCCTGGTATTGTCAG (SEQ ID NO: 1431)

GACACACCCAGGCTTGATTTGGATC (SEQ ID NO: 1432)

206326_at
GRP
BN, GRP-10,
gastrin-releasing
2922
AGAGCACAGGGGAGTCTTCTTCTGT (SEQ ID NO: 1433)

preproGRP,
peptide

CCTTGGGCAATCAGCAGCCTTCGTG (SEQ ID NO: 1434)

proGRP

CAAAGTTGGTAGACTCTCTGCTCCA (SEQ ID NO: 1435)

CTGCTCCAGGTTCTCAACGTGAAGG (SEQ ID NO: 1436)

AACCCCCAGCTGAACCAGCAATGAT (SEQ ID NO: 1437)

AGCAATGATAATGATGGCCTCTCTC (SEQ ID NO: 1438)

GCAAGCATCAGTTCTACGGATCATC (SEQ ID NO: 1439)

TATTCTGTATCTTTCATCCTTGACT (SEQ ID NO: 1440)

CGTGATTTTCAAGCAGCATCTTCTG (SEQ ID NO: 1441)

GCTTTTTTATATCTAGGCTACCTGT (SEQ ID NO: 1442)

GTTGGTTAGATTCAAGGCCCCGAGC (SEQ ID NO: 1443)

201520_s_at
GRSF1
FLJ13125
G-rich RNA
2926
TCTTCTCTGCATTTTGTCCACATGA (SEQ ID NO: 1444)

sequence binding

TGAGAGGATTACCTTTCCAAGCCAA (SEQ ID NO: 1445)

factor 1

TAAACTTTTTTGCTCCACTCAAGCC (SEQ ID NO: 1446)

TCAAGCCTGTTAGAATCACCATGGA (SEQ ID NO: 1447)

GGAATACAGCTCCAGTGGGAAGGCC (SEQ ID NO: 1448)

AGCTGATGTGCACTTTGAGACCCAT (SEQ ID NO: 1449)

GAGGATGCTGTTGCAGCGATGCTCA (SEQ ID NO: 1450)

GCAGCGATGCTCAAGGATCGGTCCC (SEQ ID NO: 1451)

GGTCCCACGTTCATCATAGGTATAT (SEQ ID NO: 1452)

AAGACTCTAGGGGCTCCAGATAATA (SEQ ID NO: 1453)

TTTGCACATCTTTCTTGGACTTGGG (SEQ ID NO: 1454)

205770_at
GSR
MGC78522
glutathione reductase
2936
TACCAACGTCAAAGGCATCTATGCA (SEQ ID NO: 1455)

GCAATAGCTGCTGGCCGAAAACTTG (SEQ ID NO: 1456)

AACTTGCCCATCGACTTTTTGAATA (SEQ ID NO: 1457)

CAACATCCCAACTGTGGTCTTCAGC (SEQ ID NO: 1458)

TATTCAACGAGCTTTACCCCGATGT (SEQ ID NO: 1459)

TTACCCCGATGTATCACGCAGTTAC (SEQ ID NO: 1460)

AAATGCTGCAGGGTTTTGCTGTTGC (SEQ ID NO: 1461)

TTTGACAACACAGTCGCCATTCACC (SEQ ID NO: 1462)

TTCACCCTACCTCTTCAGAAGAGCT (SEQ ID NO: 1463)

AAGAGCTGGTCACACTTCGTTGAGA (SEQ ID NO: 1464)

GAACCAGGAGACACGTGTGGCGGGC (SEQ ID NO: 1465)

215766_at
GSTA1
GST2, GSTA1-1,
Glutathione S-
2938
CCCAATGCCACAAAACCACATCAGA (SEQ ID NO: 1466)

GTH1,
transferase A1

ACTGTGCCTGGCTACATTTAGATCT (SEQ ID NO: 1467)

MGC131939

GAGCATCTTTCCTCTGTTGAGTAGT (SEQ ID NO: 1468)

GTGGATTCTCTATTTTATTGGTCAT (SEQ ID NO: 1469)

CAAGGCTAGTGGGCTTTCACACTCC (SEQ ID NO: 1470)

CACACTCCAGACTGCTGTATTCCAG (SEQ ID NO: 1471)

CTGTATTCCAGCCCAAATTACTCAA (SEQ ID NO: 1472)

AGCTAATGCAATCCGCTTGCCTTAC (SEQ ID NO: 1473)

CTCAGGTTGCTGTTACTCTGTTTCA (SEQ ID NO: 1474)

CTCTGTTTCAGATGCAACCCTCTGT (SEQ ID NO: 1475)

CCCAAGTTCTCTCATTCTTAGCTAT (SEQ ID NO: 1476)

205752_s_at
GSTM5
GSTM5-5, GTM5
glutathione S-
2949
CCTAGCACTGTCCTCAAAGACCATC (SEQ ID NO: 1477)

transferase M5

CTCAAAGACCATCTGTATGCCCTGC (SEQ ID NO: 1478)

AGCTCCGTGTGATGCCCAGTAAAGC (SEQ ID NO: 1479)

TGCCCAGTAAAGCCTGAACCATGCC (SEQ ID NO: 1480)

CTGAGGCTCCCTTGAACTCAGGACT (SEQ ID NO: 1481)

GGGGTGGTGATCAGGCAGGTTCATA (SEQ ID NO: 1482)

CTCCTGTAGGCCGTCTAGAACTGGC (SEQ ID NO: 1483)

CTCCCAGGCAGACTGCCTTCTTTCA (SEQ ID NO: 1484)

TCTTTCACCCTGTCCTGATAGACTT (SEQ ID NO: 1485)

AGACTTCCCTGATCTAGATATCCTT (SEQ ID NO: 1486)

ATCTAGATATCCTTCGTCATGACAC (SEQ ID NO: 1487)

211555_s_at
GUCY1B3
GC-S-beta-1,
guanylate cyclase 1,
2983
GTTTACCAGAGCCATGCATTCACCA (SEQ ID NO: 1488)

GC-SB3,
soluble, beta 3

TGCATTCACCATGCACGATCCATCT (SEQ ID NO: 1489)

GUC1B3,

GTGTCATAGGACAGCGGATGCCTCG (SEQ ID NO: 1490)

GUCB3,

ACAGCGGATGCCTCGATACTGTCTT (SEQ ID NO: 1491)

GUCSB3,

TGGGAATACTGTCAACCTCACAAGC (SEQ ID NO: 1492)

GUCY1B1

ACCTCACAAGCCGAACAGAAACCAC (SEQ ID NO: 1493)

AATTCAGATCCACAATTCCACTTGG (SEQ ID NO: 1494)

TCCACTTGGAGCACAGAGGCCCAGT (SEQ ID NO: 1495)

ATGCAAGTTTGGTTTCTATCCAGAA (SEQ ID NO: 1496)

ACAGACTAGGTTCCAGTTTTCTCCT (SEQ ID NO: 1497)

CCAGGAGCAGTTCTTCCCTATGGAT (SEQ ID NO: 1498)

200853_at
H2AFZ
H2A.z, H2A/z,
H2A histone family,
3015
ACCTCACCGCAGAGGTACTTGAACT (SEQ ID NO: 1499)

H2AZ,
member Z

GAGGTACTTGAACTGGCAGGAAATG (SEQ ID NO: 1500)

MGC117173

GAACTGGCAGGAAATGCATCAAAAG (SEQ ID NO: 1501)

AGAATTGGATTCTCTCATCAAGGCT (SEQ ID NO: 1502)

GGATTCTCTCATCAAGGCTACAATT (SEQ ID NO: 1503)

CTCTCATCAAGGCTACAATTGCTGG (SEQ ID NO: 1504)

TCAAGGCTACAATTGCTGGTGGTGG (SEQ ID NO: 1505)

AGTGTTGGTGATTCCAGTGGACTGT (SEQ ID NO: 1506)

GTGATTCCAGTGGACTGTATCTCTG (SEQ ID NO: 1507)

ACATTTGGTTTTGTTCAGACCTTAT (SEQ ID NO: 1508)

GTTTTGTTCAGACCTTATTTCCACT (SEQ ID NO: 1509)

201036_s_at
HADH
HAD, HADH1,
hydroxyacyl-
3033
CTTGCCCTACATTTTGGGCATGACA (SEQ ID NO: 1510)

HADHSC, HHF4,
Coenzyme A

AGATGTGTCTTTATTCAGCTCGTCG (SEQ ID NO: 1511)

M/SCHAD,
dehydrogenase

TTCAGCTCGTCGTGAAGATGCTGCT (SEQ ID NO: 1512)

MGC8392,

CTGAATGGGTCAGCATATCTCTGTT (SEQ ID NO: 1513)

SCHAD

GCATATCTCTGTTTGCATGGTTTGC (SEQ ID NO: 1514)

CATGGTTTGCAGGAGGTCGGTTTTC (SEQ ID NO: 1515)

GCAGGAGGTCGGTTTTCATGGTCAT (SEQ ID NO: 1516)

ATGGTCATTCAGTTCCACAGATCTG (SEQ ID NO: 1517)

TGAATGATTACTGTCTGTCTGTGTC (SEQ ID NO: 1518)

TTTCCATGAGAAATCACTGTTGCAA (SEQ ID NO: 1519)

ATTGCCTATAAATTGACTCTACTAA (SEQ ID NO: 1520)

202299_s_at
HBXIP
MGC71071, XIP
hepatitis B virus x
10542
TCTGACCCCACTGATATTCCTGTGG (SEQ ID NO: 1521)

interacting protein

ACCCCACTGATATTCCTGTGGTGTG (SEQ ID NO: 1522)

GATCCAGAAACACGATGGCATCACG (SEQ ID NO: 1523)

TGGCATCACGGTGGCAGTGCACAAA (SEQ ID NO: 1524)

TCAGCAGCCTGTCATAGGAACTGGA (SEQ ID NO: 1525)

ACTGGATCCTACCTATGTTAATTAC (SEQ ID NO: 1526)

TGTTAATTACCTTATAGAACTACTA (SEQ ID NO: 1527)

AAGTTCCAGTAGTTAGGCCATTCAT (SEQ ID NO: 1528)

TAGTTAGGCCATTCATTTAATGTGC (SEQ ID NO: 1529)

TAATGTGCATTAGGCACTTTTCTGT (SEQ ID NO: 1530)

ATGTTTTGAAGCAGCAGGTCCAGGT (SEQ ID NO: 1531)

208826_x_at
HINT1
FLJ30414,
histidine triad
3094
CCCGCGCGGGAGAGAGGCCGAGATG (SEQ ID NO: 1532)

FLJ32340, HINT,
nucleotide binding

GAGATTGCCAAGGCTCAGGTCGCTC (SEQ ID NO: 1533)

PKCI-1,
protein 1

CTGGTGGCGACACGATCTTTGGGAA (SEQ ID NO: 1534)

PRKCNH1

TTTTGAGGATGACCGGTGCCTTGCT (SEQ ID NO: 1535)

CCTCAAGCACCAACACATTTTCTGG (SEQ ID NO: 1536)

AGAAATGTGCTGCTGATCTGGGCCT (SEQ ID NO: 1537)

TGGACAGTCTGTCTATCACGTTCAT (SEQ ID NO: 1538)

TCACGTTCATCTCCATGTTCTTGGA (SEQ ID NO: 1539)

CAAATGCATTGGCCTCCTGGTTAAG (SEQ ID NO: 1540)

GGGATAATTTTCTCTTCTTTAGGCA (SEQ ID NO: 1541)

AAGTAACACACTTATTTTTGCCTGT (SEQ ID NO: 1542)

216526_x_at
HLA-B ///
CDABP0067,
major
3106
CCATCATGGGCATCGTTGCTGGCCT (SEQ ID NO: 1543)

HLA-C ///
AS, HLA-B-7301,
histocompatibility
3107
AGCTGTGGTCACCGCTATGATGTGT (SEQ ID NO: 1544)

MICA ///
HLA-B73, HLAB,
complex, class I, B ///
4276
GAAGAGCTCAGGTGGTGTGTGGGAC (SEQ ID NO: 1545)

MICB ///
HLAC, SPDA1 ///
major
4277
AGATGCAGGATTTCTTCACACCTCT (SEQ ID NO: 1546)

XXbac-
XXbac-
histocompatibility
100129668
GTGACTTCAAGAGCCTCTGGCATCT (SEQ ID NO: 1547)

BPG181B23.1
BCX101P6.2,
complex, class I, C ///

GCATCTCTTTCTGCAAAGGCGTCTG (SEQ ID NO: 1548)

D6S204,
MHC class I

AAGGCGTCTGAATGTGTCTGCGTTC (SEQ ID NO: 1549)

FLJ27082, HLA-
polypeptide-related

CGATCATCTTTCCTGTTCCAGAGAG (SEQ ID NO: 1550)

Cw, HLA-Cw12,
sequence A /// MHC

AGAGGTGGGGCTGGATGTCTCCATC (SEQ ID NO: 1551)

HLA-JY3, HLC-C,
class I polypeptide-

TCTCCATCTCTGTCTCAAATTCATG (SEQ ID NO: 1552)

PSORS1 ///
related sequence B

GCACTGAGCTGCAACTTCTTACTTC (SEQ ID NO: 1553)

DAMA-345G11.2,
/// MHC class I

MGC111087,
polypeptide-related

PERB11.1 ///
sequence A

DAAP-210H10.1,

PERB11.2

/// MICA

213356_x_at
HNRNPA1
HNRPA1,
heterogeneous
3178
AACTACTCATGTGTATGGCGCCGAT (SEQ ID NO: 1554)

///
MGC1028350 ///
nuclear
664709
GGCGCCGATAAATCTCGAGGACTGT (SEQ ID NO: 1555)

HNRPA1L-2
/// /// /// /// /// /// ///
ribonucleoprotein A1
664721
GGTTATTGCTAGTTTCTGTTCTGTG (SEQ ID NO: 1556)

///
/// /// /// /// /// ///
/// heterogeneous
100128836
TTGCACCCCATGCTGTTGATTGCTA (SEQ ID NO: 1557)

HNRPA1P5
LOC144983;
nuclear
391670
GTAACAGTCTGATCGTGACGCTGAA (SEQ ID NO: 1558)

///
MGC102957
ribonucleoprotein A1
402112
AGTTAGTCTACTCTTAAGCCATCTT (SEQ ID NO: 1559)

LOC100128

pseudogene ///
440125
GCCATCTTGGTAAATTTCCCCAACA (SEQ ID NO: 1560)

836 ///

heterogeneous
642817
GAATTCCTTCAGGGTGATGCCAGGT (SEQ ID NO: 1561)

LOC391670

nuclear
643033
AAGCCATTGTCTTCGGAAACCTTGG (SEQ ID NO: 1562)

///

ribonucleoprotein A1
644037
GTGATTGTTGGCACATCCTATGCAA (SEQ ID NO: 1563)

LOC402112

pseudogene 5 ///
645001
GAAGCTTGTGTATCCATTATCATGT (SEQ ID NO: 1564)

///

similar to
728732

LOC440125

heterogeneous
729366

///

nuclear
729423

LOC642817

ribonucleoprotein A1
730246

///

/// heterogeneous
144983

LOC643033

nuclear

///

ribonucleoprotein A1-

LOC644037

like /// similar to

///

heterogeneous

LOC645001

nuclear

///

ribonucleoprotein A1

LOC728170

/// similar to

///

heterogeneous

LOC728732

nuclear

///

ribonucleoprotein A1

LOC729366

/// similar to

///

heterogeneous

LOC729423

nuclear

///

ribonucleoprotein A1

LOC730246

/// hypothetical

/// RP11-

LOC642817 ///

78J21.1

similar to

Heterogeneous

nuclear

ribonucleoprotein A1

(Helix-destabilizing

protein) (Single-

strand binding

protein) (hnRNP core

protein A1) (HDP-1)

(Topoisomerase-

inhibitor suppressed)

/// hypothetical

LOC644037 ///

similar to

heterogeneous

nuclear

ribonucleoprotein A1

/// similar to

heterogeneous

nuclear

ribonucleoprotein A1

/// similar to

heterogeneous

nuclear

ribonucleoprotein A1

/// similar to

heterogeneous

nuclear

ribonucleoprotein A1

/// similar to

Heterogeneous

nuclear

ribonucleoprotein A1

(Helix-destabilizing

protein) (Single-

strand RNA-binding

protein) (hnRNP core

protein A1) (HDP) ///

hypothetical

LOC730246 ///

heterogeneous

nuclear

ribonucleoprotein A1-

like

206289_at
HOXA4
HOXA-4
homeobox A4
3201
CCATCTGGACCATAATAGGGACACC (SEQ ID NO: 1565)

CGGTTAAGAGTCTGTGCTGGTTGCC (SEQ ID NO: 1566)

GAGAACAGTTGTCCAGGATGCTGGC (SEQ ID NO: 1567)

ACAACCTGCTGGCCCGAAACAAGGC (SEQ ID NO: 1568)

AACAAGGCTGCCAGGTGTGGAACAG (SEQ ID NO: 1569)

AACAGCCCATGCTGACTGGGGACAT (SEQ ID NO: 1570)

GACTGGGGACATACACTTGCATCTT (SEQ ID NO: 1571)

CCCCATTAAGGCAGCTCATCCAAGC (SEQ ID NO: 1572)

GACATGTTAGTTTTTCTTACTTGCA (SEQ ID NO: 1573)

CAGAGATACTGTTGTCACCTTCTGG (SEQ ID NO: 1574)

GGGGAGTGCATTTAGACTTATGTGG (SEQ ID NO: 1575)

204778_x_at
HOXB7
HHO.C1, HOX2,
homeobox B7
3217
CCGGCTATGGGCTCGAGCCGAGTTC (SEQ ID NO: 1576)

HOX2C, Hox-2.3

GGGCGCCAAGGAGCAGAGGGACTCG (SEQ ID NO: 1577)

GGACTCGGACTTGGCGGCCGAGAGT (SEQ ID NO: 1578)

GGCCGAGAGTAACTTCCGGATCTAC (SEQ ID NO: 1579)

TCTACCCCTGGATGCGAAGCTCAGG (SEQ ID NO: 1580)

CAGGAACTGACCGCAAACGAGGCCG (SEQ ID NO: 1581)

CGCTACCAGACCCTGGAGCTGGAGA (SEQ ID NO: 1582)

AGAATTTCACTACAATCGCTACCTG (SEQ ID NO: 1583)

ACGCTCTGCCTCACGGAAAGACAGA (SEQ ID NO: 1584)

ACCACCGGCCAAGACAGGGCTGAAG (SEQ ID NO: 1585)

GCCCAGCTCTGGGAACTGAATCAGG (SEQ ID NO: 1586)

205580_s_at
HRH1
H1-R, hisH1
histamine receptor
3269
TTAGGTGATAGCCAATCCTTCTCTC (SEQ ID NO: 1587)

H1

TCGAACGGACTCAGATACCACCACA (SEQ ID NO: 1588)

GAGGAGTGGGTCTAACACAGGCCTG (SEQ ID NO: 1589)

TTTACTTGGAAGAGGCTCCGCTCGC (SEQ ID NO: 1590)

CTCCGCTCGCATTCAAGACAGTATG (SEQ ID NO: 1591)

GGTTTTATCATGGCAGCCTTCATCC (SEQ ID NO: 1592)

GGTCATTGCCTTCTGCAAGAACTGT (SEQ ID NO: 1593)

CATCTACCCCTTGTGCAATGAGAAC (SEQ ID NO: 1594)

GAGAATTCTGCATATTCGCTCCTAA (SEQ ID NO: 1595)

CCAGGCAGGCACCTGGGCTTTCTGG (SEQ ID NO: 1596)

GAATCCAAACCACAGTCTTAGGGGC (SEQ ID NO: 1597)

208744_x_at
HSPH1
RP11-173P16.1,
heat shock
10808
GAAGGGGGCCTTTTGAGCTAGAAGC (SEQ ID NO: 1598)

DKFZp686M05240,
105 kDa/110 kDa

TAGAAGCTTTCTATTCTGATCCCCA (SEQ ID NO: 1599)

HSP105,
protein 1

GATCCCCAAGGAGTTCCATATCCAG (SEQ ID NO: 1600)

HSP105A,

AATAGGCCGCTTTGTAGTTCAGAAT (SEQ ID NO: 1601)

HSP105B,

GTCAACACCCATGGCATTTTCACCA (SEQ ID NO: 1602)

KIAA0201, NY-

GTGAAGCTGGAACACAGCCCCAGGT (SEQ ID NO: 1603)

CO-25

AGCCCCAGGTACAAACTGATGCTCA (SEQ ID NO: 1604)

TGATGCTCAACAAACCTCACAGTCT (SEQ ID NO: 1605)

CCCTTCACCTGAACTTACCTCAGAA (SEQ ID NO: 1606)

AAAGTTGACCAGCCTCCAGAAGCTA (SEQ ID NO: 1607)

GAGCTGCCTATTGAAGCCAACTTGG (SEQ ID NO: 1608)

216615_s_at
HTR3A
5-HT-3, 5-HT3A,
5-hydroxytryptamine
3359
CCCCTCAGGACCCAGGGAATGCCAG (SEQ ID NO: 1609)

5-HT3R, 5HT3R,
(serotonin) receptor

GCCAGGGACATTTTCAAGACACAGA (SEQ ID NO: 1610)

HTR3
3A

CCCTGTTTCCAATGCCAATTCATCT (SEQ ID NO: 1611)

ATGCCAATTCATCTCAGCAATCACA (SEQ ID NO: 1612)

CACAAGCCAAGGTCTGAACCCTTCC (SEQ ID NO: 1613)

TGGGTGTTCAAGGCCCTTACACCCT (SEQ ID NO: 1614)

CCAGCAGCTCACCATGGCTTTAAAA (SEQ ID NO: 1615)

GGCTTTAAAACATGCTCTCTTAGAT (SEQ ID NO: 1616)

TCAGGAGAAACTCGGGCACTCCCTA (SEQ ID NO: 1617)

ACTCCCTAAGTCCACTCTAGTTGTG (SEQ ID NO: 1618)

TAGTTGTGGACTTTTCCCCATTGAC (SEQ ID NO: 1619)

217756_x_at
HYPK ///
/// 4F5REL,
Huntingtin interacting
25764
GCAACGTCCGACAGAACGAGGGGAC (SEQ ID NO: 1620)

SERF2
FAM2C,
protein K /// small
10169
GAGGGGACGTAACGGAGGCAGGTTG (SEQ ID NO: 1621)

FLJ20431,
EDRK-rich factor 2

CGGAGGCAGGTTGGAGCCGCTGCCG (SEQ ID NO: 1622)

FLJ37527,

GCTCGCCCGCCAGAAGAATATGAAA (SEQ ID NO: 1623)

FLJ38557,

AAGCGCCGAGATGACGGGCTTTCTG (SEQ ID NO: 1624)

H4F5rel,

CCGCCCGCAAGCAGAGGGACTCGGA (SEQ ID NO: 1625)

HsT17089,

GGGACTCGGAGATCATGCAGCAGAA (SEQ ID NO: 1626)

MGC48826

GGAACCCAAGTAGCTTTGTGGCTTC (SEQ ID NO: 1627)

TCCTCCTGTAGTGCTCACAGGTCCC (SEQ ID NO: 1628)

CTTCCCAGTGTTTTTTATTCCTGTG (SEQ ID NO: 1629)

TTATTCCTGTGGGGCTCACCCCAAA (SEQ ID NO: 1630)

215485_s_at
ICAM1
BB2, CD54,
intercellular adhesion
3383
ACAGTGAAGTGTGAGGCCCACCCTA (SEQ ID NO: 1631)

P3.58
molecule 1 (CD54),

GCCCACCCTAGAGCCAAGGTGACGC (SEQ ID NO: 1632)

human rhinovirus

GTGACGCTGAATGGGGTTCCAGCCC (SEQ ID NO: 1633)

receptor

TATACACAAGAACCAGACCCGGGAG (SEQ ID NO: 1634)

GTCCGGGAAACTGGACGTGGCCAGA (SEQ ID NO: 1635)

CATTGCCCGAGCTCAAGTGTCTAAA (SEQ ID NO: 1636)

TAAAGGATGGCACTTTCCCACTGCC (SEQ ID NO: 1637)

AGTGACTGTCACTCGAGATCTTGAG (SEQ ID NO: 1638)

CGAGATCTTGAGGGCACCTACCTCT (SEQ ID NO: 1639)

GAGCACTCAAGGGGAGGTCACCCGC (SEQ ID NO: 1640)

CCCCCCGGTATGAGATTGTCATCAT (SEQ ID NO: 1641)

203327_at
IDE
RP11-366I13.1,
insulin-degrading
3416
TCATCACTTCCTTCTGGTTTTATGT (SEQ ID NO: 1642)

FLJ35968,
enzyme

TTCCGATCCACCACTGTACTAGTAA (SEQ ID NO: 1643)

INSULYSIN

GTCTTCCATGAACCTGCAATTGTTT (SEQ ID NO: 1644)

TATGCGTCAGCATTTTCCAATTTCC (SEQ ID NO: 1645)

AGGTTGGATCTAGAGCTGCTGTTGA (SEQ ID NO: 1646)

GCTGCTGTTGATCACTCAGGCATAC (SEQ ID NO: 1647)

GTCCAAGCTGCAGTCCATGAGCAAT (SEQ ID NO: 1648)

CATGAGCAATAACAGACTACCCCAG (SEQ ID NO: 1649)

GACTACCCCAGATACTGCAGTTTAC (SEQ ID NO: 1650)

GAAAGTCTTCTTTTTTGACCAGTTG (SEQ ID NO: 1651)

GAGGGAGCATGTGACACAGCCAGTA (SEQ ID NO: 1652)

204703_at
IFT88
AW552028,
intraflagellar transport
8100
AATGTCTGCGTTTCTTAGTTCGTCT (SEQ ID NO: 1653)

Tg737,
88 homolog

AGTTCGTCTCTGCACAGATCTTGGA (SEQ ID NO: 1654)

Tg737Rpw,
(Chlamydomonas)

GGGAACAGCGCATAAAGTCAGGCAG (SEQ ID NO: 1655)

TgN737Rpw,

GGGCTCCCGTGGCAAAAGAGAAGGA (SEQ ID NO: 1656)

Ttc10, flexo, fxo,

GTGCTAGCGGTGATAGTGGCCAGAA (SEQ ID NO: 1657)

orpk, polaris

GGTGAACGACTAAGTGCCAGACTCA (SEQ ID NO: 1658)

AAGTGCCAGACTCAGAGCTTTACCT (SEQ ID NO: 1659)

AAATAGATGCCTCCTATGTGGACCC (SEQ ID NO: 1660)

CCCACTTGGCCCTCAAATAGAACGA (SEQ ID NO: 1661)

GAAATTGCCTTATGAGATCATCCTC (SEQ ID NO: 1662)

AGATCATCCTCATGTTAAACCTTGG (SEQ ID NO: 1663)

207375_s_at
IL15RA
RP11-536K7.2,
interleukin 15
3601
TGCGCGAGGGAGCAGGTTCTCCGCA (SEQ ID NO: 1664)

MGC104179
receptor, alpha

CCCAGCTTCCCAGGAGAGACCAAAG (SEQ ID NO: 1665)

GAGACCAAAGGCTTCTGAGCAGGAT (SEQ ID NO: 1666)

GTGAGCTGCCTGGAATACATGTGGT (SEQ ID NO: 1667)

CATACCCAAAGCTCTCTGTCAATTA (SEQ ID NO: 1668)

GCTTCTCCTGGCGTGGGAGACGTCT (SEQ ID NO: 1669)

AGACACCAGCGTTTGGGCTTCTAAC (SEQ ID NO: 1670)

GCTGCTCTGCACACATGGACAGGGA (SEQ ID NO: 1671)

GAGATGCTGAGCCCAGCGAATCCTC (SEQ ID NO: 1672)

CCAGCGAATCCTCTCCATTGAAGGA (SEQ ID NO: 1673)

ACTCAACTCAGTGCCATTTTACGAA (SEQ ID NO: 1674)

207526_s_at
IL1RL1
DER4, FIT-1,
interleukin 1 receptor-
9173
GTGTTTCTGAGACTTTGATCACCTG (SEQ ID NO: 1675)

MGC32623, ST2,
like 1

TGATCACCTGAACTTTCTCTAGCAA (SEQ ID NO: 1676)

ST2L, ST2V, T1

GGAGTGTGGTTCCAAGAGATCCATC (SEQ ID NO: 1677)

GCCTGTGCCATAAAATGTGCTTCTC (SEQ ID NO: 1678)

TCTTCGGGATGTTGTTTGCTGTCTG (SEQ ID NO: 1679)

GATCTTTGTAGACTGTTCCTGTTTG (SEQ ID NO: 1680)

AGACTGTTCCTGTTTGCTGGGAGCT (SEQ ID NO: 1681)

CTCTGCTGCTTAAATTGTTCGTCCT (SEQ ID NO: 1682)

CCTCCTATCGTTGGTTTGTCTAGAA (SEQ ID NO: 1683)

GTCTAGAACACTCAGCTGCTTCTTT (SEQ ID NO: 1684)

CTAACTTTATGAACTCCCTCTGTGT (SEQ ID NO: 1685)

200955_at
IMMT
DKFZp779P1653,
inner membrane
10989
AGAGCTCTGCCCTGAGGATATAAAC (SEQ ID NO: 1686)

HMP,
protein, mitochondrial

ATTACTGTCATATGCTTCCTATTGC (SEQ ID NO: 1687)

MGC111146,
(mitofilin)

GGGGGAATCCAGACGAGTGGCACAG (SEQ ID NO: 1688)

P87, P87/89,

GAAGCCCGAATGACCCTAGAAACGA (SEQ ID NO: 1689)

P89, PIG4,

AATCCTGACAGCATATGCCAGCGCC (SEQ ID NO: 1690)

PIG52

GCCAGCGCCGTAGGAATAGGAACCA (SEQ ID NO: 1691)

ATAGGAACCACTCAGGTGCAGCCAG (SEQ ID NO: 1692)

GCAGCGAGAGTCCCGGACTTGTCTA (SEQ ID NO: 1693)

TATTCTTTCCATTTGCTATCATGTC (SEQ ID NO: 1694)

GAACGCCAGGAGTGCTTTCTTTGCA (SEQ ID NO: 1695)

GATCTCTACTACTGTTGATTTTGCC (SEQ ID NO: 1696)

33304_at
ISG20
CD25, HEM45
interferon stimulated
3669
GTTCATCCGGCCTGAGGGAGAGATC (SEQ ID NO: 1697)

exonuclease gene

TCATCCGGCCTGAGGGAGAGATCAC (SEQ ID NO: 1698)

20 kDa

CCGGCCTGAGGGAGAGATCACCGAT (SEQ ID NO: 1699)

CCAGGCTAGAGATCCTGCAGCTCCT (SEQ ID NO: 1700)

TAGAGATCCTGCAGCTCCTGAAAGG (SEQ ID NO: 1701)

TGGTGGGTCATGACCTGAAGCACGA (SEQ ID NO: 1702)

ACATGAGCGGCTACACAATCTACGA (SEQ ID NO: 1703)

CATGAGCGGCTACACAATCTACGAC (SEQ ID NO: 1704)

AAGCTGGACCACTGCAGGCGTGTCT (SEQ ID NO: 1705)

AGAGCATCCAGAACAGCCTGCTTGG (SEQ ID NO: 1706)

CCCGCCTGGCTGTGTCAGACTGAAG (SEQ ID NO: 1707)

CCGCCTGGCTGTGTCAGACTGAAGC (SEQ ID NO: 1708)

GGCTGTGTCAGACTGAAGCCCCATC (SEQ ID NO: 1709)

GAGGCTTTCGGCTTTTTGGGACAGC (SEQ ID NO: 1710)

GGCTTTTTGGGACAGCAACTACCTT (SEQ ID NO: 1711)

GGACAGCAACTACCTTGCTTTTGGA (SEQ ID NO: 1712)

205055_at
ITGAE
CD103,
integrin, alpha E
3682
AGAGATCTCCTGGGATCACTCTGAG (SEQ ID NO: 1713)

HUMINAE,
(antigen CD103,

TCACTGTCGTCTTCCTGAAAGATGA (SEQ ID NO: 1714)

MGC141996
human mucosal

TACCATTCTTTGCCTATCATCATTA (SEQ ID NO: 1715)

lymphocyte antigen

AAGGCAGCGTTGGTGGACTTCTGGT (SEQ ID NO: 1716)

1; alpha polypeptide)

GGACTTCTGGTGTTGATCGTGATTC (SEQ ID NO: 1717)

TGATCGTGATTCTGGTCATCCTGTT (SEQ ID NO: 1718)

GTCATCCTGTTCAAGTGTGGCTTTT (SEQ ID NO: 1719)

CTGGGAGAGGCTATCAGCCAGTCCT (SEQ ID NO: 1720)

CTTTGCATTACTTTTTCCTTCAGGA (SEQ ID NO: 1721)

TAGTTTTTAACCATACATTGTCCCA (SEQ ID NO: 1722)

CATTGTCCCAAAAGTGTCTGTGCAT (SEQ ID NO: 1723)

204487_s_at
KCNQ1
GAIP, RGSGAIP
potassium voltage-
3784
GCCCAGGAGCCCATTTGGAGGGCCT (SEQ ID NO: 1724)

gated channel, KQT-

AGACTGTGGAGACTGCTCCTGAGCC (SEQ ID NO: 1725)

like subfamily,

CATTTCCCCAGGGCACGTGGTTGAG (SEQ ID NO: 1726)

member 1

GCACGTGGTTGAGTGGGGGGAACGC (SEQ ID NO: 1727)

ACTTCCCTGGGTTAGACTGCCAGCT (SEQ ID NO: 1728)

GCCAGCTGCTGAGCCGCAGAGAAGT (SEQ ID NO: 1729)

GCCGCAGAGAAGTGACGGTTCCTAC (SEQ ID NO: 1730)

GACGGTTCCTACACAGGACAGGGGT (SEQ ID NO: 1731)

TTCCTTCTGGGCATTACATCGCATA (SEQ ID NO: 1732)

GGGCATTACATCGCATAGAAATCAA (SEQ ID NO: 1733)

TAATTTGTGGTGATTTGGATCTGTG (SEQ ID NO: 1734)

212357_at
KIAA0280
KIAA0280,
KIAA0280
23201
GATAGCAGGGGGATTTTCCTTCCTA (SEQ ID NO: 1735)

TCRP1

GCAAAGTACCGGCCCATAGGAATCA (SEQ ID NO: 1736)

CCTTTCTCCTCAGGCCTAAGAGAGT (SEQ ID NO: 1737)

AGAGAGGAGACTGTCCCAGAGACCT (SEQ ID NO: 1738)

TCCTCGGGTCAGCCAGATAGTCTGG (SEQ ID NO: 1739)

GGGGTAAGGCCAGGCCTCTAGCTAC (SEQ ID NO: 1740)

GGCCTCTAGCTACTTGGAGTTGTCT (SEQ ID NO: 1741)

TCCCTGTTTCATATCACATGACAGA (SEQ ID NO: 1742)

GACAGAGAAACCTGTTCTCATGGCA (SEQ ID NO: 1743)

TCTCATGGCATGTAACATCCCTGTG (SEQ ID NO: 1744)

CATCCCTGTGAAGAGAGCGTTGTAT (SEQ ID NO: 1745)

212311_at
KIAA0746 ///
DKFZp781J1697,
KIAA0746 protein ///
23231
GGAAGGTACGATAATCCCACACCAT (SEQ ID NO: 1746)

SERINC2
FLJ21629,
serine incorporator 2
347735
TCCCACACCATATCTTGGATTTCTT (SEQ ID NO: 1747)

FLJ41299 ///

TTGACTCAACTCTCCATTCTAATAA (SEQ ID NO: 1748)

TDE2; TDE2L;

GAGCCACAGTAACGAGGAGTCCTTC (SEQ ID NO: 1749)

FKSG84;

CTCAGCCCTGATCTACTTTCTGGGA (SEQ ID NO: 1750)

PRO0899;

TTTCTGGGAACCTTTCTGCTATCCA (SEQ ID NO: 1751)

MGC90340

GCAGTATTTCCAGTCTGTCTCAGCA (SEQ ID NO: 1752)

TGCAGATGCCTCTGACCAAGACCAG (SEQ ID NO: 1753)

AAGACCAGCCCACAGTAACTAATAA (SEQ ID NO: 1754)

GTAACTAATAACCCGGAGCCACGTG (SEQ ID NO: 1755)

CACGTGGGTGAACTGTGCACTCCAG (SEQ ID NO: 1756)

212314_at
KIAA0746 ///
DKFZp781J1697,
KIAA0746 protein ///
23231
TATTTTGGTACCTGTGCTTGCCACA (SEQ ID NO: 1757)

SERINC2
FLJ21629,
serine incorporator 2
347735
TTGATAGATTTCTCTTTGACTTCCA (SEQ ID NO: 1758)

FLJ41299 ///

TTGACTTCCAAGACCTAGCAGTTAT (SEQ ID NO: 1759)

TDE2; TDE2L;

GTCCTAGTGCTTCCGAATCATTTAA (SEQ ID NO: 1760)

FKSG84;

AATGGCATTGTCGGATATCTTTTAC (SEQ ID NO: 1761)

PRO0899;

ATCTTTTACATTTCAATTGCAATCC (SEQ ID NO: 1762)

MGC90340

AGTACTTAACTGTAGTCTTCTCCAT (SEQ ID NO: 1763)

GTAGTCTTCTCCATGAATTACACGT (SEQ ID NO: 1764)

GCCTCTAGCTTATAGTTTCATCCCT (SEQ ID NO: 1765)

GCCTGCGTGAGTCTGTACAGGGATA (SEQ ID NO: 1766)

GGTCCAAACTACTCTTTGCACTACT (SEQ ID NO: 1767)

202962_at
KIF13B
GAKIN,
kinesin family
23303
ATGTTTCTGGGCCTACCAAGGTTCA (SEQ ID NO: 1768)

KIAA0639
member 13B

CTGGGAATGTGACTGCTGGAGCCTG (SEQ ID NO: 1769)

TGAGAGTGTGTGTTGGTGGCTGTGC (SEQ ID NO: 1770)

ACAAGACGGGAGTCACCCTGTGCTT (SEQ ID NO: 1771)

CCAAGATACTGACCCATTGAACCCC (SEQ ID NO: 1772)

TTCTCTCCACAAAGTCCGTGGTGCC (SEQ ID NO: 1773)

GGTGGGCTGCAGACACTAATGGTGT (SEQ ID NO: 1774)

GGTCTTGGAACAGCTTCTCTATGTG (SEQ ID NO: 1775)

GCTTCTCTATGTGTGGATTCGTGTA (SEQ ID NO: 1776)

AACCACCTGTAATTTTGTACCATAT (SEQ ID NO: 1777)

GTACCATATGTGTCTTTCCATCAAA (SEQ ID NO: 1778)

213656_s_at
KLC1
KLC, KNS2,
kinesin light chain 1
3831
CAGCAGCAGTGGCCTGGAAGACGCC (SEQ ID NO: 1779)

KNS2A,

GCAGTGGCCTGGAAGACGCCACCGC (SEQ ID NO: 1780)

MGC15245

TTCTCCTGCGTCTGTGTGCATAGGA (SEQ ID NO: 1781)

CCTGCGTCTGTGTGCATAGGACATG (SEQ ID NO: 1782)

GTCTGTGTGCATAGGACATGATACT (SEQ ID NO: 1783)

GACATGATACTAATAACCACACGGC (SEQ ID NO: 1784)

AATAACCACACGGCTGGCGTGACCT (SEQ ID NO: 1785)

CCATGTGTAACTTCCTCACGTTGTG (SEQ ID NO: 1786)

TGTAACTTCCTCACGTTGTGTGCGA (SEQ ID NO: 1787)

ACTTCCTCACGTTGTGTGCGATAAC (SEQ ID NO: 1788)

GTGTGCGATAACGTATTTTATTGTA (SEQ ID NO: 1789)

206966_s_at
KLF12
AP-2rep,
Kruppel-like factor 12
11278
CCGCCTTCAAGTCCCATGAATTTAC (SEQ ID NO: 1790)

AP2REP,

CAAACTGAGTCATGTTCACCGCATC (SEQ ID NO: 1791)

HSPC122

CATCCCCGTGGTGGTACAGTCGGTG (SEQ ID NO: 1792)

TGGTACAGTCGGTGCCTGTTGTCTA (SEQ ID NO: 1793)

GTCTACACAGCTGTAAGGTCACCTG (SEQ ID NO: 1794)

GAACAACACTATTGTCGTGCCGCTT (SEQ ID NO: 1795)

GTCGTGCCGCTTTTGGAGGATGGGA (SEQ ID NO: 1796)

TGGCAAAGCACAAATGGACCCCCGA (SEQ ID NO: 1797)

AGGCCTATCTCCCAGACAAAGTAAA (SEQ ID NO: 1798)

AAATGTGACCTTAGATAGCGTTAAT (SEQ ID NO: 1799)

CCCTTTCCATAGCCAGAGCAGTACA (SEQ ID NO: 1800)

205569_at
LAMP3
CD208, DC-
lysosomal-associated
27074
AGCCTATCCTTAATAAATCCTCCAC (SEQ ID NO: 1801)

LAMP, DCLAMP,
membrane protein 3

AATCCTCCACTCTCTGGAAGGAGAC (SEQ ID NO: 1802)

LAMP, TSC403

GAAACTTCGCTAACCAACTGTTCTT (SEQ ID NO: 1803)

GTTCTTTCTTGAGTGTATAGCCCCA (SEQ ID NO: 1804)

ATAGCCCCATCTTGTGGTAACTTGC (SEQ ID NO: 1805)

GCTTCTGCACTTCATATCCATATTT (SEQ ID NO: 1806)

ATCCATATTTCCTATTGTTCACTTT (SEQ ID NO: 1807)

TTTATTCTGTAGAGCAGCCTGCCAA (SEQ ID NO: 1808)

AAAGTCCACATAACCCTAGAATTCT (SEQ ID NO: 1809)

GCCTAGAGACCATGTTGACTTTCCT (SEQ ID NO: 1810)

GGCAAGGTCCTGACTTTAGTCTTAA (SEQ ID NO: 1811)

202019_s_at
LANCL1
GPR69A, p40
LanC lantibiotic
10314
TCTACAACCTCACACAGGACATGAA (SEQ ID NO: 1812)

synthetase

GAAGTACCTGTATAGGGCCTGTAAG (SEQ ID NO: 1813)

component C-like 1

GGGCCTGTAAGTTTGCTGAATGGTG (SEQ ID NO: 1814)

(bacterial)

TTCTCTCTCTTTGAAGGAATGGCTG (SEQ ID NO: 1815)

CAATATATTTCCTGGCTGACCTGCT (SEQ ID NO: 1816)

CCTGCTAGTCCCCACAAAAGCCAGG (SEQ ID NO: 1817)

AGCCAGGTTCCCTGCATTTGAACTC (SEQ ID NO: 1818)

AAAGGATAGCATGCCACCTGCAACT (SEQ ID NO: 1819)

CTGCATGACCCTTTCTGTATATTCA (SEQ ID NO: 1820)

AACCCAAGCTAAGTGCTTCCGTTGC (SEQ ID NO: 1821)

GTGCTTCCGTTGCTTTCCAAGGAAA (SEQ ID NO: 1822)

217933_s_at
LAP3
LAP, LAPEP,
leucine
51056
ATGTACAGCTGCAGCATTCCTGAAA (SEQ ID NO: 1823)

PEPS
aminopeptidase 3

GTAACTCATCCTAAGTGGGCACATT (SEQ ID NO: 1824)

TGGGCACATTTAGACATAGCAGGCG (SEQ ID NO: 1825)

GCAGGCGTGATGACCAACAAAGATG (SEQ ID NO: 1826)

GAAGTTCCCTATCTACGGAAAGGCA (SEQ ID NO: 1827)

GAAAGGCATGACTGGGAGGCCCACA (SEQ ID NO: 1828)

GGCCCACAAGGACTCTCATTGAGTT (SEQ ID NO: 1829)

GAGTTCTTACTTCGTTTCAGTCAAG (SEQ ID NO: 1830)

GACAATGCTTAGTTCAGATACTCAA (SEQ ID NO: 1831)

AGAACTTCCTAATCACTTTTCAGAG (SEQ ID NO: 1832)

GAAAATTACTATGCACTTGTCAGAA (SEQ ID NO: 1833)

218717_s_at
LEPREL1
FLJ10718,
leprecan-like 1
55214
GAAACTACAACTCTCACGTGTGCTC (SEQ ID NO: 1834)

MLAT4, P3H2

TAGGTGCTAACGGCCATGAGCTCCG (SEQ ID NO: 1835)

GCTCCGACTCTCCAAAGTGAGCTCC (SEQ ID NO: 1836)

CCACGCTGCCTCAGGTATCATGGGC (SEQ ID NO: 1837)

TGGGCGTAATGATCACCCAGGCTCC (SEQ ID NO: 1838)

CAGGCTCCGGGAGATCTCATGGATG (SEQ ID NO: 1839)

GAATTTTTGGCTCTGGTGTTTTCGC (SEQ ID NO: 1840)

ACTGGAAGCTTTGATTCACCCTCCA (SEQ ID NO: 1841)

TAGTAGAATGGCTTTTCACCCTGGT (SEQ ID NO: 1842)

GAAACTCTTGAATACTGCCTGCATC (SEQ ID NO: 1843)

CACCATGGCCAGGTTGCCTAGGAGT (SEQ ID NO: 1844)

203236_s_at
LGALS9
HUAT,
lectin, galactoside-
3965
ATCCAGCTGACCCATGTGCAGACAT (SEQ ID NO: 1845)

LGALS9A,
binding, soluble, 9

ATGTGCAGACATAGGCGGCTTCCTG (SEQ ID NO: 1846)

MGC117375,
(galectin 9)

GGATCTGGGCTTTAATGCAGAGGCC (SEQ ID NO: 1847)

MGC125973,

TTTAATGCAGAGGCCATGTCCTTGT (SEQ ID NO: 1848)

MGC125974

GCCACCCTGGAACGGAGAAGGCAGC (SEQ ID NO: 1849)

AGGCAGCTGACGGGGATTGCCTTCC (SEQ ID NO: 1850)

CCCAGGAGGCAGGCACAGCCAGGGA (SEQ ID NO: 1851)

GGAGAGGGGAGGAGTGGGCAGTGAA (SEQ ID NO: 1852)

CCCCTCCTGGAAAGCAGGCCTGATG (SEQ ID NO: 1853)

TGGAAAGCAGGCCTGATGGCTTCCC (SEQ ID NO: 1854)

CCACCTGACCAGAGTGTTCTCTTCA (SEQ ID NO: 1855)

218272_at
LL22NC03-
LL22NC03-
hypothetical protein
55020
TACAGATCAGCGCGCACATGGGGTC (SEQ ID NO: 1856)

5H6.5
5H6.5, FLJ20699
FLJ20699

TGTCTCTGGGGCGAGTCTTGGAGCC (SEQ ID NO: 1857)

CTGTTGGTGCTGATTTGGACCCGTT (SEQ ID NO: 1858)

GAGCTGCTCTGTTGTGGCAAAACCC (SEQ ID NO: 1859)

AAGTGCTGTGATGTGTGGCTGTGAC (SEQ ID NO: 1860)

GGCTGTGACAAGCCTGGAGCGGGTC (SEQ ID NO: 1861)

CACTGAACGCCTGCTGAATGTGCCG (SEQ ID NO: 1862)

CTGAATGTGCCGCTGACTCAGCTGT (SEQ ID NO: 1863)

GAAGCAGGCAGGCCTCTCAGAAGGG (SEQ ID NO: 1864)

GAGGCCTCCAAATCTATTGAGTCCC (SEQ ID NO: 1865)

TTGAGTCCCCACAGTTTGCTCAAGC (SEQ ID NO: 1866)

219095_at
LOC100131005
/// JMJD7,
similar to PLA2G4B
100131005
TGGGGAGGTGAACCTGTCTTCATCG (SEQ ID NO: 1867)

///
FLJ20543,
protein /// jumonji
100137047
TCTCCCTACCACTACACGAAGGTGA (SEQ ID NO: 1868)

LOC100137047
FLJ20656,
domain containing 7
8681
GTGACCTACAGCCAGGAGGACGTGG (SEQ ID NO: 1869)

///
FLJ20807,
/// JMJD7-PLA2G4B
100137049
CTGCTGCACCTGACACATTACAATG (SEQ ID NO: 1870)

LOC100137047-
FLJ77014,
readthrough

GCGCCAGGCAGTGCAGCGGAGGCGG (SEQ ID NO: 1871)

PLA2G4B ///
FLJ78330 ///
transcript ///

TCCCTGGCTGCTGAGTTGCAGGTGG (SEQ ID NO: 1872)

PLA2G4B
JMJD7-
phospholipase A2,

GGAACTGTCATCACGCAGTGCTTCA (SEQ ID NO: 1873)

PLA2G4B,
group IVB (cytosolic)

GCTTCAGAGCCTCGGGCTCAGGTGG (SEQ ID NO: 1874)

HsT16992,

TCCCAGGGTCCAGGCTGAGGGCTGG (SEQ ID NO: 1875)

PLA2G4B,

GGAGGCCAAGCCCATTTGTGTAATC (SEQ ID NO: 1876)

cPLA2-beta ///

CCTTCTGCGCTACCTTGAGTAGTTG (SEQ ID NO: 1877)

DKFZp686N12131,

FLJ17693,

FLJ42498,

HsT16992,

cPLA2-beta

201569_s_at
LOC100131861
OMP85; SAM50;
sorting and assembly
100131861
GGATATGTGATGGCGTCCAGTTTGG (SEQ ID NO: 1878)

///
TOB55; TRG-3;
machinery
25813
GATGGCGTCCAGTTTGGAGCTGGGA (SEQ ID NO: 1879)

SAMM50
CGI-51;
component 50

GGCGTCCAGTTTGGAGCTGGGATAA (SEQ ID NO: 1880)

YNL026W
homolog (S. cerevisiae)

GAGCTGGGATAAGGTTCCTGTAGCC (SEQ ID NO: 1881)

///

ACACCGTCTCTCGAGGAAACGCGGT (SEQ ID NO: 1882)

hypothetical protein

GTCTCTCGAGGAAACGCGGTTCAGC (SEQ ID NO: 1883)

LOC100131861

GAGGAAACGCGGTTCAGCGATTCTT (SEQ ID NO: 1884)

GAAACGCGGTTCAGCGATTCTTTGA (SEQ ID NO: 1885)

CGCGGTTCAGCGATTCTTTGACTGC (SEQ ID NO: 1886)

GGTTCAGCGATTCTTTGACTGCGGA (SEQ ID NO: 1887)

TTCAGCGATTCTTTGACTGCGGACC (SEQ ID NO: 1888)

214133_at
LOC100133432
/// mucin 6,
hypothetical protein
100131861
GACAGACAGGAAAACACCCACCAGC (SEQ ID NO: 1889)

///
gastric
LOC100131861 ///
4588
CTCCCTGGGGCACCGGTTGGAGAGG (SEQ ID NO: 1890)

MUC6

mucin 6, oligomeric

GAGGCGGACAGTGGTCACGGACCTC (SEQ ID NO: 1891)

mucus/gel-forming

GGCCCAGAACCCTGCAGATGAAGCC (SEQ ID NO: 1892)

GACCCATCAGGGGCGAGGAGGGCAC (SEQ ID NO: 1893)

GGAGGGCACGGAAACCTGTGCCGAG (SEQ ID NO: 1894)

GTGCCGAGATGGGGGCAAGAGGCCC (SEQ ID NO: 1895)

GAGGAGATCCCCAGAGTCAGGGAGG (SEQ ID NO: 1896)

GCCTGTCCTTGGGAGAGGGCGTCAC (SEQ ID NO: 1897)

TCACCCGGTCAGAGACTCCAAATAA (SEQ ID NO: 1898)

GAGACTCCAAATAAACCGGTTCTTG (SEQ ID NO: 1899)

220009_at
LONRF3
RP23-145O4.1,
LON peptidase N-
79836
GGTTTCATTCGCTCAAATTATCCCT (SEQ ID NO: 1900)

4932412G04Rik,
terminal domain and

GATACTCAATCACTTTGGTCCCATG (SEQ ID NO: 1901)

5730439E01Rik,
ring finger 3

AGAAAGACGCCGATCCTCAGATGAA (SEQ ID NO: 1902)

A830039N02Rik,

CTCAGATGAACCCGAATGGCCCAGC (SEQ ID NO: 1903)

AU023707,

GGTGGATGTTAGCAGTTCTTCCCTT (SEQ ID NO: 1904)

Rnf127

GTTCTTCCCTTGGAAAGCCGAGCTC (SEQ ID NO: 1905)

TCCCCTTCCTAGCAATGAGGTCCTT (SEQ ID NO: 1906)

AATGGTATTCGACGAGTCCTGGCCT (SEQ ID NO: 1907)

TGGCCTTCATATCCCGAAACCAAAA (SEQ ID NO: 1908)

GTGGATTGCCGAAGAGGAGCTCCCA (SEQ ID NO: 1909)

GAGGCATCAGCCTGCTGTTGATCAC (SEQ ID NO: 1910)

220816_at
LPAR3
EDG7, Edg-7,
lysophosphatidic acid
23566
TGGCCCCCATTTACAGCAGGAGTTA (SEQ ID NO: 1911)

FLJ98231,
receptor 3

GGAGTTACCTTGTTTTCTGGACAGT (SEQ ID NO: 1912)

GPCR,

CCTTCCTCATCATGGTTGTGGTGTA (SEQ ID NO: 1913)

HOFNH30, LP-

GTACCTGCGGATCTACGTGTACGTC (SEQ ID NO: 1914)

A3, LPA3, RP4-

GAGGAAAACCAACGTCTTGTCTCCG (SEQ ID NO: 1915)

678I3

TCTCCGCATACAAGTGGGTCCATCA (SEQ ID NO: 1916)

GCCGGAGGACACCCATGAAGCTAAT (SEQ ID NO: 1917)

GGGCGTTTGTGGTATGCTGGACCCC (SEQ ID NO: 1918)

GAGAACCCAGAGAGGCGTCCCTCTC (SEQ ID NO: 1919)

CAGGAGTGACACAGGCAGCCAGTAC (SEQ ID NO: 1920)

GCACTTCCTAAACTCTGGATGCCTC (SEQ ID NO: 1921)

201932_at
LRRC41
MGC126571,
leucine rich repeat
10489
CTGGCTGGACCAGGATGCAGTCACA (SEQ ID NO: 1922)

MGC126573,
containing 41

GGCTACCTGCCATGTGGTTAGCGAC (SEQ ID NO: 1923)

MUF1, PP7759,

TGGTTAGCGACTCATGGACTCATCC (SEQ ID NO: 1924)

RP4-636H5.2

TCCCAGGCCTTCGCAGATTATGTTA (SEQ ID NO: 1925)

CGGTACCATCAGCTTGCAGGGGCTG (SEQ ID NO: 1926)

TGCAGGGGCTGAAGCATGGGCTGCC (SEQ ID NO: 1927)

GAGGCCCAGCAAACAGGCATTCTCA (SEQ ID NO: 1928)

GGCATTCTCACAGCTGGGTTTATAG (SEQ ID NO: 1929)

CTCAGTATCCTGGGAACCCTGGGCC (SEQ ID NO: 1930)

ATAATTGCTGAAGAGATCCCCTCCC (SEQ ID NO: 1931)

TCAAACCCTTTCATACCTTTATTCT (SEQ ID NO: 1932)

212904_at
LRRC47
KIAA1185; RP1-
leucine rich repeat
57470
TATGTATTCGTTGTTCTGTTTTTCC (SEQ ID NO: 1933)

286D6.3
containing 47

GATGATTCTGTCGTAAAGTGATGCT (SEQ ID NO: 1934)

AAGTGATGCTATGTTGTCGTTACAA (SEQ ID NO: 1935)

GTGCTGTTACGTGGCACTGTACAGT (SEQ ID NO: 1936)

CAGTCATGTGCCACGTAACAGCGTC (SEQ ID NO: 1937)

CACGTAACAGCGTCTGGGTCAGTGA (SEQ ID NO: 1938)

GGGTCAGTGACGGACACTTACCTGA (SEQ ID NO: 1939)

ACTTACCTGACAGCGGATCCACAAT (SEQ ID NO: 1940)

GATCCACAATATTCTCGTGCAGTGT (SEQ ID NO: 1941)

GCAGTGTGTTTGGAATCCTGGTCTG (SEQ ID NO: 1942)

GTGAGTGATGTTCAGTCATGCTGCT (SEQ ID NO: 1943)

211370_s_at
MAP2K5
AI324775,
mitogen-activated
5607
CATTCTGATGTCTGGAGCTTAGGAA (SEQ ID NO: 1944)

AI428457, MEK5,
protein kinase kinase 5

CTCCAGCTTCTGCAGTGCATTGTTG (SEQ ID NO: 1945)

Mapkk5, Prkmk5

TTGTTGATGAGGATTCGCCCGTCCT (SEQ ID NO: 1946)

CCCGTCCTTCCAGTTGGAGAGTTCT (SEQ ID NO: 1947)

GGAGAGTTCTCGGAGCCATTTGTAC (SEQ ID NO: 1948)

GGAGCCATTTGTACATTTCATCACT (SEQ ID NO: 1949)

ACATTTCATCACTCAGTGTATGCGA (SEQ ID NO: 1950)

GCCAAAAGAAAGGCCAGCACCTGAA (SEQ ID NO: 1951)

GCACCTGAAGAATTGATGGGCCACC (SEQ ID NO: 1952)

AAGAATTGATGGGCCACCCGTTCAT (SEQ ID NO: 1953)

ATGATGGAAATGCCGCCGTGGTGTC (SEQ ID NO: 1954)

206854_s_at
MAP3K7
TAK1, TGF1a
mitogen-activated
6885
GCATGCTCATTGTGTGAAGGCTAGC (SEQ ID NO: 1955)

protein kinase kinase

GGAGGTATCAAACTAGCTGCTATGT (SEQ ID NO: 1956)

kinase 7

CTGCTATGTGCAAACAGCGTCCATT (SEQ ID NO: 1957)

ACAGCGTCCATTTTTTCATATTAGA (SEQ ID NO: 1958)

GGTGGAACCTCAAGAATGACTTTAT (SEQ ID NO: 1959)

ATGACTTTATTCTTGTATCTCATCT (SEQ ID NO: 1960)

GGGATAGTTCCGTGTAAGGGCTTTG (SEQ ID NO: 1961)

GGCTTTGATGCCAGCATCCTTGGAT (SEQ ID NO: 1962)

AGCATCCTTGGATCAGTACTGAACT (SEQ ID NO: 1963)

TGAACTCAGTTCCATCCGTAAAATA (SEQ ID NO: 1964)

GGTAAGTGGCAGCTGCTCTATTTAA (SEQ ID NO: 1965)

243_g_at
MAP4
DKFZp779A1753,
microtubule-
4134
TTCTTTTCTAACCAAGAGGCTGGTT (SEQ ID NO: 1966)

MGC8617
associated protein 4

TTGGCATCTCTGTCCCATTCCCTGG (SEQ ID NO: 1967)

AGATGGAATTCCTTCAGGCCGGCAC (SEQ ID NO: 1968)

TCCAAGGGAGCCTCATGCAGATAGT (SEQ ID NO: 1969)

AAGGGAGCCTCATGCAGATAGTAGG (SEQ ID NO: 1970)

GAGCCTCATGCAGATAGTAGGAAAT (SEQ ID NO: 1971)

CCTCATGCAGATAGTAGGAAATCAG (SEQ ID NO: 1972)

GAGACTAAGGCTATCTGCTTCCCTT (SEQ ID NO: 1973)

ACTAAGGCTATCTGCTTCCCTTATG (SEQ ID NO: 1974)

AAGGCTATCTGCTTCCCTTATGCCC (SEQ ID NO: 1975)

TCTGCTTCCCTTATGCCCTGACTGG (SEQ ID NO: 1976)

AGGGCATCCCAGCTAGGCCTTGGGA (SEQ ID NO: 1977)

GAGAAATCCCGGGAACTGTATTGAC (SEQ ID NO: 1978)

AATCCCGGGAACTGTATTGACACAA (SEQ ID NO: 1979)

ATTGACACAAAGATTCTTATTGCAC (SEQ ID NO: 1980)

ACACAAAGATTCTTATTGCACTTGT (SEQ ID NO: 1981)

218181_s_at
MAP4K4
FLH21957,
mitogen-activated
9448
GTAACTTCTCCACAGAAGTGCCAAT (SEQ ID NO: 1982)

FLJ10410,
protein kinase kinase

AAACAGTATTGCAATGACACCATTA (SEQ ID NO: 1983)

FLJ20373,
kinase kinase 4

TGTTAGAGGAGTGCTCTTCCAAACA (SEQ ID NO: 1984)

FLJ90111, HGK,

AGGTTTAGTCAGAGCTTTCACAAGT (SEQ ID NO: 1985)

KIAA0687, NIK

GAGTAACCCTTTCTGTATTGAGTGC (SEQ ID NO: 1986)

GTTTTGTTACACTAATGCGCACCAC (SEQ ID NO: 1987)

CACTAATGCGCACCACATATTTATG (SEQ ID NO: 1988)

GGTTTTCGTCTTAGTTGTAGCACAC (SEQ ID NO: 1989)

GTAGCACACTTACCCTAATTTTGCC (SEQ ID NO: 1990)

GACTGGTGGCAAGTACACAGCCCTT (SEQ ID NO: 1991)

CCCTTTTTTTTGCAGTGCTAACTTG (SEQ ID NO: 1992)

203552_at
MAP4K5
GCKR, KHS,
mitogen-activated
11183
ACACACACATGCAATTTTGCTTAAC (SEQ ID NO: 1993)

KHS1,
protein kinase kinase

GAAGGGGTGTGTATGTCTAGCTGTG (SEQ ID NO: 1994)

MAPKKKK5
kinase kinase 5

ATGTCTAGCTGTGTCTACCATGTGT (SEQ ID NO: 1995)

GTCTACCATGTGTATGTATTCTTGA (SEQ ID NO: 1996)

AATCTTCATATATATTATCATCCCT (SEQ ID NO: 1997)

ATATTATCATCCCTAATGTAGCAGG (SEQ ID NO: 1998)

GGGAAGTATTTAATTGCCCATGATA (SEQ ID NO: 1999)

ATTTTACTTATACTATGCCAGAGAG (SEQ ID NO: 2000)

TTACACATGTAATCTTGGGTTTTTC (SEQ ID NO: 2001)

GTTTTTCACATATGTAGGTATTCAT (SEQ ID NO: 2002)

GAATTCCTGATGGGATAGTATCAAT (SEQ ID NO: 2003)

212871_at
MAPKAPK5
MAPKAPK5,
mitogen-activated
8550
TGCCTTCTGCTCAGCTGATGATGGA (SEQ ID NO: 2004)

PRAK
protein kinase-

GTTGCAGGAATCCAGCAGGCTCACG (SEQ ID NO: 2005)

activated protein

GGCTCACGCGGAACAGTTGGCCAAC (SEQ ID NO: 2006)

kinase 5

GGCCAACATGAGAATCCAGGATCTG (SEQ ID NO: 2007)

ACAACCCCATTCTGCGGAAGAGGAA (SEQ ID NO: 2008)

AGAGGAAGTTACTTGGCACCAAGCC (SEQ ID NO: 2009)

GACAGTGTCTATATCCACGACCATG (SEQ ID NO: 2010)

GGAGCCGAGGATTCCAATGTTGCCT (SEQ ID NO: 2011)

ATGTGATTGCTCAGTGTATTCTCCC (SEQ ID NO: 2012)

CCCACGAATCCCAATAATGACAGCT (SEQ ID NO: 2013)

ATGACAGCTTCAGACTTTGTTTTTT (SEQ ID NO: 2014)

205018_s_at
MBNL2
RP11-128N14.1,
muscleblind-like 2
10150
CCTGTTTCCTCCTCAATAGAATTGC (SEQ ID NO: 2015)

DKFZp781H1296,
(Drosophila)

GTTCTTCTGGACAGACCACAACTCT (SEQ ID NO: 2016)

MBLL, MBLL39,

GAAGCTAGTGCTGCTATCTCATATA (SEQ ID NO: 2017)

MGC120625,

GATAGTTAACTACCTGAGACCAGCT (SEQ ID NO: 2018)

MGC120626,

AGGAATATTGTCTTATCTCCATAAC (SEQ ID NO: 2019)

MGC120628,

CAAGGGCAGGTTCGATTCTAGCTCT (SEQ ID NO: 2020)

PRO2032

TTCTAGCTCTAATTACTGTCATGTC (SEQ ID NO: 2021)

TACTGTCATGTCATTTACCCACTGG (SEQ ID NO: 2022)

GGTATGTTTCACTTCTTGACAATAT (SEQ ID NO: 2023)

AACCGATACCTGTCCTGCAGGTCTA (SEQ ID NO: 2024)

CAAGCACAAGTACTGGGGACACATC (SEQ ID NO: 2025)

201755_at
MCM5
CDC46,
minichromosome
4174
CATCGCGGAAGCCCTCAGCAAGATG (SEQ ID NO: 2026)

MGC5315, P1-
maintenance

GCTCTTCCAAGTGTCCACGTTGGAT (SEQ ID NO: 2027)

CDC46
complex component 5

TTGTCCGGTACCCTGTCAGGGGTGG (SEQ ID NO: 2028)

TGTCAGGGGTGGAGGGCTTCACCAG (SEQ ID NO: 2029)

GAGGACCAGGAGATGCTGAGCCGCA (SEQ ID NO: 2030)

ATGCTGAGCCGCATCGAGAAGCAGC (SEQ ID NO: 2031)

CATCGAGAAGCAGCTCAAGCGCCGC (SEQ ID NO: 2032)

TCCCAGGTGTCTGAGCACAGCATCA (SEQ ID NO: 2033)

GCACAGCATCATCAAGGACTTCACC (SEQ ID NO: 2034)

GGACTTCACCAAGCAGAAATACCCG (SEQ ID NO: 2035)

CGCCCGCTCTAGCGGGTTCTGGGAA (SEQ ID NO: 2036)

216237_s_at
MCM5
CDC46,
minichromosome
4174
CGGCGAGATCCAGCATCGCATGCAG (SEQ ID NO: 2037)

MGC5315, P1-
maintenance

GCGAGATCCAGCATCGCATGCAGCG (SEQ ID NO: 2038)

CDC46
complex component 5

CCAGCATCGCATGCAGCGCAAGGTT (SEQ ID NO: 2039)

GCATCGCATGCAGCGCAAGGTTCTC (SEQ ID NO: 2040)

TCGCATGCAGCGCAAGGTTCTCTAC (SEQ ID NO: 2041)

CTGCCTGCCATTGACAATGTTGCTG (SEQ ID NO: 2042)

TTGACAATGTTGCTGGGACCTCTGC (SEQ ID NO: 2043)

GAGGAAGGAGCTGTAGTGTCCTGCT (SEQ ID NO: 2044)

GAAGGAGCTGTAGTGTCCTGCTGCC (SEQ ID NO: 2045)

GTTCTGGGAAGTGTGCTTTTGGCAT (SEQ ID NO: 2046)

CTGGGAAGTGTGCTTTTGGCATCCG (SEQ ID NO: 2047)

202556_s_at
MCRS1
ICP22BP,
microspherule protein 1
10445
GGGTCCGGCCTGGAAGATATCCCGG (SEQ ID NO: 2048)

INO80Q,

GAACAACGGTGATTTCTTCATTGCC (SEQ ID NO: 2049)

MCRS2, MSP58,

TGCCAATGAGGGTCGACGGCCCATC (SEQ ID NO: 2050)

P78

GACGGCCCATCTACATCGATGGACG (SEQ ID NO: 2051)

CGCCTCAGCAACAACTCTGTGGTGG (SEQ ID NO: 2052)

TCGTCTTCCTTATCAACCAGGACCT (SEQ ID NO: 2053)

AGGAGTGGTGGCAGGACTCGTGGGC (SEQ ID NO: 2054)

TGAGCTGGGAACTCAGGCTCCTGGA (SEQ ID NO: 2055)

GCTGCGGGCCATTGATTTGAGCCTT (SEQ ID NO: 2056)

GAGGGAGGATAGGGCTGGCCTTTGT (SEQ ID NO: 2057)

GTCTCCAGCTGATTAGCCTCAGACT (SEQ ID NO: 2058)

219051_x_at
METRN
MGC2601;
meteorin, glial cell
79006
CGCTTTGAGCTGCGCGAGGACGGGC (SEQ ID NO: 2059)

C16orf23;
differentiation

GCACCAGCGACTTCGTAATTCACGG (SEQ ID NO: 2060)

c380A1.2
regulator

CAGCGACTTCGTAATTCACGGGATC (SEQ ID NO: 2061)

TCACGGGATCATCCATGGGGTCACC (SEQ ID NO: 2062)

TCACCCATGACGTGGAGCTGCAGGA (SEQ ID NO: 2063)

GCTGCAGGAGTCTGTCATCACTGTG (SEQ ID NO: 2064)

TCATGGGCTGGAGCCGCTTTGGGGA (SEQ ID NO: 2065)

GCTGCACTGAGGGGCTGGGTGCTGG (SEQ ID NO: 2066)

TGCTGGGGAGGGGCTGGTAGGAGGG (SEQ ID NO: 2067)

TGGTAGGAGGGAGGGTGGGCCCACT (SEQ ID NO: 2068)

GGCCCACTGCTTTGGAGGTGATGGG (SEQ ID NO: 2069)

213653_at
METTL3
M6A, MGC4336,
methyltransferase
56339
CTGTTATCTGTGGTGAGCAGGTTGG (SEQ ID NO: 2070)

MT-A70, Spo8
like 3

ATCTGTGGTGAGCAGGTTGGTGTCA (SEQ ID NO: 2071)

GTGGTGAGCAGGTTGGTGTCAAAGG (SEQ ID NO: 2072)

GATCGTAGCTGAGGTATGTGCTTCC (SEQ ID NO: 2073)

TAGCTGAGGTATGTGCTTCCCAGGC (SEQ ID NO: 2074)

CCTCCAAAGCTTCCACATTTTTGTT (SEQ ID NO: 2075)

GGGTGTATTCTCATCCCAGATTTTT (SEQ ID NO: 2076)

GATTTTTCTCATTTAGATCATAAAC (SEQ ID NO: 2077)

GAAAGGGCTAGAATTGCAATCTTGT (SEQ ID NO: 2078)

GGCTAGAATTGCAATCTTGTGTAAC (SEQ ID NO: 2079)

GAATTGCAATCTTGTGTAACTTAAA (SEQ ID NO: 2080)

213457_at
MFHAS1
FLJ23354,
malignant fibrous
9258
TCACCCCAGCGTGTTCTGTGAACTT (SEQ ID NO: 2081)

LRRC65, MASL1
histiocytoma

TGACAACGCGTGCTTGCAGGGTGCT (SEQ ID NO: 2082)

amplified sequence 1

AGGGTGCTTTTTGGATGACTGGGGA (SEQ ID NO: 2083)

GAACCTCAGAACTGTGATCCTCCAA (SEQ ID NO: 2084)

TCCTCCAAGGAGCGCGCTACTTGAA (SEQ ID NO: 2085)

GTCGAATGGCTTCTCAGGGATTTTG (SEQ ID NO: 2086)

GGGATTTTGTTTTCCGTGCACATAT (SEQ ID NO: 2087)

AGAGCACTCAGATTTCAGTTCTGTT (SEQ ID NO: 2088)

GAGGGATCGACTGACGTTCATTGCT (SEQ ID NO: 2089)

GACGTTCATTGCTGTTCCATAACTA (SEQ ID NO: 2090)

GAAGCTTCTAGCGTTAGTTCACACT (SEQ ID NO: 2091)

207013_s_at
MMP16
MMP-X2, MT-
matrix
4325
CTATCCCAAGCCAATCACAGTCTGG (SEQ ID NO: 2092)

MMP2, MT-
metallopeptidase 16

TCCTCAGGGAGCATTTGTACACAAA (SEQ ID NO: 2093)

MMP3, MT3-
(membrane-inserted)

GACACAGCCCACCAGATGATGTAGA (SEQ ID NO: 2094)

MMP

AACTGGACAACACAGCCAGCACTGT (SEQ ID NO: 2095)

AGCCATAGCTATTGTCATTCCCTGC (SEQ ID NO: 2096)

ATGCCTCCTTGTATTGGTTTACACT (SEQ ID NO: 2097)

TACTGTACTGTAAACGCTCTATGCA (SEQ ID NO: 2098)

GAGTGGGTGTGATGTAGGGTTTTTT (SEQ ID NO: 2099)

GCTGTTATGCTGTTTCCTAGCTAGG (SEQ ID NO: 2100)

TAGCTAGGAGCAGGCTTGTGGCAGC (SEQ ID NO: 2101)

TTGTGGCAGCCTGATTCGGGGCTGA (SEQ ID NO: 2102)

205828_at
MMP3
MGC126102,
matrix
4314
GAAAATCGATGCAGCCATTTCTGAT (SEQ ID NO: 2103)

MGC126103,
metallopeptidase 3

TTTATTTCTTTACTGGATCTTCACA (SEQ ID NO: 2104)

MGC126104,
(stromelysin 1,

GATCTTCACAGTTGGAGTTTGACCC (SEQ ID NO: 2105)

MMP-3, SL-1,
progelatinase)

TAATTCTTCACCTAAGTCTCTGTGA (SEQ ID NO: 2106)

STMY, STMY1,

ATTGAAATGTTCGTTTTCTCCTGCC (SEQ ID NO: 2107)

STR1

GTGACTCGAGTCACACTCAAGGGAA (SEQ ID NO: 2108)

TGAGCGTGAATCTGTATCTTGCCGG (SEQ ID NO: 2109)

GTATCTTGCCGGTCATTTTTATGTT (SEQ ID NO: 2110)

CAAATGGGCTGCTGCTTAGCTTGCA (SEQ ID NO: 2111)

TTAGCTTGCACCTTGTCACATAGAG (SEQ ID NO: 2112)

GGGGAAGCACTCGTGTGCAACAGAC (SEQ ID NO: 2113)

218853_s_at
MOSPD1
RP3-473B4.2,
motile sperm domain
56180
GTCCCCTAAGCACAACTATTTACAT (SEQ ID NO: 2114)

DJ473B4
containing 1

TACATTTCTTTATAGCCTCTTCTGA (SEQ ID NO: 2115)

TTATAGCCTCTTCTGATCTCTAACA (SEQ ID NO: 2116)

GTAACTGATCTTTTGTCTAAGGATT (SEQ ID NO: 2117)

GAACTTATGCACTGCTACTGTAGTA (SEQ ID NO: 2118)

AACAGTCTCTGCTTCTAAAAACTTC (SEQ ID NO: 2119)

AAAACTTCTATGTCTAGTCTTCCAT (SEQ ID NO: 2120)

TAGGAAATCCTCACTGTTTAACCAT (SEQ ID NO: 2121)

GGAGCCTAAGTCATTAAACGGATCA (SEQ ID NO: 2122)

AACGGATCATGTCTGTACATTGTGT (SEQ ID NO: 2123)

GGAGGCTATTCTTGTTTCTCCATCT (SEQ ID NO: 2124)

64883_at
MOSPD2
MGC26706
motile sperm domain
158747
CAGTTGTCTGCCTGTAAAATGTTGA (SEQ ID NO: 2125)

containing 2

CTGCCTGTAAAATGTTGAGTTTCGA (SEQ ID NO: 2126)

GATATAACAGTTCCTTCAAAATTGG (SEQ ID NO: 2127)

TTCCTTCAAAATTGGCCTAGGAAAT (SEQ ID NO: 2128)

CACCTCCAGCTGTGAAATGGACTGC (SEQ ID NO: 2129)

TCCAGCTGTGAAATGGACTGCAGTC (SEQ ID NO: 2130)

TGAAATGGACTGCAGTCCACCCTAA (SEQ ID NO: 2131)

CCTGTGTGTGTGCACAGTGGCTTCC (SEQ ID NO: 2132)

TATGTTTTCTGTTCCTTGGCAAATA (SEQ ID NO: 2133)

GTTTTCTGTTCCTTGGCAAATAAAT (SEQ ID NO: 2134)

CTGTTCCTTGGCAAATAAATGAAGA (SEQ ID NO: 2135)

AATGTATTGTCCTAACGGTGTCCCT (SEQ ID NO: 2136)

TGTCCTAACGGTGTCCCTTTAATGT (SEQ ID NO: 2137)

TAACGGTGTCCCTTTAATGTTTCAT (SEQ ID NO: 2138)

GTGTCCCTTTAATGTTTCATATGAA (SEQ ID NO: 2139)

AATATCCTTGCTCAATGTCTGGTCA (SEQ ID NO: 2140)

221771_s_at
MPHOSPH8
RP11-523H24.1,
M-phase
54737
CTATACTCTCTTTGACAGCAGTTTG (SEQ ID NO: 2141)

FLJ35237,
phosphoprotein 8

GACAGCAGTTTGGAATTCTTCTAGC (SEQ ID NO: 2142)

HSMPP8, TWA3,

GGAATTCTTCTAGCACATCTATGTA (SEQ ID NO: 2143)

mpp8

AGTTTTGTCTGTAAACCTCTTGCAG (SEQ ID NO: 2144)

GTGTCTGTGCCAGTATGCCGGAATC (SEQ ID NO: 2145)

TGCCAGTATGCCGGAATCTCAGTGC (SEQ ID NO: 2146)

GCCGGAATCTCAGTGCAGTGTCCAG (SEQ ID NO: 2147)

GGAATCTCAGTGCAGTGTCCAGACT (SEQ ID NO: 2148)

CAGTGTCCAGACTGCGTATTTCAGT (SEQ ID NO: 2149)

TGCGTATTTCAGTTTTTCCACAATG (SEQ ID NO: 2150)

GTGGATAGTACATATGAGGATTATT (SEQ ID NO: 2151)

217980_s_at
MRPL16
FLJ20484,
mitochondrial
54948
TTGGGCATCGCATGGGGGGAGGCAA (SEQ ID NO: 2152)

L16mt, MRP-L16,
ribosomal protein L16

GTGCTATTGACCACTACGTGACACC (SEQ ID NO: 2153)

PNAS-111

ACGTGACACCTGTGAAGGCTGGCCG (SEQ ID NO: 2154)

GCAAGGTTTCCTTGACCAGGTTGCC (SEQ ID NO: 2155)

TTGCCCTTCGCAGCAAAGGCTGTGA (SEQ ID NO: 2156)

CTGTGAGCCGCGGGACTCTAGAGAA (SEQ ID NO: 2157)

AGAACCCCTGGACATTTGAGCGAAT (SEQ ID NO: 2158)

AGCGAATAGCCACTGCCAACATGCT (SEQ ID NO: 2159)

GTACTGAGCCCATATGACTTGACCC (SEQ ID NO: 2160)

TCAGCCTACCCACTGAAGTCTTTGG (SEQ ID NO: 2161)

GTCTTTGGGTAGCTCTTAAGCCATA (SEQ ID NO: 2162)

203152_at
MRPL40
FLJ41774,
mitochondrial
64976
TATTACCCCTCTAAAGTTCTTGGAT (SEQ ID NO: 2163)

MGC9400, MRP-
ribosomal protein L40

AGCAAGAGAGCGGCCTCAGGTGGAG (SEQ ID NO: 2164)

L22, NLVCF,

GGAGCTCACCTTTGAGGAGACTGAG (SEQ ID NO: 2165)

URIM

GACACCATCAGGGCTATGCTAGAAG (SEQ ID NO: 2166)

GAAGCTCTGGAGGAACTGCAACTGG (SEQ ID NO: 2167)

AACTGCAACTGGAATCCCCGAAGCT (SEQ ID NO: 2168)

TCCATGCTGAGGCCATCAAGCGGGA (SEQ ID NO: 2169)

ATCAAGCGGGATCCTAACCTGTTCC (SEQ ID NO: 2170)

GAAGGAAGGGCCACATTACACACCA (SEQ ID NO: 2171)

GGCTGCTATCCTTAACATGCTGCCC (SEQ ID NO: 2172)

TTAACATGCTGCCCCTGAGAGTAGG (SEQ ID NO: 2173)

219244_s_at
MRPL46
LIECG2;
mitochondrial
26589
GGAACCTTGTCCTGTTAGTCAGAGA (SEQ ID NO: 2174)

P2ECSL;
ribosomal protein L46

CAGGATGTTTGGATACTGCCCCAGG (SEQ ID NO: 2175)

C15orf4;

GCCTGGGGAGACCCTTCGAGGAACA (SEQ ID NO: 2176)

MGC22762

GAAATGCACCCTGTGGGCACTACAC (SEQ ID NO: 2177)

GTAACCTCGGAGCCAAGGIGTTCTT (SEQ ID NO: 2178)

GGTGTTCTTCTTCAAAGCACTGCTA (SEQ ID NO: 2179)

ACTGGAGACTTTTCCCAGGCTGGGA (SEQ ID NO: 2180)

AAGGGCCATCATGTGTGGGTCACTA (SEQ ID NO: 2181)

TTTCAGACCTCTGATGGGCCGAGCT (SEQ ID NO: 2182)

GTGGACGGTGCTCAGACAAGTCTGG (SEQ ID NO: 2183)

GTGATTGCCTCACATTTGCAGGTAA (SEQ ID NO: 2184)

211595_s_at
MRPS11
FLJ22512,
mitochondrial
64963
ACACAGATCCAGGTAGTCTCTGCTA (SEQ ID NO: 2185)

FLJ23406, HCC-2
ribosomal protein

GTCTCTGCTAGTAATGAGCCCCTTG (SEQ ID NO: 2186)

S11

AGCACAGACAGCAGGCATAGCCGCA (SEQ ID NO: 2187)

AGCCGCAGCGGCGAGAGCTAAACAA (SEQ ID NO: 2188)

CAAAAGGGCGTGATCCACATCCGAG (SEQ ID NO: 2189)

TTGTCTGCCATGCACGGACTGATCA (SEQ ID NO: 2190)

GGACTGATCATGGGCGGCCTGGAAG (SEQ ID NO: 2191)

CTCAGCTCCAGTGGGACCTTGTAAA (SEQ ID NO: 2192)

GGACCTTGTAAAATGCTCCCTGTCA (SEQ ID NO: 2193)

TCCCTGTCAGAGCTCTCCAGAATAT (SEQ ID NO: 2194)

GGTGTGCCCCAGAAGTAAGCTTTGC (SEQ ID NO: 2195)

212096_s_at
MTUS1
ATIP; MP44;
mitochondrial tumor
57509
TGGGTCATTTACATGTACACTACAT (SEQ ID NO: 2196)

MTSG1;
suppressor 1

GATACTCATGTTGCATGTTCTTTTA (SEQ ID NO: 2197)

FLJ14295;

TAGTGATTTTGTGTCTTAAGTCTTT (SEQ ID NO: 2198)

KIAA1288;

TAAGTCTTTAACTTCCAATACTTCA (SEQ ID NO: 2199)

DKFZp586D1519;

GTATGTAACCTTCCATGTTTGCTTC (SEQ ID NO: 2200)

DKFZp686F20243

GGAAATGTAGGTTCACTGCCACTTC (SEQ ID NO: 2201)

GGTTCACTGCCACTTCATGAGATAT (SEQ ID NO: 2202)

CATGAGATATCTCTGCTCACGCTTC (SEQ ID NO: 2203)

CAAAGTTGGGTTTGCCATTCATCCC (SEQ ID NO: 2204)

ATGGTAAATCTTGTGTTGTTCCCTG (SEQ ID NO: 2205)

TGTCCTCCGTATTACGTGACCGGCA (SEQ ID NO: 2206)

204056_s_at
MVK
FLJ96772, LRBP,
mevalonate kinase
4598
GCTCCTGACACTGCTGGAGAGGCCC (SEQ ID NO: 2207)

MK, MVLK

GCAGTCCCAGCGGTGGGACCTAGGG (SEQ ID NO: 2208)

ACCTAGGGAGGCATGGTCTGCCCTC (SEQ ID NO: 2209)

CCAGCCGAGCAGGAGGCCTAGGAGG (SEQ ID NO: 2210)

GCCTAGGAGGGTCCTCTGAGACTCC (SEQ ID NO: 2211)

CTGAGACTCCAGACCTGAGGCGAGA (SEQ ID NO: 2212)

TGAGGCGAGAAGGGCTGCTTCCCTG (SEQ ID NO: 2213)

CCTGGGTCCAATGCTCAGGTGCTGG (SEQ ID NO: 2214)

GGGCCTGGTTCCCGGAGAAGTGTGC (SEQ ID NO: 2215)

CCTTCTACCTAGCGGGATGGGGCTC (SEQ ID NO: 2216)

CTTTCTTCCGATCTGTACCTGAGAG (SEQ ID NO: 2217)

203359_s_at
MYCBP
AMY-1
c-myc binding protein
26292
TGTGCTGTTTTTCAATTTGCCTAAT (SEQ ID NO: 2218)

GCCTGCCTTATTTGCTTACTGAGCA (SEQ ID NO: 2219)

CAACTCTGGGTTCACACACAAGCTG (SEQ ID NO: 2220)

AATTATATAGTGCTTTTCTCCCTCA (SEQ ID NO: 2221)

TCTCCCTCAAAGTATTTTTCTAGCC (SEQ ID NO: 2222)

ATTCATTTTATCTTCATTATCCCTG (SEQ ID NO: 2223)

GAGGGGTGCTGAATTTTTAGGCCAA (SEQ ID NO: 2224)

ATCACTCACTAACTGTAGAGCCTTG (SEQ ID NO: 2225)

GAGCCTTGGGCATTATCAGTGAACT (SEQ ID NO: 2226)

TACTCTGAGATTTACTGTCTTCATC (SEQ ID NO: 2227)

TAATGAGTAGAATGTCCGTGATGCC (SEQ ID NO: 2228)

214156_at
MYRIP
DKFZp586F1018,
myosin VIIA and Rab
25924
GGCTTTTTGTTCTGTTGGTGTGATT (SEQ ID NO: 2229)

FLJ44025,
interacting protein

TGACTTCCGAATAGAATGTTTTCTT (SEQ ID NO: 2230)

MGC130034,

GCAACTATTGTTGTGTTACAGTGTT (SEQ ID NO: 2231)

MGC130035,

GTGTACTGTGTAAGCCTTGCAAACA (SEQ ID NO: 2232)

SLAC2-C,

AGCCTGCTGTGTGGCATCTGAACTT (SEQ ID NO: 2233)

SLAC2C

AGGTTTCCTTGTGCCAAATAAGTGC (SEQ ID NO: 2234)

GCATATGTTATAGTTCCAGAAGAAT (SEQ ID NO: 2235)

GGATAATATCTTTGATGACTTCTGA (SEQ ID NO: 2236)

GATGACTTCTGAAAGTTATGCTTCC (SEQ ID NO: 2237)

TTATGCTTCCCTTCATGTTATATGC (SEQ ID NO: 2238)

CACATTGCCAAGAATTACTGTCAAG (SEQ ID NO: 2239)

202259_s_at
N4BP2L2
RP11-298P3.3,
NEDD4 binding
10443
TTTTTCCTTCACTACCTTAAATATG (SEQ ID NO: 2240)

92M18.3, CG005,
protein 2-like 2

GGGTACCTTAGTTTTCTCTATTCAT (SEQ ID NO: 2241)

FLJ36195,

ATTTCAGCTGATTGATCTGTGTGAC (SEQ ID NO: 2242)

FLJ41089,

ATAATCAGCACATCACTTAGTTCAA (SEQ ID NO: 2243)

FLJ43077,

ACAAAATTCCCCAGCAAATGTTAGA (SEQ ID NO: 2244)

PFAAP5

GTAGGTATATCAGTCACCTGGGGAG (SEQ ID NO: 2245)

TGGGGAGTTTTCTTCATAATATGCA (SEQ ID NO: 2246)

CATACATAGTTATCATCCTCCTTCT (SEQ ID NO: 2247)

CCACATGCTTGCCAGTTCTTGAAGG (SEQ ID NO: 2248)

TGGACAGTTGCTTAACATGGTCATA (SEQ ID NO: 2249)

ATATTTCTCTCACTGGATAGTTTTT (SEQ ID NO: 2250)

209272_at
NAB1

NGFI-A binding
4664
ACGTTTCCTGTATTCTAATCTATTT (SEQ ID NO: 2251)

protein 1 (EGR1

ATCTTCCAACTTCCAATATTTATCC (SEQ ID NO: 2252)

binding protein 1)

TTTATCCATTCGTTGTGGACCCACA (SEQ ID NO: 2253)

GTGGACCCACAGATTGCATCTTTAA (SEQ ID NO: 2254)

TTATGTTTCTAGTCTTTCAAGCTTA (SEQ ID NO: 2255)

GGTTACCTCAGTATTACAGCCAATA (SEQ ID NO: 2256)

TATAGTCCAAGGGACCATTTCTCCC (SEQ ID NO: 2257)

CCCGAGTCTCTTACACTTTATTGTG (SEQ ID NO: 2258)

GATGTCCACGTTTTTGTGACTCTTC (SEQ ID NO: 2259)

GAGGTGGGACGAATGCACTTGCTTC (SEQ ID NO: 2260)

TGCACTTGCTTCCTGTGGCAATAAA (SEQ ID NO: 2261)

218189_s_at
NANS
RP11-404F11.3,
N-acetylneuraminic
54187
CTTTCCTGACATTCCCATAGGGTAT (SEQ ID NO: 2262)

SAS
acid synthase (sialic

AGCGATATCTGTGGCCGCAGTGGCT (SEQ ID NO: 2263)

acid synthase)

GGCTCTGGGGGCCAAGGTGTTGGAA (SEQ ID NO: 2264)

GGAACGTCACATAACTTTGGACAAG (SEQ ID NO: 2265)

GAGCCTGGAGAACTGGCCGAGCTGG (SEQ ID NO: 2266)

AATTCCGGAAGGCACCATTCTAACA (SEQ ID NO: 2267)

TTCTAACAATGGACATGCTCACCGT (SEQ ID NO: 2268)

AAGGCTATCCTCCTGAAGACATCTT (SEQ ID NO: 2269)

GAAGACATCTTTAATCTAGTGGGCA (SEQ ID NO: 2270)

GTGGGCAAGAAGGTCCTGGTCACTG (SEQ ID NO: 2271)

GAAGGTCCTGGTCACTGTTGAAGAG (SEQ ID NO: 2272)

200027_at
NARS
ASNRS, NARS1
asparaginyl-tRNA
4677
ATCTTTTCTAACTCTGCTTAGCTGC (SEQ ID NO: 2273)

synthetase

AGCTGCTAATAATCCTGAGGCATAG (SEQ ID NO: 2274)

TAGTGATTCACAGTATCCCTCTTAG (SEQ ID NO: 2275)

AGTATCCCTCTTAGCATTAATTTAA (SEQ ID NO: 2276)

GAGGCAGATTGATTTTCCCTCTTTC (SEQ ID NO: 2277)

CCCACCATGTCCTTAGATCTAATCT (SEQ ID NO: 2278)

TAGATCTAATCTGTGCTACCTTATT (SEQ ID NO: 2279)

GCTACCTTATTAACTCACAGCAGGC (SEQ ID NO: 2280)

ACAGCAGGCTTACTGAATGGCTTCA (SEQ ID NO: 2281)

CAGATTTAGTTGATTTCTCCACCAA (SEQ ID NO: 2282)

GCATGTCATGTATTCTCAATAGGCT (SEQ ID NO: 2283)

214440_at
NAT1
AAC1, NATI
N-acetyltransferase 1
9
GATGGGGTTCACTGTTTGGTGGGCT (SEQ ID NO: 2284)

(arylamine N-

TTCACCCTCACCCATAGGAGATTCA (SEQ ID NO: 2285)

acetyltransferase)

GAAAGCTTGTGCCCAAACATGGTGA (SEQ ID NO: 2286)

AATCTTGTCTATTTGTCATCCAGCT (SEQ ID NO: 2287)

CATCCAGCTCACCAGTTATCAACTG (SEQ ID NO: 2288)

GTTATCAACTGACGACCTATCATGT (SEQ ID NO: 2289)

GACGACCTATCATGTATCTTCTGTA (SEQ ID NO: 2290)

TATCATGTATCTTCTGTACCCTTAC (SEQ ID NO: 2291)

AATCCTAGACATCAAATCATTTCAC (SEQ ID NO: 2292)

AGATGGCCTGTGGTTATCTTGGAAA (SEQ ID NO: 2293)

GTTGGTTTATTGTTGAATTCCTAGA (SEQ ID NO: 2294)

209061_at
NCOA3
RP5-1049G16.3,
nuclear receptor
8202
ATCTGAGGTGAGTTGGGGGTATCTA (SEQ ID NO: 2295)

ACTR, AIB-1,
coactivator 3

GGCTTGATGTCCTAGAAGTTCTTTG (SEQ ID NO: 2296)

AIB1, CAGH16,

AGTTCTTTGATCCAGAGGTGGGTGC (SEQ ID NO: 2297)

CTG26, KAT13B,

GAGGTGGGTGCAGCTGAAAGTAAAC (SEQ ID NO: 2298)

MGC141848,

TGCCAGTTACATGTATGCCTGCCCA (SEQ ID NO: 2299)

RAC3, SRC3,

CCAGTTCCCTTTTTATTTGCAGAAG (SEQ ID NO: 2300)

TNRC14,

TTTTGTTCACAATTAGGTTCCTAGG (SEQ ID NO: 2301)

TNRC16, TRAM-

AACGAGCAGGGTGTTTTCTCTCTTC (SEQ ID NO: 2302)

1, pCIP

CAGGAATTGACTTATACTCTTGAGA (SEQ ID NO: 2303)

ATGGGGGATGGTGAGCTGTGACTGC (SEQ ID NO: 2304)

ACTGCTTTGCTGACCATTTTGGATG (SEQ ID NO: 2305)

203478_at
NDUFC1
MGC117464,
NADH
4717
GGGGCCCAAGGAATTCGCAAGATGG (SEQ ID NO: 2306)

MGC126847,
dehydrogenase

AGGAATTCGCAAGATGGCGCCGTCC (SEQ ID NO: 2307)

MGC138266
(ubiquinone) 1,

GCCCTTCAGTGCGATCAAAGTTCTA (SEQ ID NO: 2308)

subcomplex

GTGCGATCAAAGTTCTACGTGCGAG (SEQ ID NO: 2309)

unknown, 1, 6 kDa

TTCTACGTGCGAGAGCCGCCGAATG (SEQ ID NO: 2310)

CCGCCGAATGCCAAACCTGACTGGC (SEQ ID NO: 2311)

ACCTGACTGGCTGAAAGTTGGGTTC (SEQ ID NO: 2312)

TGAAAGTTGGGTTCACCTTGGGCAC (SEQ ID NO: 2313)

GTCTTCTTGTGGATCTATCTCATCA (SEQ ID NO: 2314)

GGATCTATCTCATCAAACAACACAA (SEQ ID NO: 2315)

CAAGCCAGCATTTGTATTTTGCATC (SEQ ID NO: 2316)

212530_at
NEK7

NIMA (never in
140609
AAGCTATATCTATTCTAAACCTTAT (SEQ ID NO: 2317)

mitosis gene a)-

TTAGACATTGGTACCAGTTACCCAG (SEQ ID NO: 2318)

related kinase 7

GGTGGATGAAGGGTATCTCTATATA (SEQ ID NO: 2319)

AAGTGCTCAACAATGTGCAATGATT (SEQ ID NO: 2320)

GTAAGATATTACAGCCATTTCATGA (SEQ ID NO: 2321)

ATGCTTTACCATTCAACATAGTATC (SEQ ID NO: 2322)

GTATCTATTACAAAACACCTTTCTT (SEQ ID NO: 2323)

AACACCTTTCTTGTATCCATATACT (SEQ ID NO: 2324)

GTATCCATATACTTCAGGTGTTGCT (SEQ ID NO: 2325)

AACCCACAAATGCATACTTACCCTG (SEQ ID NO: 2326)

TTACCCTGTGCCTCATATTTCAATA (SEQ ID NO: 2327)

204321_at
NEO1
DKFZp547A066,
neogenin homolog 1
4756
GAAGCCTGTGTCGAGGCAGCTTCCC (SEQ ID NO: 2328)

DKFZp547B146,
(chicken)

TCCCTTTGCCTGCTGATATTCTGCA (SEQ ID NO: 2329)

HsT17534, NGN

GCAACCTGCATTTCACTTTGTGGTC (SEQ ID NO: 2330)

TTTCACTTTGTGGTCAGGCCGTGTC (SEQ ID NO: 2331)

CGTGTCTTTGTGCTGTGACTGCATC (SEQ ID NO: 2332)

GTGACTGCATCACCTTTATGGAGTG (SEQ ID NO: 2333)

GTCCTTGGTGTTCTCCACAAGTGGT (SEQ ID NO: 2334)

GGTTGACATTTGACTGCTTGTTCCA (SEQ ID NO: 2335)

TTTGACAGTGTGGGTCGTTCCTGGG (SEQ ID NO: 2336)

TTCTGAGTCATTGCATCCTCTACCA (SEQ ID NO: 2337)

TCTACCAGCTGTTAATCCATCACTC (SEQ ID NO: 2338)

206948_at
NEU3
FLJ12388, SIAL3
sialidase 3
10825
ATTTTGCCTTAGCTACTGCAGTGGA (SEQ ID NO: 2339)

(membrane sialidase)

TGGCTTGCTTTTGGACCTTGGATGT (SEQ ID NO: 2340)

TTGGATGTGTCACCTGAACTCTCTG (SEQ ID NO: 2341)

TCTGGACCTCAGGTTTCCATCTGTA (SEQ ID NO: 2342)

ATCTTCTCATCCCTAGGACAAGCAT (SEQ ID NO: 2343)

GCATAGTGCCTGCATGCTTCATGAT (SEQ ID NO: 2344)

ATGATCAGTAAGTCCTGGCTGCATA (SEQ ID NO: 2345)

ACCAGGGGACTTACCTTTTCACATG (SEQ ID NO: 2346)

ACTTACCCCTCATCCGAGTGTGAGG (SEQ ID NO: 2347)

CAAGCAGGTGTCATGGCAGGAAGGA (SEQ ID NO: 2348)

GACCAGATCTGTATGATTTGTTCCA (SEQ ID NO: 2349)

209289_at
NFIB
RP11-280O24.2,
nuclear factor I/B
4781
TGAACGAATTTATTTTCCCCTCAGT (SEQ ID NO: 2350)

HMGIC/NFIB,

TATGTTGGTTTAGCTGCAGCCTCCT (SEQ ID NO: 2351)

NFI-RED, NFIB2,

GTTGCATCAAGAACCCATAGGGTGT (SEQ ID NO: 2352)

NFIB3

TGGGAACGCCAGGGTGTAGGATATA (SEQ ID NO: 2353)

AGGATATAAAAACGCACTCTTGAGA (SEQ ID NO: 2354)

GTGCTGAAAACTTGCATGGTGCTTT (SEQ ID NO: 2355)

GGTGCTTTCAGACATTAGCCTTGTT (SEQ ID NO: 2356)

GACAGATCCATAGTGTGCATGGGCA (SEQ ID NO: 2357)

GGCAGACACATTTTGCCTCTATGTC (SEQ ID NO: 2358)

ACTCTTTCCAGTAATCCTAATTTGC (SEQ ID NO: 2359)

TGCACGAAGATATAATGTCCACATT (SEQ ID NO: 2360)

204109_s_at
NFYA
CBF-A, CBF-B,
nuclear transcription
4800
ATGCAGGATCCAAACCAAGCCGATG (SEQ ID NO: 2361)

FLJ11236, HAP2,
factor Y, alpha

CTAACCCCACGCCATGTGATGGAGC (SEQ ID NO: 2362)

NF-YA

GCTGATCAAGGTCATGTTTCTCACT (SEQ ID NO: 2363)

ACATTGATGATCACATTCTGCCCTT (SEQ ID NO: 2364)

CATTCTGCCCTTTACTACAGGACAG (SEQ ID NO: 2365)

GAAGTTGCAAGCCTTTGTCTTACTC (SEQ ID NO: 2366)

GTCTTACTCTTTCAGTCAGGACCTA (SEQ ID NO: 2367)

GCCAGCCATCTCAGCAGGGAAGAAC (SEQ ID NO: 2368)

GAACAACCTTCTCAACCAAAACTGC (SEQ ID NO: 2369)

GGTGGGGGAATCTCACACTGACTAA (SEQ ID NO: 2370)

GGACGCTTTGTATTCAGAGATGGCT (SEQ ID NO: 2371)

217896_s_at
NIP30
CDA018, CDA10,
NEFA-interacting
80011
GCAGGCAGAGCAGCTACTGACTTTG (SEQ ID NO: 2372)

FLJ21799,
nuclear protein NIP30

AGTACAGTGACACTCTGGTGCCCAT (SEQ ID NO: 2373)

MGC74898

CATTGGCAGATGGCGACTTCCCTGC (SEQ ID NO: 2374)

TTCCTCCTTTTCAGAACTACTCTGT (SEQ ID NO: 2375)

ACTACTCTGTGCTAATTGTTCTGCC (SEQ ID NO: 2376)

TGCCAGTATGGGCGCATCAGCTCCA (SEQ ID NO: 2377)

AAACTTTGTAGGCACCTTCTGCTTC (SEQ ID NO: 2378)

CTCTGCTTCATTGTTCCTGTGATAG (SEQ ID NO: 2379)

GTTCCTGTGATAGTCCTGTTGTTAT (SEQ ID NO: 2380)

GGAGGCAGGCCAGGACATCAAAGTC (SEQ ID NO: 2381)

GTATCTCATGGCCTCTTGATGTGGA (SEQ ID NO: 2382)

201591_s_at
NISCH
1200007D05Rik,
nischarin
11188
TTGGGAGTGAGAATGCCGGGCCCCT (SEQ ID NO: 2383)

3202002H23Rik,

CAGGGCTGTCGGTGTGCTGTCAGCC (SEQ ID NO: 2384)

AW494485, I-1

ACACCAGTGTCGTGTCTGCTGTTGT (SEQ ID NO: 2385)

GGGACCGTTGTTAACACGTGACACT (SEQ ID NO: 2386)

GTGACACTGTGGGTCTGACTTTCTC (SEQ ID NO: 2387)

ACGTCCTTTCCTGAAGTGTCGAGTC (SEQ ID NO: 2388)

AGAATGCACATTGGAAGCTCCCACC (SEQ ID NO: 2389)

CCCACCCCATATTGTTCTTCAAAGT (SEQ ID NO: 2390)

TCAAAGTGGAGGTCTCCCCTGATCC (SEQ ID NO: 2391)

CAGCACCAAGCGTGATTCCTGCTGC (SEQ ID NO: 2392)

CTGCCTGTATTCTCTATTCCAATAA (SEQ ID NO: 2393)

221691_x_at
NPM1
B23,
nucleophosmin
4869
GGGGCTTTGAAATAACACCACCAGT (SEQ ID NO: 2394)

MGC104254,
(nucleolar

CACCACCAGTGGTCTTAAGGTTGAA (SEQ ID NO: 2395)

NPM
phosphoprotein B23,

GAAGTGTGGTTCAGGGCCAGTGCAT (SEQ ID NO: 2396)

numatrin)

GGGCCAGTGCATATTAGTGGACAGC (SEQ ID NO: 2397)

TATATCTGGAAAGCGGTCTGCCCCT (SEQ ID NO: 2398)

TCTGCCCCTGGAGGTGGTAGCAAGG (SEQ ID NO: 2399)

GAGATACTCCAGCCAAAAATGCACA (SEQ ID NO: 2400)

GACTCAAAACCATCATCAACACCAA (SEQ ID NO: 2401)

ACACCAAAAGGACCTAGTTCTGTAG (SEQ ID NO: 2402)

AAAGCGCATTGAACAGTCCTGGGCA (SEQ ID NO: 2403)

AACAGTCCTGGGCACTACATGTAAA (SEQ ID NO: 2404)

214066_x_at
NPR2
AMDM, ANPRB,
natriuretic peptide
4882
AGAGCGGAAAGGACCTCCTGGACTC (SEQ ID NO: 2405)

GUC2B,
receptor B/guanylate

CCAAGTCAGATAGTCTTCTGCTGCT (SEQ ID NO: 2406)

GUCY2B, NPRB,
cyclase B

CAGATAGTCTTCTGCTGCTGGTACC (SEQ ID NO: 2407)

NPRBi
(atrionatriuretic

TGCTGGTACCTGGGTGGGCAATGGC (SEQ ID NO: 2408)

peptide receptor B)

GGTGGGCAATGGCCACCATGTCTGC (SEQ ID NO: 2409)

GAAATGGACATTTTCATATGCAATG (SEQ ID NO: 2410)

ATATGCAATGGAAAACAGCCACAAA (SEQ ID NO: 2411)

GCCACAAAAAAACCTACCTTATATG (SEQ ID NO: 2412)

TATATGGAAGTTGTAGCCCTCTGCA (SEQ ID NO: 2413)

CTTCCTCCCTACTTTCTGTAAATAT (SEQ ID NO: 2414)

TCTGTAAATATCTGTATCTAAACCA (SEQ ID NO: 2415)

219789_at
NPR3
ANPRC,
natriuretic peptide
4883
TTATGATTAATCACCATCTGCCTCC (SEQ ID NO: 2416)

GUCY2B, NPRC
receptor C/guanylate

CCAGGCCTTTCATCTCATGACAAAC (SEQ ID NO: 2417)

cyclase C

ATCGTGTCACTCTGTTAAATGTTCA (SEQ ID NO: 2418)

(atrionatriuretic

TGTTCATACTGTTTCAAGCCCATAT (SEQ ID NO: 2419)

peptide receptor C)

TGTTGTCTCCATATCTTGATGGCTT (SEQ ID NO: 2420)

GGCTTTTGGGAGCATTTCACACAAG (SEQ ID NO: 2421)

CAGGTTTGTGGTTGAGGACTTCTCT (SEQ ID NO: 2422)

GGACTTCTCTGTCCGATGTCTACAT (SEQ ID NO: 2423)

GTCTACATTCAGGTTCTGACTTCAT (SEQ ID NO: 2424)

TCCCTGTCTTTTTCAGTGTCTCATA (SEQ ID NO: 2425)

GTCTCATAAACGCTACTCTGGATTG (SEQ ID NO: 2426)

219214_s_at
NT5C
DNT, DNT1,
5′,3′-nucleotidase,
30833
GAAGTACCACCACTGTGTGGGTGAG (SEQ ID NO: 2427)

P5N2, PN-I, PN-
cytosolic

AGTACCGCTGGGTGGAGCAGCACCT (SEQ ID NO: 2428)

II, UMPH2, cdN,

GTAGAACGAATTATCCTGACAAGGG (SEQ ID NO: 2429)

dNT-1

TCTTGGGGGACCTGCTCATTGATGA (SEQ ID NO: 2430)

GACAAGGACACAGTTCGAGGCCAGG (SEQ ID NO: 2431)

GCCAGGAGGAGACCCCAAGCTGGGA (SEQ ID NO: 2432)

CAAGCTGGGAGCACATCTTGTTCAC (SEQ ID NO: 2433)

GATAGCAAGCGCGGAGCTGCGCAGC (SEQ ID NO: 2434)

GCTGCGCAGCGGGAATGAGCGGGGA (SEQ ID NO: 2435)

GGAATGAGCGGGGATGCCGCGGGCA (SEQ ID NO: 2436)

AGGAAGGGCAGGCCCACAGGGGCCA (SEQ ID NO: 2437)

205136_s_at
NUFIP1
MGC95323
nuclear fragile X
26747
AGGGATGTTGTTGATCCCCACACTG (SEQ ID NO: 2438)

mental retardation

ATCCCCACACTGCCTTAAGGTATAT (SEQ ID NO: 2439)

protein interacting

TCCCCTGGCTGTATGTCTGACAGTC (SEQ ID NO: 2440)

protein 1

ATAGCCTGTATGGTTTCTACTTTAT (SEQ ID NO: 2441)

GGGTGGGTAGAGGGGTGCTTTGCCT (SEQ ID NO: 2442)

TGTTAATTGTTCAAACTTTCTGCCT (SEQ ID NO: 2443)

ACATTCCTATCTTATTGTTCGTTTA (SEQ ID NO: 2444)

GACTATTGGTGAGTTGTGCCTTTTA (SEQ ID NO: 2445)

TTACTTTTTCTCATATCCTCTATAA (SEQ ID NO: 2446)

ATAATTGACTTCTATTTTCCTTAAT (SEQ ID NO: 2447)

TATTTTCCTTAATCAAACCAGCTCT (SEQ ID NO: 2448)

209073_s_at
NUMB
S171
numb homolog
8650
TTGTTTTTCAGGCCATTCACCTGCC (SEQ ID NO: 2449)

(Drosophila)

CCTGTCAGTAGTGGCCTGTATTAGA (SEQ ID NO: 2450)

AAGAGTGGTTTGTGCTCAGGCTGGG (SEQ ID NO: 2451)

GGAACAGAGAGGCACGCTATGCTGC (SEQ ID NO: 2452)

CGCTATGCTGCCAGAATTCCCAGGA (SEQ ID NO: 2453)

TTCCCAGGAGGGCATATCAGCAACT (SEQ ID NO: 2454)

TTGAGCTTCCATTTTGAGTAACAGA (SEQ ID NO: 2455)

TTTATCATTGATGCCTACTGAAATA (SEQ ID NO: 2456)

AGACAGGATCCCTAGCTTGTTTTCT (SEQ ID NO: 2457)

GCAACAACAATCATGCTTATGACCA (SEQ ID NO: 2458)

GACCAATACAGTCACTAGGTTGTAG (SEQ ID NO: 2459)

207563_s_at
OGT
FLJ23071,
O-linked N-
8473
AGCGTGTTCCCAATAGTGTACTCTG (SEQ ID NO: 2460)

HRNT1,
acetylglucosamine

TACTCTGGCTGTTGCGTTTTCCAGC (SEQ ID NO: 2461)

MGC22921, O-
(GlcNAc) transferase

GCCCCAGAACCGTATCATTTTTTCA (SEQ ID NO: 2462)

GLCNAC
(UDP-N-

GAGGAACACGTCAGGAGAGGCCAGC (SEQ ID NO: 2463)

acetylglucosamine:polypeptide-

GGACACTCCACTCTGTAATGGGCAC (SEQ ID NO: 2464)

N-

GATGGATGTCCTCTGGGCAGGGACC (SEQ ID NO: 2465)

acetylglucosaminyl

ACCCCCATGGTGACTATGCCAGGAG (SEQ ID NO: 2466)

transferase)

AGGAGAGACTCTTGCTTCTCGAGTT (SEQ ID NO: 2467)

ATCCCAGCTCACTTGCTTAGGTTGT (SEQ ID NO: 2468)

GAGCGGCTCTATCTACAGATGTGGG (SEQ ID NO: 2469)

TGCAGCTGGCAACAAACCTGACCAC (SEQ ID NO: 2470)

212307_s_at
OGT
FLJ23071,
O-linked N-
8473
GATAACATACTTCTTACTTGTCTGT (SEQ ID NO: 2471)

HRNT1,
acetylglucosamine

ACTTGTCTGTACAGTACCTTGTTGC (SEQ ID NO: 2472)

MGC22921, O-
(GlcNAc) transferase

AGACTTGCTTCCTGCATGGTAGGGA (SEQ ID NO: 2473)

GLCNAC
(UDP-N-

AACTGCTTTTCCACAAGGAATCTCC (SEQ ID NO: 2474)

acetylglucosamine:polypeptide-

GAATTTTGCGGCGACCAGATGGTGC (SEQ ID NO: 2475)

N-

AGGTCTGGAAGGTCTGATCTCCCTT (SEQ ID NO: 2476)

acetylglucosaminyl

TCCCTTGGTCTTCCATGGGATGGTT (SEQ ID NO: 2477)

transferase)

GGAGATATAGATTGTCCGGCCGCTT (SEQ ID NO: 2478)

GGCCGCTTTGTGATTCCATGGATTG (SEQ ID NO: 2479)

ATGTTACTCCCTGTTTTAGTTTCTG (SEQ ID NO: 2480)

GGGACTTTGCTGGTGTAGTCTTTTT (SEQ ID NO: 2481)

212213_x_at
OPA1
FLJ12460,
optic atrophy 1
4976
TTATGATATTGCCCTCTTTGTATTC (SEQ ID NO: 2482)

KIAA0567,
(autosomal dominant)

TGTATTCCCATTTTCCACAGTTTTT (SEQ ID NO: 2483)

MGM1, NPG,

GTTTTTTCCGCAGACTTCTTTCTGC (SEQ ID NO: 2484)

NTG, largeG

AATTATTCAGCCTCCAAATGCAAAT (SEQ ID NO: 2485)

ATGGCAGAGAGTGGTGCTTCCCAGC (SEQ ID NO: 2486)

TGCTTCCCAGCCTCACAATGTGGGA (SEQ ID NO: 2487)

TAATGGTTTTTCTCTCAGTTCTCTA (SEQ ID NO: 2488)

AGTTCTCTAAGCTGGTCTATGTTAT (SEQ ID NO: 2489)

AATATGCTTACCTTTTGAATGATCA (SEQ ID NO: 2490)

AACTTACCTTGTTTTCACTTGTGCA (SEQ ID NO: 2491)

ACTTATATTTTGCCTGAGCTTGATC (SEQ ID NO: 2492)

222327_x_at
OR7E156P

olfactory receptor,
283491
GGTACCTCCGTCGGCAGATTTGAGC (SEQ ID NO: 2493)

family 7, subfamily E,

AGATTTGAGCTTTCTCCTTGGACAC (SEQ ID NO: 2494)

member 156

CCTTGGACACCTAATACCCACAGTC (SEQ ID NO: 2495)

pseudogene

TGCGTTCTGACACCTGTCGGATAGT (SEQ ID NO: 2496)

GTCGGCAGATTTGAGCTTTCTTCTT (SEQ ID NO: 2497)

TTTCTTCTTGGACACCTATACCCAC (SEQ ID NO: 2498)

CAGTCCTCCAGTGTTTTAGACGCCC (SEQ ID NO: 2499)

GCCCAGCTGCACAACTTGATTGCCT (SEQ ID NO: 2500)

GATTGCCTTACAAATGACCTGCTTC (SEQ ID NO: 2501)

ATGACCTGCTTCCAGGATGCGGAAA (SEQ ID NO: 2502)

AATTCCTAATTTCTTCTGTGACCCT (SEQ ID NO: 2503)

219073_s_at
OSBPL10
FLJ20363,
oxysterol binding
114884
TGGTCACAGCGCTAGTCATTCATTT (SEQ ID NO: 2504)

ORP10, OSBP9
protein-like 10

TGAAAACATGCACAACCACAGCCTC (SEQ ID NO: 2505)

CCACAGCCTCAATCTTGTATTTAGT (SEQ ID NO: 2506)

TTTCCTGTGGATTATTTTTTCCTCA (SEQ ID NO: 2507)

GACTAAAACATACATAACGCCTGCA (SEQ ID NO: 2508)

AACGCCTGCATAAATATTCCATGGT (SEQ ID NO: 2509)

TTTCAGTTTTTAGCCTTTACACATG (SEQ ID NO: 2510)

AATATCTGGTTTTTGCTGAATGCTT (SEQ ID NO: 2511)

TTACTGTGCCACTCCAATATTTATC (SEQ ID NO: 2512)

GCTTTCTTAAGACCAGTTGTTCACA (SEQ ID NO: 2513)

GACCAGTTGTTCACACTTTGTAGAT (SEQ ID NO: 2514)

209626_s_at
OSBPL3
1200014M06Rik,
oxysterol binding
26031
ATAGCTTCACACAGTTTGCGCTGGA (SEQ ID NO: 2515)

6720421I08Rik,
protein-like 3

CAAAGTCTTTATTGCCACCTACTGA (SEQ ID NO: 2516)

A530055M08,

GACACTCGATTTAGGCCAGACCAGA (SEQ ID NO: 2517)

MGC102333,

GAGAGAAAGGCGGCGGGTCTTAGAA (SEQ ID NO: 2518)

ORP3, OSBP3

GGAAATCCGACGATGACTCTTGGGT (SEQ ID NO: 2519)

GAGCAACGGCACCTATTTGGAACTT (SEQ ID NO: 2520)

ACTGGACCATCCTGTCTTATGGTGA (SEQ ID NO: 2521)

ATAACATTAGTGTATTTCTCCTGTG (SEQ ID NO: 2522)

GATGATCACTTGTGCTTAGCTTAGC (SEQ ID NO: 2523)

TCTTTAAGTCTATATTTTCCTCAGT (SEQ ID NO: 2524)

TTTCCTCAGTGCGTTTCTTTACAAT (SEQ ID NO: 2525)

209627_s_at
OSBPL3
1200014M06Rik,
oxysterol binding
26031
GTTATGCCTTCTGGCTACTACAGAA (SEQ ID NO: 2526)

6720421I08Rik,
protein-like 3

ACAGAATCTCCGCAGACCTTTTAGT (SEQ ID NO: 2527)

A530055M08,

GAAGGTGTCCTTATGGTCTTAGGAA (SEQ ID NO: 2528)

MGC102333,

ATAGCTATTTTCATTTGCTCTATTT (SEQ ID NO: 2529)

ORP3, OSBP3

TGCTCTATTTTCCTCTGCATTGTAC (SEQ ID NO: 2530)

GCATTGTACTAATCTGTTACTCAGT (SEQ ID NO: 2531)

GTTACTCAGTGTTAGTCTTCATTTT (SEQ ID NO: 2532)

GTGTTGGAAACCTGCGTCATGTAAA (SEQ ID NO: 2533)

AATCTTCCACTTAACCACTGAAAAT (SEQ ID NO: 2534)

AGCTCCTATTAATTTGCTTATCCCC (SEQ ID NO: 2535)

TATCCCCCTCATGTAGCTAGTTGAA (SEQ ID NO: 2536)

200656_s_at
P4HB
PDI
procollagen-proline,
5034
AGTGCCGACAGGACGGTCATTGATT (SEQ ID NO: 2537)

2-oxoglutarate 4-

GGACGGTCATTGATTACAACGGGGA (SEQ ID NO: 2538)

dioxygenase (proline

GATTACAACGGGGAACGCACGCTGG (SEQ ID NO: 2539)

4-hydroxylase), beta

TACAACGGGGAACGCACGCTGGATG (SEQ ID NO: 2540)

polypeptide

GGGAACGCACGCTGGATGGTTTTAA (SEQ ID NO: 2541)

GAAGCAGAGGAGCCAGACATGGAGG (SEQ ID NO: 2542)

AAGATGAACTGTAATACGCAAAGCC (SEQ ID NO: 2543)

GTTTCCTGAAACCATGATGTACTTT (SEQ ID NO: 2544)

GTACTTTTTCATACATGAGTCTGTC (SEQ ID NO: 2545)

CATACATGAGTCTGTCCAGAGTGCT (SEQ ID NO: 2546)

TGCTTGCTACCGTGTTCGGAGTCTC (SEQ ID NO: 2547)

201013_s_at
PAICS
ADE2, ADE2H1,
phosphoribosylaminoimidazole
10606
AACTGGCATTACTGACTCCCAGCTA (SEQ ID NO: 2548)

AIRC,
carboxylase,

CCAGCTATATTTCTCCAGACTTGCA (SEQ ID NO: 2549)

DKFZp781N1372,
phosphoribosylaminoimidazole

AATTGCTGATGTGACCCATGAAGGG (SEQ ID NO: 2550)

MGC1343,
succinocarboxamide

TTTTCCTCGTAATTTTGGACTGCCA (SEQ ID NO: 2551)

MGC5024, PAIS
synthetase

TGGACTGCCACACATTGGTACCTTT (SEQ ID NO: 2552)

ACATTGGTACCTTTAGTTCTCTGAA (SEQ ID NO: 2553)

TTCTCTGAAGGCCCACGTTTTTATC (SEQ ID NO: 2554)

GTAGAGCTTTATGTTCGCTGTCCAT (SEQ ID NO: 2555)

GCTGTCCATGAAACCTTCTGTAACC (SEQ ID NO: 2556)

TGACTACAAGTAGTTCTTTCTCTAT (SEQ ID NO: 2557)

GCTATGCTTAGCTATCTGTCAGAGA (SEQ ID NO: 2558)

212958_x_at
PAM
PAL, PHM
peptidylglycine alpha-
5066
AATTTCCACAGATACTTCCCTTAGA (SEQ ID NO: 2559)

amidating

TGAGCGAGGCCTTGTCAATTTTAAG (SEQ ID NO: 2560)

monooxygenase

TAGGAAGGACCACAACATGACCCGT (SEQ ID NO: 2561)

TACACACTTTATTTACTTCGTTTTG (SEQ ID NO: 2562)

GTTGGCTTCTGTTTCTAGTTGAGGA (SEQ ID NO: 2563)

TCCTCTTTTTCCATCATAATTCTAA (SEQ ID NO: 2564)

GATTTGCCCATTTACACTTTTGAGA (SEQ ID NO: 2565)

GTAAATAACCCCATTCTTTGCTTGA (SEQ ID NO: 2566)

GTATTTTCCCAATAGCACTTTCATT (SEQ ID NO: 2567)

ATTGCCAGTGTCTTTCTTTGGTGCC (SEQ ID NO: 2568)

TTCAGCATTCTTAGCCTGTGGCAAT (SEQ ID NO: 2569)

219148_at
PBK
SPK; TOPK;
PDZ binding kinase
55872
AGCATACTATGCAGCGTTGGGAACT (SEQ ID NO: 2570)

Nori-3; FLJ14385

CAGCGTTGGGAACTAGGCCACCTAT (SEQ ID NO: 2571)

TGAACTCTTCTCTGTATGCACTAAT (SEQ ID NO: 2572)

AGACCCTAAAGATCGTCCTTCTGCT (SEQ ID NO: 2573)

ATGTCTAGTGATCATCTCAGCTGAA (SEQ ID NO: 2574)

GTGTGGCTTGCGTAAATAACTGTTT (SEQ ID NO: 2575)

GAGGACCATAGTTTCTTGTTAACAT (SEQ ID NO: 2576)

AAGCACTTGGAATTGTACTGGGTTT (SEQ ID NO: 2577)

GTACTTTGATACTGCTCATGCTGAC (SEQ ID NO: 2578)

TGCTCATGCTGACTTAAAACACTAG (SEQ ID NO: 2579)

GGATCTACTGACATTAGCACTTTGT (SEQ ID NO: 2580)

204476_s_at
PC
PCB
pyruvate carboxylase
5091
GGTGACCTCACCCATGGAGGGTACT (SEQ ID NO: 2581)

GGTACTGTCCGCAAGGTTCATGTGA (SEQ ID NO: 2582)

TGGAAGGTGACGACCTCATCCTGGA (SEQ ID NO: 2583)

GGAGATCGAGTGATCTTGCCCCAGA (SEQ ID NO: 2584)

TCAACAGAAGCTGTGCTGCCACGGC (SEQ ID NO: 2585)

CAGTGCCCGAGGCCAGGAAGGCCGG (SEQ ID NO: 2586)

GACACCGCCTGCGGTGGTTCATTCC (SEQ ID NO: 2587)

GACAGCTGCTTACATGTTCATCTCT (SEQ ID NO: 2588)

ATCTCTTGCCAAATAAGGGTCCCCT (SEQ ID NO: 2589)

GGGTCAGGTGGTCCTAGGACCCAGG (SEQ ID NO: 2590)

AGATCTAAGATGTCCCAGGTCCTGG (SEQ ID NO: 2591)

214239_x_at
PCGF2
MEL-18,
polycomb group ring
7703
AGATTTCCTCAAGTGTGCATAGATC (SEQ ID NO: 2592)

MGC10545,
finger 2

GTGTGCATAGATCTGAGAGGAGTCG (SEQ ID NO: 2593)

RNF110, ZNF144

GTCGAGACTCGAGATTCCATCATAG (SEQ ID NO: 2594)

GAGATTCCATCATAGCGTAGGTGTG (SEQ ID NO: 2595)

TAGCGTAGGTGTGTGGGGTTGGGAG (SEQ ID NO: 2596)

CCCTGATGGGCTTGTCTGTGTTTGC (SEQ ID NO: 2597)

CTGTGTCTGAGGTCCTGTGACTGTA (SEQ ID NO: 2598)

TCTGAGGTCCTGTGACTGTACCCTC (SEQ ID NO: 2599)

TCCTTTGCCCTGGGACATCTGTATC (SEQ ID NO: 2600)

CATCTGTATCTCTTGGCTTTGTAAT (SEQ ID NO: 2601)

GGCTTTGTAATAAATGCTGCATACT (SEQ ID NO: 2602)

210836_x_at
PDE4D
DPDE3,
phosphodiesterase
5144
GACATAGCACGAATCTGTTACCAGT (SEQ ID NO: 2603)

HSPDE4D,
4D, cAMP-specific

AATTTTCTAATTTCAAGTCTTCCTG (SEQ ID NO: 2604)

PDE4DN2,
(phosphodiesterase

GAATAGTGTGGTTCAGTGAGCTGCA (SEQ ID NO: 2605)

STRK1
E3 dunce homolog,

CTGCACTGACCTCTACATTTTGTAT (SEQ ID NO: 2606)

Drosophila)

ATGTTCAGAACTTCATCTGCCACTG (SEQ ID NO: 2607)

ATCTGCCACTGGTTATTTTTTTCTA (SEQ ID NO: 2608)

GAATTTTACTTGCACCTTATAGTTC (SEQ ID NO: 2609)

TGCAGGAAACCCTTTTTGTAAGTCT (SEQ ID NO: 2610)

TTTGCATTTTGTTTCACTCTTTCCA (SEQ ID NO: 2611)

GATAAGCAGAGTTGCTCTTCACCAG (SEQ ID NO: 2612)

TGCTCTTCACCAGTGTTTTTCTTCA (SEQ ID NO: 2613)

205463_s_at
PDGFA
PDGF-A, PDGF1
platelet-derived
5154
TACACCGATAACACACAGGCTGCTG (SEQ ID NO: 2614)

growth factor alpha

CAGGCTGCTGTAACTGTCAGGACAG (SEQ ID NO: 2615)

polypeptide

GACAGTGCGACGGTATTTTTCCTAG (SEQ ID NO: 2616)

ATGGTATACCTACCTATGCATCATT (SEQ ID NO: 2617)

AATGTTTCTGGCTTTGTGTTTCTCC (SEQ ID NO: 2618)

ATGCGTCAACCAATCGTACGCCGTC (SEQ ID NO: 2619)

CCCAGAGCCCGTTTGTGGCTGAGTG (SEQ ID NO: 2620)

GTGGCTGAGTGACAACTTGTTCCCC (SEQ ID NO: 2621)

CCCGCAGTGCACACCTAGAATGCTG (SEQ ID NO: 2622)

GGCACGTGAGATGCATTGCCGCTTC (SEQ ID NO: 2623)

GCTGCCAGTGTTTGGACAGAACCCA (SEQ ID NO: 2624)

205353_s_at
PEBP1
HCNP, PBP,
phosphatidylethanolamine
5037
TCACTCACTCTGATTTATGTTTTGA (SEQ ID NO: 2625)

PEBP, RKIP
binding protein 1

TTGGGGGGTATTTTGGTACTGTGAT (SEQ ID NO: 2626)

ATTTTGGTACTGTGATGGGGTCATC (SEQ ID NO: 2627)

AAGACCAGGTCTACAGTGATAGAGC (SEQ ID NO: 2628)

GATCCTGAGTCCAGAATGGTACACA (SEQ ID NO: 2629)

GTGATGTCACTCACCTAGACAACCA (SEQ ID NO: 2630)

CTCACCTAGACAACCAGAGGCTGGC (SEQ ID NO: 2631)

CCAGAGGCTGGCATTGAGGCTAACC (SEQ ID NO: 2632)

GGCATTGAGGCTAACCTCCAACACA (SEQ ID NO: 2633)

TAACCTCCAACACAGTGCATCTCAG (SEQ ID NO: 2634)

TGCATCTCAGATGCCTCAGTAGGCA (SEQ ID NO: 2635)

211941_s_at
PEBP1
HCNP, PBP,
phosphatidylethanolamine
5037
CACAGTCCTCTCCGATTATGTGGGC (SEQ ID NO: 2636)

PEBP, RKIP
binding protein 1

CACCGCTATGTCTGGCTGGTTTACG (SEQ ID NO: 2637)

GGCCGCTAAAGTGTGACGAGCCCAT (SEQ ID NO: 2638)

CCATCCTCAGCAACCGATCTGGAGA (SEQ ID NO: 2639)

CAAATTCAAGGTGGCGTCCTTCCGT (SEQ ID NO: 2640)

CTGGCACGTGTTACCAGGCCGAGTG (SEQ ID NO: 2641)

GGATGACTATGTGCCCAAACTGTAC (SEQ ID NO: 2642)

TGGGGACCTGAACTGTCCTGGAGGC (SEQ ID NO: 2643)

TTCCCCAGTTCAGTGTTGCATGTAT (SEQ ID NO: 2644)

CCCCCCTTGGCATGGGTGAGACCTG (SEQ ID NO: 2645)

CCTGCTGCCTGGCCTTTATAATTTT (SEQ ID NO: 2646)

217923_at
PEF1
PEF1A, PEFLIN
penta-EF-hand
553115
GGGGCTGAGGCCACACAGATAGGAG (SEQ ID NO: 2647)

domain containing 1

GAATGTCCTGATGGCCATGAGCAGT (SEQ ID NO: 2648)

CATGAGCAGTTGAGTGGCACAGCCT (SEQ ID NO: 2649)

GGCACCAGGAGCAGGTCCTTGTAAT (SEQ ID NO: 2650)

AGTTAGTGTCCAGTCAGCTGAGCTC (SEQ ID NO: 2651)

CAGTGGTGAGTGTTCATCGGCCTGT (SEQ ID NO: 2652)

ATCGGCCTGTTACCGTTAGTACCTG (SEQ ID NO: 2653)

ACCAGGCCATCCTGTCAAACGAGCC (SEQ ID NO: 2654)

GATCTGTCTATGGGACCAGTGGCTT (SEQ ID NO: 2655)

TCTGCCACACCCATAAATCCTTGTG (SEQ ID NO: 2656)

TTGTGTGTTAACTTCTAGCTGCCTG (SEQ ID NO: 2657)

200634_at
PFN1

profilin 1
5216
GAAAACGTTCGTCAACATCACGCCA (SEQ ID NO: 2658)

ATCACGCCAGCTGAGGTGGGTGTCC (SEQ ID NO: 2659)

TCCTGGTTGGCAAAGACCGGTCAAG (SEQ ID NO: 2660)

GACCGGTCAAGTTTTTACGTGAATG (SEQ ID NO: 2661)

AATGTTCGGTGATCCGGGACTCACT (SEQ ID NO: 2662)

GAATTTAGCATGGATCTTCGTACCA (SEQ ID NO: 2663)

TTCGTACCAAGAGCACCGGTGGGGC (SEQ ID NO: 2664)

ACCTTCAATGTCACTGTCACCAAGA (SEQ ID NO: 2665)

CTGACAAGACGCTAGTCCTGCTGAT (SEQ ID NO: 2666)

GTGTCCACGGTGGTTTGATCAACAA (SEQ ID NO: 2667)

CCCTTATTGCTGCCAAAACCACATG (SEQ ID NO: 2668)

206726_at
PGDS

prostaglandin D2
27306
CTTACTCTTCACCAGAGCCTAGCAA (SEQ ID NO: 2669)

synthase,

TGAGCTGCTCACGTATAATGCGCCT (SEQ ID NO: 2670)

hematopoietic

GTAACTTGGGCAGACTTCTACTGGG (SEQ ID NO: 2671)

GGAGATTTGCAGTACCACACTTTTG (SEQ ID NO: 2672)

AGCCTGACCTGTTAGACAACCATCC (SEQ ID NO: 2673)

CCATCCAAGGCTGGTGACTTTACGG (SEQ ID NO: 2674)

TTCCTGCCGTCGCTAACTGGATAAA (SEQ ID NO: 2675)

CAAACCAAACTCTAGCTGATCCATG (SEQ ID NO: 2676)

GATCCATGTTGCCTTCAAGTTTGTT (SEQ ID NO: 2677)

TCAGCCTGCCAGATAATCCACATGC (SEQ ID NO: 2678)

CCCAGCTCCACTAAGATTTTCACTT (SEQ ID NO: 2679)

215832_x_at
PICALM
CALM, CLTH,
phosphatidylinositol
8301
GAGAACCCGCTGGTTTATTGCGACG (SEQ ID NO: 2680)

LAP
binding clathrin

CGCGGTGCATCAAGCTTGCTATGGC (SEQ ID NO: 2681)

assembly protein

ATGGCATTGTTCAAGTACCCACTGG (SEQ ID NO: 2682)

GTACCCACTGGACCGTGGTTTTGCA (SEQ ID NO: 2683)

GAGAGAGCAGCCAGAGTGGCACCCC (SEQ ID NO: 2684)

CCTATCCTGCTACTACACCAACAGG (SEQ ID NO: 2685)

GTGTTCCTGTAATGACGCAACCAAC (SEQ ID NO: 2686)

CCCCTTTGGCCCTGTATCAGGAGCA (SEQ ID NO: 2687)

AGCAGCAAAATCCTTACTTCCAGCA (SEQ ID NO: 2688)

CAAACTGCTGTCTCTTAAATCTCTT (SEQ ID NO: 2689)

AAACTCTCTTCTTCCATTAAAATGT (SEQ ID NO: 2690)

205078_at
PIGF
MGC32646,
phosphatidylinositol
5281
TGTATCTACTTTCTTATGTCTTGTT (SEQ ID NO: 2691)

MGC33136
glycan anchor

TACTTTCTTATGTCTTGTTTCTCCT (SEQ ID NO: 2692)

biosynthesis, class F

ATTTTTGTTCTGTATGGAGCACCAC (SEQ ID NO: 2693)

GGAGCACCACTGATAGAGTTGGCAT (SEQ ID NO: 2694)

GTGCCTTGCTTATGTTTGTTAGGAC (SEQ ID NO: 2695)

TTTGTTAGGACCAAACCTCAAAGCA (SEQ ID NO: 2696)

GAGAATAGTCTCCAGATCACTACAA (SEQ ID NO: 2697)

CAGATCACTACAATTTCTAGCTTTG (SEQ ID NO: 2698)

AGGAGCATGGCTTGGAGCACTTCCT (SEQ ID NO: 2699)

GCACTTCCTATTCCACTGGATTGGG (SEQ ID NO: 2700)

AAGACCATGGCAGGTATGGCCCATC (SEQ ID NO: 2701)

204213_at
PIGR
FLJ22667,
polymeric
5284
TTTGTTGCCACCACTGAGAGCACCA (SEQ ID NO: 2702)

MGC125361,
immunoglobulin

CCCCCAGGAAGCCTAGACGGTGTCG (SEQ ID NO: 2703)

MGC125362
receptor

CACCCATGACAATCACCTTCAGAAT (SEQ ID NO: 2704)

CAGAATCATGTCGATCCTGGGGGCC (SEQ ID NO: 2705)

GCTCTAACACCTGCCTAGGTTTTTC (SEQ ID NO: 2706)

TTCCTACTGTCCTCAGAGGCGTGCT (SEQ ID NO: 2707)

TCAAAGCCTGGCCTAATTGTTCCTA (SEQ ID NO: 2708)

CATGAGGAGGTCCCACTTGCAACTT (SEQ ID NO: 2709)

GGTCCTCATGGGTCCCTTGAAGGAA (SEQ ID NO: 2710)

AGAAAGGAGAGACGTGCAGCGCCCC (SEQ ID NO: 2711)

CCCTCTGCACCCTTATCATGGGATG (SEQ ID NO: 2712)

217770_at
PIGT
CGI-06,
phosphatidylinositol
51604
CAGCATGCCCTACAACGTGATCTGC (SEQ ID NO: 2713)

FLJ41596,
glycan anchor

ACAACGTGATCTGCCTCACGTGCAC (SEQ ID NO: 2714)

MGC8909, NDAP
biosynthesis, class T

ACTGTGGTGGCCGTGTGCTACGGCT (SEQ ID NO: 2715)

TGGCCAAGCGGCTGGCCAACCTTAT (SEQ ID NO: 2716)

CTCTCCTCAGAGTTGGCTTTTGAAC (SEQ ID NO: 2717)

GGCTTTTGAACCAAAGTGCCCTGGA (SEQ ID NO: 2718)

TCCAGTACAGGAGCCACGAGCCAAA (SEQ ID NO: 2719)

CCTGTAGTGGCCACCTCTATATTGA (SEQ ID NO: 2720)

AAAAGTGGTCGGTGGCTGCTGTATT (SEQ ID NO: 2721)

AGAAAGGTCGGCTGGCAGCACTGGC (SEQ ID NO: 2722)

GGTGATGGGGTGTGCTACACAGTGT (SEQ ID NO: 2723)

217620_s_at
PIK3CB
DKFZp779K1237,
phosphoinositide-3-
5291
AAGCAGATGTTATGGAAGCAAGTTC (SEQ ID NO: 2724)

MGC133043,
kinase, catalytic, beta

GGAAGCAAGTTCACAATTACCCAAT (SEQ ID NO: 2725)

PI3K, PI3KCB,
polypeptide

ATTACCCAATGTTCAACCTCCTTAT (SEQ ID NO: 2726)

PI3Kbeta,

AATGTTCAACCTCCTTATGGATATT (SEQ ID NO: 2727)

PIK3C1, p110-

TGCATGTGTGAATCAGACTGCTGTA (SEQ ID NO: 2728)

BETA

CAGACTGCTGTATATGAGGAGCTTG (SEQ ID NO: 2729)

GAAACACGAAGACTCTGTGATGTCA (SEQ ID NO: 2730)

TGTGATGTCAGACCTTTTCTTCCAG (SEQ ID NO: 2731)

TTCTTCCAGTTCTCAAATTAGTGAC (SEQ ID NO: 2732)

GACAAGAAGTTGTGACCCAGGGGAA (SEQ ID NO: 2733)

CTCAAAAATTGGAGTCCTTATAGGA (SEQ ID NO: 2734)

207469_s_at
PIR

pirin (iron-binding
8544
ACTCGCACACCAACCTTATATTTGG (SEQ ID NO: 2735)

nuclear protein)

GGACTTCAAATTGGACCCAGGAGCC (SEQ ID NO: 2736)

GGACAAGCTTCATTTACACGATATC (SEQ ID NO: 2737)

GGAGATGTGTATATTGGGCCCGATG (SEQ ID NO: 2738)

ATTGGGCCCGATGATGCACAACAAA (SEQ ID NO: 2739)

CTCATCACACAGCAGTGCTTGGAGA (SEQ ID NO: 2740)

GAAGCCACTTTGTCTTAATTGCTGG (SEQ ID NO: 2741)

GAGAACCAGTTATCCAACATGGTCC (SEQ ID NO: 2742)

CGGAAGAGCAGGTCTTGATGTGTCC (SEQ ID NO: 2743)

GAAGGCATTCCATTTCTAAAGCTTA (SEQ ID NO: 2744)

GCTTCTAAAGAATTCCACACTAACG (SEQ ID NO: 2745)

210183_x_at
PNN
DRS, SDK3,
pinin, desmosome
5411
GGCAAATCTTTAAGTCTGTTCCCTT (SEQ ID NO: 2746)

memA, pinin
associated protein

TCTGTTCCCTTCTAATTCTGTATCA (SEQ ID NO: 2747)

ACATTGCTTTTGGCGGCCGCGAATT (SEQ ID NO: 2748)

GCTCGCCCGCCAGAAGAATATGAAA (SEQ ID NO: 2749)

AAGCGCCGAGATGACGGGCTTTCTG (SEQ ID NO: 2750)

CCGCCCGCAAGCAGAGGGACTCGGA (SEQ ID NO: 2751)

GGGACTCGGAGATCATGCAGCAGAA (SEQ ID NO: 2752)

GGAACCCAAGTAGCTTTGTGGCTTC (SEQ ID NO: 2753)

TCCTCCTGTAGTGCTCACAGGTCCC (SEQ ID NO: 2754)

CTTCCCAGTGTTTTTTATTCCTGTG (SEQ ID NO: 2755)

TTATTCCTGTGGGGCTCACCCCAAA (SEQ ID NO: 2756)

206789_s_at
POU2F1
OCT1, OTF1
POU class 2
5451
GGTGGCTCTCTTCCAATAACATCAC (SEQ ID NO: 2757)

homeobox 1

GCTCTCTTCCAATAACATCACTTGA (SEQ ID NO: 2758)

CATCACTTGATGCAACTGGGAACCT (SEQ ID NO: 2759)

GCAACTGGGAACCTGGTATTTGCCA (SEQ ID NO: 2760)

TATTTGCCAATGCGGGAGGAGCCCC (SEQ ID NO: 2761)

TGCAGGGAACTCTGCACCTGTAGCC (SEQ ID NO: 2762)

GCCTCCAAGGCACAGTGAGCTGGGC (SEQ ID NO: 2763)

GCCTTTTTCACTCTGCAGTGTGATT (SEQ ID NO: 2764)

TGTGATTGGACTGCCAGCCAGGTTA (SEQ ID NO: 2765)

TTCCTCTCGCCGTGTTGTGAGGGCA (SEQ ID NO: 2766)

TGGAGACGGAACATTTGCCTAATTT (SEQ ID NO: 2767)

218341_at
PPCS
RP11-163G10.1,
phosphopantothenoyl
79717
AAACCAAGTTATTGCTATCAAGGAA (SEQ ID NO: 2768)

FLJ11838,
cysteine synthetase

TAATCTTCAGTCTCGACACACAGCT (SEQ ID NO: 2769)

MGC117357,

GTCTCGACACACAGCTTTTATAGGT (SEQ ID NO: 2770)

MGC138220

AAATTGTTCAGGGCTCTTAGAGATG (SEQ ID NO: 2771)

AAACCATGGCTTTCATATGGACAGA (SEQ ID NO: 2772)

AAGGCAGTGGTGTGTAGGCAAATAT (SEQ ID NO: 2773)

AAATATGGTTTGGCATTCGTCTTTT (SEQ ID NO: 2774)

GGCATTCGTCTTTTAATGACACCTG (SEQ ID NO: 2775)

TACATGGGGGCCTGAATGTCAGCCA (SEQ ID NO: 2776)

GAATGGTCATGCTTTGGAGATCAAA (SEQ ID NO: 2777)

TGAATGCCTATGTATGTCAGGCCCT (SEQ ID NO: 2778)

204228_at
PPIH
CYP-20, CYPH,
peptidylprolyl
10465
ATGGAGATGGTACTGGAGTCGCCAG (SEQ ID NO: 2779)

MGC5016,
isomerase H

TCGCCAGTATTTACCGGGGGCCATT (SEQ ID NO: 2780)

SnuCyp-20,
(cyclophilin H)

TTTAAACTTAGACACTCAGCTCCAG (SEQ ID NO: 2781)

USA-CYP

GCTTTCCATGGCGAACAGTGGTCCA (SEQ ID NO: 2782)

ATCACCTGCTCTAAGTGCGATTGGC (SEQ ID NO: 2783)

AAAATCATCGATGGACTTCTAGTGA (SEQ ID NO: 2784)

TTCCCACAGGCCCCAACAATAAGCC (SEQ ID NO: 2785)

CTACCTGTGGTGATCTCGCAGTGTG (SEQ ID NO: 2786)

AAAGACTGAATCAGGCCTTCCCTTC (SEQ ID NO: 2787)

AGTAAGATAATCTGGACTGGCCCCC (SEQ ID NO: 2788)

CTGCTGCCCCATTTGATCAAGAGAC (SEQ ID NO: 2789)

218273_s_at
PPM2C
RP23-203A12.1,
protein phosphatase
54704
ATTGACTTTGCAGCAGGGTGGCAGG (SEQ ID NO: 2790)

Gm1024
2C, magnesium-

GTCCTGCCTAGCTCAGATTTCATGG (SEQ ID NO: 2791)

dependent, catalytic

CAGATTTCATGGCACCTGCACTTGA (SEQ ID NO: 2792)

subunit

CACTTCTTTATCACAGGTGTCTTGA (SEQ ID NO: 2793)

TAGCTTCTTTTACCAACCTGAGAAA (SEQ ID NO: 2794)

GTATCTTGCTGTGTGTAGTCTCTTG (SEQ ID NO: 2795)

TCACACCTTTCTTCACTGAGATTCC (SEQ ID NO: 2796)

TCCAGTTCTTCAAGCCATAAATGAC (SEQ ID NO: 2797)

GATTATTTGACTGGAATGCTTCTTA (SEQ ID NO: 2798)

GAATAACTATACTCCGTTATCCACC (SEQ ID NO: 2799)

TATCCACCCGATTTCCTAATGTAAT (SEQ ID NO: 2800)

202313_at
PPP2R2A
B55-ALPHA,
protein phosphatase
5520
GTTTGACAGTGTGCCATTCGACAAC (SEQ ID NO: 2801)

B55A, FLJ26613,
2 (formerly 2A),

GATTCATCACTGTGGTGTTCTCCAT (SEQ ID NO: 2802)

MGC52248,
regulatory subunit B,

CTCCATGTCTGCTAGCCATTTAGGT (SEQ ID NO: 2803)

PR52A, PR55A
alpha isoform

CTTCTTGCACCATCTTGCCTAATGG (SEQ ID NO: 2804)

AACATTGATTTACTCCACTTTTTAT (SEQ ID NO: 2805)

TATGCCTTCCATTGTGATGACGTCA (SEQ ID NO: 2806)

AAGCCTTCAGTCATGCTATGGGATT (SEQ ID NO: 2807)

GTGTATCCTCATTACTGTATCATTT (SEQ ID NO: 2808)

TGTATCATTTGTGGGGTACACCCCT (SEQ ID NO: 2809)

TTACTGTGGCTTGTAGCATTCCTCC (SEQ ID NO: 2810)

CTCCACCCGGTCTTGGTGGTGGTAT (SEQ ID NO: 2811)

209817_at
PPP3CB
RP11-345K20.1,
protein phosphatase
5532
TAGAGTTAACTACCTGCTTAGGCCC (SEQ ID NO: 2812)

CALNA2, CALNB
3 (formerly 2B),

GCTTAGGCCCCAGAACATTACTTAT (SEQ ID NO: 2813)

catalytic subunit, beta

AGAACATTACTTATGCCCTTCAGTT (SEQ ID NO: 2814)

isoform

TGTGCAAGGTTTTGTACCCTGGTAA (SEQ ID NO: 2815)

AGTTTGTTTTCTGTGGTGTTTGTCA (SEQ ID NO: 2816)

AATTAACTGTCTGTAACATGCTGTT (SEQ ID NO: 2817)

CTGTCTGTCTTTCTTTAGGTTAGCT (SEQ ID NO: 2818)

ACACTTGTCTGTCTTGCAATGTAGA (SEQ ID NO: 2819)

GAAGCAGCTTTGTAGCACCTTGTTT (SEQ ID NO: 2820)

TGCTGCATTTGTTGCTGCACTTTGT (SEQ ID NO: 2821)

GCACTTTGTGCATTCTGAACATGAA (SEQ ID NO: 2822)

205277_at
PRDM2
RP5-1177E19.1,
PR domain
7799
AATGGTGGTCATTGGCCGACATCAC (SEQ ID NO: 2823)

HUMHOXY1,
containing 2, with

CCGACATCACAGTTTTCCTGTTTCC (SEQ ID NO: 2824)

KMT8, MTB-ZF,
ZNF domain

CTACAGCTAACCCTCACAAGCATGA (SEQ ID NO: 2825)

RIZ, RIZ1, RIZ2

AGCATGAAGTGCTGTGGCTGTTCCT (SEQ ID NO: 2826)

GGCTGTTCCTTATCCTAATGATGCG (SEQ ID NO: 2827)

CTAATGATGCGCTTTTGTCCCGTAA (SEQ ID NO: 2828)

GCAAGGAAAGCTCACGAACCCCAAA (SEQ ID NO: 2829)

CTGCAGCCCATGGTGAGCTCTGGGA (SEQ ID NO: 2830)

GGTCACTCCTTTTTTGCATGTGCAA (SEQ ID NO: 2831)

AAAGTGGCATTTCCTGGTCAGTGGT (SEQ ID NO: 2832)

AAGACGACAGCTCTGTATCTGCCAT (SEQ ID NO: 2833)

37022_at
PRELP
MGC45323,
proline/arginine-rich
5549
ACCGGATCTGCTCTGACCGCACTTG (SEQ ID NO: 2834)

MST161,
end leucine-rich

GCTCTGACCGCACTTGAAGGCTGGG (SEQ ID NO: 2835)

MSTP161,
repeat protein

TGTGCCGGCCATTCGTTTTCTCTCT (SEQ ID NO: 2836)

SLRR2A

TGCCGGCCATTCGTTTTCTCTCTCT (SEQ ID NO: 2837)

CACCCTCGAGGCAGGGAAAAGCCAT (SEQ ID NO: 2838)

CCAGTTGAAAGACACCCAGTGCACA (SEQ ID NO: 2839)

ACATCTGGGCCGTGGACTATCTGAT (SEQ ID NO: 2840)

CGTGGACTATCTGATCTTGGTCCTG (SEQ ID NO: 2841)

CTATCTGATCTTGGTCCTGGCCGAG (SEQ ID NO: 2842)

CAGCCCGGAGTAAGGTTCAGAAAGT (SEQ ID NO: 2843)

CGAGAAACCCAGTTCTCCTGGGCCA (SEQ ID NO: 2844)

TCCTGGGCCAAGGATCCCTTCTGGC (SEQ ID NO: 2845)

TTCTGGCAAAGCTGCTGCTCCGCCG (SEQ ID NO: 2846)

GCAAAGCTGCTGCTCCGCCGCTTGG (SEQ ID NO: 2847)

CAAAGCTGCTGCTCCGCCGCTTGGT (SEQ ID NO: 2848)

GTAAGGGCTCCCAGGTCTTCATCTG (SEQ ID NO: 2849)

215194_at
PRKCA
AAG6,
protein kinase C,
5578
GGAGGGTACCAGATGACAGATTCAC (SEQ ID NO: 2850)

MGC129900,
alpha

ACAGATTCACCCAACACTCATCTGA (SEQ ID NO: 2851)

MGC129901,

AACTGCTGGACCATGGTTGGGTTAG (SEQ ID NO: 2852)

PKC-alpha,

TGATTAGGTTTATCCCGGCCTTTCA (SEQ ID NO: 2853)

PKCA, PRKACA

CCCGGCCTTTCAGATTCTAGGGGCT (SEQ ID NO: 2854)

GATTCTAGGGGCTGTTTCCATGGAG (SEQ ID NO: 2855)

ATGGGGCAACAGTCTGCTTGCTTTC (SEQ ID NO: 2856)

GAAGGGTTAACCTAGAGCCAGACGT (SEQ ID NO: 2857)

GAGCCAGACGTAACTTCTACAGAAT (SEQ ID NO: 2858)

AACTGGACACTGAGCATGACGTACC (SEQ ID NO: 2859)

ATGACGTACCATCTTCCACTAAGAT (SEQ ID NO: 2860)

209158_s_at
PSCD2
ARNO, CTS18,
pleckstrin homology,
9266
GCCTCTACTACTTTGAGTACACCAC (SEQ ID NO: 2861)

CTS18.1,
Sec7 and coiled-coil

GGACAAGGAGCCCCGAGGAATCATC (SEQ ID NO: 2862)

CYTH2,
domains 2

GAATCATCCCCCTGGAGAATCTGAG (SEQ ID NO: 2863)

PSCD2L, SEC7L,
(cytohesin-2)

GAATCTGAGCATCCGAGAGGTGGAC (SEQ ID NO: 2864)

Sec7p-L, Sec7p-

CTGCTTTGAACTTTACATCCCCAAC (SEQ ID NO: 2865)

like

ACAAGGGGCAGCTCATCAAAGCCTG (SEQ ID NO: 2866)

GAGGGAAACCACATGGTGTACCGGA (SEQ ID NO: 2867)

GAGTGGATCAAGTCCATCCAGGCGG (SEQ ID NO: 2868)

TCCATCCAGGCGGCTGTGAGTGTGG (SEQ ID NO: 2869)

CCATTATTTATTACGGAGCTGCCCC (SEQ ID NO: 2870)

AACACGCTGTTGGTAATCTTATTAA (SEQ ID NO: 2871)

203396_at
PSMA4
HC9, HsT17706,
proteasome
5685
GGCTTTCAGCTCTATCAGAGTGACC (SEQ ID NO: 2872)

MGC111191,
(prosome,

AGAGTGACCCTAGTGGAAATTACGG (SEQ ID NO: 2873)

MGC12467,
macropain) subunit,

GGGGGATGGAAGGCCACATGCATTG (SEQ ID NO: 2874)

MGC24813,
alpha type, 4

GAAATAATAGCGCTGCAGCTGTGTC (SEQ ID NO: 2875)

PSC9

GCGCTGCAGCTGTGTCAATGTTGAA (SEQ ID NO: 2876)

GAAATGACCTTGAAGTCAGCACTTG (SEQ ID NO: 2877)

CATGGATGTTAGTAAACTCTCTGCT (SEQ ID NO: 2878)

AAGACAGTAATCAGAGTTCTCAAAC (SEQ ID NO: 2879)

TACTGAATTGGGTCCTTGTCATTTC (SEQ ID NO: 2880)

GTCCTTGTCATTTCTGTCCAATTGA (SEQ ID NO: 2881)

TACCCTTCATGGACGTCTTAATCTT (SEQ ID NO: 2882)

201274_at
PSMA5
MGC117302,
proteasome
5686
CAAGCTGTGTCCAATCTGGCTTTGC (SEQ ID NO: 2883)

MGC125802,
(prosome,

ATGTCTCGTCCCTTTGGAGTAGCAT (SEQ ID NO: 2884)

MGC125803,
macropain) subunit,

AAAGGACCCCAGCTGTTTCATATGG (SEQ ID NO: 2885)

MGC125804,
alpha type, 5

TGGACCCATCTGGGACCTTTGTACA (SEQ ID NO: 2886)

PSC5, ZETA

GCTCGAGCAATTGGCTCTGCTTCAG (SEQ ID NO: 2887)

CTGCTTCAGAGGGTGCCCAGAGCTC (SEQ ID NO: 2888)

GAGCTCCTTGCAAGAACTTTACCAC (SEQ ID NO: 2889)

GAAGCCATCAAGTCTTCACTCATCA (SEQ ID NO: 2890)

ATTGAGCTAGCCACAGTGCAGCCTG (SEQ ID NO: 2891)

AGGAATCCTGATCCTCAGAACTTCT (SEQ ID NO: 2892)

TAAATTTTATTTCCAGCTCCTGTTC (SEQ ID NO: 2893)

201114_x_at
PSMA7
RP5-1005F21.4,
proteasome
5688
CCAGAGCCACCGGCTGACTGTAGAG (SEQ ID NO: 2894)

C6, HSPC,
(prosome,

GGACCCGGTCACTGTGGAGTACATC (SEQ ID NO: 2895)

MGC3755, RC6-
macropain) subunit,

CGCTACATCGCCAGTCTGAAGCAGC (SEQ ID NO: 2896)

1, XAPC7
alpha type, 7

CAGAGCAATGGGCGCAGGCCGTTTG (SEQ ID NO: 2897)

CCCTCATCGTGGGTTTCGACTTTGA (SEQ ID NO: 2898)

TTCGACTTTGATGGCACTCCTAGGC (SEQ ID NO: 2899)

GGGCACATACCATGCCTGGAAGGCC (SEQ ID NO: 2900)

ATAGGCCGGGGTGCCAAGTCAGTGC (SEQ ID NO: 2901)

AAGCTGGTGATCAAGGCACTCCTGG (SEQ ID NO: 2902)

GAACTTGCTGTCATGAGGCGAGATC (SEQ ID NO: 2903)

ATGAGTCTCGATGTGTAGGCCTTTC (SEQ ID NO: 2904)

200039_s_at
PSMB2
RP23-120H2.2,
proteasome
5690
TAACTTCACACGCCGAAACCTGGCT (SEQ ID NO: 2905)

AU045357,
(prosome,

CGAAACCTGGCTGACTGTCTTCGGA (SEQ ID NO: 2906)

AW108089, C7-I,
macropain) subunit,

GGGCCAGCGCTGTATTACATGGACT (SEQ ID NO: 2907)

D4Wsu33e
beta type, 2

ACTCTCAGTATCCTCGACCGATACT (SEQ ID NO: 2908)

TACACACCGACTATCTCACGTGAGA (SEQ ID NO: 2909)

GTGAGAGGGCAGTGGAACTCCTTAG (SEQ ID NO: 2910)

GCTCCAGAAACGCTTCATCCTGAAT (SEQ ID NO: 2911)

TGAATCTGCCAACCTTCAGTGTTCG (SEQ ID NO: 2912)

TGACCTGGATAACATTTCCTTCCCC (SEQ ID NO: 2913)

AACAGGGCTCCTAACATCATGTCCT (SEQ ID NO: 2914)

TCTTTTCAGGCGCACTCTTGATAAA (SEQ ID NO: 2915)

201388_at
PSMD3
P58, RPN3, S3
proteasome
5709
GATATCCACAACATGTCTGTCAAGG (SEQ ID NO: 2916)

(prosome,

TCTGTCAAGGCCATGAGGTTTCCTC (SEQ ID NO: 2917)

macropain) 26S

GTTTCCTCCCAAATCGTACAACAAG (SEQ ID NO: 2918)

subunit, non-ATPase, 3

GGAACGGCGTGAGCGAGAACAGCAG (SEQ ID NO: 2919)

GAACAGCAGGACTTGGAGTTTGCCA (SEQ ID NO: 2920)

TTTCCCACACACAGCTCATATGCTG (SEQ ID NO: 2921)

ACAGCTCATATGCTGCATTCGTGCA (SEQ ID NO: 2922)

TGCTGCATTCGTGCAGGGGGTGGGG (SEQ ID NO: 2923)

CCCAGCCGGTGACTTACTGTACAGC (SEQ ID NO: 2924)

GATAGTTCTGTGTACTCCTTTAGGG (SEQ ID NO: 2925)

TTAGGGAGTGGGGGACTAGAACTGG (SEQ ID NO: 2926)

207805_s_at
PSMD9
MGC8644, Rpn4,
proteasome
5715
TGTGGAGTTCGGCTCTGTGAACACC (SEQ ID NO: 2927)

p27
(prosome,

CCCAGAACTTCCAGTCACTGCATAA (SEQ ID NO: 2928)

macropain) 26S

GAATGTGACAGTGATCCGCAGGGGG (SEQ ID NO: 2929)

subunit, non-ATPase, 9

CCAGCTTAGACTTGTTCCAACACGC (SEQ ID NO: 2930)

AAAAGGACTGCTGGGCTGCAACATT (SEQ ID NO: 2931)

GGGTCTAGGGATTTCCAACTTGTCT (SEQ ID NO: 2932)

AGAGGCTTGTAACCTGAACTTCTGT (SEQ ID NO: 2933)

GTGTGGTGGCAGTACTGTGGCCCAC (SEQ ID NO: 2934)

CCCACCAGTGTAATCTCCCTGGATT (SEQ ID NO: 2935)

TCTTTCACAAATTAGGCCACGGCCC (SEQ ID NO: 2936)

GTGGGCGGAAGTTATTCTGGCAGGT (SEQ ID NO: 2937)

218371_s_at
PSPC1
RP11-523H24.2,
paraspeckle
55269
ATGTGGCTGAAGTTACCCGAAGTTC (SEQ ID NO: 2938)

DKFZp566B1447,
component 1

GTTACCCGAAGTTCAGCTTGCAGTG (SEQ ID NO: 2939)

FLJ10955,

AGTTCAGCTTGCAGTGTAATTCAGA (SEQ ID NO: 2940)

PSP1

GAATCATACTTCCTTTCAGGTCAAA (SEQ ID NO: 2941)

GTGGGAAATATCCTGTTCGTGACCT (SEQ ID NO: 2942)

TCCTGTTCGTGACCTAGGAGAAACA (SEQ ID NO: 2943)

TTCTTACTCCATACAAGCAGTTTAT (SEQ ID NO: 2944)

AAACATGCTACAGGGGCACATTTTC (SEQ ID NO: 2945)

ACAGGGGCACATTTTCTGTGGTTAA (SEQ ID NO: 2946)

GCAGTTTTCCTTTGCATTGAGGGTT (SEQ ID NO: 2947)

CTTTGCATTGAGGGTTTTGGCTTTT (SEQ ID NO: 2948)

210832_x_at
PTGER3
EP3, EP3-I, EP3-
prostaglandin E
5733
GTCTCCGCTCCTGATAATGATGTTG (SEQ ID NO: 2949)

II, EP3-III, EP3-
receptor 3 (subtype

ACTTCTTCTTAATAGCTGTTCGCCT (SEQ ID NO: 2950)

IV, EP3e,
EP3)

TTCGCCTGGCTTCACTGAACCAGAT (SEQ ID NO: 2951)

MGC141828,

TCTTGGATCCTTGGGTTTACCTGCT (SEQ ID NO: 2952)

MGC141829,

GTTTTGCCAGATCAGGTACCACACA (SEQ ID NO: 2953)

MGC27302

ACAAACAACTATGCATCCAGCTCCA (SEQ ID NO: 2954)

CCAGTGTTCCTCAACCTTGATGTGG (SEQ ID NO: 2955)

TAAAACCTGCCTTTCTGCCAGGATC (SEQ ID NO: 2956)

GGATCACATCACTGGAAGCTCCATG (SEQ ID NO: 2957)

GCTCCATGACTCTCTTTTTGTAAAA (SEQ ID NO: 2958)

TCCCAAACTATTCTCTTTTACTTCT (SEQ ID NO: 2959)

211756_at
PTHLH
HHM,
parathyroid hormone-
5744
AAAACTTCACATTTATGTGGCTTGT (SEQ ID NO: 2960)

MGC14611, PLP,
like hormone

TGTGGCTTGTTTATCCTTAGCTCAC (SEQ ID NO: 2961)

PTHR, PTHRP

TGTTTATCCTTAGCTCACAGATTGA (SEQ ID NO: 2962)

GGTAATAATGACACTCCTAGACTTT (SEQ ID NO: 2963)

GACACTCCTAGACTTTGGGATCAAA (SEQ ID NO: 2964)

TAACTTAGGGCCAAGTCTTGGGTCT (SEQ ID NO: 2965)

GTTCACAACCTAGGGCAAGTTACTC (SEQ ID NO: 2966)

AAGTTACTCTGCCTTTCTAAGACTC (SEQ ID NO: 2967)

CTAAGACTCACTTACATCTTCTGTG (SEQ ID NO: 2968)

TAATTGTACCAACCTCATAGAGTTT (SEQ ID NO: 2969)

ATGTGGACTAAATATCTGTCATATA (SEQ ID NO: 2970)

202990_at
PYGL
GSD6
phosphorylase,
5836
AGAGCAGATTTCCACTGCAGGCACC (SEQ ID NO: 2971)

glycogen; liver (Hers

GTTCATGCTAAATGGGGCCCTAACT (SEQ ID NO: 2972)

disease, glycogen

GGCCCTAACTATCGGGACCATGGAT (SEQ ID NO: 2973)

storage disease type

AGAGAACCTGTTCATCTTTGGCATG (SEQ ID NO: 2974)

VI)

GGATAGATGATGTGGCTGCTTTGGA (SEQ ID NO: 2975)

GCAGCCTGACCTCTTCAAAGATATC (SEQ ID NO: 2976)

GTCTTTGCAGACTACGAAGCCTATG (SEQ ID NO: 2977)

AAGGCCTGGAACACAATGGTACTCA (SEQ ID NO: 2978)

GGTACTCAAAAACATAGCTGCCTCG (SEQ ID NO: 2979)

ATAGCTGCCTCGGGGAAATTCTCCA (SEQ ID NO: 2980)

GGAACGTGGAACCTTCAGATCTAAA (SEQ ID NO: 2981)

212866_at
R3HCC1
DKFZp564N123
R3H domain and
203069
GACCTTGCCCACGTGGTAGAGATCT (SEQ ID NO: 2982)

coiled-coil containing 1

GATCTATGACTTTGAACCAGCGCTC (SEQ ID NO: 2983)

CCAGCGCTCAAGACGGAGGACCTGC (SEQ ID NO: 2984)

GCTGGCAACGTTTTCTGAGTTCCAA (SEQ ID NO: 2985)

GGGGTTCAGGATTCAGTGGGTGGAT (SEQ ID NO: 2986)

GTGGGTGGATGATACTCACGCACTC (SEQ ID NO: 2987)

GCAGTCAAAGCTCAAAGCCTTGCAG (SEQ ID NO: 2988)

TGCAGAGGCCAAAACTCCTGCGTCT (SEQ ID NO: 2989)

AAAGAAAGAGCGGCCTGCTGTCCGG (SEQ ID NO: 2990)

CAACACCATAAGCCTTCACAGACGC (SEQ ID NO: 2991)

CACCCTCGAGCTTCACCATGGGGTG (SEQ ID NO: 2992)

221792_at
RAB6B

RAB6B, member
51560
ACACTAGGTTCTTCCCAGCATATGA (SEQ ID NO: 2993)

RAS oncogene family

AGTCCCCAAGTCTACTCTGATTGAT (SEQ ID NO: 2994)

TGATTGATTGTCATGGGCACCCACA (SEQ ID NO: 2995)

AATGTGCAAACTCCTTGGACTCCAG (SEQ ID NO: 2996)

TCCAGACCCCTGTCTGGTTGGCACT (SEQ ID NO: 2997)

GCACTCCCAGCAGTGTGTGGTTTCA (SEQ ID NO: 2998)

AGGTGGGAAGCCTCCATAGCATTGA (SEQ ID NO: 2999)

AGCATTGAAGGCCAGCCTGCATCTC (SEQ ID NO: 3000)

CACCCATCCCTTTAAAGTGATTGGC (SEQ ID NO: 3001)

GAGGGTGGCAATTCCATCTGTTATG (SEQ ID NO: 3002)

GACATAGCCGCCATGTTGATTTCAC (SEQ ID NO: 3003)

204478_s_at
RABIF
MSS4,
RAB interacting
5877
TGTGGCCTTGGAACGAGTTTCCCAT (SEQ ID NO: 3004)

RASGFR3,
factor

TCTCCAAAGATAAACCTACTCCCCA (SEQ ID NO: 3005)

RASGRF3

TCCCCACAAGAACTGGCCTTTAATG (SEQ ID NO: 3006)

AATGTGGTATAACTGTTCCGCTGCC (SEQ ID NO: 3007)

ACTGAGTACCAGCATGTCCATTTGA (SEQ ID NO: 3008)

CCTCCTGCTTAGTTCACTTTGTATC (SEQ ID NO: 3009)

TCCCCCAGTTTTGGGACACTGTGCT (SEQ ID NO: 3010)

ACACTGTGCTTACCTCCAAAAATCT (SEQ ID NO: 3011)

TCCAAAAATCTCATCTCTTCCCTGG (SEQ ID NO: 3012)

GAGTGACTTTGTTGTATGGCTACCC (SEQ ID NO: 3013)

TATGGCTACCCTTGTGATCTACAGT (SEQ ID NO: 3014)

205326_at
RAMP3

receptor (G protein-
10268
TCTGCCTGCAGGTTTCTATGCTGTT (SEQ ID NO: 3015)

coupled) activity

TCTTAGCACAGAATCCAGCCTAGCC (SEQ ID NO: 3016)

modifying protein 3

CCTAGCCTTAGCCGCAGTCTAGGCC (SEQ ID NO: 3017)

TCTAGGCCCTGCTTGGACTAGGACT (SEQ ID NO: 3018)

TTGGACTAGGACTCCTTGCTTGACC (SEQ ID NO: 3019)

GGCTCTTGGAAGACGTTCCGTGCTG (SEQ ID NO: 3020)

GCAGAGTCCATTCCATCATGATGCT (SEQ ID NO: 3021)

CATGATGCTGTGCCCGCTATGGGCT (SEQ ID NO: 3022)

TGCCCGCTATGGGCTGTGTCCATGA (SEQ ID NO: 3023)

GTGGGGGTGTGTTATAGCCCCTCAC (SEQ ID NO: 3024)

CCCTCTGGAATGGCATCCCATGAGC (SEQ ID NO: 3025)

202033_s_at
RB1CC1
CC1,
RB1-inducible coiled-
9821
TGATTTGTCCTGCAGTGCTCATTCA (SEQ ID NO: 3026)

DRAGOU14,
coil 1

AACAGCAGGCCATCTTTTTATGCAA (SEQ ID NO: 3027)

FIP200

ACTTCACTGGTGTACATCGTTTACT (SEQ ID NO: 3028)

TCGTTTACTTTTTAACTGGCTTCAT (SEQ ID NO: 3029)

AGAAATGCGGACCAAACTACTTCAT (SEQ ID NO: 3030)

ACTACTTCATTTTCTCAAAGGGCAT (SEQ ID NO: 3031)

GCATACCTTGTGCATTGTGGCTTAT (SEQ ID NO: 3032)

GATGAGCCATATTAATTGCCTGTTA (SEQ ID NO: 3033)

GTTATTATTACCAGCATTTGTCCTT (SEQ ID NO: 3034)

ATACTTGCACTCTTTAACACATTCT (SEQ ID NO: 3035)

AGAGGAGTGTTATTGCATGCTGATA (SEQ ID NO: 3036)

216215_s_at
RBM9
FOX2, Fox-2,
RNA binding motif
23543
ACATGCAACATGCTGTTCCTCCAGC (SEQ ID NO: 3037)

HNRBP2,
protein 9

GTACCTTTGGGGCATGGGGGCATTA (SEQ ID NO: 3038)

HRNBP2, RTA,

GGGATGCTTGTGTAATCGACCACCT (SEQ ID NO: 3039)

dJ106I20.3, fxh

TCCAGAGAAGCATCCCAGGGCTTTG (SEQ ID NO: 3040)

GGCTTTGTGACAGTCTCTAATTCCC (SEQ ID NO: 3041)

TCCCTTCCCTTCTCGTTAAGAATCA (SEQ ID NO: 3042)

GTATTCATTGGGTTACTCCTATTAT (SEQ ID NO: 3043)

AGATCTTTAGCTTTTATTCCTTATT (SEQ ID NO: 3044)

TTATTGATCATGTTGCTGGCTTTTA (SEQ ID NO: 3045)

GCGAAGGAGGAGCACTGCCTCAGCC (SEQ ID NO: 3046)

GCCTCAGCCTTTGCACATGGTAATG (SEQ ID NO: 3047)

210568_s_at
RECQL
RECQL1, RecQ1
RecQ protein-like
5965
AACAGAGTACTGCAGAGATCTAATC (SEQ ID NO: 3048)

(DNA helicase Q1-

AAAACTCACTCCATTGAAACTGATT (SEQ ID NO: 3049)

like)

GAAACTGATTGATTCTTGGATGGGA (SEQ ID NO: 3050)

GGATGGGAAAGGGTGCAGCAAAACT (SEQ ID NO: 3051)

TCCCACACTTCCTCGTGAAGATCTG (SEQ ID NO: 3052)

GGAGAAGATTATTGCACACTTTCTA (SEQ ID NO: 3053)

AGAACTCTTTCAGGGCTGAATCGTC (SEQ ID NO: 3054)

AGGGCTGAATCGTCTCAAACTTGTC (SEQ ID NO: 3055)

TCGTCTCAAACTTGTCATTCTGAAC (SEQ ID NO: 3056)

CCAGAAGAAGGCTGCAAACATGCTT (SEQ ID NO: 3057)

GATGATGCCTGATATGAATGTTACT (SEQ ID NO: 3058)

218767_at
REXO4
RP11-244N20.5,
REX4, RNA
57109
CATCTTCGGTGACACCCTGGGGTGA (SEQ ID NO: 3059)

REX4, XPMC2,
exonuclease 4

TCTCGAGGAGCCACATTTTCCTCCT (SEQ ID NO: 3060)

XPMC2H
homolog (S. cerevisiae)

GGACCCAGACCAGGTGTCTGCAGTC (SEQ ID NO: 3061)

ACATCAGGGGTTTCCTGTGGCCGTT (SEQ ID NO: 3062)

GTTGGCTGGTGGGTCACCCAGCAGA (SEQ ID NO: 3063)

GACTGCGGTTATTCCTGGAGGTCGG (SEQ ID NO: 3064)

GGAGGTCGGCAGACATGCCAACCTT (SEQ ID NO: 3065)

ATGCCAACCTTGGGCTATTTGAGCT (SEQ ID NO: 3066)

TGTGATGCTAGCCGGTGGCTTTCTG (SEQ ID NO: 3067)

GTTTGAGGCTCCCCTGGGAACTAGA (SEQ ID NO: 3068)

CAAGGCGTTATTGGGCCACCTGACA (SEQ ID NO: 3069)

208021_s_at
RFC1
A1, MGC51786,
replication factor C
5981
TTGACCACGTCTCTGCTGTGAATAG (SEQ ID NO: 3070)

MHCBFB, PO-
(activator 1) 1,

CTCAGACATTCTTATCCTTCTGGAG (SEQ ID NO: 3071)

GA, RECC1,
145 kDa

TCTTATCCTTCTGGAGTCTCAACCC (SEQ ID NO: 3072)

RFC, RFC140

GAGTCTCAACCCATCAGGTTCAGAC (SEQ ID NO: 3073)

AACCCATCAGGTTCAGACCAGTAGG (SEQ ID NO: 3074)

GACCAGTAGGAACCAGGCTGGGTCA (SEQ ID NO: 3075)

CAGGCTGGGTCAGGCTCTTAATTTC (SEQ ID NO: 3076)

AGGCTCTTAATTTCACTACGGTGGG (SEQ ID NO: 3077)

AAATGCTCAGAGGTCTGTGCTACCT (SEQ ID NO: 3078)

TAAGGATCGTATTCCCTGCTTTAAG (SEQ ID NO: 3079)

TGGTAGTCTTGTTTGGGTGATGAGA (SEQ ID NO: 3080)

204336_s_at
RGS19
GAIP, RGSGAIP
regulator of G-protein
10287
CAGTGGGGAGTGCTGTGTCTCCTGG (SEQ ID NO: 3081)

signaling 19

GCCAAGCAGGAACTCCAGGTGCAGG (SEQ ID NO: 3082)

TGGGGGCTCTTGCGTGGTGAGAGTA (SEQ ID NO: 3083)

TGCGTGGTGAGAGTAGGGGTCCCCC (SEQ ID NO: 3084)

TTGGTGGGGAACAGAACCTCCGCAT (SEQ ID NO: 3085)

ACCTCCGCATCGTGTAGTTTTGTGA (SEQ ID NO: 3086)

TACTTGAGCTGTCTGTACCCCAGAA (SEQ ID NO: 3087)

TGTACCCCAGAATCAAACACAGAAC (SEQ ID NO: 3088)

CTCAGAATCCTGCACTCAAGGTGGC (SEQ ID NO: 3089)

TAAACCTGGAAACATGTCCTTACTA (SEQ ID NO: 3090)

ACATGTCCTTACTAGGTGTTTTATC (SEQ ID NO: 3091)

214811_at
RIMBP2
KIAA0318,
RIMS binding protein 2
23504
TGGTAAAGCACCAGTACTCCAACCT (SEQ ID NO: 3092)

MGC15831,

CTCCAACCTTCCAGAAAGCCGATTA (SEQ ID NO: 3093)

RBP2, RIM-BP2

AGCCGATTATCTTCATTGCTTTTAA (SEQ ID NO: 3094)

CTGTGGCATATGGTTTTCTGTTACT (SEQ ID NO: 3095)

TTTCGTTGTCAAAATGCCATACCCA (SEQ ID NO: 3096)

TCCACATAATGCATAAGCCACACCA (SEQ ID NO: 3097)

GCCACACCAAAACCAGACTCAATTT (SEQ ID NO: 3098)

CCAAATGAGTCCATACCCATCTTCA (SEQ ID NO: 3099)

TTTTGTAATTCTTGTCCACTTGTAA (SEQ ID NO: 3100)

CATACTTTTCAGACTGCCTTTCTTT (SEQ ID NO: 3101)

ATCCATGTGTGGTTAAGCTCTGTGT (SEQ ID NO: 3102)

212479_s_at
RMND5A
CTLH, FLJ12753,
required for meiotic
64795
AATACACCAGCAGTTGTCATTCAAT (SEQ ID NO: 3103)

FLJ13910,
nuclear division 5

ATGCAGGTTTTTGTACTTAATTATA (SEQ ID NO: 3104)

FLJ21795,
homolog A (S. cerevisiae)

GCAGAAACGGAAATTGACCTCCCCG (SEQ ID NO: 3105)

MGC78451,

CTCCCCGCCATGTGTTTAATATTCC (SEQ ID NO: 3106)

RMD5, p44CTLH

CCATGTGTTTAATATTCCTCCTGCT (SEQ ID NO: 3107)

ATCGTAAGCCTTGAGAGTGTTTGTG (SEQ ID NO: 3108)

GATAGATTCCAGATATGCTTTTTGA (SEQ ID NO: 3109)

GCACACCTGCATTTTAGCTCTGCAT (SEQ ID NO: 3110)

GCAGGCTGCGTGTTTAAGAATTTCA (SEQ ID NO: 3111)

CTGGCTGGTGTGAGAAGTCTTCCGT (SEQ ID NO: 3112)

GAAGTCTTCCGTTAGCATAGAGTGG (SEQ ID NO: 3113)

212696_s_at
RNF4
RES4-26,
ring finger protein 4
6047
CTGAAGGAGTGTCCCTCCTCTATGT (SEQ ID NO: 3114)

SNURF

GAAGAGGGCAGAATCCGCAGCTCTC (SEQ ID NO: 3115)

TGTGATGTGTAGCATGTCTGCCCTC (SEQ ID NO: 3116)

CCCTCTGACTGGACATCATTGCCAT (SEQ ID NO: 3117)

CATCATTGCCATTAACTTTCTTCTG (SEQ ID NO: 3118)

TTTCTTCTGGGCATCACGGCAATGT (SEQ ID NO: 3119)

GTCACGATGCCCAGACTTGGAGCAA (SEQ ID NO: 3120)

AGGCAACCTTGGAGTCAGTCCACTC (SEQ ID NO: 3121)

ATGTACATAGTTCAACTCTTTCTTT (SEQ ID NO: 3122)

TATCCATGGATATCAGTCTGCTTTG (SEQ ID NO: 3123)

GACTCCTCTGCTAGTGTTACAGATG (SEQ ID NO: 3124)

222279_at
RP3-
FLJ35429
hypothetical protein
285830
AAATCTTAATCTGGACCCTTTTCAT (SEQ ID NO: 3125)

377H14.5

FLJ35429

GGACCCTTTTCATAAGATGGTGCCA (SEQ ID NO: 3126)

AAAACAAGATCCACATGTCACCCAC (SEQ ID NO: 3127)

TCCGGAGGCAGCCCAAATATCCTTG (SEQ ID NO: 3128)

GAGAAATAAGCTTGACCACCATGTT (SEQ ID NO: 3129)

ACCACCATGTTATCATCAAGTTTCC (SEQ ID NO: 3130)

CGCTGACCACTGAGTAGGCTGTGAA (SEQ ID NO: 3131)

ACAACAGCCTACTTGTGTTCACTGT (SEQ ID NO: 3132)

AAGTCAACACTCTGATTCAGTCTGA (SEQ ID NO: 3133)

CTCCTGACTACGATGCTTTGGTTGT (SEQ ID NO: 3134)

GATGCTTTGGTTGTTGCCACCAAAA (SEQ ID NO: 3135)

220960_x_at
RPL22
EAP, HBP15,
ribosomal protein L22
6146
AATTCTGATGTCGTACCTAAGGCTT (SEQ ID NO: 3136)

HBP15/L22

ACCTAAGGCTTGTCCATCTTTGTTG (SEQ ID NO: 3137)

TTGTTGGAGGTGCCATGGCTCCTGT (SEQ ID NO: 3138)

TGAAGTTCACTCTTGATTGCACCCA (SEQ ID NO: 3139)

ATTGCACCCACCCTGTAGAAGATGG (SEQ ID NO: 3140)

GGAGCAAGAGCAAGATCACCGTGAC (SEQ ID NO: 3141)

ATCACCGTGACATCCGAGGTGCCTT (SEQ ID NO: 3142)

GAATAATCTACGTGACTGGTTGCGC (SEQ ID NO: 3143)

CTGGTTGCGCGTAGTTGCTAACAGC (SEQ ID NO: 3144)

TACGAATTACGTTACTTCCAGATTA (SEQ ID NO: 3145)

TTTATCCTTGTATCTCTGCAGTGTG (SEQ ID NO: 3146)

200937_s_at
RPL5
MGC117339,
ribosomal protein L5
6125
GTGGAGGTGACTGGTGATGAATACA (SEQ ID NO: 3147)

MSTP030

GTGACTGGTGATGAATACAATGTGG (SEQ ID NO: 3148)

AAGCATTGATGGTCAGCCAGGTGCC (SEQ ID NO: 3149)

ATTGATGGTCAGCCAGGTGCCTTCA (SEQ ID NO: 3150)

TGCCTTCACCTGCTATTTGGATGCA (SEQ ID NO: 3151)

GCTATTTGGATGCAGGCCTTGCCAG (SEQ ID NO: 3152)

AGGCCTTGCCAGAACTACCACTGGC (SEQ ID NO: 3153)

CAGAACTACCACTGGCAATAAAGTT (SEQ ID NO: 3154)

GCAGAAGTACATCGGAAGCACATCA (SEQ ID NO: 3155)

TGCAGATTACATGCGCTACTTAATG (SEQ ID NO: 3156)

TACATGCGCTACTTAATGGAAGAAG (SEQ ID NO: 3157)

214167_s_at
RPLP0 ///
RPLP0 ///
ribosomal protein,
6175
CCATTGCCCCATGTGAAGTCACTGT (SEQ ID NO: 3158)

RPLP0-like
RPLP0-like,
large, P0 ///
220717
CCCCATGTGAAGTCACTGTGCCAGC (SEQ ID NO: 3159)

L10E,
ribosomal protein P0-

CCAGCCCAGAACACTGGTCTCGGGC (SEQ ID NO: 3160)

MGC111226,
like

AGCCCAGAACACTGGTCTCGGGCCC (SEQ ID NO: 3161)

MGC88175, P0,

GAACACTGGTCTCGGGCCCGAGAAG (SEQ ID NO: 3162)

PRLP0, RPP0

TGGTCTCGGGCCCGAGAAGACCTCC (SEQ ID NO: 3163)

TTTTTCCAGGCTTTAGGTATCACCA (SEQ ID NO: 3164)

GGTATCACCACTAAAATCTCCAGGG (SEQ ID NO: 3165)

CACCACTAAAATCTCCAGGGGCACC (SEQ ID NO: 3166)

TAAAATCTCCAGGGGCACCATTGAA (SEQ ID NO: 3167)

ATCTCCAGGGGCACCATTGAAATCC (SEQ ID NO: 3168)

211487_x_at
RPS17
MGC72007,
ribosomal protein
6218
GCCAAGGCAGGCGATCACATGAGGT (SEQ ID NO: 3169)

RPS17L1,
S17

CGCGTTCGCACCAAAACCGTGAAGA (SEQ ID NO: 3170)

RPS17L2

TAGAAAAGTACTACACGCGCCTGGG (SEQ ID NO: 3171)

TGCGAGGAGATCGCCATTATCCCCA (SEQ ID NO: 3172)

TATCCCCAGCAAAAAGCTCCGCAAC (SEQ ID NO: 3173)

GATAGCAGGTTATGTCACGCATCTG (SEQ ID NO: 3174)

GTAAGAGGTATCTCCATCAAGCTGC (SEQ ID NO: 3175)

TCCTGAGGTCTCAGCCTTGGATCAG (SEQ ID NO: 3176)

GCTTTTGGACTTCGGCAGTCTGTCC (SEQ ID NO: 3177)

GTCACTCAGCCTACAGTTGGGATGA (SEQ ID NO: 3178)

GATGAATTTCAAAACGCCTCGGGGA (SEQ ID NO: 3179)

218007_s_at
RPS27L
40S ribosomal
ribosomal protein
51065
GCTAGCTGTGTGGGCTGGGAGGTCT (SEQ ID NO: 3180)

protein S27-like
S27-like

GCTGGGAGGTCTGGTAGGGCTGAGC (SEQ ID NO: 3181)

AGAGGATCAACATGCCTTTGGCTAG (SEQ ID NO: 3182)

TAGAGATTTACTACATCCGTCCTTG (SEQ ID NO: 3183)

GAAACGCCTAGTACAAAGTCCAAAT (SEQ ID NO: 3184)

GGATGTAAAATGTCCAGGTTGCTAC (SEQ ID NO: 3185)

GTTGCTACAAGATCACCACGGTTTT (SEQ ID NO: 3186)

GCCATGCTCAGACAGTGGTTCTTTG (SEQ ID NO: 3187)

CACTAATGATTCAAACAGCTTCCTG (SEQ ID NO: 3188)

GTGTTGTCTCACAGAAAGCCTTATC (SEQ ID NO: 3189)

GGTATACAGCAGTAATCTCCTATTT (SEQ ID NO: 3190)

200099_s_at
RPS3A ///
FTE1, MFTL,
ribosomal protein
6189
TTGAAGTGAGTCTTGCTGATTTGCA (SEQ ID NO: 3191)

LOC439992
MGC23240 ///
S3A /// similar to v-
439992
GAGTCTTGCTGATTTGCAGAATGAT (SEQ ID NO: 3192)

fos transformation

TCAAGCTGATTACTGAAGATGTTCA (SEQ ID NO: 3193)

effector protein

GTAAAAACTGCCTGACTAACTTCCA (SEQ ID NO: 3194)

AAACTGCCTGACTAACTTCCATGGC (SEQ ID NO: 3195)

GGCAGACAATGATTGAAGCTCACGT (SEQ ID NO: 3196)

TTGAAGCTCACGTTGATGTCAAGAC (SEQ ID NO: 3197)

TACGGAAGACCTCTTATGCTCAGCA (SEQ ID NO: 3198)

GGAAATCATGACCCGAGAGGTGCAG (SEQ ID NO: 3199)

GACCCGAGAGGTGCAGACAAATGAC (SEQ ID NO: 3200)

GAGAGGTGCAGACAAATGACTTGAA (SEQ ID NO: 3201)

213098_at
RQCD1
RCD1; CNOT9;
RCD1 required for
9215
ACAGCTCAGGTTTTATCACCGACTG (SEQ ID NO: 3202)

RCD1+
cell differentiation1

ACCTCAATGCTGAACCGCACTGGAG (SEQ ID NO: 3203)

homolog (S. pombe)

CAAGGTACCCCTGCTGAGGTGTATG (SEQ ID NO: 3204)

CCCTCTGCTACTCCCAGGAAATGGG (SEQ ID NO: 3205)

ACCACAGCCCCAGGAGGGTGTCAAC (SEQ ID NO: 3206)

ATAGCAGCAGCACTCTAGGCATGGT (SEQ ID NO: 3207)

GCATGGTGAACGCCTGGGACCAAGC (SEQ ID NO: 3208)

GGGACCAAGCCATGTGGCGTTTTTT (SEQ ID NO: 3209)

AAGATATGTCTCTTCATTCTCTCTC (SEQ ID NO: 3210)

TCATTCTCTCTCAGTATTTGTTTAC (SEQ ID NO: 3211)

GCAAAACTTTGTCGACTGGCACTGT (SEQ ID NO: 3212)

34408_at
RTN2
NSP2, NSPL1
reticulon 2
6253
TCCGAGCTAAAATCCCAGGGACCGG (SEQ ID NO: 3213)

TTACCTGAGCGACCAGGACTACATT (SEQ ID NO: 3214)

GCCTGCTGGGACTTGTAGTTGCCTA (SEQ ID NO: 3215)

TGCTGGGACTTGTAGTTGCCTAGAC (SEQ ID NO: 3216)

TGGGACTTGTAGTTGCCTAGACAGG (SEQ ID NO: 3217)

TGTAGTTGCCTAGACAGGGCACCAC (SEQ ID NO: 3218)

GTAGTTGCCTAGACAGGGCACCACC (SEQ ID NO: 3219)

AGGCGTTGGTGTCTCCTGGATGCTA (SEQ ID NO: 3220)

GGCGTTGGTGTCTCCTGGATGCTAC (SEQ ID NO: 3221)

GCGTTGGTGTCTCCTGGATGCTACT (SEQ ID NO: 3222)

CGTTGGTGTCTCCTGGATGCTACTA (SEQ ID NO: 3223)

GGGAGGCCTGAGCTTGGATTTACAC (SEQ ID NO: 3224)

GGAGGCCTGAGCTTGGATTTACACT (SEQ ID NO: 3225)

GGCCTGAGCTTGGATTTACACTGTA (SEQ ID NO: 3226)

CTGAGCTTGGATTTACACTGTAATA (SEQ ID NO: 3227)

CTTGGATTTACACTGTAATAAAGAC (SEQ ID NO: 3228)

216976_s_at
RYK
D3S3195, JTK5,
RYK receptor-like
6259
AGGCCAGTTCGTTGGATGGCTCTTG (SEQ ID NO: 3229)

JTK5A, RYK1
tyrosine kinase

CTCTAGCGCTAGTGATGTGTGGGCC (SEQ ID NO: 3230)

TGGGAACTCATGACTCTGGGCCAGA (SEQ ID NO: 3231)

ATGGTTACCGAATAGCCCAGCCAAT (SEQ ID NO: 3232)

CCCAGCCAATCAACTGTCCTGATGA (SEQ ID NO: 3233)

TATTTGCTGTGATGGCCTGTTGCTG (SEQ ID NO: 3234)

CCTGTTGCTGGGCCTTAGATCCAGA (SEQ ID NO: 3235)

GTTTCAGCAGCTGGTACAGTGCCTA (SEQ ID NO: 3236)

GCCTAACAGAGTTTCATGCAGCCCT (SEQ ID NO: 3237)

AGGAAGAAGGTGCCTGTCGGGGCTC (SEQ ID NO: 3238)

TCGGGGCTCACTTGAAGCCTGTCAG (SEQ ID NO: 3239)

218276_s_at
SAV1
SAV, WW45,
salvador homolog 1
60485
AGTTGCTAACATCATCTTCCTTATT (SEQ ID NO: 3240)

WWP4
(Drosophila)

TTCAGCCAGTGCTGTTACTGCATTT (SEQ ID NO: 3241)

GTTACTGCATTTAGCATGGCTCTGA (SEQ ID NO: 3242)

GCATGGCTCTGACGAGGCAGTGGAG (SEQ ID NO: 3243)

GCAGTGGAGAGTTCCTGACAGCATA (SEQ ID NO: 3244)

GACAGCATAGCATACTGCCTTCTGA (SEQ ID NO: 3245)

AGCATACTGCCTTCTGACAGACTGG (SEQ ID NO: 3246)

GACAGACTGGGTTAAGCTACCAAAA (SEQ ID NO: 3247)

GACTTTAACACCATATATTTCCCTC (SEQ ID NO: 3248)

GTCTTCCAGAATACAAACTACTCCC (SEQ ID NO: 3249)

ACTACTCCCAGTTAGATATCAGTGA (SEQ ID NO: 3250)

212416_at
SCAMP1
SCAMP,
secretory carrier
9522
TTAGAACCCACATATCTTTTTTTGT (SEQ ID NO: 3251)

SCAMP37
membrane protein 1

GATTGGCATTTGTTAAGTGTTCTAT (SEQ ID NO: 3252)

TAAAATGGTCTTCACACAGCAGTCA (SEQ ID NO: 3253)

TTCACACAGCAGTCATCCGTGTCAT (SEQ ID NO: 3254)

GTCATCCGTGTCATTTATCATTTTG (SEQ ID NO: 3255)

GGGACTTGGATTATTTATCTAGAGA (SEQ ID NO: 3256)

TAACTAATACTGCGCTGCCATCATG (SEQ ID NO: 3257)

GCGCTGCCATCATGGTGACTGTCAT (SEQ ID NO: 3258)

GTCATGGTTCTACAGAAATGCCCTC (SEQ ID NO: 3259)

TCCATGTGTCCCTCTAATGTTGCAT (SEQ ID NO: 3260)

AATGTTGCATGTTTCAGTGGGTTGG (SEQ ID NO: 3261)

204035_at
SCG2
CHGC, SN, SgII
secretogranin II
7857
CCCGGTGAGCAAAAGGTTCCCTGTG (SEQ ID NO: 3262)

(chromogranin C)

TCCCTGTGGGGCCCCCGAAGAATGA (SEQ ID NO: 3263)

ATGATACCCCAAATAGGCAGTACTG (SEQ ID NO: 3264)

GAAAGTGCTGGAATACCTCAATCAA (SEQ ID NO: 3265)

CATTAATTACCCTACTTTCATTCCT (SEQ ID NO: 3266)

AGTGTGTTGACTTCTATCCTGTTAA (SEQ ID NO: 3267)

CAGGCAGATGAAACCAGGTCACTGG (SEQ ID NO: 3268)

CTGAGCTGTTATCTTGTGTATGGAT (SEQ ID NO: 3269)

GTGTAAATGTTATGACTCCTTGATA (SEQ ID NO: 3270)

GCTGTGGCATTGTTGATGCTCACAT (SEQ ID NO: 3271)

GTTACTGTCTGTAGCGTTTTGTGGA (SEQ ID NO: 3272)

212698_s_at
SEPT10
FLJ11619
septin 10
151011
GATCTTAAGCTTTTGTGTCAGATTA (SEQ ID NO: 3273)

TGATGACTTCATGCTTTATTATGCC (SEQ ID NO: 3274)

TATGCCTTATTATGGCTGACGTATT (SEQ ID NO: 3275)

GGCTGACGTATTACTGTGGTGAAAC (SEQ ID NO: 3276)

ATAAAGTACCTTTGAGCATGAGTGT (SEQ ID NO: 3277)

GCATGAGTGTATCACAGCTTTCATT (SEQ ID NO: 3278)

GGAAAACTTTTCATTACATACTTGT (SEQ ID NO: 3279)

ACTTGTTTAAACTCTGTCTTCCAGG (SEQ ID NO: 3280)

TTCAGGTGGTATTTGCATTCAGTGC (SEQ ID NO: 3281)

AGTGCCTTACTGGTATTCTCAGAAC (SEQ ID NO: 3282)

AATAAAACTGACATTTACTCTTGAC (SEQ ID NO: 3283)

214720_x_at
SEPT10
FLJ11619
septin 10
151011
GCTACAGGCCAAATTTGAGCACCTT (SEQ ID NO: 3284)

GAGCACCTTAAGAGACTTCACCAAG (SEQ ID NO: 3285)

CTACCTCCGAGATATTTCACAGCCA (SEQ ID NO: 3286)

TTCACAGCCAGTCCTTTCTGGCAAC (SEQ ID NO: 3287)

GTCCTTTCTGGCAACAGGCAGCAAC (SEQ ID NO: 3288)

GACAAGGACCGTAAGAACTCCAATT (SEQ ID NO: 3289)

GAGCACAGAAGGTCATCATCACAAG (SEQ ID NO: 3290)

GCTGTTATTTGTTTTATCACTTCTA (SEQ ID NO: 3291)

GGTGAACAGCCACAGTTACTGATAT (SEQ ID NO: 3292)

GATACTACAAGTTGAGCATCTCTAA (SEQ ID NO: 3293)

TCTTTTTGAGCACTGACTTGACCCC (SEQ ID NO: 3294)

217724_at
SERBP1
CGI-55, CHD3IP,
SERPINE1 mRNA
26135
AGTTACCTACTATTCTGACATTTTA (SEQ ID NO: 3295)

DKFZp564M2423,
binding protein 1

CTTGTGCTGGTGTTTTGGATCTTAT (SEQ ID NO: 3296)

FLJ90489,

GATGCTGAGCATGTTCTGCACTGGT (SEQ ID NO: 3297)

HABP4L, PAI-

TTTACACACATACGTGCTACCCAGA (SEQ ID NO: 3298)

RBP1, PAIRBP1

AGACAGCAACATACGCACTCCTAAA (SEQ ID NO: 3299)

AAGTATCTAACTCATTTCCAAACAT (SEQ ID NO: 3300)

TAAACCTCTTGATTTCCAGCAACAT (SEQ ID NO: 3301)

AACACCTGCTACTCAAAACACAACT (SEQ ID NO: 3302)

ATATCTGGTATGTTGCAAGCTTTCA (SEQ ID NO: 3303)

ATAAATTTGCCTCCTAGTTCACTTT (SEQ ID NO: 3304)

TGAACCTAACTTTCTCTTATGGTG (SEQ ID NO: 3305)

202833_s_at
SERPINA1
A1A, A1AT, AAT,
serpin peptidase
5265
GAAGCGTTTAGGCATGTTTAACATC (SEQ ID NO: 3306)

MGC23330,
inhibitor, clade A

GCATGTTTAACATCCAGCACTGTAA (SEQ ID NO: 3307)

MGC9222, PI,
(alpha-1

AGCACTGTAAGAAGCTGTCCAGCTG (SEQ ID NO: 3308)

PI1, PRO2275
antiproteinase,

GAGGGGAAACTACAGCACCTGGAAA (SEQ ID NO: 3309)

antitrypsin), member 1

CACCTGGAAAATGAACTCACCCACG (SEQ ID NO: 3310)

ATGAACTCACCCACGATATCATCAC (SEQ ID NO: 3311)

CCCACGATATCATCACCAAGTTCCT (SEQ ID NO: 3312)

GAAGACAGAAGGTCTGCCAGCTTAC (SEQ ID NO: 3313)

GAAGGTCTGCCAGCTTACATTTACC (SEQ ID NO: 3314)

GCTTACATTTACCCAAACTGTCCAT (SEQ ID NO: 3315)

TTACCCAAACTGTCCATTACTGGAA (SEQ ID NO: 3316)

211429_s_at
SERPINA1
A1A, A1AT, AAT,
serpin peptidase
5265
TACTGGAACCTATGATCTGAAGAGC (SEQ ID NO: 3317)

MGC23330,
inhibitor, clade A

ACCTATGATCTGAAGAGCGTCCTGG (SEQ ID NO: 3318)

MGC9222, PI,
(alpha-1

TGGGTCAACTGGGCATCACTAAGGT (SEQ ID NO: 3319)

PI1, PRO2275
antiproteinase,

GGTCAACTGGGCATCACTAAGGTCT (SEQ ID NO: 3320)

antitrypsin), member 1

GGCCGTGCATAAGGCTGTGCTGACC (SEQ ID NO: 3321)

TGCATAAGGCTGTGCTGACCATCGA (SEQ ID NO: 3322)

AAACCCTTTGTCTTCTTAATGATTG (SEQ ID NO: 3323)

CCTTTGTCTTCTTAATGATTGAACA (SEQ ID NO: 3324)

TGAACAAAATACCAAGTCTCCCCTC (SEQ ID NO: 3325)

CACCCAAAAATAACTGCCTCTCGCT (SEQ ID NO: 3326)

CCCCCTCCCTGGATGACATTAAAGA (SEQ ID NO: 3327)

201070_x_at
SF3B1
PRP10, PRPF10,
splicing factor 3b,
23451
TGGATGGGCTGAGACTCCTCGAACA (SEQ ID NO: 3328)

SAP155,
subunit 1, 155 kDa

TGGGTGGAAGCACTCCAGTTCTGAC (SEQ ID NO: 3329)

SF3b155

AGTTCTGACCCCTGGAAAGACACCA (SEQ ID NO: 3330)

AAAGACACCAATTGGCACACCAGCC (SEQ ID NO: 3331)

ACCCCTACTCCAGGTCACATAATGA (SEQ ID NO: 3332)

TGAACAGCTTCAGGCTTGGCGGTGG (SEQ ID NO: 3333)

AAATCGCCCACTTTCTGATGAGGAA (SEQ ID NO: 3334)

AGGATATAAGGTACTTCCTCCTCCA (SEQ ID NO: 3335)

TCCTCCAGCTGGTTATGTTCCTATT (SEQ ID NO: 3336)

GTTCCTATTCGAACTCCAGCTCGAA (SEQ ID NO: 3337)

CAGCTACTCCAACACCTTTGGGTGG (SEQ ID NO: 3338)

201586_s_at
SFPQ
POMP100, PSF
splicing factor
6421
GCCATTCATGCTTCTATGCATATTA (SEQ ID NO: 3339)

proline/glutamine-rich

ATATTAGGCTACGTATTCCACATTG (SEQ ID NO: 3340)

(polypyrimidine tract

AAGCATGAGAGTGTCTAGGCCTTTG (SEQ ID NO: 3341)

binding protein

TAGGCCTTTGAATGGCATATGCCAT (SEQ ID NO: 3342)

associated)

TCTGGGAAATGCATCTGGAGGCTAA (SEQ ID NO: 3343)

GGAGGCTAAGTATTGCTTTCTACAA (SEQ ID NO: 3344)

GTTTGGCATATAGGAAGCACGCTGG (SEQ ID NO: 3345)

GCACGCTGGTGCTAAGTATTTTTTA (SEQ ID NO: 3346)

AAATGGATCTTTTATGGCCCTATGA (SEQ ID NO: 3347)

GCCCTATGATCTATCCTTTACTTGA (SEQ ID NO: 3348)

AAAGACCAACAAATCTCAAGCCCTA (SEQ ID NO: 3349)

214492_at
SGCD
35DAG, CMD1L,
sarcoglycan, delta
6444
ATCAGGCTACCTAGACTGCCTCATG (SEQ ID NO: 3350)

DAGD,
(35 kDa dystrophin-

GATCCTACACGCCTACAGGAACGAG (SEQ ID NO: 3351)

MGC22567, SG-
associated

CAGAAGGTCTTCGAGATCTGCGTCT (SEQ ID NO: 3352)

delta, SGCDP,
glycoprotein)

TCTGCGTCTGCGCCAATGGGAGATT (SEQ ID NO: 3353)

SGD

GAGCTGGGTCCACTTGTCAGATAAA (SEQ ID NO: 3354)

AAACACAAGTGTCTGCCTCTGAAAG (SEQ ID NO: 3355)

CCTTTTTTGGCTTTAGACACTGGCT (SEQ ID NO: 3356)

ACACTGGCTGCCAGCTATTTTTACT (SEQ ID NO: 3357)

GTGTGCGTGCTTGAGTGTGTTCGCG (SEQ ID NO: 3358)

GTGTTCGCGTGTGTGGGTGGATATA (SEQ ID NO: 3359)

CTGCGATATCCACTGTCATTTTCCA (SEQ ID NO: 3360)

210796_x_at
SIGLEC6
CD327, CD33L,
sialic acid binding Ig-
946
AATCTCTCTGAGTCTCTTTGTGCAT (SEQ ID NO: 3361)

CD33L1,
like lectin 6

CTTTGTGCATTGGTCATCAGCACCA (SEQ ID NO: 3362)

CDw327,

ATCAGCACCAGTTCCAGACAGGCAT (SEQ ID NO: 3363)

OBBP1, SIGLEC-6

GACAGGCATAGTTTCAGACCACCCT (SEQ ID NO: 3364)

GTCCTACACTTCCACAAGGTGCAAC (SEQ ID NO: 3365)

AAAGGTCACCGACACTGAGTACTCA (SEQ ID NO: 3366)

GAACATGGTACCTCTCAGTGTATTG (SEQ ID NO: 3367)

CTAAGGCCTCTCTTGTTGGCTTGTA (SEQ ID NO: 3368)

ACATGGTCTTTCCTCTGAGTGTGTT (SEQ ID NO: 3369)

TGTCCTAATCTTCTCTTCTTATAAA (SEQ ID NO: 3370)

ATATTGGATTAGGGCCTCCCCATGA (SEQ ID NO: 3371)

204587_at
SLC25A14
RP1-20I3.5,
solute carrier family
9016
CTGAATTATATGTGAGCCCAGCCCT (SEQ ID NO: 3372)

BMCP1,
25 (mitochondrial

TTTTCCCGTGTTCTAATGTATTTTG (SEQ ID NO: 3373)

MGC149543,
carrier, brain),

GTGTTTACCAAGCCGTTGGTCTCCT (SEQ ID NO: 3374)

UCP5
member 14

TCTCCTAAGGGCCTCCTGATGGAAG (SEQ ID NO: 3375)

GTGTTAACATTGAGACTCTGGCCCC (SEQ ID NO: 3376)

TGGCCCCAGATTGGTATCTTCTATG (SEQ ID NO: 3377)

GGGTGACATTGAAAACGGCCTGCTT (SEQ ID NO: 3378)

TGAAAACGGCCTGCTTTCCAAATGT (SEQ ID NO: 3379)

GTAATTGGTTAGCCCCAGACTTGGG (SEQ ID NO: 3380)

GAAGGCATAGGCCAGGGTGGTTATT (SEQ ID NO: 3381)

ATGTGTTACAGACCTCGGTTCTCAT (SEQ ID NO: 3382)

200030_s_at
SLC25A3
D1S155E,
solute carrier family
5250
ACACCATGATGAAGTTCGCCTGCTT (SEQ ID NO: 3383)

MGC165858
25 (mitochondrial

TCGCCTGCTTTGAACGTACTGTTGA (SEQ ID NO: 3384)

carrier; phosphate

TGTACAAGTTTGTGGTTCCTAAGCC (SEQ ID NO: 3385)

carrier), member 3

TCCTAAGCCCCGCAGTGAATGTTCA (SEQ ID NO: 3386)

ACCCTGCTGATTCTGTGGTATCTGT (SEQ ID NO: 3387)

AAAGGTAGCAGTGCTTCTCTGGTCC (SEQ ID NO: 3388)

GTGCTTCTCTGGTCCTCAAGAGACT (SEQ ID NO: 3389)

TCATCATGATTGGTACCCTGACTGC (SEQ ID NO: 3390)

GTACCCTGACTGCACTACAGTGGTT (SEQ ID NO: 3391)

GTGGTTTATCTATGACTCCGTGAAG (SEQ ID NO: 3392)

GTGAAGGTCTACTTCAGACTTCCTC (SEQ ID NO: 3393)

209267_s_at
SLC39A8
BIGM103; LZT-
solute carrier family
64116
AATGCAAAACAACAGCTGGACTGCT (SEQ ID NO: 3394)

Hs6
39 (zinc transporter),

AGCTGGACTGCTGTACATCAAGGAC (SEQ ID NO: 3395)

member 8

GTTCCTTATGTGTGATTGAGAGCCA (SEQ ID NO: 3396)

GCCATTCAGAAAAGACTTCCTTTGT (SEQ ID NO: 3397)

TTGTGTTCAGCCTATACTTTTCCAT (SEQ ID NO: 3398)

TACTTTTCCATATGGTATACCTTGA (SEQ ID NO: 3399)

ATTAGCACACCATGGTTATTTTTCT (SEQ ID NO: 3400)

AAGACAGAGCCTGTTTACTCATTTA (SEQ ID NO: 3401)

TGAACATCCTAGATTCACACTCCCA (SEQ ID NO: 3402)

GACAAAGCCCAACAATGATCTCAGG (SEQ ID NO: 3403)

ATGTTTTCATGTAGCAGCAATGCAG (SEQ ID NO: 3404)

219869_s_at
SLC39A8
BIGM103; LZT-
solute carrier family
64116
GGATGATAACGCTCTGCGATGCCCT (SEQ ID NO: 3405)

Hs6
39 (zinc transporter),

TGCCCTCCACAATTTCATCGATGGC (SEQ ID NO: 3406)

member 8

TCGATGGCCTGGCGATTGGGGCTTC (SEQ ID NO: 3407)

GACTCAGTACTTCCATAGCAATCCT (SEQ ID NO: 3408)

ATGTGAGGAGTTTCCCCACGAGTTA (SEQ ID NO: 3409)

GAGACTTTGTGATCCTACTCAATGC (SEQ ID NO: 3410)

AGGGATGAGCACTCGACAAGCCTTG (SEQ ID NO: 3411)

ACAAGCCTTGCTATTCAACTTCCTT (SEQ ID NO: 3412)

TGGTGGGCAACAATTTCGCTCCAAA (SEQ ID NO: 3413)

GAAAAACCGATTTCACCTTCTTCAT (SEQ ID NO: 3414)

GCCATTCTACTCATTACCTTGTATG (SEQ ID NO: 3415)

209257_s_at
SMC3
BAM, BMH,
structural
9126
GTAGATCCCTTCAGTTCAAAACATA (SEQ ID NO: 3416)

CDLS3, CSPG6,
maintenance of

GAGTTTAGTCATCTTCGTCCAGAAC (SEQ ID NO: 3417)

HCAP, SMC3L1
chromosomes 3

TCGTCCAGAACAGCGGTTGGCTTTA (SEQ ID NO: 3418)

ATTGCATGAAGGTACTGGTCCTCGT (SEQ ID NO: 3419)

AGGTACTGGTCCTCGTGTTATTTCT (SEQ ID NO: 3420)

AATTCAGACAACCGGTTACCAATCG (SEQ ID NO: 3421)

ACTTCGAAGAGTTATTGGTGCCAAA (SEQ ID NO: 3422)

AAATGATGTGATGAACCTCCTTGAA (SEQ ID NO: 3423)

GAACCTCCTTGAAAGCGCTGGTTTT (SEQ ID NO: 3424)

GCGCTGGTTTTTCTCGAAGCAATCC (SEQ ID NO: 3425)

GCAACAGCACCAGATTCTCAGAGAT (SEQ ID NO: 3426)

201793_x_at
SMG7
RP1-127C7.1,
Smg-7 homolog,
9887
CCCCGCCTGTGGCATTTTCTATGGG (SEQ ID NO: 3427)

C1orf16, EST1C,
nonsense mediated

TTTCTATGGGCTCAGGTTACACCTT (SEQ ID NO: 3428)

FLJ23717,
mRNA decay factor

CAGCTGGTGTTTCTGTCCCAGGAAC (SEQ ID NO: 3429)

KIAA0250,
(C. elegans)

CTCACTCTCCAGCAGGAAACCAGGT (SEQ ID NO: 3430)

SGA56M, SMG-7

GACCAGGGCCAATGAACCAGGGACC (SEQ ID NO: 3431)

ATCTTTACCAGCTCAGCCAACAGCA (SEQ ID NO: 3432)

GCCAACAGCACAGTCTACAAGCCAG (SEQ ID NO: 3433)

GCTGCAGGTTCAAGCTCTAACTCAG (SEQ ID NO: 3434)

CTAACTCAGCAACAACAATCCCCTA (SEQ ID NO: 3435)

CCTCACCACTCTGGATTCCAGCAGT (SEQ ID NO: 3436)

TGTTTGAGCCGTCATTGCAACCTCC (SEQ ID NO: 3437)

205596_s_at
SMURF2
DKFZp686F0270,
SMAD specific E3
64750
GGTCTTTATGCTTTGCCATGAGGCC (SEQ ID NO: 3438)

MGC138150
ubiquitin protein

GAGGCCACATTCAGCTGCTATTTAA (SEQ ID NO: 3439)

ligase 2

GAATGCTGACTTTTCCTACATTTCC (SEQ ID NO: 3440)

TGACTTTTCCTACATTTCCAGAGTT (SEQ ID NO: 3441)

GAGTTAGGCAGTATTCTACACTTAA (SEQ ID NO: 3442)

TACACTTAAAGACTACTACTATTTT (SEQ ID NO: 3443)

TCTTCACAGATTTCAAGTCTCTCAA (SEQ ID NO: 3444)

AGATTTCAAGTCTCTCAAACATCAA (SEQ ID NO: 3445)

TCAAGACAACTTCAGCAGTCGGTAC (SEQ ID NO: 3446)

GCAGTCGGTACAAGTCACATTTCAT (SEQ ID NO: 3447)

ACAAGTCACATTTCATTTTGATTGA (SEQ ID NO: 3448)

200826_at
SNRPD2
SMD2, SNRPD1
small nuclear
6633
GAGCGTAGTGACCATCATGAGCCTC (SEQ ID NO: 3449)

ribonucleoprotein D2

GCCCAAGAGTGAGATGACCCCAGAG (SEQ ID NO: 3450)

polypeptide 16.5 kDa

GAGGAATTTAACACCGGTCCACTCT (SEQ ID NO: 3451)

CACTCTCTGTGCTCACACAGTCAGT (SEQ ID NO: 3452)

GAACAATACCCAAGTGCTCATCAAC (SEQ ID NO: 3453)

TGCTCATCAACTGCCGCAACAATAA (SEQ ID NO: 3454)

GAAGGCCTTCGATAGGCACTGCAAC (SEQ ID NO: 3455)

GTGGACTGAGGTACCCAAGAGTGGC (SEQ ID NO: 3456)

ACATCTCCAAGATGTTCCTGCGCGG (SEQ ID NO: 3457)

TCATCGCCGGCAAGTAGGGGCCGCC (SEQ ID NO: 3458)

TCCTATGAAGACCGCTGCCATTGGT (SEQ ID NO: 3459)

201562_s_at
SORD
SORD1
sorbitol
6652
GATGTTAATGGGCTCTGCTCATCCC (SEQ ID NO: 3460)

dehydrogenase

GGGTGGGCTCTGATGCAGAACTTTC (SEQ ID NO: 3461)

GGAACTTGTAGCCAGAATGCCCTGT (SEQ ID NO: 3462)

GAATGCCCTGTTCATGCTGAGCAAA (SEQ ID NO: 3463)

TTCTTCCTGGAGTGCCTTCATTGAG (SEQ ID NO: 3464)

TCCACTGCTACTGACCCAGAGGGGA (SEQ ID NO: 3465)

TCATGAAGACTTAACTGGCCCAGAA (SEQ ID NO: 3466)

AAAATCTGCCACTCAGGGTCTGGGA (SEQ ID NO: 3467)

GGGTCTGGGATGAAGGCTTGTCAGC (SEQ ID NO: 3468)

GCTTGTCAGCACTTCCAGTTTAGAA (SEQ ID NO: 3469)

GAAAAGGCATCACTTTCCTGGATCC (SEQ ID NO: 3470)

201417_at
SOX4
EVI16
SRY (sex
6659
GTAAACCACATCTTTTTTGCACTTT (SEQ ID NO: 3471)

determining region

ACGTGCCGTTTAAACCACTGGATCT (SEQ ID NO: 3472)

Y)-box 4

ACCACTGGATCTATCTAAATGCCGA (SEQ ID NO: 3473)

AATGCCGATTTGAGTTCGCGACACT (SEQ ID NO: 3474)

GCGACACTATGTACTGCGTTTTTCA (SEQ ID NO: 3475)

TGTACTGCGTTTTTCATTCTTGTAT (SEQ ID NO: 3476)

TGACTATTTAATCCTTTCTACTTGT (SEQ ID NO: 3477)

TCCTTTCTACTTGTCGCTAAATATA (SEQ ID NO: 3478)

GCACTAGGACGTCTGCCTTTTTAAG (SEQ ID NO: 3479)

TTTTTTTGCCATCCATCCTGTGCAA (SEQ ID NO: 3480)

TCCATCCTGTGCAATATGCCGTGTA (SEQ ID NO: 3481)

222163_s_at
SPATA5L1
FLJ12286,
spermatogenesis
79029
GAAGTGTCATGATTATTGCAGCAAC (SEQ ID NO: 3482)

MGC5347
associated 5-like 1

AGACCTGATGTGTTAGATACTGCTT (SEQ ID NO: 3483)

AGATACTGCTTTGTTACGACCTGGA (SEQ ID NO: 3484)

CTCCTTAGAAAACCTCGCAGCAGAA (SEQ ID NO: 3485)

GCACAGAAGCTGCTTTGCTGGCTCT (SEQ ID NO: 3486)

CTGCTTTGCTGGCTCTGCAAGAAAA (SEQ ID NO: 3487)

AATGGACTAGACGCAACTACAGTGA (SEQ ID NO: 3488)

ACCGTCGTTAAGTTGCAAGGACTTG (SEQ ID NO: 3489)

AAATCACCTTAAACTCTTGTTCAGT (SEQ ID NO: 3490)

AAATGTGAACTTGCCTGTCGTTTGC (SEQ ID NO: 3491)

GTCGTTTGCAACTTCACACTTTTAG (SEQ ID NO: 3492)

220192_x_at
SPDEF
PDEF, RP11-
SAM pointed domain
25803
TGAACTACGACAAGCTGAGCCGCTC (SEQ ID NO: 3493)

375E1_A.3,
containing ets

GGGCATCATCCGGAAGCCAGACATC (SEQ ID NO: 3494)

bA375E1.3
transcription factor

GGAAAACGGGCAGTCTGCTCTGCTG (SEQ ID NO: 3495)

CTGCTCTGACCTTCCAGAGCCCAAG (SEQ ID NO: 3496)

GCTGCTCCCCTGGAGGACAGAGGGA (SEQ ID NO: 3497)

AGAGGGAGACAGGGCTGCTCCCCAA (SEQ ID NO: 3498)

CCAGCATTTCCAGAGCAGAGCCTAC (SEQ ID NO: 3499)

GGGCAGTGACTCGACAAAGGCCACA (SEQ ID NO: 3500)

AAAGGCCACAGGCAGTCCAGGCCTC (SEQ ID NO: 3501)

TGCAGGGAGACATCTGCACCCCTGA (SEQ ID NO: 3502)

GAGTTGGGCAGCCAGGAGTGCCCCC (SEQ ID NO: 3503)

205064_at
SPRR1B
CORNIFIN,
small proline-rich
6699
TACAGAGTATTCCTCTCTTCACACC (SEQ ID NO: 3504)

GADD33,
protein 1B (cornifin)

ACCAGCCACTGTTGCAGCATGAGTT (SEQ ID NO: 3505)

MGC61901,

TGTTGCAGCATGAGTTCCCAGCAGC (SEQ ID NO: 3506)

SPRR1

TCCCATTCTGTGTATGAGTCCCATT (SEQ ID NO: 3507)

TCTGTGTATGAGTCCCATTTGCCTT (SEQ ID NO: 3508)

GAGTCCCATTTGCCTTGCAATTAGC (SEQ ID NO: 3509)

GAATGTGCTATGAAGCTTTCTTTCC (SEQ ID NO: 3510)

TTTCCTACACACTCTGAGTCTCTGA (SEQ ID NO: 3511)

GCTGAAGGTCTTAGTACCAGAGCTA (SEQ ID NO: 3512)

ACCAGAGCTAGTTTTCAGCTGCTCA (SEQ ID NO: 3513)

GTTTTCAGCTGCTCAGAATTCATCT (SEQ ID NO: 3514)

217995_at
SQRDL
CGI-44
sulfide quinone
58472
TACGTCAAAGACCGCTGCTGCAGTA (SEQ ID NO: 3515)

reductase-like (yeast)

GCAGTAGCTGCCCAGTCAGGAATAC (SEQ ID NO: 3516)

GCTACACATCATGTCCACTGGTGAC (SEQ ID NO: 3517)

CACTGGTGACCGGCTACAACCGTGT (SEQ ID NO: 3518)

ACAACCGTGTGATTCTTGCTGAGTT (SEQ ID NO: 3519)

GCGCCTTTCCATGTATCTCATGAAA (SEQ ID NO: 3520)

GACCAGCGTTTCTGCGCAAGTTGTT (SEQ ID NO: 3521)

TAAGGATGGCTCAGCACTTGCTCAT (SEQ ID NO: 3522)

GGCTTCTGGGCCAAAACTGCAGTCA (SEQ ID NO: 3523)

GTAATGGTGACCAAATGCCTCCCTT (SEQ ID NO: 3524)

GTGGGCTACTCATGATGGGCTTGAT (SEQ ID NO: 3525)

208801_at
SRP72

signal recognition
6731
GGTCACATGGGTTTGGACTGTCTCA (SEQ ID NO: 3526)

particle 72 kDa

GTATCTGAGTTGCATACCAGGCAGT (SEQ ID NO: 3527)

CTAACAGGTCTGTTTGGCCCATTGA (SEQ ID NO: 3528)

CTGTTTGGCCCATTGATAGATACTC (SEQ ID NO: 3529)

TGGTGTCTCCTTCTGGTTATGGATT (SEQ ID NO: 3530)

ATTTTGACCATTGATTACCTTTCTC (SEQ ID NO: 3531)

GTCTTTCCTTGCTTACAAACTACTT (SEQ ID NO: 3532)

AACTACTTTCACATTGAACAGCTGT (SEQ ID NO: 3533)

GTATTCATTTTATGCTGCCCAAGAT (SEQ ID NO: 3534)

GTGATTATATTACTCTGTCCTTGTT (SEQ ID NO: 3535)

TAAAGTGCTGCTGTGTTTGACTCTG (SEQ ID NO: 3536)

210378_s_at
SSNA1
N14, NA-14,
Sjogren syndrome
8636
AGCGTTCTCAAGAGGGAAGCTGGGA (SEQ ID NO: 3537)

NA14
nuclear autoantigen 1

TGGGAACCTGACCAAGGCTACAGCC (SEQ ID NO: 3538)

GACCAGAAAAGTAGCGGCGGCAGGG (SEQ ID NO: 3539)

GCCCCAGCAAGTGTGTGCTCAGAGC (SEQ ID NO: 3540)

TGCTCAGAGCATCTTTGTTCTTCAC (SEQ ID NO: 3541)

CAGGTGCCGAGAGGGGCAGGTGCCA (SEQ ID NO: 3542)

CTTCATGCTCACACAGGCTATGGGG (SEQ ID NO: 3543)

CTGCAAGGGGCTTGTCTCTGTGGCA (SEQ ID NO: 3544)

TGCCAGGGAGGCTCTGGTTGTCTGA (SEQ ID NO: 3545)

TGGTTGTCTGAGCACCATGGGGGCC (SEQ ID NO: 3546)

CCTGTGGCCTGTGATTATGAATAAA (SEQ ID NO: 3547)

210242_x_at
ST20
HCCS-1
suppressor of
400410
GCCATTACCAATCGCGAAACCCGAA (SEQ ID NO: 3548)

tumorigenicity 20

TGAGGAGGCGGTTCATCTGTGGCCA (SEQ ID NO: 3549)

GGCCCTGCTATATGCGGGGGCCTCG (SEQ ID NO: 3550)

CGGCTGGAGTGAGCGGCGTGGACGC (SEQ ID NO: 3551)

TTCCCTTGTTGCTGCGAGAGCGAGA (SEQ ID NO: 3552)

TAACGTGAACGCGGACCAGGAGGCT (SEQ ID NO: 3553)

CTCTGTCTCCCAGGTTCAGGAAAAT (SEQ ID NO: 3554)

AATCTGGCTGGATGACTTTTCTAGA (SEQ ID NO: 3555)

TCTGTGAAATGCTCTTCTGTCCTGA (SEQ ID NO: 3556)

GCCTAATTTTTCTGACTCTTACGAA (SEQ ID NO: 3557)

TTGCCAACACATACTTCTACTTTTA (SEQ ID NO: 3558)

204068_at
STK3
FLJ90748, KRS1,
serine/threonine
6788
ATAGATCTATCGTGTTTAAAACCAA (SEQ ID NO: 3559)

MST2
kinase 3 (STE20

GAAATCAATGGAACCCTTGCACAAA (SEQ ID NO: 3560)

homolog, yeast)

AAACTGTAATAAGCTCATCAATTTC (SEQ ID NO: 3561)

AATGTGCTCTGTTGTCACAGGATGT (SEQ ID NO: 3562)

ATTTCCTGGGAATTGGTAAACATCA (SEQ ID NO: 3563)

GTTCCTGATGATAACCCAGTAGCAA (SEQ ID NO: 3564)

GAGTGGTACAAGCCTTGGGGACTGA (SEQ ID NO: 3565)

AAAGAAACTCATTTTTACGCTGAAT (SEQ ID NO: 3566)

GCATTGGGACCAGTCATTTCCTAAG (SEQ ID NO: 3567)

ATTTCCTAAGCTACATATGGCCATC (SEQ ID NO: 3568)

TATGGCCATCTTGACAGTGTTTTTT (SEQ ID NO: 3569)

204287_at
SYNGR1
MGC: 1939
synaptogyrin 1
9145
TGAGGGGCTAATTCCCAGGGGACTG (SEQ ID NO: 3570)

CTTCCCTGGTGATTCTTGATCTTCA (SEQ ID NO: 3571)

TCAAAGCCTCGGGGATCCCAGGTTT (SEQ ID NO: 3572)

GGTTTCCCCATGTAACTGAGACACC (SEQ ID NO: 3573)

CCCCTTTGATTCTCTAAGGAGCACG (SEQ ID NO: 3574)

ATGCCCCTCCCAGGAGTTTATGGGA (SEQ ID NO: 3575)

GCAGCGTTACTGCCTGTGTATAGTA (SEQ ID NO: 3576)

CGTGTGTGTGCGGTGAAGGGCGGTC (SEQ ID NO: 3577)

CCCACCACCTGGTTAAGTCTCGAGT (SEQ ID NO: 3578)

AAGTCTCGAGTGAATCCAGTGGCCC (SEQ ID NO: 3579)

GACATCCATCCATCTGTGGTGAACC (SEQ ID NO: 3580)

218746_at
TAPBPL
TAPBPR;
TAP binding protein-
55080
CTCATCTGCGACATTGCTGGCTATT (SEQ ID NO: 3581)

TAPBP-R;
like

TCTGCGACATTGCTGGCTATTACCC (SEQ ID NO: 3582)

FLJ10143

TGGTGACGTGGACCCGAGAGGAGCT (SEQ ID NO: 3583)

CGTGGACCCGAGAGGAGCTGGGTGG (SEQ ID NO: 3584)

TCTCCAGCCTCAGGCAAAGCGTGGC (SEQ ID NO: 3585)

GCCTCAGGCAAAGCGTGGCAGGCAC (SEQ ID NO: 3586)

GCAGGTGCCACTTACACCTGCCAGG (SEQ ID NO: 3587)

CACTTACACCTGCCAGGTCACACAC (SEQ ID NO: 3588)

CCATGAAGACCGCACAGCGCGTGTA (SEQ ID NO: 3589)

CCAGCTGACCTAAAGCGACATGAGA (SEQ ID NO: 3590)

AACAACAACCAAGCCAGTTTAATGG (SEQ ID NO: 3591)

218747_s_at
TAPBPL
TAPBPR;
TAP binding protein-
55080
GTCACACACATCTCTCTGGAGGAGC (SEQ ID NO: 3592)

TAPBP-R;
like

GAGCGGAGAACAGCCTTGGGAGTCA (SEQ ID NO: 3593)

FLJ10143

GAACAGCCTTGGGAGTCATCTTTGC (SEQ ID NO: 3594)

AGCCTTGGGAGTCATCTTTGCCAGC (SEQ ID NO: 3595)

GGGGCTTCAGAGACGGCAAGCACCT (SEQ ID NO: 3596)

CAGAGACGGCAAGCACCTACAGGAC (SEQ ID NO: 3597)

AGCACCTACAGGACTTGGGCTGCTT (SEQ ID NO: 3598)

GCTTCAGGCTGAACGCTGGGAGACC (SEQ ID NO: 3599)

CAGGCTGAACGCTGGGAGACCACTT (SEQ ID NO: 3600)

AAGCGACATGAGACTACTAGAAAGA (SEQ ID NO: 3601)

GACTACTAGAAAGAAACGACACCCT (SEQ ID NO: 3602)

200803_s_at
TEGT
BI-1, TMBIM6
testis enhanced gene
7009
CTTGCTGGATTTGCATTCCTTACAG (SEQ ID NO: 3603)

transcript (BAX

CCCTGCCCTGGAGTTTTGTATTGCT (SEQ ID NO: 3604)

inhibitor 1)

TGTATTGCTGTCAACCCCAGCATCC (SEQ ID NO: 3605)

TCCCACTGCTTTCATGGGCACAGCA (SEQ ID NO: 3606)

AGCAATGATCTTTACCTGCTTCACC (SEQ ID NO: 3607)

TGATGTCAGCCCTGAGCTTGTTGCT (SEQ ID NO: 3608)

GGGACTGGTGGTCATGTGTGGCTTC (SEQ ID NO: 3609)

TATCTGGCACTGCATTGATCTCTTC (SEQ ID NO: 3610)

GAAAACTCATGATGATCCTGGCCAT (SEQ ID NO: 3611)

AAATGAAGTGACCATCCAGCCTTTC (SEQ ID NO: 3612)

ATTTCCTTTTTGCACACATTACAGG (SEQ ID NO: 3613)

200804_at
TEGT
BI-1, TMBIM6
testis enhanced gene
7009
GACAGCTACCCCCAGAAGGGTCAAT (SEQ ID NO: 3614)

transcript (BAX

GTTGGGAGTGGTTGTGGCTCTGAGC (SEQ ID NO: 3615)

inhibitor 1)

TGCTCTACAGAGCTTCAGTGTGAGA (SEQ ID NO: 3616)

TTCACAACCAGTGCACAGTTTGACA (SEQ ID NO: 3617)

TTGACAGTGGCCTCAGGTTCACAGT (SEQ ID NO: 3618)

AGTGCACCATGTCACTGTGCTATCC (SEQ ID NO: 3619)

CCCGAATGGCTCACTTTCACTGAGG (SEQ ID NO: 3620)

TGCTGTCCTCTGATTTAGCTGCTGC (SEQ ID NO: 3621)

CAGCCTCTGGCTTGAGAACTTACTA (SEQ ID NO: 3622)

GTGATTCTCTGCTAGGCCTAAGATT (SEQ ID NO: 3623)

AACATCTCTTGAAGCCAAACTCCAC (SEQ ID NO: 3624)

202720_at
TES
DKFZp586B2022,
testis derived
26136
GTATAGATGATTTTTGGCTTGGACA (SEQ ID NO: 3625)

MGC1146,
transcript (3 LIM

GGACATAAAAGCCAAGCCACCCATT (SEQ ID NO: 3626)

TESS, TESS-2
domains)

AGCCACCCATTTGCTTTTAATCCAA (SEQ ID NO: 3627)

GAACATGTATAGTTTTTGTACCCAG (SEQ ID NO: 3628)

TATTGATTGCACTTGCCTGCCATGA (SEQ ID NO: 3629)

GCACTTGCCTGCCATGATTTAGATA (SEQ ID NO: 3630)

TATTCTTTCCTAATGGATCCTGTTT (SEQ ID NO: 3631)

ATACTTCCAAGCCTGTCCATGGATA (SEQ ID NO: 3632)

TGTCTTCACTTGTATGTTTTCATGG (SEQ ID NO: 3633)

ATGTTTTCATGGCTAGGTATTTCTA (SEQ ID NO: 3634)

TGTACTTCTACACATAGCTATGCAC (SEQ ID NO: 3635)

218099_at
TEX2
DKFZp781G0721,
testis expressed 2
55852
TGACAGGATGGGTCCTCTCATACAG (SEQ ID NO: 3636)

HT008,

TTTTTCCATCTGGCGTTTCTGTGTC (SEQ ID NO: 3637)

KIAA1738,

GTTTCTGTGTCCTCCAGGTTTATAT (SEQ ID NO: 3638)

TMEM96

GGGAGAGTTCCATGGGCAGATTTCC (SEQ ID NO: 3639)

GAAGGCCAAAACGGAGAACTGCTCT (SEQ ID NO: 3640)

AGACCAAAAGTTTGCTCAGCATCAC (SEQ ID NO: 3641)

TCAGCATCACACTACATCTCAAAAT (SEQ ID NO: 3642)

TAGTTTACAAGGTTGGGGGCTCTCT (SEQ ID NO: 3643)

GGGCTCTCTTTGCTTCGAGAAGTAA (SEQ ID NO: 3644)

GCTGCATTCAACGTCAAAATTACCT (SEQ ID NO: 3645)

GCACCTTGCCTGAACATGACTTTAA (SEQ ID NO: 3646)

213135_at
TIAM1
FLJ36302
T-cell lymphoma
7074
GTTCAGTACATCATGCTCTTGTGCC (SEQ ID NO: 3647)

invasion and

TTTCCAGGGCTTCGAGCTTGATCTT (SEQ ID NO: 3648)

metastasis 1

TTGCTATATCTTCTGGTTTTCTGAA (SEQ ID NO: 3649)

ATACCCTTTGTATCACTGCATTTTT (SEQ ID NO: 3650)

CATTTTTCCATATCATCTCCGGTTC (SEQ ID NO: 3651)

GGTTCGATCGCGTCCAGATGGAAAA (SEQ ID NO: 3652)

AGCAGAGGCTTCTAATCGTCGCATT (SEQ ID NO: 3653)

CGTCGCATTTACTGGCTCCAGTGCA (SEQ ID NO: 3654)

CTCCAGTGCAACACATCCATCTGAA (SEQ ID NO: 3655)

AACACTCGGAAGTCTGGTGCTTGGA (SEQ ID NO: 3656)

GAGAGGGTGCCATTGTCTCTTGTAC (SEQ ID NO: 3657)

219258_at
TIPIN
FLJ20516
TIMELESS
54962
GAACATGATGTCACTTCTACTGAAT (SEQ ID NO: 3658)

interacting protein

CTACTGAATTAGATCCCTTTCTGAC (SEQ ID NO: 3659)

GATCCCTTTCTGACAAACTTATCTG (SEQ ID NO: 3660)

GTTAATGAATACACCCAGGGCACAC (SEQ ID NO: 3661)

CCCAGGGCACACACGGTTGAAGAGG (SEQ ID NO: 3662)

AACGAAGACATTCTGGACAATCCAT (SEQ ID NO: 3663)

GAAACACTGCTGGACCAGTCTTTTA (SEQ ID NO: 3664)

GCAACAGCAACTTGATGCTACATCC (SEQ ID NO: 3665)

TGTATCTGTTAAGTCATCGTCCTGC (SEQ ID NO: 3666)

TTAAGTCATCGTCCTGCAAGCTTGG (SEQ ID NO: 3667)

GCAAGCTTGGCGTTACTATGTATTT (SEQ ID NO: 3668)

203254_s_at
TLN1
ILWEQ,
talin 1
7094
GAAGATGGTTGGCGGCATTGCCCAG (SEQ ID NO: 3669)

KIAA1027, TLN

TGGTTGGCGGCATTGCCCAGATCAT (SEQ ID NO: 3670)

TGCCCAGATCATCGCAGCACAGGAA (SEQ ID NO: 3671)

AATGCTTCGGAAGGAACGAGAGCTG (SEQ ID NO: 3672)

GAAGAGGCGCGGAAGAAACTGGCCC (SEQ ID NO: 3673)

CCGGCAGCAGCAGTACAAGTTTCTG (SEQ ID NO: 3674)

GTACAAGTTTCTGCCTTCAGAGCTT (SEQ ID NO: 3675)

GAGCTTCGAGATGAGCACTAAAGAA (SEQ ID NO: 3676)

CTTCTATTTAATGCAGACCCGGCCC (SEQ ID NO: 3677)

CTCCAAGAGTATTATTAACGCTGCT (SEQ ID NO: 3678)

TTATTAACGCTGCTGTACCTCGATC (SEQ ID NO: 3679)

209387_s_at
TM4SF1
H-L6, L6, M3S1,
transmembrane 4 L
4071
TTGGCTCTTGGTGGAATTGAATTCA (SEQ ID NO: 3680)

TAAL6
six family member 1

GAATTGAATTCATCTTGTGTCTTAT (SEQ ID NO: 3681)

ATTCATCTTGTGTCTTATTCAAGTA (SEQ ID NO: 3682)

GTAATAAATGGAGTGCTTGGAGGCA (SEQ ID NO: 3683)

GGAGTGCTTGGAGGCATATGTGGCT (SEQ ID NO: 3684)

GAGGCATATGTGGCTTTTGCTGCTC (SEQ ID NO: 3685)

CTTTTGCTGCTCTCACCAACAGCAA (SEQ ID NO: 3686)

TCCCCACAGTCTACTTTTACAAACG (SEQ ID NO: 3687)

TTTACAGACTGAGTGACAGTACTCA (SEQ ID NO: 3688)

GAGTGACAGTACTCAGTATATCTGA (SEQ ID NO: 3689)

TATATCTGAGATAAACTCTATAATG (SEQ ID NO: 3690)

215033_at
TM4SF1
H-L6, L6, M3S1,
transmembrane 4 L
4071
AAGGTTACCCACATTGAGCTCATAC (SEQ ID NO: 3691)

TAAL6
six family member 1

GAGCTCATACCAGTGTGAAACTTCC (SEQ ID NO: 3692)

GAAACTTCCATGGCATTATCTTTTA (SEQ ID NO: 3693)

ACCCCACACAAATGCACTCAAAGCA (SEQ ID NO: 3694)

AAAGCAACCCAACATCAGTATCCTG (SEQ ID NO: 3695)

TGCAGTTTCTATGGGCCCTTTCTGC (SEQ ID NO: 3696)

TTCTGCAGCCTTTACTCATGGAAGA (SEQ ID NO: 3697)

AGCATTGTCCAAGCCCTAAGTATGG (SEQ ID NO: 3698)

GTATGGTTGGCCTAAGCTTTGCTGA (SEQ ID NO: 3699)

AGATCAGTCTGTTTATGTTTGCTTA (SEQ ID NO: 3700)

AATGTCATCGTTATTTATCCTGATT (SEQ ID NO: 3701)

215034_s_at
TM4SF1
H-L6, L6, M3S1,
transmembrane 4 L
4071
TATGACTGCTAAAAGAACCAACCCA (SEQ ID NO: 3702)

TAAL6
six family member 1

AAAGAACCAACCCAGGACAGAGCCA (SEQ ID NO: 3703)

ACCCAGGACAGAGCCACAATCTTCC (SEQ ID NO: 3704)

CAGGACAGAGCCACAATCTTCCTCT (SEQ ID NO: 3705)

ACAGAGCCACAATCTTCCTCTATTT (SEQ ID NO: 3706)

TTTCACTTGTATTCATTTGTAAAAC (SEQ ID NO: 3707)

TTTGTATTAGTGTAACATACTCCCC (SEQ ID NO: 3708)

AAACGCCTGTAAAGACTGGCATCTT (SEQ ID NO: 3709)

GCCTGTAAAGACTGGCATCTTCACA (SEQ ID NO: 3710)

GACTGGCATCTTCACAGGATGTCAG (SEQ ID NO: 3711)

ATCTTCACAGGATGTCAGTGTTTAA (SEQ ID NO: 3712)

213349_at
TMCC1
DKFZp686M0169,
transmembrane and
23023
GATGAGGGCAAACCAGTTAAACCTA (SEQ ID NO: 3713)

FLJ42680
coiled-coil domain

TCCCTATCCCAGACTAACTTTACTG (SEQ ID NO: 3714)

family 1

TGGATTCGGGGTGGATTTTCGTTGT (SEQ ID NO: 3715)

GTGGATTTTCGTTGTCCGTGGAAGA (SEQ ID NO: 3716)

GGAAGAACACATGGATCTCTCTGGC (SEQ ID NO: 3717)

CTGCCCCTTAACCTTGACGAGGATA (SEQ ID NO: 3718)

CCCCCAAAGGATCACTGCACAGTCC (SEQ ID NO: 3719)

ATCACTGCACAGTCCTACTACAGTA (SEQ ID NO: 3720)

ATATGTGTATAGTTACCAACCTAAA (SEQ ID NO: 3721)

AAAATCCGAACAGCATACTTGAAGA (SEQ ID NO: 3722)

AATACTCAAACTCTCAGTGCTTCCT (SEQ ID NO: 3723)

201764_at
TMEM106C
MGC111210,
transmembrane
79022
CTACCCCCACGTGGTGTAAGCAGAG (SEQ ID NO: 3724)

MGC5576
protein 106C

GAATTGGTTCACTTAACTCCCAGCA (SEQ ID NO: 3725)

AAACATCCTCCTGCCACTTAGGAGG (SEQ ID NO: 3726)

AACACCTCCCTATGGTACCATTTAT (SEQ ID NO: 3727)

AGCAGAATCAGTGCCTAGCCTGTGC (SEQ ID NO: 3728)

TGAGTGACCTGCAGGCCATTATCAG (SEQ ID NO: 3729)

GCCATTATCAGTGCCTCATCTGTGC (SEQ ID NO: 3730)

GAGAGGGACCATCCAAATACCTAAG (SEQ ID NO: 3731)

TTTCAGCTGTTCCCAAAGGCCTGGG (SEQ ID NO: 3732)

ATGTGGGGCTTGATTCACCCTTCAT (SEQ ID NO: 3733)

TTCACCCTTCATCCATTGGCTGGAA (SEQ ID NO: 3734)

202475_at
TMEM147
MGC1936,
transmembrane
10430
AAGGCGGCATCTATGACTTCATTGG (SEQ ID NO: 3735)

NIFIE14
protein 147

CCTTGTCATGTCCCGGAATGCCGGC (SEQ ID NO: 3736)

TGCTGAGCTTATTATGTCCCGCTGC (SEQ ID NO: 3737)

AGCCCGGGGCATTGAGTTTGACTGG (SEQ ID NO: 3738)

ATCAGTCTGGGTCCATACATCGTCG (SEQ ID NO: 3739)

CGCGTCTGCTCAGGTCTGGATGATA (SEQ ID NO: 3740)

TAACACGCTATGATCTGTACCACAC (SEQ ID NO: 3741)

CTCCTGCTGATGTTCCTCAGAGTTT (SEQ ID NO: 3742)

TATGGAGACGTTTGTCCACCTATGC (SEQ ID NO: 3743)

TTGCCGTTGTCAATGTGCACTCCTA (SEQ ID NO: 3744)

TCCTAGGCTTGGTGTCTCAGACATT (SEQ ID NO: 3745)

218804_at
TMEM16A
FLJ10261,
transmembrane
55107
CACCAAGCCGACCTCAGAGTTGTTC (SEQ ID NO: 3746)

ORAOV2,
protein 16A

AGAGTTGTTCATCTTCCTTATGGGA (SEQ ID NO: 3747)

TAOS2,

TATGGGACAAAACCGGTTGACCAGA (SEQ ID NO: 3748)

TMEM16A

GAGAGATGACCTCGGAAGCATTTCC (SEQ ID NO: 3749)

GCATTTCCACAGATGGTGTCAGGGT (SEQ ID NO: 3750)

TCCCCTGGAAGCTTTAGAATATTTA (SEQ ID NO: 3751)

GGATTTTTTTTCTGTAGCTCAAAGG (SEQ ID NO: 3752)

ATTTTGGTAACACTTCTCTATATTT (SEQ ID NO: 3753)

GCAATGATACTAAACAACTCTCTGA (SEQ ID NO: 3754)

AACTCTCTGAAATTTCTCAAGCACC (SEQ ID NO: 3755)

AACATCATTTTAGCAAAGGCCAGGA (SEQ ID NO: 3756)

218465_at
TMEM33
1600019D15Rik,
transmembrane
55161
GCATTTCAGTCTCAACGCATAGATA (SEQ ID NO: 3757)

FLJ10525,
protein 33

AAATCCTGTTCATTGAACTCCCATC (SEQ ID NO: 3758)

SHINC3

GAACTCCCATCAACTCTTATGAAAT (SEQ ID NO: 3759)

TCATGCTGATCTTCATTACCGTTGC (SEQ ID NO: 3760)

TTGTGACCAGTTTCTGTCTGCATGT (SEQ ID NO: 3761)

GTCTGCATGTAATTTGGATTTCTCA (SEQ ID NO: 3762)

TATTTTTGTTCATCTCCTTATCTAT (SEQ ID NO: 3763)

TTTGTAATATTTGTCCACTAAGCTG (SEQ ID NO: 3764)

AAGCAGCCTCATACAGTTGATTTTG (SEQ ID NO: 3765)

GTTGATTTTGTGTATGTGGCTAGTC (SEQ ID NO: 3766)

GTGGCTAGTCTTATTGTCACTATGT (SEQ ID NO: 3767)

212204_at
TMEM87A
DKFZp564G2022
transmembrane
25963
GCTTAACTCTTTTGACATCTGCTAT (SEQ ID NO: 3768)

protein 87A

TATTGTGACACATCCCATTGCTGGC (SEQ ID NO: 3769)

GGTGCACACTCCGAAACTTTTAACT (SEQ ID NO: 3770)

ACTACTGTTTTGTAAGCCTCCAAGG (SEQ ID NO: 3771)

GCCTCCAAGGGTGGCATTGCAGGGT (SEQ ID NO: 3772)

GAGAGGTGCTCCAAGTGCTGTGATT (SEQ ID NO: 3773)

GAGCACCGTGCTAGAGGAACTGTAA (SEQ ID NO: 3774)

ATGAAGTAGCGTGGAGGCCCTGGAC (SEQ ID NO: 3775)

ACTGCTGCTCGTTCTTTAGGATGGA (SEQ ID NO: 3776)

GGACTGTTCTGGTATCTGGTATTGG (SEQ ID NO: 3777)

GAAGCACTCTATTTCTGTTTTAATG (SEQ ID NO: 3778)

218419_s_at
TMUB2
FP2653,
transmembrane and
79089
TCTCAGCCAAATACTCATCTTTTGA (SEQ ID NO: 3779)

MGC3123
ubiquitin-like domain

CTGAAATCACACTGGCGGGAATGAA (SEQ ID NO: 3780)

containing 2

GGCGGGAATGAAGATTGTGCCAGCC (SEQ ID NO: 3781)

AGCAGGAATAGGGTGTCCTCCCTTC (SEQ ID NO: 3782)

AAGCACTTTGCTTGCATTTTATTTT (SEQ ID NO: 3783)

GAGTCCTTCATAGAGCTCAGTCAGG (SEQ ID NO: 3784)

GGGATGGGGCACCAAGCCAAGCCCC (SEQ ID NO: 3785)

TCCTCAGGCTGTAAGCAAGAGACAG (SEQ ID NO: 3786)

CCTGCCCAACTCCAAGGACTGGGTA (SEQ ID NO: 3787)

GGGCTATTGGAGGGTCAGTGTCTGT (SEQ ID NO: 3788)

AGTGTCTGTGACTGAATAAAGTTCC (SEQ ID NO: 3789)

209294_x_at
TNFRSF10B
CD262, DR5,
tumor necrosis factor
8795
GGTGATCCCACTGAGACTCTGAGAC (SEQ ID NO: 3790)

KILLER,
receptor superfamily,

ATGACTTTGCAGACTTGGTGCCCTT (SEQ ID NO: 3791)

KILLER/DR5,
member 10b

ACTCCTGGGAGCCGCTCATGAGGAA (SEQ ID NO: 3792)

TRAIL-R2,

GGACACCTTGTACACGATGCTGATA (SEQ ID NO: 3793)

TRAILR2,

CAAAACCGGGCGAGATGCCTCTGTC (SEQ ID NO: 3794)

TRICK2,

GAGGACCACTTGTTGAGCTCTGGAA (SEQ ID NO: 3795)

TRICK2A,

AATGCAGACTCTGCCATGTCCTAAG (SEQ ID NO: 3796)

TRICK2B,

CAGGAAGTCAGACCTTCCCTGGTTT (SEQ ID NO: 3797)

TRICKB,

GGAAAAAGCCCAACTGGACTCCAGT (SEQ ID NO: 3798)

ZTNFR9

GGTACTGGAAGAAACTCTCCCATCC (SEQ ID NO: 3799)

CATCCTGTAACTTTTCACTGCACTT (SEQ ID NO: 3800)

207037_at
TNFRSF11A
CD265, FEO,
tumor necrosis factor
8792
GCCTGCTTTACGTATTTTCTTTTGT (SEQ ID NO: 3801)

LOH18CR1,
receptor superfamily,

TGCCCCTGCTCACAGTGTTTTAGAG (SEQ ID NO: 3802)

ODFR, OFE,
member 11a, NFKB

GTTTTAGAGATGGCTTTCCCAGTGT (SEQ ID NO: 3803)

OSTS, PDB2,
activator

GTGAGGCCTGGAGATAGTTGCTAAG (SEQ ID NO: 3804)

RANK,

GAAACCCGATTTATTTCTCCTGAAT (SEQ ID NO: 3805)

TRANCER

AAGTTTGTGTCGTTCCTTAAGCAGA (SEQ ID NO: 3806)

TGACCTTACCCGCTAGGTGGTTAAT (SEQ ID NO: 3807)

GGTGGTTAATTTATCCATGCTGGCA (SEQ ID NO: 3808)

GCAGAGGCACTCAGGTACTTGGTAA (SEQ ID NO: 3809)

CAAGTTGCTGCAGCTTGGCATTCTT (SEQ ID NO: 3810)

TTCTTCTTATTCTAGAGGTCTCTCT (SEQ ID NO: 3811)

211841_s_at
TNFRSF25
RP4-650H14.2,
tumor necrosis factor
8718
AGTGAGAAGATCTGCACCGTCCAGT (SEQ ID NO: 3812)

APO-3, DDR3,
receptor superfamily,

TGCACCGTCCAGTTGGTGGGTAACA (SEQ ID NO: 3813)

DR3, LARD,
member 25

TGCCCGCAGGTGACATGGTCCTGGG (SEQ ID NO: 3814)

TNFRSF12, TR3,

ACATGGTCCTGGGACCAGTTGCCCA (SEQ ID NO: 3815)

TRAMP, WSL-1,

CGCTGGAAGGAGTTCGTGCGCACGC (SEQ ID NO: 3816)

WSL-LR

GCTGGGGCTGCGCGAGGCAGAGATC (SEQ ID NO: 3817)

GCAGAGATCGAAGCCGTGGAGGTGG (SEQ ID NO: 3818)

CTTCCGAGACCAGCAGTACGAGATG (SEQ ID NO: 3819)

GCCCTGGAGCGCATGGGGCTGGACG (SEQ ID NO: 3820)

GCTGGACGGCTGCGTGGAAGACTTG (SEQ ID NO: 3821)

TGCGTGGAAGACTTGCGCAGCCGCC (SEQ ID NO: 3822)

202687_s_at
TNFSF10
APO2L, Apo-2L,
tumor necrosis factor
8743
GTAGCAGCTCACATAACTGGGACCA (SEQ ID NO: 3823)

CD253, TL2,
(ligand) superfamily,

CATTGTCTTCTCCAAACTCCAAGAA (SEQ ID NO: 3824)

TRAIL
member 10

TGGGCCGCAAAATAAACTCCTGGGA (SEQ ID NO: 3825)

GGGCATTCATTCCTGAGCAACTTGC (SEQ ID NO: 3826)

TTTTACTACATCTATTCCCAAACAT (SEQ ID NO: 3827)

TCCCAAACATACTTTCGATTTCAGG (SEQ ID NO: 3828)

AATACACAAGTTATCCTGACCCTAT (SEQ ID NO: 3829)

GGACTCTATTCCATCTATCAAGGGG (SEQ ID NO: 3830)

TGAGCACTTGATAGACATGGACCAT (SEQ ID NO: 3831)

GGACCATGAAGCCAGTTTTTTCGGG (SEQ ID NO: 3832)

GCCTTTTTAGTTGGCTAACTGACCT (SEQ ID NO: 3833)

211828_s_at
TNIK

TRAF2 and NCK
23043
GAAATATATGCTTGGGCTCCTAAAC (SEQ ID NO: 3834)

interacting kinase

AAGTCTTTTGCAGATCTCCAGCACA (SEQ ID NO: 3835)

GCACAAGCCTCTGCTAGTTGATCTC (SEQ ID NO: 3836)

GGTTCACACACTGGTTTCCATGTAA (SEQ ID NO: 3837)

CATACCATCTCATATTCAGGGCAAT (SEQ ID NO: 3838)

TTCAGGGCAATATCACTCCTCATGC (SEQ ID NO: 3839)

CCTCATGCTATTGTCATCTTGCCTA (SEQ ID NO: 3840)

GTAAACACCTATGGCCGGATAACTA (SEQ ID NO: 3841)

GTCTGTGGCCTACATTCATTCCAAT (SEQ ID NO: 3842)

GGTATTTTTTGCATCCGTGCGATCT (SEQ ID NO: 3843)

TAGCCAAGTGTTTTTCATGACCCTC (SEQ ID NO: 3844)

213107_at
TNIK

TRAF2 and NCK
23043
AATCAGCAAGATATCCTCCTCATGG (SEQ ID NO: 3845)

interacting kinase

GGTCCCTTTAGCTCTCAAAAGCAAT (SEQ ID NO: 3846)

TCCTGTTCTCATTTTTACTGCTGTG (SEQ ID NO: 3847)

CATTTTTACTGCTGTGGTTGTGCTG (SEQ ID NO: 3848)

GCTGCTGAACAATACTATCTTCTCA (SEQ ID NO: 3849)

AATTCCATGCCACAAATTCAGCAAT (SEQ ID NO: 3850)

ACTGTAATTGGATGCTGATGTGGAC (SEQ ID NO: 3851)

CACTCCCGAATGTGATTGCCACCAG (SEQ ID NO: 3852)

GATTGCCACCAGCTCTTTATATTGC (SEQ ID NO: 3853)

GCTCTTTATATTGCTGCTGTGGTAT (SEQ ID NO: 3854)

TGCAGTCTTGTTTACAGTATGTACA (SEQ ID NO: 3855)

213109_at
TNIK

TRAF2 and NCK
23043
AACTCATGTGGACTTATGCCAGTCT (SEQ ID NO: 3856)

interacting kinase

TTGGTTGAACATATCGCTTTCCCTT (SEQ ID NO: 3857)

TCCCAGTACAGTCCATCTTTCAATG (SEQ ID NO: 3858)

ATCTTTCAATGTTGCAGCCTGGTTG (SEQ ID NO: 3859)

GGCAGGAATTTCCAGGAGATCCCCA (SEQ ID NO: 3860)

TCCCCAAGAATGCTGCCTTGTCTGT (SEQ ID NO: 3861)

CAAAGATGGACCATGTGCCCTTCGG (SEQ ID NO: 3862)

TTTACCCCTTTACTCTGCAAGAATG (SEQ ID NO: 3863)

AAATTCTGTCTGCCTACTAGTTTTA (SEQ ID NO: 3864)

CAATAAATGTACCTTATCTCCTTAG (SEQ ID NO: 3865)

GGCTGAAGGCCATAACTACATAGTG (SEQ ID NO: 3866)

220339_s_at
TPSG1
PRSS31, TMT,
tryptase gamma 1
25823
GGTGAAAGTCTCCGTGGTGGACACA (SEQ ID NO: 3867)

trpA

GCCTCTGGTCTGCCAGGTGAACGGT (SEQ ID NO: 3868)

AGGTGAACGGTGCCTGGGTGCAGGC (SEQ ID NO: 3869)

GGTGCAGGCTGGCATTGTGAGCTGG (SEQ ID NO: 3870)

CCGCCACATCACAGCATCAGGGGGC (SEQ ID NO: 3871)

CTCAGAGTCTGGGTACCCCAGGCTC (SEQ ID NO: 3872)

GCTGCACCCATCTGCGGATGGTACT (SEQ ID NO: 3873)

CCGCCCCTGACTGATGGCAGGAATC (SEQ ID NO: 3874)

ATAAGTTACTATTTATTCCGCTCCG (SEQ ID NO: 3875)

TCCCTCTCCCTTGAGAAGCTGAGTC (SEQ ID NO: 3876)

GAAGCTGAGTCTTCTGCATCAGATT (SEQ ID NO: 3877)

213593_s_at
TRA2A
HSU53209
transformer-2 alpha
29896
GGTGGGACGAGCCTAATGAAGTGGT (SEQ ID NO: 3878)

GAAGTGGTTAGTCAACGACCGCACC (SEQ ID NO: 3879)

GCACCGACCCTTAAGCGTTCTTAAG (SEQ ID NO: 3880)

AAGCGTTCTTAAGACGAGAGCTGTG (SEQ ID NO: 3881)

GTGAGGGGAAACTACGCAAGGAGCC (SEQ ID NO: 3882)

GAATGTGGAAATGCTGTCACGCCTT (SEQ ID NO: 3883)

TCACGCCTTATTTTTCTAATTCCTC (SEQ ID NO: 3884)

TCTAATTCCTCGATGTTGGGTTTTT (SEQ ID NO: 3885)

CTCTTCTTTATATCTCAACTTTTAA (SEQ ID NO: 3886)

TCTCAACTTTTAATGCTCTTCTTCC (SEQ ID NO: 3887)

GAACGAATTCATTGGCTCAGTATTT (SEQ ID NO: 3888)

219736_at
TRIM36
HAPRIN,
tripartite motif-
55521
CATTCTATCTAAATTGTGTGTCTGT (SEQ ID NO: 3889)

RBCC728,
containing 36

GTGTGTCTGTTTTTGAAAGGTGTGT (SEQ ID NO: 3890)

RNF98

AGGTGTGTGCTTTCAAGTAGGTGGT (SEQ ID NO: 3891)

TATGCATTGTAGCAGTAATCATTTA (SEQ ID NO: 3892)

GGAATGCTTTTGACATGTTTTAACA (SEQ ID NO: 3893)

TTAATGGAAATCTGTTACTCAGGCT (SEQ ID NO: 3894)

TTAGCTTTTTACCCTCAACTCAAGT (SEQ ID NO: 3895)

AGCAGGCTGTTAATTTCCCATCTAT (SEQ ID NO: 3896)

ATTTCCCATCTATGAATAGCACTTT (SEQ ID NO: 3897)

ATGCAGCGTTATGTGGATCATTATG (SEQ ID NO: 3898)

TTGTGGTTGATACTCAAGCCTTGTA (SEQ ID NO: 3899)

209890_at
TSPAN5
Tm4sf9, Tspan-5
tetraspanin 5
10098
CACAGATTCCAATGCAAGTCGAGAG (SEQ ID NO: 3900)

AGTCGAGAGCGATGTGGCGTTCCAT (SEQ ID NO: 3901)

CCTGCTGCACTAAAGATCCCGCAGA (SEQ ID NO: 3902)

CGAAAGGCTGTGTGCCCCAGTTTGA (SEQ ID NO: 3903)

GCAGGACAATTTAACCATCGTTGCT (SEQ ID NO: 3904)

CAGATATTTGGGATATGCCTGGCCC (SEQ ID NO: 3905)

GCCTGGCCCAGAATTTGGTTAGCGA (SEQ ID NO: 3906)

ATCGAAGCTGTCAGGGCGAGCTGGT (SEQ ID NO: 3907)

GCTGCTGCAAGACACTGGACAGACC (SEQ ID NO: 3908)

CTTCGAGCTGCATGGACCTAATCAC (SEQ ID NO: 3909)

CACAGATGCAGCCTGCAGTCTCGCC (SEQ ID NO: 3910)

213726_x_at
TUBB2C
RP13-122B23.2,
tubulin, beta 2C
10383
CCACCTTCATTGGCAACAGCACGGC (SEQ ID NO: 3911)

TUBB2

ACAGCACGGCCATCCAGGAGCTGTT (SEQ ID NO: 3912)

CAGGAGCTGTTCAAGCGCATCTCCG (SEQ ID NO: 3913)

TGCACTGGTACACGGGCGAGGGCAT (SEQ ID NO: 3914)

ACGAGATGGAGTTCACCGAGGCCGA (SEQ ID NO: 3915)

GTACCAGCAGTACCAGGATGCCACA (SEQ ID NO: 3916)

GGGCGAGTTCGAGGAGGAGGCTGAG (SEQ ID NO: 3917)

GAGGAGGAGGTGGCCTAGAGCCTTC (SEQ ID NO: 3918)

TGTGAACTCTTTATTCACTCCCAGC (SEQ ID NO: 3919)

GTCCACATCCATGCTGTACAGACAC (SEQ ID NO: 3920)

GTACAGACACCACCATTAAAGCATT (SEQ ID NO: 3921)

218382_s_at
U2AF2
U2AF65
U2 small nuclear
11338
GCAAGTGCCGGGCTTGATGAGCTCC (SEQ ID NO: 3922)

RNA auxiliary factor 2

AGCTCCCAGGTGCAGATGGGCGGCC (SEQ ID NO: 3923)

GAGGTCCTGTGCCTCATGAACATGG (SEQ ID NO: 3924)

GAGGATGTGCGGGACGAGTGCAGCA (SEQ ID NO: 3925)

GTACGGGCTTGTCAAGTCCATCGAG (SEQ ID NO: 3926)

AGGTGCCCGGCTGCGGAAAGATCTT (SEQ ID NO: 3927)

GGAGTTCACCTCTGTGTTTGACTGC (SEQ ID NO: 3928)

GGCCGCAAGTTCGCCAACAGAGTGG (SEQ ID NO: 3929)

CACAAAATACTGTGACCCCGACTCT (SEQ ID NO: 3930)

CCGGGACTTCTGGTAGAGGCGGCTG (SEQ ID NO: 3931)

GCAGAGGAGTGACAGCCGCAGACAC (SEQ ID NO: 3932)

215057_at
U66046*

Clone 161455-2-3 B

ACCAATGTTCAGCCTCTGAGACCAG (SEQ ID NO: 3933)

cell expressed mRNA

AAGCAGTGGCCATGAATGTTCCCTC (SEQ ID NO: 3934)

from chromosome X

GAAGAAGTGTACTCACACTGCCCCA (SEQ ID NO: 3935)

ACTGCCCCAACACCAGTGAGTGGAA (SEQ ID NO: 3936)

TATTTATAGGTCTCTCATTTGGTTT (SEQ ID NO: 3937)

CACAAAATTAACCATTACCCACATT (SEQ ID NO: 3938)

CATTCCTACCAACAAGAAGTAACCA (SEQ ID NO: 3939)

TGCAGACAACATATTAGCACATTGC (SEQ ID NO: 3940)

TCCATGTTCTTCCCATTTATACAGG (SEQ ID NO: 3941)

CATTTATACAGGAGCAATTCTTGCA (SEQ ID NO: 3942)

TCCTTGCTCCTCAAATGCCTTAGAG (SEQ ID NO: 3943)

201377_at
UBAP2L
FLJ42300,
ubiquitin associated
9898
CCCCCTTACAAGCATTTCTGGACGG (SEQ ID NO: 3944)

KIAA0144, NICE-4
protein 2-like

GCTGAGAGCTAATTTGGCCCAAGGC (SEQ ID NO: 3945)

ACCAGACCACTGAGGAGAGCCTGCT (SEQ ID NO: 3946)

CATGGCCTGCGTGGCTTGGGGAAAT (SEQ ID NO: 3947)

GAGTTGGTGGATACCTTCTGGGCTT (SEQ ID NO: 3948)

TTCTGGGCTTTTGAACTTGCCCCTC (SEQ ID NO: 3949)

CTGTCTTACCCATTTCAAGTTCAAG (SEQ ID NO: 3950)

TTCAAGTTCAAGCGGTGCAGCACCT (SEQ ID NO: 3951)

GTGCAGCACCTTCGAAGCATCAATG (SEQ ID NO: 3952)

AAGCATCAATGCACACACCTGCTGT (SEQ ID NO: 3953)

GCTGTTGCTTTTGATTTCTGGAAGG (SEQ ID NO: 3954)

200683_s_at
UBE2L3
E2-F1, L-UBC,
ubiquitin-conjugating
7332
GAAGCCCTATAATCACAGGTCTGTG (SEQ ID NO: 3955)

UBCH7, UbcM4
enzyme E2L 3

ATGAATCTCGCCAGAAAGGCTCCTG (SEQ ID NO: 3956)

TTCTCCCTGCAGCCATTGTAGAAGA (SEQ ID NO: 3957)

TGTAGAAGATCTGCTGGTCCTTGCA (SEQ ID NO: 3958)

AAGCTACAGCCAGAATGTCCGTTTG (SEQ ID NO: 3959)

TGTCCGTTTGAAACTCCTAGCTCAT (SEQ ID NO: 3960)

CTAGCTCATCTGTCACCGAGCTTCA (SEQ ID NO: 3961)

CGAGCTTCATCCGAATGTGCCACGG (SEQ ID NO: 3962)

GCACACTTTGACCCTTTGTAGGATT (SEQ ID NO: 3963)

TAAAGCACCAGTCTGGGGTCGCCTG (SEQ ID NO: 3964)

AGCTCACTCAGTAATATCCTTTCAA (SEQ ID NO: 3965)

201649_at
UBE2L6
MGC40331, RIG-
ubiquitin-conjugating
9246
GTGTGTTGTGTATGGACTCACTCCC (SEQ ID NO: 3966)

B, UBCH8
enzyme E2L 6

CCTTTACATTCCCCAGAGCCAAGGG (SEQ ID NO: 3967)

GTTTGCAGTTACAGGCCAGTTCTCC (SEQ ID NO: 3968)

TTCTCCAGCTCTCCATCTTAGAGAG (SEQ ID NO: 3969)

TGAATCCAGCAGCCAACTCGAATCC (SEQ ID NO: 3970)

CCCCCTAGGGCTCAGGCACTGAGGG (SEQ ID NO: 3971)

GGAGGGTACCCTATTTACAACTGAG (SEQ ID NO: 3972)

GAGTCAGCCAAGCCACTGATGGGAA (SEQ ID NO: 3973)

GTATATATCCTCCAGCATTCAGTCC (SEQ ID NO: 3974)

CCAGGGGGAGCCACGGAAACCATGT (SEQ ID NO: 3975)

GAAACCATGTTCTTGCTTAAGCCAT (SEQ ID NO: 3976)

208997_s_at
UCP2
SLC25A8, UCPH
uncoupling protein 2
7351
TAAAGGTCCGATTCCAAGCTCAGGC (SEQ ID NO: 3977)

(mitochondrial, proton

ACCAAAGCACCGTCAATGCCTACAA (SEQ ID NO: 3978)

carrier)

CTCTCCCAATGTTGCTCGTAATGCC (SEQ ID NO: 3979)

TGAGCTGGTGACCTATGACCTCATC (SEQ ID NO: 3980)

GCCAACCTCATGACAGATGACCTCC (SEQ ID NO: 3981)

CCTCCCCTGTAGACGTGGTCAAGAC (SEQ ID NO: 3982)

AGACGAGATACATGAACTCTGCCCT (SEQ ID NO: 3983)

CTGCCCTGGGCCAGTACAGTAGCGC (SEQ ID NO: 3984)

TACAAAGGGTTCATGCCCTCCTTTC (SEQ ID NO: 3985)

AGCTGAAACGAGCCCTCATGGCTGC (SEQ ID NO: 3986)

GAGAGGCTCCCTTCTGAGCCTCTCC (SEQ ID NO: 3987)

208998_at
UCP2
SLC25A8, UCPH
uncoupling protein 2
7351
TCTACATTCTCATCTACTCATTGTC (SEQ ID NO: 3988)

(mitochondrial, proton

ACATTCTCATCTACTCATTGTCTCA (SEQ ID NO: 3989)

carrier)

CTCATTGTCTCAGTGCTGGTGGAGT (SEQ ID NO: 3990)

GTCTCAGTGCTGGTGGAGTTGACAT (SEQ ID NO: 3991)

AGTGCTGGTGGAGTTGACATTTGAC (SEQ ID NO: 3992)

CCGTCCCTTGGAAAGTTCAGCCAGA (SEQ ID NO: 3993)

GAAAGTTCAGCCAGAATCTTCGTCC (SEQ ID NO: 3994)

AAGTTCAGCCAGAATCTTCGTCCTG (SEQ ID NO: 3995)

TAGCCCACTTGTCATCCATAAAGCA (SEQ ID NO: 3996)

AGCCCACTTGTCATCCATAAAGCAA (SEQ ID NO: 3997)

GTCATCCATAAAGCAAGCTCAACCT (SEQ ID NO: 3998)

212074_at
UNC84A
FLJ12407,
unc-84 homolog A
23353
AATGAGATATCTACAAGGCACTTAA (SEQ ID NO: 3999)

KIAA0810,
(C. elegans)

GTGTTACAGATGTTTTACCTTAAGA (SEQ ID NO: 4000)

MGC176649,

GACAGTTTTCAGTGTACCGTAAATG (SEQ ID NO: 4001)

SUN1

GTACCGTAAATGTTGTGTTTTCAGA (SEQ ID NO: 4002)

GATGGTGCTGACTGGTTTTCTGTAT (SEQ ID NO: 4003)

ATTGCACAACAGTCCTCAAATACAC (SEQ ID NO: 4004)

AACTATTCATACATCAAGCAGCATT (SEQ ID NO: 4005)

TTTTCACTCTCCTTAGAATTGGAAC (SEQ ID NO: 4006)

AATGCTTTTCAAAATATCTGTCTTT (SEQ ID NO: 4007)

ATCTGTCTTTGGTAGTGCTTCTGCT (SEQ ID NO: 4008)

CTGCTGCCACCAAATTGATAAGATG (SEQ ID NO: 4009)

208909_at
UQCRFS1
RIP1, RIS1,
ubiquinol-cytochrome
7386
GAGAGGCAAACCCCTGTTTGTGCGT (SEQ ID NO: 4010)

RISP, UQCR5
c reductase, Rieske

CTGTTTGTGCGTCATAGAACCCAGA (SEQ ID NO: 4011)

iron-sulfur

GGACCCACAGCATGATCTAGATCGA (SEQ ID NO: 4012)

polypeptide 1

GATAGGTGTTTGCACTCATCTTGGC (SEQ ID NO: 4013)

TCATCTTGGCTGTGTACCCATTGCA (SEQ ID NO: 4014)

TTTTGGTGGTTATTACTGCCCTTGC (SEQ ID NO: 4015)

GGGTCACACTATGATGCATCTGGCA (SEQ ID NO: 4016)

CAGGATCAGATTGGGTCCTGCTCCT (SEQ ID NO: 4017)

TGAAGTCCCCACGTATGAGTTCACC (SEQ ID NO: 4018)

GGACTCAAGTCATAGGCTTCTTTCA (SEQ ID NO: 4019)

GGCTTCTTTCAGTCTTTATGTCACC (SEQ ID NO: 4020)

202233_s_at
UQCRH
MGC111572,
ubiquinol-cytochrome
7388
GCTCGTGTTGAATCTAGAACCGTAG (SEQ ID NO: 4021)

QCR6
c reductase hinge

AGAACCGTAGCCAGACATGGGACTG (SEQ ID NO: 4022)

protein

GACATGGGACTGGAGGACGAGCAAA (SEQ ID NO: 4023)

GATGCTTACCGAATCCGGAGATCCT (SEQ ID NO: 4024)

GATCCCCTAACAACAGTGAGAGAGC (SEQ ID NO: 4025)

GGATTGCACGGAGGAGCTCTTTGAC (SEQ ID NO: 4026)

AGCTCTTTGACTTCTTGCATGCGAG (SEQ ID NO: 4027)

TGCATGCGAGGGACCATTGCGTGGC (SEQ ID NO: 4028)

CATTGCGTGGCCCACAAACTCTTTA (SEQ ID NO: 4029)

TGGCCCACAAACTCTTTAACAACTT (SEQ ID NO: 4030)

GTAATTCGCAATGATTCCATCTAAA (SEQ ID NO: 4031)

201568_at
UQCRQ
QCR8, QP-C,
ubiquinol-cytochrome
27089
TTGGTTCAGTTTTCCGGAGGGCGAG (SEQ ID NO: 4032)

c reductase, complex

TGGGCCGCGAGTTTGGGAATCTGAC (SEQ ID NO: 4033)

QPC
III subunit VII, 9.5 kDa

GAATCTGACGCGGATGCGGCATGTG (SEQ ID NO: 4034)

GTGATCAGCTACAGCTTGTCACCGT (SEQ ID NO: 4035)

CTATCCGCACGTCTTCACTAAAGGA (SEQ ID NO: 4036)

TAAAGGAATCCCCAATGTTCTGCGC (SEQ ID NO: 4037)

CGCATTCGGGAGTCTTTCTTTCGCG (SEQ ID NO: 4038)

TGGTGCCGCAGTTTGTAGTGTTTTA (SEQ ID NO: 4039)

AGAGGAGGATCCAGCTGCCTATGAA (SEQ ID NO: 4040)

AAATGAGCAACGCATCCGGATGACG (SEQ ID NO: 4041)

TGTCTCTGAAAGACCTTTCTCTGGA (SEQ ID NO: 4042)

213327_s_at
USP12
USP12L1
ubiquitin specific
219333
GACAGGAACCAGGAGGCTTGGGAAC (SEQ ID NO: 4043)

peptidase 12

TATTATGTGGGTCTTGGGGCCTCTA (SEQ ID NO: 4044)

GGGGCCTCTAACCATCAGTATAGGG (SEQ ID NO: 4045)

TTTTTCTTTCCTTGATGGCAGTAGA (SEQ ID NO: 4046)

GCAGTAGAAAGACCTCATTTTCATA (SEQ ID NO: 4047)

AGACCTCATTTTCATAACATAACTA (SEQ ID NO: 4048)

ACATAACTACTCTTGATACTTTCTT (SEQ ID NO: 4049)

GATTCTATCATGAGGTATTTGGCTG (SEQ ID NO: 4050)

TGAGGTATTTGGCTGGGAGCTGGGA (SEQ ID NO: 4051)

CTTCAGTCTCCCTGTCTTGTAAAAT (SEQ ID NO: 4052)

GGTTCTTGAAGAAGGCACTATATAA (SEQ ID NO: 4053)

221654_s_at
USP3
MGC129878,
ubiquitin specific
9960
TCTCACTTTGAGGCACATTTACATC (SEQ ID NO: 4054)

MGC129879,
peptidase 3

TACATCAATGCTTTTGTTCCTCTCA (SEQ ID NO: 4055)

SIH003, UBP

AAGCAAGATGTGTTCCTTATTGTGA (SEQ ID NO: 4056)

GTGAAGAGCGACACAACTGCCTGCT (SEQ ID NO: 4057)

GCTGCCTTTCCACAGCTATAATGGA (SEQ ID NO: 4058)

TGGACATCAGGTTGACTCTAAATCA (SEQ ID NO: 4059)

GTGTGCACAATACTTGTGGCCCACA (SEQ ID NO: 4060)

GACCAGGTAATTACTGCTTGTCTCT (SEQ ID NO: 4061)

TTACTGCTTGTCTCTCAAGGCTGCT (SEQ ID NO: 4062)

TCAAGGCTGCTGTCTTTATCAGCAC (SEQ ID NO: 4063)

GGTTCAGTTGTACTTGTCCTGCAAA (SEQ ID NO: 4064)

205139_s_at
UST
2OST
uronyl-2-
10090
AAACATTCATCCTCTTACTGCAAGT (SEQ ID NO: 4065)

sulfotransferase

TATCTGGGTACTTTTACCTGTGTGT (SEQ ID NO: 4066)

AAGGCATTTCTTTTCAGCAGTGATC (SEQ ID NO: 4067)

TGACGGATTTACTTACAGGGCCTTA (SEQ ID NO: 4068)

GCCTTAATGTTATTTTGTCCCAGCC (SEQ ID NO: 4069)

CACCCTCTAGGTCCTAAAAGTCAAG (SEQ ID NO: 4070)

CCTGGGCCCAACAGTTTGTACTTCA (SEQ ID NO: 4071)

ATTATAACCTTTCAGCACATTCCAA (SEQ ID NO: 4072)

CATTCCAAGGTTTTAGTTACTCAGG (SEQ ID NO: 4073)

ATTATTATGAACCTTCAGCCTACTT (SEQ ID NO: 4074)

AGCCTACTTTCTTGAGTGCCGTAAA (SEQ ID NO: 4075)

208626_s_at
VAT1
FLJ20230, VATI
vesicle amine
10493
CAAAAACAGGTGCCCTCATCGTGGT (SEQ ID NO: 4076)

transport protein 1

GTCCCGTCTCTATGGTGGTTGAGGA (SEQ ID NO: 4077)

homolog (T. californica)

AAAAATCCAAGCACATTCCCCTTGC (SEQ ID NO: 4078)

GCCCTACTGCCTTCTCAAAGCAGAG (SEQ ID NO: 4079)

GGATGGTCAGGACCTGGGCCATTGC (SEQ ID NO: 4080)

GGTAGGGAGGTCACTCCCTCTACTC (SEQ ID NO: 4081)

CTCCCTCTACTCACTGAGCTAGGAT (SEQ ID NO: 4082)

TAGGGAGGGTTATTGCCCCAACCAT (SEQ ID NO: 4083)

GAGGTGGAGGGACAGGCTCAGCCTC (SEQ ID NO: 4084)

GTGAAGTGCGATTTCTGCTTTTGTG (SEQ ID NO: 4085)

CCATTACCACAGCTGCCTTTGTGTG (SEQ ID NO: 4086)

210849_s_at
VPS41
HVPS41,
vacuolar protein
27072
ATTTCTTCATCTATTCCTGTACTAA (SEQ ID NO: 4087)

HVSP41,
sorting 41 homolog

AGAATTTGGGGCTCTCTTCATGCCT (SEQ ID NO: 4088)

hVps41p
(S. cerevisiae)

CAACTGAGAATTCTCCCAGCTGCCT (SEQ ID NO: 4089)

GCCTGAAAGCGTCGCCAACTGTGGT (SEQ ID NO: 4090)

GCAAGCTGCTACCTGCAACTTGGAC (SEQ ID NO: 4091)

AACTTGGACGTTGTTTCCACGTGCT (SEQ ID NO: 4092)

CTGGCTACGATTCTTGCATTCTGGG (SEQ ID NO: 4093)

GGCTTTTTTCTGTGTCATCAACTAT (SEQ ID NO: 4094)

AGCAGGCTGATGTCCTGCACCATTA (SEQ ID NO: 4095)

TTCTGTGTGCTGTGACGACTGTCAA (SEQ ID NO: 4096)

AGTATCTGGCCATGGCGGACACTCA (SEQ ID NO: 4097)

205126_at
VRK2

vaccinia related
7444
GCGCTGAGTCCTGTGCAACATGGAA (SEQ ID NO: 4098)

kinase 2

AGCTATACACAATTCCCAAACTCAT (SEQ ID NO: 4099)

GATTTTACCAGTCCAGATATATTCA (SEQ ID NO: 4100)

ACACTTCCACAGTCAGCACGGGGAT (SEQ ID NO: 4101)

TCAGCACGGGGATCACAGACTTAGA (SEQ ID NO: 4102)

TGGACTTTGGCCTACAATTTCCCAG (SEQ ID NO: 4103)

ATTTCCCAGTTTACTCTTAGTGAAG (SEQ ID NO: 4104)

TATTATCGCATCATCATACCTGTCC (SEQ ID NO: 4105)

CATACCTGTCCTTTTGATGTTAGTA (SEQ ID NO: 4106)

TTCCAGCTCTTCACCGAAATGTTGT (SEQ ID NO: 4107)

CTTATTTCAGTGTTTCCTTCCAGAC (SEQ ID NO: 4108)

200628_s_at
WARS
GAMMA-2, IFI53,
tryptophanyl-tRNA
7453
GGACGTGTCTTTCATGTACCTGACC (SEQ ID NO: 4109)

IFP53
synthetase

GGACGACGACAAGCTCGAGCAGATC (SEQ ID NO: 4110)

GAAGGATTACACCAGCGGAGCCATG (SEQ ID NO: 4111)

GAGCCATGCTCACCGGTGAGCTCAA (SEQ ID NO: 4112)

CATAGAGGTTCTGCAGCCCTTGATC (SEQ ID NO: 4113)

GTCCTTCGACTTTCAGTAGCACTCG (SEQ ID NO: 4114)

TCAATAATCCCAGCCCAGTCAAAGC (SEQ ID NO: 4115)

ACCTGTAGGCTTCTGTCTCATGGTA (SEQ ID NO: 4116)

GTTTCTTCCTGTGAGTTCCATTATT (SEQ ID NO: 4117)

CAAAGCAGCCCCACAGTGGAGCCTT (SEQ ID NO: 4118)

GTGGAGCCTTCGGCTGGAAGTCCAT (SEQ ID NO: 4119)

200609_s_at
WDR1
AIP1, NORI-1
WD repeat domain 1
9948
GGCTCTCACTATCTGTCAGGGGAGG (SEQ ID NO: 4120)

GCAAAGCCGGAATTCTGTGTTGAAC (SEQ ID NO: 4121)

TGAACAGATGTCTGTCTCCCTAGTG (SEQ ID NO: 4122)

AGTGTGTGACTCACACCTTGTGGCT (SEQ ID NO: 4123)

CGCCACCTCCAGATCAGATGGGGAC (SEQ ID NO: 4124)

GACACACAACCCCTGGATATGTTTC (SEQ ID NO: 4125)

GTTGCCTGTCAGTGTTTACAAACTA (SEQ ID NO: 4126)

TGACGGCACCGTGTCCAAGTTTTTA (SEQ ID NO: 4127)

TTTAGAACCCTTGTTAGCCAGACCG (SEQ ID NO: 4128)

TAGCCAGACCGAGGTGTCCTGGTCA (SEQ ID NO: 4129)

ACCATCATGCTTTGATGTTCCCCTG (SEQ ID NO: 4130)

209592_s_at
WDR68
AN11; HAN11
WD repeat domain
10238
GATGGCTCGGTGCGGATGTTTGACC (SEQ ID NO: 4131)

68

ACAGCACCATCATTTACGAAGACCC (SEQ ID NO: 4132)

CATTTACGAAGACCCACAGCATCAC (SEQ ID NO: 4133)

TGCTTCGCCTCTGCTGGAACAAGCA (SEQ ID NO: 4134)

GAGATCAACAATGTGCAGTGGGCAT (SEQ ID NO: 4135)

CAGTGGGCATCAACTCAGCCCGACT (SEQ ID NO: 4136)

CCATCTGCTACAACAACTGCCTGGA (SEQ ID NO: 4137)

CTGCCTGGAGATACTCAGAGTGTAG (SEQ ID NO: 4138)

AGAGTGTAGTGTTGGTGGCGCTGTG (SEQ ID NO: 4139)

TGTGCCCACGAGGCAGGGGCTTTTG (SEQ ID NO: 4140)

GCAGGGGCTTTTGTATTTCCTGCCT (SEQ ID NO: 4141)

208459_s_at
XPO7
KIAA0745,
exportin 7
23039
TTATTGCAAGCCTGGAACCTCACGT (SEQ ID NO: 4142)

RANBP16

GAACCTCACGTCATCATGTATATTC (SEQ ID NO: 4143)

ACTTACTGCACTTGACACCATGGTA (SEQ ID NO: 4144)

CCATGGTATGCACAGGCTGCTGCTC (SEQ ID NO: 4145)

GACCACATTGTGACATACCTCTTCA (SEQ ID NO: 4146)

TTCAAGCAGCTGTCACGTAGCACCA (SEQ ID NO: 4147)

ACCACACCCCTGAACCAGGAGAGCG (SEQ ID NO: 4148)

GCTGTCCACGGTGCTGAACATCATC (SEQ ID NO: 4149)

TCCCGACCACTACTTGGCTTGATAT (SEQ ID NO: 4150)

GCCAGCCACCGGAGAAGCAGCAGGC (SEQ ID NO: 4151)

CCTGTCAGCATTCCGTCGAGAAGTC (SEQ ID NO: 4152)

212166_at
XPO7
KIAA0745,
exportin 7
23039
ATTCCTGTTACTGTATTAACCCTTG (SEQ ID NO: 4153)

RANBP16

GGAACTCTAAGCCATGCCAGAACAC (SEQ ID NO: 4154)

CCCTAGCCCCTTGCAGTGATAAATA (SEQ ID NO: 4155)

GTGTTTGGTGTTCTTATCTCCACCC (SEQ ID NO: 4156)

TCAGACAGATGCCTCTTGCTTTTAA (SEQ ID NO: 4157)

ACGTGTTGTAGGGTTCTTGGTCTGT (SEQ ID NO: 4158)

GAGAAGGAAGTGAGCCCACTGCTCT (SEQ ID NO: 4159)

ATGTGGGTGAGTCCACCAGAGGCCC (SEQ ID NO: 4160)

CCAGCCCTCGAGGCAGTGTGTGTGG (SEQ ID NO: 4161)

ATATGTACCCTGCACTCATGAATGT (SEQ ID NO: 4162)

GAAGTATTTAACATTCTCCCATCCC (SEQ ID NO: 4163)

208627_s_at
YBX1
YB1; BP-8;
Y box binding protein 1
4904
TAACCCCAGGAAGTACCTTCGCAGT (SEQ ID NO: 4164)

CSDB; DBPB;

GCGGAGGCAGCAAATGTTACAGGTC (SEQ ID NO: 4165)

YB-1; CSDA2;

GGTGGTGTTCCAGTTCAAGGCAGTA (SEQ ID NO: 4166)

NSEP1; NSEP-1;

GCAGACCGTAACCATTATAGACGCT (SEQ ID NO: 4167)

MDR-NF1;

GACGCTATCCACGTCGTAGGGGTCC (SEQ ID NO: 4168)

MGC104858;

GAGGGATCGGAGAGTGCTCCCGAAG (SEQ ID NO: 4169)

MGC110976;

GTTCCCACCTTACTACATGCGGAGA (SEQ ID NO: 4170)

MGC117250

CTATGGGCGTCGACCACAGTATTCC (SEQ ID NO: 4171)

TTCCAACCCTCCTGTGCAGGGAGAA (SEQ ID NO: 4172)

GGGTGCTGACAACCAGGGTGCAGGA (SEQ ID NO: 4173)

GGGATATAGACCACGATTCCGCAGG (SEQ ID NO: 4174)

208628_s_at
YBX1
YB1; BP-8;
Y box binding protein 1
4904
AACTTCAATTACCGACGCAGACGCC (SEQ ID NO: 4175)

CSDB; DBPB;

GAAAACCCTAAACCACAAGATGGCA (SEQ ID NO: 4176)

YB-1; CSDA2;

AGAGACAAAAGCAGCCGATCCACCA (SEQ ID NO: 4177)

NSEP1; NSEP-1;

ATCCACCAGCTGAGAATTCGTCCGC (SEQ ID NO: 4178)

MDR-NF1;

TGAGTAAATGCCGGCTTACCATCTC (SEQ ID NO: 4179)

MGC104858;

ATCTCTACCATCATCCGGTTTAGTC (SEQ ID NO: 4180)

MGC110976;

TCATCCGGTTTAGTCATCCAACAAG (SEQ ID NO: 4181)

MGC117250

GATTGGAGCTGAAGACCTAAAGTGC (SEQ ID NO: 4182)

CCTAAAGTGCTTGCTTTTTGCCCGT (SEQ ID NO: 4183)

CTTTTTGCCCGTTGACCAGATAAAT (SEQ ID NO: 4184)

GCATTATCTATGCAGCATGGGGTTT (SEQ ID NO: 4185)

200640_at
YWHAZ
KCIP-1,
tyrosine 3-
7534
ATACTCTTATAGCCTGCCTTCAATT (SEQ ID NO: 4186)

MGC111427,
monooxygenase/tryptophan

TATTCTTTCTATTTGTCAGGTGCAC (SEQ ID NO: 4187)

MGC126532,
5-

GTCAGGTGCACAAGATTACCTTCCT (SEQ ID NO: 4188)

MGC138156
monooxygenase

CAAGATTACCTTCCTGTTTTAGCCT (SEQ ID NO: 4189)

activation protein,

CTTGTCACCAACCATTCTTACTTGG (SEQ ID NO: 4190)

zeta polypeptide

AACCATTCTTACTTGGTGGCCATGT (SEQ ID NO: 4191)

AAAAAGGCCGCATGATCTTTCTGGC (SEQ ID NO: 4192)

CTGGCTCCACTCAGTGTCTAAGGCA (SEQ ID NO: 4193)

CCTCATCCTATTTACTGCAGCAAAT (SEQ ID NO: 4194)

GCAAATCTCTCCTTAGTTGATGAGA (SEQ ID NO: 4195)

GATGAGACTGTGTTTATCTCCCTTT (SEQ ID NO: 4196)

205383_s_at
ZBTB20
RP23-283M18.1,
zinc finger and BTB
26137
GGAGAGAAGTCCTACGAGTGCTACA (SEQ ID NO: 4197)

1300017A20Rik,
domain containing 20

AAAGAAGTTCTCTCACAAGACCCTC (SEQ ID NO: 4198)

7330412A13Rik,

CTCCGTCTGCCCAGCAAAGTTTGAC (SEQ ID NO: 4199)

A930017C21Rik,

CGAGCAGTTCAACGACCACATGAGG (SEQ ID NO: 4200)

D16Wsu73e,

TGAAGAACTGTTTTTTGCCTGCTGG (SEQ ID NO: 4201)

DPZF, HOF,

GGTACATTACATTTCCGGAGGCTTG (SEQ ID NO: 4202)

ODA-8S, Oda8,

GAATAATAGTTTTCCCAGTCTCCCT (SEQ ID NO: 4203)

Zfp288

CCCTCGGATGGTGGCCTTAAGGCCT (SEQ ID NO: 4204)

GCCTTAAGGCCTGGTAGTGCTTCAA (SEQ ID NO: 4205)

GAGGTCCACTGGTTGGATCTCTAGC (SEQ ID NO: 4206)

ATCTCTAGCTACTGGCCTCTAAATA (SEQ ID NO: 4207)

206169_x_at
ZC3H7B
DKFZp434K0920,
zinc finger CCCH-
23264
CATGGTGGCATGCTTCTGTAATCCC (SEQ ID NO: 4208)

FLJ13787,
type containing 7B

ATGGTGGCATGCTTCTGTAATCCCA (SEQ ID NO: 4209)

KIAA1031,

GCTACTCAGGAGGCCGAGATTAGAG (SEQ ID NO: 4210)

RoXaN

GAGGCCGAGATTAGAGAATCACTTG (SEQ ID NO: 4211)

GAATCACTTGAATGTGGGAGTCGGA (SEQ ID NO: 4212)

CTTGAATGTGGGAGTCGGAGGTTGT (SEQ ID NO: 4213)

GAATGTGGGAGTCGGAGGTTGTAAT (SEQ ID NO: 4214)

GTGGGAGTCGGAGGTTGTAATGAGC (SEQ ID NO: 4215)

GGAGTCGGAGGTTGTAATGAGCTGA (SEQ ID NO: 4216)

GTCGGAGGTTGTAATGAGCTGAGAT (SEQ ID NO: 4217)

GAGGTTGTAATGAGCTGAGATCACA (SEQ ID NO: 4218)

202778_s_at
ZMYM2
FIM, MYM,
zinc finger, MYM-type 2
7750
GAGTGAAAGTTGCCATTATTCTATG (SEQ ID NO: 4219)

RAMP, SCLL,

GAGAATGTGCCATGTATAATTTTTT (SEQ ID NO: 4220)

ZNF198

ACATCCATATTGCACAACTCTACTG (SEQ ID NO: 4221)

AACTCTACTGTTGCAAAGCTTCCTT (SEQ ID NO: 4222)

TCCTTGGAAGGGGGCTCTTTTACTG (SEQ ID NO: 4223)

TACTGGGTTCTTAACCAGATGGTTG (SEQ ID NO: 4224)

GGTTGTGTATGGGTAGCACTACTAA (SEQ ID NO: 4225)

GAACTTGCAGTGTCTTTCGGAATTT (SEQ ID NO: 4226)

ATTTTAGTTACTGAAGCCTTACAAG (SEQ ID NO: 4227)

GAGAGATACCATCTTCTGTACCAAA (SEQ ID NO: 4228)

GTAATGTGAATCTATGCTGGTGAAA (SEQ ID NO: 4229)

215948_x_at
ZMYM5
MYM; ZNF237;
zinc finger, MYM-type 5
9205
ATACCAACTTGGGAGATGTCGCTAA (SEQ ID NO: 4230)

HSPC050;

GATGTCGCTAAAGGACTTCAGTCAA (SEQ ID NO: 4231)

ZNF198L1

AATATACAAACGTACACCCCATCTT (SEQ ID NO: 4232)

CCATCTTTAACTCCACAGACCAAGA (SEQ ID NO: 4233)

GAATGTGGCAGGAGACTTATTTCAG (SEQ ID NO: 4234)

GAATTTGCAACTCATCATAGTCCTG (SEQ ID NO: 4235)

AAGGCTAATGTCATTCTTCCAGTAG (SEQ ID NO: 4236)

GAATCAAGCAAATCCTTCCAAGAAT (SEQ ID NO: 4237)

ATCTTGTTTGTCTCCCTGTGAAAAC (SEQ ID NO: 4238)

ACTCTTTCATCTACATAATGCACGT (SEQ ID NO: 4239)

TAATGCACGTGTTCTGGATGTATAA (SEQ ID NO: 4240)

207605_x_at
ZNF117
H-plk, HPF9,
zinc finger protein
51351
GCGGCAAAGCTTTTAACCGATCCTC (SEQ ID NO: 4241)

MGC22613
117

ACCGATCCTCAAAACTTACTGAACA (SEQ ID NO: 4242)

GTGACAAGGCCTTTAACCTGTCCTC (SEQ ID NO: 4243)

CCTGTCCTCAACGCTTACTAAACAT (SEQ ID NO: 4244)

TAAACAGTTCTCACACCTTGCTATA (SEQ ID NO: 4245)

TCTCACACCTTGCTATACATAATAT (SEQ ID NO: 4246)

GGCAAAGCTTTTAACTCATCCTCAA (SEQ ID NO: 4247)

TCATCCTCAAACCTTACTGCACATA (SEQ ID NO: 4248)

GCAAAGCTAACCTATCATCAACCCT (SEQ ID NO: 4249)

CAACCCTTACTCCACATAAGACAAT (SEQ ID NO: 4250)

AATGCTTGTAACTAAATCTCAAACT (SEQ ID NO: 4251)

219123_at
ZNF232
ZSCAN11
zinc finger protein
7775
TGGTCCCCTGCCCAGGAGGAAAGTT (SEQ ID NO: 4252)

232

TATAACTCACATCTTGTTGTCCACC (SEQ ID NO: 4253)

CACATCTTGTTGTCCACCAGAGAGT (SEQ ID NO: 4254)

AAACAGAGCTCAAACCTCGGTCAGC (SEQ ID NO: 4255)

AAGGCCTTCAGATGGGGTGCTCATC (SEQ ID NO: 4256)

ATGGGGTGCTCATCTTGTTCAGCAT (SEQ ID NO: 4257)

AGCTCATATCTAAGTCAGCATCGGA (SEQ ID NO: 4258)

GGTGCTCAGAGCTCATTAGACATCG (SEQ ID NO: 4259)

ACATCGGAGAGTTCATGCCAGAAAA (SEQ ID NO: 4260)

TGCCAGAAAAGAGCCTTCCCATTGA (SEQ ID NO: 4261)

GAATTCTACATCGGTCTAATCTACT (SEQ ID NO: 4262)

206829_x_at
ZNF430
DKFZp762K012,
zinc finger protein
80264
GATAAAGCCTTTAGCCAGTCTTCAA (SEQ ID NO: 4263)

FLJ13659,
430

AGCCAGTCTTCAACTCTTACTAAAC (SEQ ID NO: 4264)

MGC133232

GGAGAGAAACCCTACAACTGTGAAG (SEQ ID NO: 4265)

ATACGGCAAAGCTTTCAACCAGTCC (SEQ ID NO: 4266)

TTCAACCAGTCCTCAAACCTTATTG (SEQ ID NO: 4267)

ATTGTGGCAAAGCCTCTAACCCGTC (SEQ ID NO: 4268)

CCCGTCCTGAATTCTTACTAAACAT (SEQ ID NO: 4269)

ATGGCAAAGCCTTCAACAAGTCCTC (SEQ ID NO: 4270)

ACAAGTCCTCAATTCTTACCAGACA (SEQ ID NO: 4271)

AGATAATTCTGGCTGGGTGCGGTGG (SEQ ID NO: 4272)

GGCTGAGACGGGTGAATTACATGAG (SEQ ID NO: 4273)

All gene probe set identification numbers and Entrez Gene identification numbers of Table 1 are hereby incorporated by reference in their entirety

The term “prognosis” as used in the context of the present invention refers to the prediction of disease outcome for a subject having colon cancer. Disease outcome encompasses disease progression, reoccurrence, metastasis, and drug resistance. Determining the prognosis of a subject having colon cancer in accordance with the methods of the present invention has particular value for determining an appropriate treatment plan. For example, the prognosis of a subject determined using the methods of the present invention can predict a subject's response to a specific drug or combination of drugs, chemotherapy, radiation therapy, or surgical removal, and whether survival after following the administration of a particular treatment plan is likely.

As used herein a “disease prognosis expression profile” refers to gene expression of a collection of genes informative of disease outcome that is associated with a good disease outcome or a bad disease outcome. The gene expression of a collection of genes that is associated with a good disease outcome is a good disease prognosis expression profile. A good disease prognosis expression profile consists of genes having expression levels that are below the average tumor sample expression level and/or genes having expression levels that are above the average tumor sample expression level. In a preferred embodiment of the present invention a good disease prognosis expression profile for the group of 176 genes informative of colon cancer prognosis consists of genes having expression levels that are below that of an average tumor sample expression level that are selected from the group consisting of AK023058*, AIP, ARL2BP, C1GALT1, CDC42BPA, C8orf70, CLN5, COBL, CYB5B, MOSPD1, DOCK9, EGFR, FKBP14, DND1, GREM2, GPR177, GALNS, GRB10, GRP, GSTA1, RP3-377H14.5, HOXB7, ZNF117, TNIK, LANCL1, METRN, LEPREL1, NAB1, NISCH, OGT, OSBPL3, PDGFA, PRDM2, PRELP, PSPC1, RECQL, RYK, SMURF2, TLN1, UNC84A, USP12, ZMYM2, ZMYM5, AL359599*, ARL4A, N4BP2L2, GLS, C19orf36, TMCC1, METTL3, TMEM16A, RTN2, SCAMP1, SF3B1, SOX4, STK3, ZNF430, C6orf15, C7orf10, CHST12, ETV1, ACSL4, FLJ10357, C5orf23, AA058828*, CDR2L, KLC1, MAP4, NUMB, PAM, PGDS, PTHLH, ZC3H7B, SAV1, SGCD, SYNGR1, TES, IFT88, TRIM36 and VPS41. The good disease prognosis expression profile for the group of 176 genes further consists of genes having expression levels that are above the average tumor sample expression level that are selected from the group consisting of SERPINA1, RPLP0, RPLP0-like, CYB561, AKR1A1, AP3D1, ARL6IP4, OGFOD2, ASNA1, CFB, ERP29, SMG7, CASP1, CCNA2, LOC100131861, SAMM50, COX5A, CXCL11, DAZAP2, DDX23, FDFT1, COMMD4, GCHFR, GRHPR, GSR, ISG20, ITGAE, KIAA0746, SERINC2, FRYL, LRRC47, LAMP3, R3HCC1, MAPKAPK5, MCM5, MCRS1, TMEM106C, MMP3, MTUS1, LRRC41, NAT1, NDUFC1, YBX1, PEBP1, PIGR, PSMA5, SFPQ, SLC25A3, SLC39A8, SQRDL, SRP72, SSNA1, TAPBPL, TEGT, PBK, UCP2, UQCRH, XPO7, CCT2, CNOT7, DHX15, TMEM87A, ELP3, FAM82C, LL22NC03-5H6.5, DENND2D, WDR68, IL15RA, DENND2A, KIF13B, MFHAS1, SPATA5L1, MYRIP, PIGT, PSMD9, RPS27L, TEGT, TNFRSF10B, UBE2L6, USP3, ATP5B, CALML4, C1orf144, TMEM33, C12orf52, GHITM, H2AFZ, LAP3, MRPL46, SORD, CNPY2, TNFSF10, U2AF2, CMPK1, UQCRFS1, WARS and WDR1.

The gene expression of a collection of genes informative of disease outcome that is associated with a bad disease outcome is a bad disease prognosis expression profile. A bad disease prognosis expression profile consists of genes having expression levels above and/or below the average tumor sample expression level. In a preferred embodiment of the present invention, a bad disease prognosis expression file for the collection of 176 genes informative of colon cancer prognosis consists of genes having expression levels that are below that of an average tumor sample expression level selected from the group consisting of SERPINA1, RPLP0, RPLP0-like, CYB561, AKR1A1, AP3D1, ARL6IP4, OGFOD2, ASNA1, CFB, ERP29, SMG7, CASP1, CCNA2, LOC100131861, SAMM50, COX5A, CXCL11, DAZAP2, DDX23, FDFT1, COMMD4, GCHFR, GRHPR, GSR, ISG20, ITGAE, KIAA0746, SERINC2, FRYL, LRRC47, LAMP3, R3HCC1, MAPKAPK5, MCM5, MCRS1, TMEM106C, MMP3, MTUS1, LRRC41, NAT1, NDUFC1, YBX1, PEBP1, PIGR, PSMA5, SERPINA1, SFPQ, SLC25A3, SLC39A8, SQRDL, SRP72, SSNA1, TAPBPL, TEGT, PBK, UCP2, UQCRH, XPO7, CCT2, CNOT7, DHX15, TMEM87A, ELP3, FAM82C, LL22NC03-5H6.5, DENND2D, WDR68, IL15RA, DENND2A, KIF13B, MFHAS1, SPATA5L1, MYRIP, PIGT, PSMD9, RPS27L, TNFRSF10B, UBE2L6, USP3, ATP5B, CALML4, C1orf144, TMEM33, C12orf52, GHITM, H2AFZ, LAP3, MRPL46, SORD, CNPY2, TNFSF10, U2AF2, CMPK1, UQCRFS1, WARS and WDR; and genes having expression levels that are above the average tumor sample expression level selected from the group consisting of AK023058*, AIP, ARL2BP, C1GALT1, CDC42BPA, C8orf70, CLN5, COBL, CYB5B, MOSPD1, DOCK9, EGFR, FKBP14, DND1, GREM2, GPR177, GALNS, GRB10, GRP, GSTA1, RP3-377H14.5, HOXB7, ZNF117, TNIK, LANCL1, METRN, LEPREL1, NAB1, NISCH, OGT, OSBPL3, PDGFA, PRDM2, PRELP, PSPC1, RECQL, RYK, SMURF2, TLN1, UNC84A, USP12, ZMYM2, ZMYM5, AL359599*, ARL4A, N4BP2L2, GLS, C19orf36, TMCC1, METTL3, TMEM16A, RTN2, SCAMP1, SF3B1, SOX4, STK3, ZNF430, C6orf15, C7orf10, CHST12, ETV1, ACSL4, FLJ10357, C5orf23, AA058828*, CDR2L, KLC1, MAP4, NUMB, PAM, PGDS, PTHLH, ZC3H7B, SAV1, SGCD, SYNGR1, TES, IFT88, TRIM36 and VPS41.

TABLE 2

101 Genes Informative of Colon Cancer Prognosis

Accession

#

Probe Set
Gene

(Entrez

ID
Symbol
AKA
Gene Title
Gene ID)
Probe Sequence(s)

200027_at
NARS
ASNRS,
asparaginyl-
4677
ATCTTTTCTAACTCTGCTTAGCTGC
(SEQ ID NO: 4274)

NARS1
tRNA

AGCTGCTAATAATCCTGAGGCATAG
(SEQ ID NO: 4275)

synthetase

TAGTGATTCACAGTATCCCTCTTAG
(SEQ ID NO: 4276)

AGTATCCCTCTTAGCATTAATTTAA
(SEQ ID NO: 4277)

GAGGCAGATTGATTTTCCCTCTTTC
(SEQ ID NO: 4278)

CCCACCATGTCCTTAGATCTAATCT
(SEQ ID NO: 4279)

TAGATCTAATCTGTGCTACCTTATT
(SEQ ID NO: 4280)

GCTACCTTATTAACTCACAGCAGGC
(SEQ ID NO: 4281)

ACAGCAGGCTTACTGAATGGCTTCA
(SEQ ID NO: 4282)

CAGATTTAGTTGATTTCTCCACCAA
(SEQ ID NO: 4283)

GCATGTCATGTATTCTCAATAGGCT
(SEQ ID NO: 4284)

200609_s_—
WDR1
API, NORI-1
WD repeat
9948
GGCTCTCACTATCTGTCAGGGGAGG
(SEQ ID NO: 4285)

at

domain 1

GCAAAGCCGGAATTCTGTGTTGAAC
(SEQ ID NO: 4286)

TGAACAGATGTCTGTCTCCCTAGTG
(SEQ ID NO: 4287)

AGTGTGTGACTCACACCTTGTGGCT
(SEQ ID NO: 4288)

CGCCACCTCCAGATCAGATGGGGAC
(SEQ ID NO: 4289)

GACACACAACCCCTGGATATGTTTC
(SEQ ID NO: 4290)

GTTGCCTGTCAGTGTTTACAAACTA
(SEQ ID NO: 4291)

TGACGGCACCGTGTCCAAGTTTTTA
(SEQ ID NO: 4292)

TTTAGAACCCTTGTTAGCCAGACCG
(SEQ ID NO: 4293)

TAGCCAGACCGAGGTGTCCTGGTCA
(SEQ ID NO: 4294)

ACCATCATGCTTTGATGTTCCCCTG
(SEQ ID NO: 4295)

200629_at
WARS
GAMMA-2,
tryptophanyl-
7453
TCCAGTTTACTGAACTCCAGACCAT
(SEQ ID NO: 4296)

IF153, IFP53
tRNA

CCAGACCATGCATGTAGTCCACTCC
(SEQ ID NO: 4297)

synthetase

TGCAGAGTCAGGGTGGCTTTTCCCC
(SEQ ID NO: 4298)

CTGTGTCCGATGCCAAGGAGTCCTG
(SEQ ID NO: 4299)

GGACGGGTGGACTTAGCTAGGGAGA
(SEQ ID NO: 4300)

AAGTCGAGGCAGCAGCCCTCGAGGC
(SEQ ID NO: 4301)

TCGAGGCCCTCACAGATGTCTAGGC
(SEQ ID NO: 4302)

GTCTAGGCAGGCCTCATTTCATCAC
(SEQ ID NO: 4303)

ATTTCATCACGCAGCATGTGCAGGC
(SEQ ID NO: 4304)

ATCTCAGGGAAGTCCTTGGTTGATG
(SEQ ID NO: 4305)

TTGGTTGATGTATCTGGGTCTCCTC
(SEQ ID NO: 4306)

200877_at
CCT4
CCT-DELTA,
chaperonin
10575
GTGGTATGGAATCCTACTGCGTTCG
(SEQ ID NO: 4307)

Cctd,
containing

GCGTTCGTGCTTTTGCAGATGCTAT
(SEQ ID NO: 4308)

MGC126164,
TCP1,

GTCATTCCATCTACACTAGCTGAAA
(SEQ ID NO: 4309)

MGC126165,
subunit 4

CTAGCTGAAAATGCCGGCCTGAATC
(SEQ ID NO: 4310)

SRB
(delta)

GGCCTGAATCCCATTTCTACAGTAA
(SEQ ID NO: 4311)

GAACTAAGAAACCGGCATGCCCAGG
(SEQ ID NO: 4312)

TGGAGGAACTGGTTGTCCAGCCTCT
(SEQ ID NO: 4313)

CCAGCCTCTGTTGGTATCAGTCAGT
(SEQ ID NO: 4314)

CAGTGCTCTGACTCTTGCAACTGAA
(SEQ ID NO: 4315)

GACTAGCACCATTATGATCACCAGT
(SEQ ID NO: 4316)

TCTGGGCTTGGTCTTCCAGTTGGCA
(SEQ ID NO: 4317)

201322_at
ATP5B
ATPMB,
ATP
506
TTGGATGCTACCACTGTACTGTCGC
(SEQ ID NO: 4318)

ATPSB,
synthase, H+

TCGCGTGCCATTGCTGAGCTGGGCA
(SEQ ID NO: 4319)

MGC5231
transporting,

AGCTGTGGATCCTCTAGACTCCACC
(SEQ ID NO: 4320)

mitochondrial

GTGAGCATTACGATGTTGCCCGTGG
(SEQ ID NO: 4321)

F1 complex,

TCCTGCAGGACTACAAATCCCTCCA
(SEQ ID NO: 4322)

beta

GAAGACAAGTTGACCGTGTCCCGTG
(SEQ ID NO: 4323)

polypeptide

TTGTCTCAGCCATTCCAGGTTGCTG
(SEQ ID NO: 4324)

GAGGTCTTCACAGGTCATATGGGGA
(SEQ ID NO: 4325)

GAAGCTGGTACCCCTGAAGGAGACC
(SEQ ID NO: 4326)

ACAGGCCTTCTATATGGTGGGACCC
(SEQ ID NO: 4327)

TCGTGAGGGGTCTTTGTCCTCTGTA
(SEQ ID NO: 4328)

201562_s_—
SORD
SORD1
sorbitol
6652
GATGTTAATGGGCTCTGCTCATCCC
(SEQ ID NO: 4329)

at

dehydrogenase

GGGTGGGCTCTGATGCAGAACTTTC
(SEQ ID NO: 4330)

GGAACTTGTAGCCAGAATGCCCTGT
(SEQ ID NO: 4331)

GAATGCCCTGTTCATGCTGAGCAAA
(SEQ ID NO: 4332)

TTCTTCCTGGAGTGCCTTCATTGAG
(SEQ ID NO: 4333)

TCCACTGCTACTGACCCAGAGGGGA
(SEQ ID NO: 4334)

TCATGAAGACTTAACTGGCCCAGAA
(SEQ ID NO: 4335)

AAAATCTGCCACTCAGGGTCTGGGA
(SEQ ID NO: 4336)

GGGTCTGGGATGAAGGCTTGTCAGC
(SEQ ID NO: 4337)

GCTTGTCAGCACTTCCAGTTTAGAA
(SEQ ID NO: 4338)

GAAAAGGCATCACTTTCCTGGATCC
(SEQ ID NO: 4339)

201646_at
UBE2L6
MGC40331,
ubiquitin-
9246
GTGTGTTGTGTATGGACTCACTCCC
(SEQ ID NO: 4340)

RIG-B, UBCH8
conjugating

CCTTTACATTCCCCAGAGCCAAGGG
(SEQ ID NO: 4341)

enzyme E2L6

GTTTGCAGTTACAGGCCAGTTCTCC
(SEQ ID NO: 4342)

TTCTCCAGCTCTCCATCTTAGAGAG
(SEQ ID NO: 4343)

TGAATCCAGCAGCCAACTCGAATCC
(SEQ ID NO: 4344)

CCCCCTAGGGCTCAGGCACTGAGGG
(SEQ ID NO: 4345)

GGAGGGTACCCTATTTACAACTGAG
(SEQ ID NO: 4346)

GAGTCAGCCAAGCCACTGATGGGAA
(SEQ ID NO: 4347)

GTATATATCCTCCAGCATTCAGTCC
(SEQ ID NO: 4348)

CCAGGGGGAGCCACGGAAACCATGT
(SEQ ID NO: 4349)

GAAACCATGTTCTTGCTTAAGCCAT
(SEQ ID NO: 4350)

201762_s_—
PSME2
PA28B,
proteasome
5721
CAACACCTGATCCCCAAGATTGAAG
(SEQ ID NO: 4351)

at

PA28beta,
(prosome,

GGGGTAGCAATCCAGGAGAAGGTGC
(SEQ ID NO: 4352)

REGbeta
macropain)

GAGAGGGTGAATGCCGTCAAGACCA
(SEQ ID NO: 4353)

activator

GAAGCTTTCCAGACAACCATTTCCA
(SEQ ID NO: 4354)

subunit 2

GACAACCATTTCCAAGTACTTCTCA
(SEQ ID NO: 4355)

(PA28 beta)

GGCCTCCAAGGAGACTCATGTAATG
(SEQ ID NO: 4356)

AATGGATTACCGGGCCTTGGTGCAT
(SEQ ID NO: 4357)

GCCTTGGTGCATGAGCGAGATGAGG
(SEQ ID NO: 4358)

TATGGGGAGCTCAGGGCCATGGTGC
(SEQ ID NO: 4359)

GGGCCTTCTATGCTGAGCTTTATCA
(SEQ ID NO: 4360)

CTTTATCATATCATCAGCAGCAACC
(SEQ ID NO: 4361)

201782_s_—
AIP
ARA9,
aryl
9049
GTGCCACTTATCCACCAGGAGGGCA
(SEQ ID NO: 4362)

at

FKBP16,
hydrocarbon

AGGAGGCTGCTGCCAAGTACTACGA
(SEQ ID NO: 4363)

FKBP37,
receptor

CAAGTACTACGATGCCATTGCCTGC
(SEQ ID NO: 4364)

SMTPHN,
interacting

CATTGCCTGCCTCAAGAACCTGCAG
(SEQ ID NO: 4365)

XAP2
protein

CCTGGGTCCCCTGAATGGATCCAGC
(SEQ ID NO: 4366)

GAGGAGTACTACGAGGTGCTGGACC
(SEQ ID NO: 4367)

GTCAAGGCCTACTTCAAGCGGGGCA
(SEQ ID NO: 4368)

CGGCCGTGTGGAATGCCCAGGAGGC
(SEQ ID NO: 4369)

GCCTGTGGTGAGCCGAGAGCTGCGG
(SEQ ID NO: 4370)

CCTGGAGGCACGGATCCGGCAGAAG
(SEQ ID NO: 4371)

GGGATCTTCTCCCATTGACAGGAGC
(SEQ ID NO: 4372)

201890_at
RRM2
R2, RR2M
ribonucleotide
6241
GCTACTTTGAATTAATCTGCCTTTA
(SEQ ID NO: 4373)

reductase

TTGATCTTTTGGCCCCATTTGTTAA
(SEQ ID NO: 4374)

M2

TTGGCCCCATTTGTTAATTGTATTC
(SEQ ID NO: 4375)

polypeptide

GTATTCAGTATTTGAACGTCGTCCT
(SEQ ID NO: 4376)

GAACGTCGTCCTGTTTATTGTTAGT
(SEQ ID NO: 4377)

GTTAATCCAGATTATATGGTCCTTA
(SEQ ID NO: 4378)

TATGGTCCTTATATGTGTACAACAT
(SEQ ID NO: 4379)

GTCTTGCATTGTGAGGTACAGGCGG
(SEQ ID NO: 4380)

GTACAGGCGGAAGTTGGAATCAGGT
(SEQ ID NO: 4381)

TTAGGATTCTGTCTCTCATTAGCTG
(SEQ ID NO: 4382)

ATGTGAGGATTAACTTCTGCCAGCT
(SEQ ID NO: 4383)

201932_at
LRRC41
MGC126571,
leucine rich
10489
CTGGCTGGACCAGGATGCAGTCACA
(SEQ ID NO: 4384)

MGC126573,
repeat

GGCTACCTGCCATGTGGTTAGCGAC
(SEQ ID NO: 4385)

MUF1,
containing 41

TGGTTAGCGACTCATGGACTCATCC
(SEQ ID NO: 4386)

PP7759, RP4-

TCCCAGGCCTTCGCAGATTATGTTA
(SEQ ID NO: 4387)

636H5.2

CGGTACCATCAGCTTGCAGGGGCTG
(SEQ ID NO: 4388)

TGCAGGGGCTGAAGCATGGGCTGCC
(SEQ ID NO: 4389)

GAGGCCCAGCAAACAGGCATTCTCA
(SEQ ID NO: 4390)

GGCATTCTCACAGCTGGGTTTATAG
(SEQ ID NO: 4391)

CTCAGTATCCTGGGAACCCTGGGCC
(SEQ ID NO: 4392)

ATAATTGCTGAAGAGATCCCCTCCC
(SEQ ID NO: 4393)

TCAAACCCTTTCATACCTTTATTCT
(SEQ ID NO: 4394)

201947_s_—
CCT2
99D8.1, CCT-
chaperonin
10576
GAAGCTGTTGCAATGGAGTCTTATG
(SEQ ID NO: 4395)

at

beta, CCTB,
containing

ATGTTGCCAACCATCATAGCTGACA
(SEQ ID NO: 4396)

MGC142074,
TCP1,

GCTATGACAGTGCAGACCTGGTGGC
(SEQ ID NO: 4397)

MGC142076,
subunit 2

GCTCAGGGCTGCTCACAGTGAAGGC
(SEQ ID NO: 4398)

PRO1633,
(beta)

GAAGGCAATACCACTGCTGGATTGG
(SEQ ID NO: 4399)

TCP-1-beta

AGATATGGCTATCCTGGGTATAACA
(SEQ ID NO: 4400)

AGGTGATTCTGCGTGTGGACAACAT
(SEQ ID NO: 4401)

GGACAACATCATCAAAGCGGCACCC
(SEQ ID NO: 4402)

ACGTGCTGTCGATCTTTGGACCAGT
(SEQ ID NO: 4403)

GACCAGTTTCTAGCAAAGTTGTGTT
(SEQ ID NO: 4404)

ATTTAGCTGACCTTCGCTTTAACAT
(SEQ ID NO: 4405)

202168_at
TAF9
AD-004, AK6,
TAF9 RNA
6880
AAAAGGCATCAACTTCTGCGGGAAG
(SEQ ID NO: 4406)

CGI-137,
polymerase

GTCCCGCGGTTAAGTGTTGGTTCAG
(SEQ ID NO: 4407)

CINAP, CIP,
II, TATA box

TACTAGCAGACCAAGTACTCCCACA
(SEQ ID NO: 4408)

MGC1603,
binding

AAAGTAGGGACTCCCATGTCCCTCA
(SEQ ID NO: 4409)

MGC3647,
protein

AGTACAGATGCCTACTTCTCAGTCT
(SEQ ID NO: 4410)

MGC5067,
(TBP)-

CTACTTCTCAGTCTCCAGCTGTAAA
(SEQ ID NO: 4411)

MGD: 1603,
associated

GTAAAAGCTTCAATTCCTGCAACCT
(SEQ ID NO: 4412)

MGC: 3647,
factor, 32 kDa

AATCCATCATTAATCGGGTCCAAAA
(SEQ ID NO: 4413)

MGC:5067,

GTCCAAAAACATTCTTATTACCACT
(SEQ ID NO: 4414)

TAF2G,

GATAATCTGTAATCTAGCCTTGCTG
(SEQ ID NO: 4415)

TAFII31,

AACACAGTTACCATACTTTTCAATT
(SEQ ID NO: 4416)

TAFII32,

TAFIID32

202455_at
HDAC5
FLJ90614,
histone
10014
ACGAGTTCTCACCTGATGTGGTCCT
(SEQ ID NO: 4417)

HD5, NY-CO-9
deacetylase

GTCACCGCCAGATGTTTTGGCCACT
(SEQ ID NO: 4418)

5

TTTGGCCACTTGACCAGGCAGCTGA
(SEQ ID NO: 4419)

CTGATGACCCTGGCAGGGGGCCGGG
(SEQ ID NO: 4420)

GTCTCGGCTCTGCTCAGTGTAGAGC
(SEQ ID NO: 4421)

GCAGCCCTTGGATGAGGCAGTCTTG
(SEQ ID NO: 4422)

AAAGCCCAACATCAACGCAGTGGCC
(SEQ ID NO: 4423)

CGCAGTGGCCACGCTAGAGAAAGTC
(SEQ ID NO: 4424)

GTCATCGAGATCCAGAGCAAACACT
(SEQ ID NO: 4425)

AAGCAGGTGAGACCGAGGAGGCCGA
(SEQ ID NO: 4426)

CATGGAGCAGGAGCCTGCCCTGTGA
(SEQ ID NO: 4427)

202565_s_—
SVIL
RP11-
supervillin
6840
ATATGTATTCATTCACTTTCAAGAT
(SEQ ID NO: 4428)

at

534G20.1,

CTTCTGTTGAATTAGCTCTGCCACC
(SEQ ID NO: 4429)

DKFZp686A17191

AGCTCTGCCACCAATATGTATCTTC
(SEQ ID NO: 4430)

GTATCTTCATACACGTTTGGAAATG
(SEQ ID NO: 4431)

GGAAATGTTTCCTGCAGCATTAGGT
(SEQ ID NO: 4432)

GCATTAGGTATGACTTGTTCTGAGT
(SEQ ID NO: 4433)

TGAGTACTGCTTCCGGTGCTAAAAT
(SEQ ID NO: 4434)

TTAATGGCATGGACTCTGGAGAATC
(SEQ ID NO: 4435)

TATGCGAATCAACCTTTCTACCTTA
(SEQ ID NO: 4436)

TCTACCTTAATATCTCCCCAAAAAT
(SEQ ID NO: 4437)

GTTTGCTCTGCATTTTTGATGATGG
(SEQ ID NO: 4438)

202705_at
CCNB2
HsT17299
cyclin B2
9133
GCCACTACACTTCTTAAGGCGAGCA
(SEQ ID NO: 4439)

GCGAGCATCAAAAGCCGGGGAGGTT
(SEQ ID NO: 4440)

ATGGAGCTGACTCTCATCGACTATG
(SEQ ID NO: 4441)

ATATGGTGCATTATCATCCTTCTAA
(SEQ ID NO: 4442)

ATCCTTCTAAGGTAGCAGCAGCTGC
(SEQ ID NO: 4443)

ACTTAACTAAATTCATCGCCATCAA
(SEQ ID NO: 4444)

CAAAAGCCGTCAAAGACCTTGCCTC
(SEQ ID NO: 4445)

CTTGCCTCCCCACTGATAGGAAGGT
(SEQ ID NO: 4446)

GATAGGAAGGTCCTAGGCTGCCGTG
(SEQ ID NO: 4447)

GATTTTGTACATAGTCCTCTGGTCT
(SEQ ID NO: 4448)

AGTCCTCTGGTCTATCTCATGAAAC
(SEQ ID NO: 4449)

202806_at
DBN1
D0S1173,
drebrin 1
1627
ATAGGAGACTTGTACAGTTGACTGG
(SEQ ID NO: 4450)

DKFZp434D064

GGCTTTCCTCTCGTTGGTAGTTGAG
(SEQ ID NO: 4451)

TGAGACGCTGTTGCAAATTCCACCC
(SEQ ID NO: 4452)

TCCTTCCCTGGTCCAGATTGTAGCT
(SEQ ID NO: 4453)

TCCAGATTGTAGCTCTTAGTCCTCC
(SEQ ID NO: 4454)

TCAGCTGGCCGGGTTGGAGGCCTCA
(SEQ ID NO: 4455)

GCTCTGGTGGGAAAATGTCCCCCAC
(SEQ ID NO: 4456)

GTTTCTTGGGAAAATATCACTTTGT
(SEQ ID NO: 4457)

ATATCACTTTGTATTCTCTGTCCAG
(SEQ ID NO: 4458)

TTTGTATTCTCTGTCCAGGGCTTCA
(SEQ ID NO: 4459)

CCAGGGCTTCAGATATTTTGCACGA
(SEQ ID NO: 4460)

202875_s_—
PBX2
DAAP-
pre-B-cell
5089
CTCCCTAACGAGACTCTCTGTGCTG
(SEQ ID NO: 4461)

at

218M18.5,
leukemia

GTGCTGGGGGTGCTAATTACATGGC
(SEQ ID NO: 4462)

G17, HOX12,
homeobox 2

GAATGGGGCCTCTAAGGGGAGTGTG
(SEQ ID NO: 4463)

PBX2MHC

GAGAAACCTATTTCTCAGACCCCTT
(SEQ ID NO: 4464)

ACCCCACTTGTATGCTCTGGAATCT
(SEQ ID NO: 4465)

ATGGGGACATGACTTCTGGACAGAG
(SEQ ID NO: 4466)

TACCTCATACGCAGCTCATCTTAAA
(SEQ ID NO: 4467)

CTCGGTGGACGAGAGTGTCTGACTC
(SEQ ID NO: 4468)

GTCTGACTCAGATATCTACCTCGGA
(SEQ ID NO: 4469)

ACCTCGGAGGGAGTTTCTGCTACTT
(SEQ ID NO: 4470)

AGGGAATTATTGACTGGGCTTTGGG
(SEQ ID NO: 4471)

203210_s_—
RFC5
MGC1155,
replication
5985
ATGCGTAGGGCTCTGAACATTTTGC
(SEQ ID NO: 4472)

at

RFC36
factor C

CAGAGGAGACTGTCTACACCTGCAC
(SEQ ID NO: 4473)

(actibator 1)

CACCCGCTCAAGTCAGACATTGCCA
(SEQ ID NO: 4474)

5, 36.5 kDa

ATAGAGTTGACTTTCCATCTTCAGT
(SEQ ID NO: 4475)

GAGTACAGGCTTTCTGTTGGCACCA
(SEQ ID NO: 4476)

ACGAGAAGATCCAGCTGAGCTCCCT
(SEQ ID NO: 4477)

GCTGCATTTCAAGTCACCAGAGACC
(SEQ ID NO: 4478)

GAGACCTGATTGTTGCAGAGGCCTA
(SEQ ID NO: 4479)

GCCTAGATGCTCTGAGGGCCATTCA
(SEQ ID NO: 4480)

GGGCCATTCACAATTCTCAGGGCTC
(SEQ ID NO: 4481)

ATCAGTCACCCCGAATCTTGGAAAA
(SEQ ID NO: 4482)

203327_at
IDE
RP11-
insulin-
3416
TCATCACTTCCTTCTGGTTTTATGT
(SEQ ID NO: 4483)

366I13.1,
degrading

TTCCGATCCACCACTGTACTAGTAA
(SEQ ID NO: 4484)

FLJ35968,
enzyme

GTCTTCCATGAACCTGCAATTGTTT
(SEQ ID NO: 4485)

INSULYSIN

TATGCGTCAGCATTTTCCAATTTCC
(SEQ ID NO: 4486)

AGGTTGGATCTAGAGCTGCTGTTGA
(SEQ ID NO: 4487)

GCTGCTGTTGATCACTCAGGCATAC
(SEQ ID NO: 4488)

GTCCAAGCTGCAGTCCATGAGCAAT
(SEQ ID NO: 4489)

CATGAGCAATAACAGACTACCCCAG
(SEQ ID NO: 4490)

GACTACCCCAGATACTGCAGTTTAC
(SEQ ID NO: 4491)

GAAAGTCTTCTTTTTTGACCAGTTG
(SEQ ID NO: 4492)

GAGGGAGCATGTGACACAGCCAGTA
(SEQ ID NO: 4493)

203362_s_—
MAD2L1
HSMAD2,
MAD2 mitotic
4085
AAATGATACTTACTGAACTGTGTGT
(SEQ ID NO: 4494)

at

MAD2
arrest

GTACCTATTTGACTTACCATGGAGT
(SEQ ID NO: 4495)

deficient-

GGAGGTTTTTTTGTCAACATTGTGA
(SEQ ID NO: 4496)

like

AAGCTAGATGCTTTCCTAAATCAGA
(SEQ ID NO: 4497)

1 (yeast)

CAGAATCTTTGTTAAGGTCCTGAAA
(SEQ ID NO: 4498)

AGGTCCTGAAAGTAACTCATAATCT
(SEQ ID NO: 4499)

ATTGCTGTATAGCTCCTTTTGACCT
(SEQ ID NO: 4500)

CTCCTTTTGACCTTCATTTCATGTA
(SEQ ID NO: 4501)

ATTTCATGTATAGTTTTCCCTATTG
(SEQ ID NO: 4502)

GTTTTCCCTATTGAATCAGTTTCCA
(SEQ ID NO: 4503)

ATTTGTACTGTTTAATGTTCTGTGA
(SEQ ID NO: 4504)

203396_at
PSMA4
HC9,
proteasome
5685
GGCTTTCAGCTCTATCAGAGTGACC
(SEQ ID NO: 4505)

HsT17706,
(prosome,

AGAGTGACCCTAGTGGAAATTACGG
(SEQ ID NO: 4506)

MGC111191,
macropain)

GGGGGATGGAAGGCCACATGCATTG
(SEQ ID NO: 4507)

MGC12467,
subunit,

GAAATAATAGCGCTGCAGCTGTGTC
(SEQ ID NO: 4508)

MGC24813,
alpha type, 4

GCGCTGCAGCTGTGTCAATGTTGAA
(SEQ ID NO: 4509)

PSC9

GAAATGACCTTGAAGTCAGCACTTG
(SEQ ID NO: 4510)

CATGGATGTTAGTAAACTCTCTGCT
(SEQ ID NO: 4511)

AAGACAGTAATCAGAGTTCTCAAAC
(SEQ ID NO: 4512)

TACTGAATTGGGTCCTTGTCATTTC
(SEQ ID NO: 4513)

GTCCTTGTCATTTCTGTCCAATTGA
(SEQ ID NO: 4514)

TACCCTTCATGGACGTCTTAATCTT
(SEQ ID NO: 4515)

203478_at
NDUFC1
KFYI,
NADH
4717
GGGGCCCAAGGAATTCGCAAGATGG
(SEQ ID NO: 4516)

MGC117464,
dehydrogenase

AGGAATTCGCAAGATGGCGCCGTCC
(SEQ ID NO: 4517)

MGC126847,
(ubiquinone)

GCCCTTCAGTGCGATCAAAGTTCTA
(SEQ ID NO: 4518)

MGC138266
1,

GTGCGATCAAAGTTCTACGTGCGAG
(SEQ ID NO: 4519)

subcomplex

TTCTACGTGCGAGAGCCGCCGAATG
(SEQ ID NO: 4520)

unknow, 1,

CCGCCGAATGCCAAACCTGACTGGC
(SEQ ID NO: 4521)

6 kDa

ACCTGACTGGCTGAAAGTTGGGTTC
(SEQ ID NO: 4522)

TGAAAGTTGGGTTCACCTTGGGCAC
(SEQ ID NO: 4523)

GTCTTCTTGTGGATCTATCTCATCA
(SEQ ID NO: 4524)

GGATCTATCTCATCAAACAACACAA
(SEQ ID NO: 4525)

CAAGCCAGCATTTGTATTTTGCATC
(SEQ ID NO: 4526)

203682_s_—
IVD
ACAD2
isovaleryl
3712
GAAGTAGAGATGTGGCGGCTTTCCC
(SEQ ID NO: 4527)

at

Coenzyme A

GAGGTTGAGTTCTCCACAACAGCTC
(SEQ ID NO: 4528)

dehydrogenase

AACAGCTCCCAAGCATCATGGGCCT
(SEQ ID NO: 4529)

CTGTGCCACGGCTAGTGTTGTGTGA
(SEQ ID NO: 4530)

CACCTCCCAGGGTAGGCACCTGGGG
(SEQ ID NO: 4531)

CCACCTCCCAGGGTAGGCACCTGGG
(SEQ ID NO: 4532)

ACCTCTTTCTCTTGGGTGAGGCTCT
(SEQ ID NO: 4533)

GAGGCTCTGGCAAGGAGATCTCTCT
(SEQ ID NO: 4534)

AGATCTCTCTGCTCAAGCACAGCAG
(SEQ ID NO: 4535)

GGCCCCTCTCCATGAATTGGAACTT
(SEQ ID NO: 4536)

TCAACTTTCAGTCTCTTTTCTGGGG
(SEQ ID NO: 4537)

204228_at
PPIH
KFYI,
peptidylprolyl
10465
ATGGAGATGGTACTGGAGTCGCCAG
(SEQ ID NO: 4538)

MGC117464,
isomerase H

TCGCCAGTATTTACCGGGGGCCATT
(SEQ ID NO: 4539)

MGC126847,
(cyclophilin

TTTAAACTTAGACACTCAGCTCCAG
(SEQ ID NO: 4540)

MGC138266
H)

GCTTTCCATGGCGAACAGTGGTCCA
(SEQ ID NO: 4541)

ATCACCTGCTCTAAGTGCGATTGGC
(SEQ ID NO: 4542)

AAAATCATCGATGGACTTCTAGTGA
(SEQ ID NO: 4543)

TTCCCACAGGCCCCAACAATAAGCC
(SEQ ID NO: 4544)

CTACCTGTGGTGATCTCGCAGTGTG
(SEQ ID NO: 4545)

AAAGACTGAATCAGGCCTTCCCTTC
(SEQ ID NO: 4546)

AGTAAGATAATCTGGACTGGCCCCC
(SEQ ID NO: 4547)

CTGCTGCCCCATTTGATCAAGAGAC
(SEQ ID NO: 4548)

204321_at
NEO1
DKFZp547A066,
neogenine
4756
GAAGCCTGTGTCGAGGCAGCTTCCC
(SEQ ID NO: 4549)

DKFZp547B146,
homolog 1

TCCCTTTGCCTGCTGATATTCTGCA
(SEQ ID NO: 4550)

HsT17534,
(chicken)

GCAACCTGCATTTCACTTTGTGGTC
(SEQ ID NO: 4551)

NGN

TTTCACTTTGTGGTCAGGCCGTGTC
(SEQ ID NO: 4552)

CGTGTCTTTGTGCTGTGACTGCATC
(SEQ ID NO: 4553)

GTGACTGCATCACCTTTATGGAGTG
(SEQ ID NO: 4554)

GTCCTTGGTGTTCTCCACAAGTGGT
(SEQ ID NO: 4555)

GGTTGACATTTGACTGCTTGTTCCA
(SEQ ID NO: 4556)

TTTGACAGTGTGGGTCGTTCCTGGG
(SEQ ID NO: 4557)

TTCTGAGTCATTGCATCCTCTACCA
(SEQ ID NO: 4558)

TCTACCAGCTGTTAATCCATCACTC
(SEQ ID NO: 4559)

204533_at
CXCL10
C7, IFI10,
chemokine
3627
TAACTCTACCCTGGCACTATAATGT
(SEQ ID NO: 4560)

INP10, IP-10,
(C-X-C motif)

GCTCTACTGAGGTGCTATGTTCTTA
(SEQ ID NO: 4561)

SCYB10, crg-
ligand 10

TCTTAGTGGATGTTCTGACCCTGCT
(SEQ ID NO: 4562)

2, gIP-10,

TCTGACCCTGCTTCAAATATTTCCC
(SEQ ID NO: 4563)

mob-1

GGTACTAAGGAATCTTTCTGCTTTG
(SEQ ID NO: 4564)

GCTTTGGGGTTTATCAGAATTCTCA
(SEQ ID NO: 4565)

AATGCTCTTTACTTCATGGACTTCC
(SEQ ID NO: 4566)

TTACTTCATGGACTTCCACTGCCAT
(SEQ ID NO: 4567)

ATTCTTTCAGTGGCTACCTACATAC
(SEQ ID NO: 4568)

GCTACCTACATACAATTCCAAACAC
(SEQ ID NO: 4569)

AATGAGGTACTCTCCTGGAAATATT
(SEQ ID NO: 4570)

205565_s_—
FXN
CyaY, FA,
frataxin
2395
AACTGTCAAACTGGGTGGAGATCTA
(SEQ ID NO: 4571)

at

FARR, FRDA,

AGGAACCTATGTGATCAACAAGCAG
(SEQ ID NO: 4572)

MGC57199,

CAAGCAGACGCCAAACAAGCAAATC
(SEQ ID NO: 4573)

X25

TTCTCCATCCAGTGGACCTAAGCGT
(SEQ ID NO: 4574)

ATCCAGTGGACCTAAGCGTTATGAC
(SEQ ID NO: 4575)

TTGGCCTATTCCGGAAAAGATGCTT
(SEQ ID NO: 4576)

CGGAAAAGATGCTTGATGCCCAGCC
(SEQ ID NO: 4577)

TAAGGACATTAAAAGCTATCAGGCC
(SEQ ID NO: 4578)

TTGGGCTATGTGTCACAGCTCTGTA
(SEQ ID NO: 4579)

TTTTGGATTGTCGGATTTCCTCCCT
(SEQ ID NO: 4580)

TAATGTCTTATGCCTATACCTGAAT
(SEQ ID NO: 4581)

205890_s_—
GABBR1///
DAAP-
gamma-
10537
GATCTTAAAGCCACGGAGAAGCCTC
(SEQ ID NO: 4582)

at
UBD
188P13.3,
aminobutyric
2550
TGCCCTTGTTTCTTGTGGAGTCAGG
(SEQ ID NO: 4583)

FLJ92613,
acid (GABA)

ATGAGGCAAAGAGGCACCTCCTCCA
(SEQ ID NO: 4584)

GABAB(1e),
B receptor,

GAAGGTCCAGCTCAGTGGCACAAGT
(SEQ ID NO: 4585)

GABABR1,
1///

GACGGGTATAATCCCTGAGACCCAG
(SEQ ID NO: 4586)

GABBR1-3,
ubiquitin D

GACCCAGATTGTGACTTGCAATGGA
(SEQ ID NO: 4587)

GPRC3A,

AGAAAGGGCAACTTACTCTTCCTGG
(SEQ ID NO: 4588)

dJ271M21.1.1,

ACTCTTCCTGGCATCTTATTGTATT
(SEQ ID NO: 4589)

dJ271M21.1.2,

AATCTCTTACTCAACGAACACATCT
(SEQ ID NO: 4590)

hGF1a///

CATCTTCTGATGATTTCCCAAAATT
(SEQ ID NO: 4591)

DAMC-

ATTGCCCAACTCTATGTTTCTTTGA
(SEQ ID NO: 4592)

346D16.1,

FAT10,

GABBR1,

UBD-3

205980_s_—
ARHGAP8///
BPGAP1,
Rho GTPase
23779
GCCTGTGTCTTCGGGCTGAATTTGA
(SEQ ID NO: 4593)

at
LOC553158
FLJ20185,
activating
553158
GTGTCTTCGGGCTGAATTTGATCTG
(SEQ ID NO: 4594)

///PRR5///
PP610///
protein 8///
55615
TGAATTTGATCTGGCCATCCCAGGG
(SEQ ID NO: 4595)

ARHGAP8
LOC553158;
proline rich

AGTCCCCTGATGGCAGCCAGAAGAC
(SEQ ID NO: 4596)

ARHGAP8///
5 (renal)///

TGATGGCAGCCAGAAGACGTCTCTA
(SEQ ID NO: 4597)

PRR5-

GGCAGCCAGAAGACGTCTCTAGTGT
(SEQ ID NO: 4598)

ARHGAP8

GCCAGAAGACGTCTCTAGTGTTGCG
(SEQ ID NO: 4599)

fusion

GAAGACGTCTCTAGTGTTGCGAACA
(SEQ ID NO: 4600)

GTCTCTAGTGTTGCGAACACTCTGT
(SEQ ID NO: 4601

TGTGCACTTGTATGTTTTGTAAACT
(SEQ ID NO: 4602)

TTGTAAACTTGGCATCTGTAAAAAT
(SEQ ID NO: 4603)

206289_at
HOXA4
HOXA-4
homeobox
3201
CCATCTGGACCATAATAGGGACACC
(SEQ ID NO: 4604)

A4

CGGTTAAGAGTCTGTGCTGGTTGCC
(SEQ ID NO: 4605)

GAGAACAGTTGTCCAGGATGCTGGC
(SEQ ID NO: 4606)

ACAACCTGCTGGCCCGAAACAAGGC
(SEQ ID NO: 4607)

AACAAGGCTGCCAGGTGTGGAACAG
(SEQ ID NO: 4608)

AACAGCCCATGCTGACTGGGGACAT
(SEQ ID NO: 4609)

GACTGGGGACATACACTTGCATCTT
(SEQ ID NO: 4610)

CCCCATTAAGGCAGCTCATCCAAGC
(SEQ ID NO: 4611)

GACATGTTAGTTTTTCTTACTTGCA
(SEQ ID NO: 4612)

CAGAGATACTGTTGTCACCTTCTGG
(SEQ ID NO: 4613)

GGGGAGTGCATTTAGACTTATGTGG
(SEQ ID NO: 4614)

206441_s_—
COMMD4
FLJ20452
COMM
54939
GGAGCTGCTGGGACAGGGGATTGAT
(SEQ ID NO: 4615)

at

domain

AGCTCACGGCTGACGCCAAGTTTGA
(SEQ ID NO: 4616)

containing 4

TCCAGTGCGGCCAAGCACAGTGTCG
(SEQ ID NO: 4617)

AGTGTCGATGGCGAATCCTTGTCCA
(SEQ ID NO: 4618)

TCCTTGTCCAGTGAACTGCAGCAGC
(SEQ ID NO: 4619)

AGCTGGGGCTGCCCAAAGAGCACGC
(SEQ ID NO: 4620)

CCAGCCTGTGCCGCTGTTATGAGGA
(SEQ ID NO: 4621)

CAAAGCCCCTTGCAGAAGCACTTGC
(SEQ ID NO: 4622)

TGAACTGCTCTTCGGGAGGCAGCCC
(SEQ ID NO: 4623)

GCCCTGGTTCTAGGATGCTGAGGCC
(SEQ ID NO: 4624)

GCCTCACTTCTCTCTTGAGAACTTG
(SEQ ID NO: 4625)

206752_s_—
DFFB
RP13-
DNA
1677
TGAACAGCTATCACGTTGAACCACG
(SEQ ID NO: 4626)

at

531C17.1,
fragmentation

GAAACTGCTGTTTTCTAGGCCAAAA
(SEQ ID NO: 4627)

CAD, CPAN,
factor,

TGTGTCACAGTTTCAGGCTTTTATG
(SEQ ID NO: 4628)

DFF-40, DFF2
40 kDa, beta

TGGAAGCTGTTCAGGGCATCGGCAG
(SEQ ID NO: 4629)

DFF40
polypeptide

GGTCAGCGTTACTATCATCTCGGAT
(SEQ ID NO: 4630)

(caspase-

GGATCATATGGAGCTCATGTCAGCC
(SEQ ID NO: 4631)

activated

TCATGTCAGCCGTGTGGGTGGCGGG
(SEQ ID NO: 4632)

DNase)

GCGGGTGCACAGAGACGGTCTGGAA
(SEQ ID NO: 4633)

GGAAGGAAACACGCGGATCTGAACA
(SEQ ID NO: 4634)

GGTTGGGCTAGATTACAGAGGGCTC
(SEQ ID NO: 4635)

TACAGAGGGCTCATTTTCTACGTCA
(SEQ ID NO: 4636)

206966_s_—
KLF12
AP-2rep,
Kruppel-like
11278
CCGCCTTCAAGTCCCATGAATTTAC
(SEQ ID NO: 4637)

at

AP2REP,
factor 12

CAAACTGAGTCATGTTCACCGCATC
(SEQ ID NO: 4638)

HSPC122

CATCCCCGTGGTGGTACAGTCGGTG
(SEQ ID NO: 4639)

TGGTACAGTCGGTGCCTGTTGTCTA
(SEQ ID NO: 4640)

GTCTACACAGCTGTAAGGTCACCTG
(SEQ ID NO: 4641)

GAACAACACTATTGTCGTGCCGCTT
(SEQ ID NO: 4642)

GTCGTGCCGCTTTTGGAGGATGGGA
(SEQ ID NO: 4643)

TGGCAAAGCACAAATGGACCCCCGA
(SEQ ID NO: 4644)

AGGCCTATCTCCCAGACAAAGTAAA
(SEQ ID NO: 4645)

AAATGTGACCTTAGATAGCGTTAAT
(SEQ ID NO: 4646)

CCCTTTCCATAGCCAGAGCAGTACA
(SEQ ID NO: 4647)

207153_s_—
GLMN
FAP, FAP48,
glomulin,
11146
GAGTTTAGCTATGCTTCAGCTGTAT
(SEQ ID NO: 4648)

at

FAP68,
FKBP

TACAGGACCACAGTTGATTTCCCTT
(SEQ ID NO: 4649)

FKBPAP,
associated

GATTTCCCTTCTTGATTTGGTACTT
(SEQ ID NO: 4650)

GLML, GVM,
protein

CTCCCAGAGGGTGCAGAAACAGATT
(SEQ ID NO: 4651)

VMGLOM

AAAGCCACTTCATATAGGACTTAAT
(SEQ ID NO: 4652)

TAGCCAAGAGGCCCAGAAATCTAAA
(SEQ ID NO: 4653)

GAAGAGATCCCTAATATGCCTCCTG
(SEQ ID NO: 4654)

AATATGCCTCCTGAAATGCAGCTTA
(SEQ ID NO: 4655)

TTAAGGTCCTGCATTCAGCTCTTTT
(SEQ ID NO: 4656)

TTGAAAGTGTTCTAGCTCGAGTGGA
(SEQ ID NO: 4657)

ATAAAAACAAAGTCTACCTCTGAAG
(SEQ ID NO: 4658)

207181_s_—
CASP7
CMH-1, ICE-
caspase 7,
840
GGGAGTTAGGACCACCAATGGATTG
(SEQ ID NO: 4659)

at

LAP3, MCH3
apoptosis-

GAGATGGAGTGAGCTGAGACAGATA
(SEQ ID NO: 4660)

related

CTTACTGCCCAGGCCTATCTGGAAG
(SEQ ID NO: 4661)

cysteine

GAAATGGATGTAAGCCTGGCCCATA
(SEQ ID NO: 4662)

peptidase

AAGCCTGGCCCATAATGTGAACATA
(SEQ ID NO: 4663)

AAGTAATCACTAATGCTCAACAATT
(SEQ ID NO: 4664)

GCTCAACAATTTATCCATTCAATCA
(SEQ ID NO: 4665)

TTCATTGGGTTGTCAGATAGTCTAT
(SEQ ID NO: 4666)

TTTAGATTATTCCAAGCCTTATTTT
(SEQ ID NO: 4667)

GATTTTTGGCACTTTGTTTTCAAGA
(SEQ ID NO: 4668)

TTTTCTGCCTAATAGTAACTGGTTA
(SEQ ID NO: 4669)

207469_s_—
PIR
0
pirin (iron-
8544
ACTCGCACACCAACCTTATATTTGG
(SEQ ID NO: 4670)

at

binding

GGACTTCAAATTGGACCCAGGAGCC
(SEQ ID NO: 4671)

nuclear

GGACAAGCTTCATTTACACGATATC
(SEQ ID NO: 4672)

protein)

GGAGATGTGTATATTGGGCCCGATG
(SEQ ID NO: 4673)

ATTGGGCCCGATGATGCACAACAAA
(SEQ ID NO: 4674)

CTCATCACACAGCAGTGCTTGGAGA
(SEQ ID NO: 4675)

GAAGCCACTTTGTCTTAATTGCTGG
(SEQ ID NO: 4676)

GAGAACCAGTTATCCAACATGGTCC
(SEQ ID NO: 4677)

CGGAAGAGCAGGTCTTGATGTGTCC
(SEQ ID NO: 4678)

GAAGGCATTCCATTTCTAAAGCTTA
(SEQ ID NO: 4679)

GCTTCTAAAGAATTCCACACTAACG
(SEQ ID NO: 4680)

207507_s_—
ATP5G3
MGC125738,
ATP
518
CGCGCAGTCCCGAAGAGTGTAAGAT
(SEQ ID NO: 4681)

at

P3
synthase, H+

CCTCTCTGATCCGAGCTGGATCCAG
(SEQ ID NO: 4682)

transporting,

GCATACAGACCAATTTCTGCATCAG
(SEQ ID NO: 4683)

mitochondrial

TGCATCAGTGTTATCTCGACCAGAG
(SEQ ID NO: 4684)

F0 complex,

ATCTCGACCAGAGGCTAGTAGGACT
(SEQ ID NO: 4685)

subunit C3

TGGGGCCCAGAATGGTGTGTCTCAG
(SEQ ID NO: 4686)

(subunit 9)

GTGTCTCAGCTAATCCAAAGGGAGT
(SEQ ID NO: 4687)

TTGTTTGATGGTTGCTTTCTTGATT
(SEQ ID NO: 4688)

ACTGCTTGACATGTTGGCATTCATA
(SEQ ID NO: 4689)

TGTGTATCTTACTGTGACTCCGAAA
(SEQ ID NO: 4690)

AAAACTGTAGTATTGGTGTCATGGG
(SEQ ID NO: 4691)

208636_at
ACTN1
FLJ40884
actinin, alpha
87
AACTATTTGCACCGAAATGTCTTGT
(SEQ ID NO: 4692)

1

GTCTTGTTTTGTTGCGACATAGGAA
(SEQ ID NO: 4693)

CAAGCACAAAGTTATATTCCATCCT
(SEQ ID NO: 4694)

ATATTCCATCCTTTTTACTGATTTT
(SEQ ID NO: 4695)

CAATCTCATGTCCATTTTGGTGTGG
(SEQ ID NO: 4696)

CATTTTGGTGTGGGAGTCGGGGTAG
(SEQ ID NO: 4697)

ATGTGTGTTTGCTAGCTCACTTGTC
(SEQ ID NO: 4698)

TCTCATTTTTAAATCCCCTCAGAGG
(SEQ ID NO: 4699)

AAATCCCCTCAGAGGTGTGACTAGT
(SEQ ID NO: 4700)

GACTAGTCTCTTTATCAGCACACAC
(SEQ ID NO: 4701)

GGACAACTTTGATATTGCTTGGCAC
(SEQ ID NO: 4702)

208675_s_—
DDOST
AGE-R1,
dolichyl-
1650
CATCGTGATCCAGCAGCTCTCAAAT
(SEQ ID NO: 4703)

at

KIAA0115,
diphospho-

CTCAAATGGCAAATGGGTCCCCTTT
(SEQ ID NO: 4704)

MGC2191,
oligo-

GGTCCCCTTTGATGGCGATGACATT
(SEQ ID NO: 4705)

OK/SW-cl.45,
saccharide-

GGAGTTTGTCCGCATTGATCCTTTT
(SEQ ID NO: 4706)

OST, OST48,
protein

GATCCTTTTGTGAGGACCTTCCTGA
(SEQ ID NO: 4707)

WBP1
glycosyl-

ACAGTGTTCAGTTCAAGTTGCCCGA
(SEQ ID NO: 4708)

transferase

GTTGCCCGACGTGTATGGTGTATTC
(SEQ ID NO: 4709)

GATTACAACCGGCTAGGCTACACAC
(SEQ ID NO: 4710)

CCTGTACTCTTCCACTCAGGTATCC
(SEQ ID NO: 4711)

CACACGCAGTATGAGCGCTTCATCC
(SEQ ID NO: 4712)

ATGGCACAACTTTACCTCTGTGGGA
(SEQ ID NO: 4713)

208829_at
TAPBP
DAMC-
TAP binding
6892
TTCTTCAGCCCTAGATGGTGCTCGC
(SEQ ID NO: 4714)

227D19.13,
protein

CCTCTCAATGCTCATCACACACAGG
(SEQ ID NO: 4715)

NGS17, TAPA,
(tapasin)

TCACACACAGGGCTATTCCTTTCCT
(SEQ ID NO: 4716)

TPN, TPSN,

TCCTTTCCTCCAATGAACCAAACCG
(SEQ ID NO: 4717)

tapasin

AGACGAGGTCGGCCTCGTCATTCCC
(SEQ ID NO: 4718)

CTCTTGTGCGGTTCACCACAGTTGT
(SEQ ID NO: 4719)

TAAGTGATCGTGTGAGTCGTCGTTA
(SEQ ID NO: 4720)

GAGTCGTCGTTAAATGCCTGTCTCC
(SEQ ID NO: 4721)

GCATAGGGACCTAAGGCCCACTGGA
(SEQ ID NO: 4722)

TGGAGGGCGCTCATCAAGTAGCTGC
(SEQ ID NO: 4723)

GATCTCCGAGTCAGGACGGTCGGCC
(SEQ ID NO: 4724)

209110_s_—
RGL2
DADB-
ral guanine
5863
GCCTCAGGAACTCCTCCGAGTGAGG
(SEQ ID NO: 4725)

at

159G18.6,
nucleotide

CTCCTTTCCCAGGATCAAGGCCACA
(SEQ ID NO: 4726)

HKE1.5,
dissociation

GAAGATTGCACGGGCACTGTTCTGA
(SEQ ID NO: 4727)

KE1.5, RAB2L
stimulator-

ACTGTTCTGAGGAGGAAGCCCCGTT
(SEQ ID NO: 4728)

like 2

AGCCCCGTTGGCTTACAGAAGTCAT
(SEQ ID NO: 4729)

GTTGGATACCTGTGTATAGCTTCCC
(SEQ ID NO: 4730)

GATTCTTGGCCATATCCTAACATGC
(SEQ ID NO: 4731)

CAAAGGCTTCAAGGCTCTGAGCCCC
(SEQ ID NO: 4732)

AATGTAGGTCCTCGCAGGAGCTCTT
(SEQ ID NO: 4733)

TTCTTCCCACTCTGGGGGTTTCTAT
(SEQ ID NO: 4734)

TGGGGGTTTCTATCACTGTGACAAC
(SEQ ID NO: 4735)

209164_s_—
CYB561
FRRS2
cytochrome
1534
TTAAATGAAAAACCGCTGCTGCTGG
(SEQ ID NO: 4736)

at

b-561

CTGTTCTGGAGGACGAGCCTTCTCC
(SEQ ID NO: 4737)

TTCTGGAGGACGAGCCTTCTCCTTA
(SEQ ID NO: 4738)

CTGCCCATCTTTCCAGGAAGTCAGG
(SEQ ID NO: 4739)

CTCCAGCCCCATAAAGAGTGTCATG
(SEQ ID NO: 4740)

AGAGTGTCATGTTAGCTGAGTCACC
(SEQ ID NO: 4741)

GTGTCATGTTAGCTGAGTCACCATT
(SEQ ID NO: 4742)

TAGCTGAGTCACCATTTGGCTTCGG
(SEQ ID NO: 4743)

TCACCATTTGGCTTCGGCCTGGAAA
(SEQ ID NO: 4744)

CATTTGGCTTCGGCCTGGAAATAGT
(SEQ ID NO: 4745)

GAACACTGATCGTGTGCGAGGCCAG
(SEQ ID NO: 4746)

209228_x_—
TUSC3
D8S1992,
tumor
7991
ACCCAACTACTCTGGTACCATTGCT
(SEQ ID NO: 4747)

at

M33,
suppressor

AGACTGGTTGGGCCATGGTGTCTCT
(SEQ ID NO: 4748)

MGC13453,
candidate 3

GGTGTCTCTGTGTATAGTCTTTGCT
(SEQ ID NO: 4749)

MRT7, N33,

CTTTGCTATGACTTCTGGCCAGATG
(SEQ ID NO: 4750)

OST3A

ATGTGGAACCATATCCGTGGACCTC
(SEQ ID NO: 4751)

GGAGCAGCCAGGCTCAGTTTGTGGC
(SEQ ID NO: 4752)

TCTGGTACTGAATGCCGCTATCACC
(SEQ ID NO: 4753)

CCTAGTGGGATTGGGCCTGGTGGTC
(SEQ ID NO: 4754)

CTTCTTCTTCAGTTTTCTACTTTCA
(SEQ ID NO: 4755)

CCAAGTACCACGGCTATCCTTATAG
(SEQ ID NO: 4756)

AACTCTATAACCTCAGCCTTTTAAT
(SEQ ID NO: 4757)

209285_s_—
C3orf63
DKFZp686C2456,
chromosome
23272
GAGGGTATTGGTACATGACGACATG
(SEQ ID NO: 4758)

at

KIAA1105,
3 open

TTTAAACACAGCTTACTCTTCCTCA
(SEQ ID NO: 4759)

RAP140, se89-1
reading

ATCAAAACTAACTACAGCCATTCTT
(SEQ ID NO: 4760)

frame 63

CATTCTTTTTAAAGCCCAAGGGATG
(SEQ ID NO: 4761)

GGTGTAAGGATGTTACCTGTTTGTT
(SEQ ID NO: 4762)

GTAGTATGGTGAGTAAGGTTATGCG
(SEQ ID NO: 4763)

TTCTAACAAACACTGCCAACACGTC
(SEQ ID NO: 4764)

AACACTGCCAACACGTCAATTTTTT
(SEQ ID NO: 4765)

AAGCGTGGGCCACATTGCTAAGAAT
(SEQ ID NO: 4766)

GCCTTATTGATGTTTTGCCGTTCCA
(SEQ ID NO: 4767)

GTTTTGCCGTTCCAATGTATGCATT
(SEQ ID NO: 4768)

209409_at
GRB10
GRB-IR, Grb-
growth factor
2887
TGTATCTCTGCCTGTGATTTTCTTT
(SEQ ID NO: 4769)

10, IRBP,
receptor-

GAAACTCCATGTAGCAACCAGGACG
(SEQ ID NO: 4770)

KIAA0207,
bound

TGTGCCTCAGCCTAGATGTTTTGTC
(SEQ ID NO: 4771)

MEG1, RSS
protein 10

TTCTCTTTTCTGCACTTAATACCTG
(SEQ ID NO: 4772)

TGACAGTATGACCGATCTCTGCGCC
(SEQ ID NO: 4773)

CGCCTTTCTGGGGGCGGGCAAGCTG
(SEQ ID NO: 4774)

GCTGGCGGTAGATTTGTGATGTCAC
(SEQ ID NO: 4775)

AACCTTTATTCCATGTGCTTTGCTT
(SEQ ID NO: 4776)

CTTCATTCTGTACATAGCTCTTTGG
(SEQ ID NO: 4777)

AGCTCTTTGGCTCGTGAACCTAATT
(SEQ ID NO: 4778)

AGGGACTGATGTTCTGTTTCTTGTA
(SEQ ID NO: 4779)

209506_s_—
NR2F1
COUP-TFI,
nuclear
7025
CATCGTGCTGTTCACGTCAGACGCC
(SEQ ID NO: 4780)

at

EAR-3, EAR3,
receptor

GCAGTGCGCACTGGAGGAGTACGTG
(SEQ ID NO: 4781)

ERBAL3,
subfamily 2,

AGCCGTTTTGGCAAACTGCTGCTGC
(SEQ ID NO: 4782)

NR2F2,
group F,

GAAACTCTCATCCGCGATATGTTAC
(SEQ ID NO: 4783)

SVP44,
member1

TGTCTGGGAGCAGCTTCAACTGGCC
(SEQ ID NO: 4784)

TCFCOUP1,

CAACTGGCCTTACATGTCCATCCAG
(SEQ ID NO: 4785)

TFCOUP1

CTAGAGACTCAGAGGACCCACCTGG
(SEQ ID NO: 4786)

CGCGGGGACACCGGGAAGTGCAGCG
(SEQ ID NO: 4787)

GAGGGCCGAGACAGGAGCAGCCCAC
(SEQ ID NO: 4788)

GCCCACCCAGCAGAAATACAATCCG
(SEQ ID NO: 4789)

GGATCAGATCTGTGAGCACGTTGGC
(SEQ ID NO: 4790)

209592_s_—
WDR68
AN11; HAN11
WD repeat
10238
GATGGCTCGGTGCGGATGTTTGACC
(SEQ ID NO: 4791)

at

domain 68

ACAGCACCATCATTTACGAAGACCC
(SEQ ID NO: 4792)

CATTTACGAAGACCCACAGCATCAC
(SEQ ID NO: 4793)

TGCTTCGCCTCTGCTGGAACAAGCA
(SEQ ID NO: 4794)

GAGATCAACAATGTGCAGTGGGCAT
(SEQ ID NO: 4795)

CAGTGGGCATCAACTCAGCCCGACT
(SEQ ID NO: 4796)

CCATCTGCTACAACAACTGCCTGGA
(SEQ ID NO: 4797)

CTGCCTGGAGATACTCAGAGTGTAG
(SEQ ID NO: 4798)

AGAGTGTAGTGTTGGTGGCGCTGTG
(SEQ ID NO: 4799)

TGTGCCCACGAGGCAGGGGCTTTTG
(SEQ ID NO: 4800)

GCAGGGGCTTTTGTATTTCCTGCCT
(SEQ ID NO: 4801)

209774_x_—
CXCL2
CINC-2a,
chemokine
2920
AGAGAGACACAGCTGCAGAGGCCAC
(SEQ ID NO: 4802)

at

GROb, Gro2,
(C-X-C motif)

ACCTGGATTGCGCCTAATGTGTTTG
(SEQ ID NO: 4803)

MIP-2, MIP-2a,
ligand 2

TGATTGAATCTACTTGCACACTCTC
(SEQ ID NO: 4804)

Mgsa-b, Mip2,

GCACACTCTCCCATTATATTTATTG
(SEQ ID NO: 4805)

Scyb, Scyb2

AACCCAAGTTAGTTCAATCCTGATT
(SEQ ID NO: 4806)

GAAGGTTTGCAGATATTCTCTAGTC
(SEQ ID NO: 4807)

GACATATCACATGTCAGCCACTGTG
(SEQ ID NO: 4808)

ATGGCCAGTAAGATCAATGTGACGG
(SEQ ID NO: 4809)

TGTGACGGCAGGGAAATGTATGTGT
(SEQ ID NO: 4810)

CAGTGTGTGGTCAACATTTCTCATG
(SEQ ID NO: 4811)

ATGTTAATTATGCAGTGTTTCCCTC
(SEQ ID NO: 4812)

209796_s_—
CNPY2
MGC156825,
canopy 2
10330
TGGAGCGACCCCATTACGCTAAAGA
(SEQ ID NO: 4813)

at

Tmem4
homolog

GAGCGACCCCATTACGCTAAAGATG
(SEQ ID NO: 4814)

(zebrafish)

GACCCCATTACGCTAAAGATGAAAG
(SEQ ID NO: 4815)

GAGCCAGGATCTCCACTGTGGAGCA
(SEQ ID NO: 4816)

GAATGGGAAATTGCCCAGGTGGACC
(SEQ ID NO: 4817)

ACCCCAAGAAGACCATTCAGATGGG
(SEQ ID NO: 4818)

GACCATTCAGATGGGATCTTTCCGG
(SEQ ID NO: 4819)

GATGGGATCTTTCCGGATCAATCCA
(SEQ ID NO: 4820)

GGATCTTTCCGGATCAATCCAGATG
(SEQ ID NO: 4821)

TTTCCGGATCAATCCAGATGGCAGC
(SEQ ID NO: 4822)

TCCAGATGGCAGCCAGTCAGTGGTG
(SEQ ID NO: 4823)

209970_x_—
CASP1
ICE, IL1BC,
caspase 1,
834
CGAAGGTGATCATCATCCAGGCCTG
(SEQ ID NO: 4824)

at

P45
apoptosis-

ACAGCCCTGGTGTGGTGTGGTTTAA
(SEQ ID NO: 4825)

related

GGAAACCTATCTTTACCAACTACAG
(SEQ ID NO: 4826)

cysteine

GAAGGATTTTATCGCTTTCTGCTCT
(SEQ ID NO: 4827)

peptidase

TTTCTGCTCTTCCACACCAGATAAT
(SEQ ID NO: 4828)

(interleukin

GAGACATCCCACAATGGGCTCTGTT
(SEQ ID NO: 4829)

1, beta,

GAATATGCCTGTTCCTGTGATGTGG
(SEQ ID NO: 4830)

convertase)

TTTCCGCAAGGTTCGATTTTCATTT
(SEQ ID NO: 4831)

GATGGTAGAGCGCAGATGCCCACCA
(SEQ ID NO: 4832)

TGACAAGATGTTTCTACCTCTTCCC
(SEQ ID NO: 4833)

TTCTACCTCTTCCCAGGACATTAAA
(SEQ ID NO: 4834)

210029_at
INDO
CD107B, IDO,
idoleamine-
3620
ACCCCCAGCTATCAGACGGTCTGGT
(SEQ ID NO: 4835)

IDO1
pyrrole 2,3

AGGCCAAAGCAGCGTCTTTCAGTGC
(SEQ ID NO: 4836)

diosygenase

GCTGGTGGAGGACATGCTGCTCAGT
(SEQ ID NO: 4837)

TGCTCAGTTCCTCCAGGACATGAGA
(SEQ ID NO: 4838)

GGAACTTCCTGTGCTCATTAGAGTC
(SEQ ID NO: 4839

ATTAGAGTCAAATCCCTCAGTCCGT
(SEQ ID NO: 4830)

ATGACGCCTGTGTGAAAGCTCTGGT
(SEQ ID NO: 4831)

TGGTCTCCCTGAGGAGCTACCATCT
(SEQ ID NO: 4832)

GAGCTACCATCTGCAAATCGTGACT
(SEQ ID NO: 4833)

CATCCTGATTCCTGCAAGCCAGCAG
(SEQ ID NO: 4834)

GAATAAGACCTCTGAAGACCCTTCA
(SEQ ID NO: 4835)

210976_s_—
PFKM
GSD7,
phospho-
5213
GCGTAAGAGGGCTCTGGTCTTCCAA
(SEQ ID NO: 4836)

at

MGC8699,
fructokinase,

TTTGAGCATCGAATCCCCAAGGAAC
(SEQ ID NO: 4837)

PFK-1, PFK-M,
muscle

AACTGAGGCCCATCCTCAAAATCCT
(SEQ ID NO: 4838)

PFKX

TGACTTGGACACTTCAGACCATGCC
(SEQ ID NO: 4839)

TGCCGTCTAAACCTCTCTGGAGTGA
(SEQ ID NO: 4840)

AGCTCACACCCTAATAAGTCCACAT
(SEQ ID NO: 4841)

AAGTCCACATCTTCTCAGTGTTTTA
(SEQ ID NO: 4842)

TATTCTGTACCTTGCAGCCATGACC
(SEQ ID NO: 4843)

CCCAGCTTTATCTGTCACACAAGGC
(SEQ ID NO: 4844)

GCTACTGCTAGATATCACTTACTCA
(SEQ ID NO: 4845)

AAGAGTCTTGGTTCCTCTACTACTT
(SEQ ID NO: 4846)

211122_s_—
CXCL11
H174, I-TAC,
chemokine
6373
GAGACTTTTCTATGGTTTTGTGACT
(SEQ ID NO: 4847)

at

IP-9, IP9,
(C-X-C motif)

GTGACTTTCAACTTTTGTACAGTTA
(SEQ ID NO: 4848)

MGC102770,
ligand 11

GACAATCAGAATTCCACTGCCCAAA
(SEQ ID NO: 4849)

SCYB11,

GGCTGGTTACCATCGGAGTTTACAA
(SEQ ID NO: 4850)

SCYB9B, b-R1

TGCTTTCACGTTCTTACTTGTTGTA
(SEQ ID NO: 4851)

TACATTCATGCATTTCTAGGCTAGA
(SEQ ID NO: 4852)

AGAGAACCTTCTAGATTTGATGCTT
(SEQ ID NO: 4853)

GTCTCTAGAAGTTATCTGTCTGTAT
(SEQ ID NO: 4854)

CTGTCTGTATTGATCTTTATGCTAT
(SEQ ID NO: 4855)

GCTATATTACTATCTGTGGTTACAG
(SEQ ID NO: 4856)

TACTGGAGTCAAGCCCTTATAAGTC
(SEQ ID NO: 4857)

211340_s_—
MCAM
CD146,
melanoma
4162
GCCCTCTTGATGGATCACGTAAAAC
(SEQ ID NO: 4858)

at

MUC18
cell adhesion

AAGGCAGCGGGGAGCAGACAAAGAT
(SEQ ID NO: 4859)

molecule

AGATGAGGTCTACACTGTCCTTCAT
(SEQ ID NO: 4860)

GTCTACACTGTCCTTCATGGGGATT
(SEQ ID NO: 4861)

ACTGTCCTTCATGGGGATTAAAGCT
(SEQ ID NO: 4862)

GCTATGGTTATATTAGCACCAAACT
(SEQ ID NO: 4863)

ACCCTAGAAGGGCCCAAATGAGAGA
(SEQ ID NO: 4864)

ATGAGAGAATGGTACTTAGGGATGG
(SEQ ID NO: 4865)

GTGTATATATGGTTTTGTCAGGTGT
(SEQ ID NO: 4866)

GGTTTTGTCAGGTGTGTAAATTTGC
(SEQ ID NO: 4867)

AATTGTTTCCTTTATATATGTATGT
(SEQ ID NO: 4868)

211370_s_—
MAP2K5
AI324775,
mitogen-
5607
CATTCTGATGTCTGGAGCTTAGGAA
(SEQ ID NO: 4869)

at

AI428457,
activated

CTCCAGCTTCTGCAGTGCATTGTTG
(SEQ ID NO: 4870)

MEK5,
protein

TTGTTGATGAGGATTCGCCCGTCCT
(SEQ ID NO: 4871)

Mapkk5,
kinase kinase

CCCGTCCTTCCAGTTGGAGAGTTCT
(SEQ ID NO: 4872)

Prkmk5
5

GGAGAGTTCTCGGAGCCATTTGTAC
(SEQ ID NO: 4873)

GGAGCCATTTGTACATTTCATCACT
(SEQ ID NO: 4874)

ACATTTCATCACTCAGTGTATGCGA
(SEQ ID NO: 4875)

GCCAAAAGAAAGGCCAGCACCTGAA
(SEQ ID NO: 4876)

GCACCTGAAGAATTGATGGGCCACC
(SEQ ID NO: 4877)

AAGAATTGATGGGCCACCCGTTCAT
(SEQ ID NO: 4878)

ATGATGGAAATGCCGCCGTGGTGTC
(SEQ ID NO: 4879)

211595_s_—
MRPS11
FLJ22512,
mitochondrial
64963
ACACAGATCCAGGTAGTCTCTGCTA
(SEQ ID NO: 4880)

at

FLJ23406,
ribosomal

GTCTCTGCTAGTAATGAGCCCCTTG
(SEQ ID NO: 4881)

HCC-2
protein S11

AGCACAGACAGCAGGCATAGCCGCA
(SEQ ID NO: 4882)

AGCCGCAGCGGCGAGAGCTAAACAA
(SEQ ID NO: 4883)

CAAAAGGGCGTGATCCACATCCGAG
(SEQ ID NO: 4884)

TTGTCTGCCATGCACGGACTGATCA
(SEQ ID NO: 4885)

GGACTGATCATGGGCGGCCTGGAAG
(SEQ ID NO: 4886)

CTCAGCTCCAGTGGGACCTTGTAAA
(SEQ ID NO: 4887)

GGACCTTGTAAAATGCTCCCTGTCA
(SEQ ID NO: 4888)

TCCCTGTCAGAGCTCTCCAGAATAT
(SEQ ID NO: 4889)

GGTGTGCCCCAGAAGTAAGCTTTGC
(SEQ ID NO: 4890)

211951_at
NOLC1
KIAA0035,
nucleolar and
9221
ATTGTGTCTCCTAGTTGGTACCTGG
(SEQ ID NO: 4891)

NOPP130,
coiled-body

CCTGGGAGCAATTGACATGCCCCCT
(SEQ ID NO: 4892)

NOPP140,
phospho-

AGCTGGCCTGACGGTATGGCTGCAG
(SEQ ID NO: 4893)

NS5ATP13,
protein

TGAGCAGTAGCGGTACTCAGCCAGA
(SEQ ID NO: 4894)

P130
1

GAGGGAAGAGTCCACAGCTTTCTGG
(SEQ ID NO: 4895)

GTGGTAGAAAAGTGTGCCCCAAGCC
(SEQ ID NO: 4896)

CCCCAAGCCTTCATGGACGAGTTAT
(SEQ ID NO: 4897)

TAGTCTCCTCTTGTTTGGATTCCAT
(SEQ ID NO: 4898)

GGATTCCATACTTGCTAAATAACCT
(SEQ ID NO: 4899)

AACCTGGTTTTCCATGTAACTGCCT
(SEQ ID NO: 4900)

GAAAATGTACTGTTCATGCTGACAC
(SEQ ID NO: 4901)

212463_at
CD59
16.3A5, 1F5,
CD59
966
GATGCTGGTGTTGGTGTGACATAAT
(SEQ ID NO: 4902)

EJ16, EJ30,
molecule,

ATAATGCTATGGCCAGAACTGAAAC
(SEQ ID NO: 4903)

EL32,
complement

GGCTCCCACAGTTAGAAGGCGAAGT
(SEQ ID NO: 4904)

FLJ38134,
regulatory

GGCGAAGTCGCACAATAGGCCGTCT
(SEQ ID NO: 4905)

FLJ92039,
protein

GCCGTCTGCAAGCTGGGTTAGAGAG
(SEQ ID NO: 4906)

G344, HRF-20,

AGCCAGTAGTGGCTCAGCCTGAGTT
(SEQ ID NO: 4907)

HRF20, MAC-

AACCCACTGGTGCAAGTCCTAGATT
(SEQ ID NO: 4908)

IP, MACIF,

GAAGAACCTGGAGTCTGATGTCCAA
(SEQ ID NO: 4909)

MEM43,

TACCAAAGAGGCTACCGATTCCTTC
(SEQ ID NO: 4910)

MGC2354,

TCTGCACCTTCTAAACCTAGTTCTT
(SEQ ID NO: 4911)

MIC11, MIN1,

GCTTTCCATTACATGAGCTGTCTCA
(SEQ ID NO: 4912)

MIN2, MIN3,

MIRL, MSK21,

p18-20

212765_at
CAMSAP1L1
RP11-
calmodulin
23271
GAGTTCATTGCTCTCAGTATAAGAT
(SEQ ID NO: 4913)

93N17.1,
regulated

AAGTCTGAGGATTTTCGTCAACCTT
(SEQ ID NO: 4914)

KIAA1078,
spectrin-

CGTCAACCTTACTGAAACACACTGG
(SEQ ID NO: 4915)

MGC150680,
associated

AACACACTGGTGCTTTCATCATCAG
(SEQ ID NO: 4916)

MGC150681
protein 1-

TTGTCGTGGTTACCAGTGCAGCCTG
(SEQ ID NO: 4917)

like 1

AAATTCTGCTATTTGACACAGCTTT
(SEQ ID NO: 4918)

ATGGTTTCATGGACACTGTTGAGCA
(SEQ ID NO: 4919)

AGTGTATGGTGTGCTTACCTGTCCA
(SEQ ID NO: 4920)

TACCTGTCCACTCTAGAGCATTGCT
(SEQ ID NO: 4921)

GAGCATTGCTTACAGGIIIiiiGTT
(SEQ ID NO: 4922)

TGCTATTTCCTGGTACAGTGTAGTT
(SEQ ID NO: 4923)

213307_at
SHANK2
CORTBP1,
SH3 and
22941
AAAAATTCCAGTCCTCATATCTTTT
(SEQ ID NO: 4924)

CTTNBP1,
multiple

CTAGACTTTGCTTCCAATGGTTTCT
(SEQ ID NO: 4925)

ProSAP1,
ankyrin

TTCCAGACCACTTTTCCTAGATGAA
(SEQ ID NO: 4926)

SHANK,
repeat

GCTGCATGCAGACAGGACTGCCCGT
(SEQ ID NO: 4927)

SPANK-3
domains 2

GACTGCCCGTGCTTTGTGGGGAATC
(SEQ ID NO: 4928)

TTCCGCAGATCTCATCACTTTGATT
(SEQ ID NO: 4929)

GTTTATCGTTCCTGTAACTTGTTCT
(SEQ ID NO: 4930)

AACTTGTTCTACATTCCACAGTCTT
(SEQ ID NO: 4931)

ATTCCACAGTCTTTACCGTTTTATG
(SEQ ID NO: 4932)

CAACAATCCCTGTCCATTGATTCCA
(SEQ ID NO: 4933)

GAACTCTTTGTTCATGCCAATTTTG
(SEQ ID NO: 4934)

213656_s_—
KLC1
KLC, KNS2,
kinesin light
3831
CAGCAGCAGTGGCCTGGAAGACGCC
(SEQ ID NO: 4935)

at

KNS2A,
chain 1

GCAGTGGCCTGGAAGACGCCACCGC
(SEQ ID NO: 4936)

MGC15245

TTCTCCTGCGTCTGTGTGCATAGGA
(SEQ ID NO: 4937)

CCTGCGTCTGTGTGCATAGGACATG
(SEQ ID NO: 4938)

GTCTGTGTGCATAGGACATGATACT
(SEQ ID NO: 4939)

GACATGATACTAATAACCACACGGC
(SEQ ID NO: 4940)

AATAACCACACGGCTGGCGTGACCT
(SEQ ID NO: 4941)

CCATGTGTAACTTCCTCACGTTGTG
(SEQ ID NO: 4942)

TGTAACTTCCTCACGTTGTGTGCGA
(SEQ ID NO: 4943)

ACTTCCTCACGTTGTGTGCGATAAC
(SEQ ID NO: 4944)

GTGTGCGATAACGTATTTTATTGTA
(SEQ ID NO: 4945)

213895_at
EMP1
CL-20, EMP-1,
epithelial
2012
AAGGACTGGTATCTTTCTGTGAGCA
(SEQ ID NO: 4946)

TMP
membrane

GATAAAGACTGCATATCCTTGTGTC
(SEQ ID NO: 4947)

protein 1

ATTGCATTGATTCTTGATGCTTTCT
(SEQ ID NO: 4948)

GATGCTTTCTTAGAGGCCTACATGA
(SEQ ID NO: 4949)

GATTTCTTAGATTGCTCTGATAAAC
(SEQ ID NO: 4950)

AGAGGGAACTTTTGTCAGACTCTGC
(SEQ ID NO: 4951)

CAGACTCTGCAACAAACTCCTAGCT
(SEQ ID NO: 4952)

AACTCCTAGCTCTATCCAGAGTGTC
(SEQ ID NO: 4953)

TCCAGAGTGTCCTCTGCTGCTAAGA
(SEQ ID NO: 4954)

GTATCTTTCTCCTCAAAAGCCTGGA
(SEQ ID NO: 4955)

CACCCCAGTCCAGCCATGAGGGTAT
(SEQ ID NO: 4956)

213925_at
C1orf95
RP11-9C4.1,
Chromosome
375057
ATGAGGGTATTTCCAGCCTATTCCA
(SEQ ID NO: 4957)

DKFZp761P211
1 open

ATTTCCAGCCTATTCCAATGACTGA
(SEQ ID NO: 4958)

reading

CAATGACTGAAACCCTTCTTGGAAG
(SEQ ID NO: 4959)

frame 95

TAATGTCGGGGACGTAGGGACGCTT
(SEQ ID NO: 4960)

CTAGGGGCCAAGCAGGGTTCCAGAT
(SEQ ID NO: 4961)

AGCCTTCTGCCAGCTTTAAAACCCT
(SEQ ID NO: 4962)

AAAACCCTTCACTCAAGCAGCATTA
(SEQ ID NO: 4964)

AGCAGCATTACTGTACATGCAATGA
(SEQ ID NO: 4965)

CATACACACACCTTCCTATTATAAA
(SEQ ID NO: 4966)

AAGCATGACATCTCTTTGGCATTCC
(SEQ ID NO: 4967)

214106_s_—
GMDS
RP1-
GDP-
2762
CAGAAGCTGAACTGGAAGCCCCGGG
(SEQ ID NO: 4968)

at

118B18.1,
mannose

GGTCGCTTTCGATGAGCTGGTGAGG
(SEQ ID NO: 4969)

GMD
4,6-

GTGGAGCTCATGAGGACAAACCCCA
(SEQ ID NO: 4970)

dehydratase

TGCAGACGCGCTGCGGGGATGGGGA
(SEQ ID NO: 4971)

CCGCCGAGGTTTGTAGCAGCCGGGA
(SEQ ID NO: 4972)

TTGTAGCAGCCGGGATGTGACCCTC
(SEQ ID NO: 4973)

TTTGGGTCGCTTTGCGTTTGTCGAA
(SEQ ID NO: 4974)

TTTGTCGAAGCCTCCTCTGAATGGC
(SEQ ID NO: 4975)

GTCGAAGCCTCCTCTGAATGGCTTT
(SEQ ID NO: 4976)

AATCACATTCACTTTACTTGAAATT
(SEQ ID NO: 4977)

CAAATTGTGGGGCCTTCAAATTGTT
(SEQ ID NO: 4978)

214167_s_—
RPLP0///
L10E,
ribosomal
220717
CCATTGCCCCATGTGAAGTCACTGT
(SEQ ID NO: 4979)

at
RPLP0-like
MGC111226,
protein
6175
CCCCATGTGAAGTCACTGTGCCAGC
(SEQ ID NO: 4980)

MGC88175,
large, P0///

CCAGCCCAGAACACTGGTCTCGGGC
(SEQ ID NO: 4981)

P0, PRLP0,
ribosomal

AGCCCAGAACACTGGTCTCGGGCCC
(SEQ ID NO: 4982)

RPP0///
protein P0-

GAACACTGGTCTCGGGCCCGAGAAG
(SEQ ID NO: 4983)

like

TGGTCTCGGGCCCGAGAAGACCTCC
(SEQ ID NO: 4984)

TTTTTCCAGGCTTTAGGTATCACCA
(SEQ ID NO: 4985)

GGTATCACCACTAAAATCTCCAGGG
(SEQ ID NO: 4986)

CACCACTAAAATCTCCAGGGGCACC
(SEQ ID NO: 4987)

TAAAATCTCCAGGGGCACCATTGAA
(SEQ ID NO: 4988)

ATCTCCAGGGGCACCATTGAAATCC
(SEQ ID NO: 4989)

214175_x_—
PDLIM4
RIL
PDZ and LIM
8572
CTACTACTATACGGCTGCGAGAAGA
(SEQ ID NO: 4990)

at

domain 4

ATACGGCTGCGAGAAGACGACAGAA
(SEQ ID NO: 4991)

GACGACAGAAGGGCTACGACGTGGT
(SEQ ID NO: 4992)

AGAAGGGCTACGACGTGGTGGCGGT
(SEQ ID NO: 4993)

GGTGTACCCCAATGCCAAGGTGGAA
(SEQ ID NO: 4994)

GTACCCCAATGCCAAGGTGGAACTC
(SEQ ID NO: 4995)

ATGCCAAGGTGGAACTCGTCTGAGC
(SEQ ID NO: 4996)

AGGTGGAACTCGTCTGAGCTGGGAC
(SEQ ID NO: 4997)

CCCTGCTCGGCCGGTGTAAATATGT
(SEQ ID NO: 4998)

TGCTCGGCCGGTGTAAATATGTTTC
(SEQ ID NO: 4999)

GTGTAAATATGTTTCACCCTGTCCC
(SEQ ID NO: 5000)

214620_x_—
PAM
PAL, PHM
peptidyl-
5066
CTCCTCCTGAAAACCAAGCTTTGAT
(SEQ ID NO: 5001)

at

glycine

CAGAATGTCAGATTCCTTTCCCTTT
(SEQ ID NO: 5002)

alpha-

GACTGTACACACTTTATTTACTTCG
(SEQ ID NO: 5003)

amidating

AGTTCATAACAGTGCCATTGTCTTT
(SEQ ID NO: 5004)

monooxygenase

TAGACTAGAGAAACCGTCCTCTTTT
(SEQ ID NO: 5005)

TCCTCTTTTTCCATCATAATTCTAA
(SEQ ID NO: 5006)

GATTTGCCCATTTACACTTTTGAGA
(SEQ ID NO: 5007)

GTGTTTTCAGAGCATTAGCTGTCAG
(SEQ ID NO: 5008)

TAGCTGTCAGTGTATTTTCCAGTTT
(SEQ ID NO: 5009)

TTCCAGTTTTGGGTATTGCAGATTT
(SEQ ID NO: 5010)

TGCAGATTTTACATACAACTTTTAT
(SEQ ID NO: 5011)

215034_s_—
TM4SF1
H-L6, L6,
transmembrane
4071
TATGACTGCTAAAAGAACCAACCCA
(SEQ ID NO: 5012)

at

M3S1, TAAL6
4 L six

AAAGAACCAACCCAGGACAGAGCCA
(SEQ ID NO: 5013)

family

ACCCAGGACAGAGCCACAATCTTCC
(SEQ ID NO: 5014)

member 1

CAGGACAGAGCCACAATCTTCCTCT
(SEQ ID NO: 5015)

ACAGAGCCACAATCTTCCTCTATTT
(SEQ ID NO: 5016)

TTTCACTTGTATTCATTTGTAAAAC
(SEQ ID NO: 5017)

TTTGTATTAGTGTAACATACTCCCC
(SEQ ID NO: 5018)

AAACGCCTGTAAAGACTGGCATCTT
(SEQ ID NO: 5019)

GCCTGTAAAGACTGGCATCTTCACA
(SEQ ID NO: 5020)

GACTGGCATCTTCACAGGATGTCAG
(SEQ ID NO: 5021)

ATCTTCACAGGATGTCAGTGTTTAA
(SEQ ID NO: 5022)

215440_s_—
BEX4
RP4-
BEX family
56271
GACAACCATTATGACTTTTGCCTCA
(SEQ ID NO: 5023)

at

635G19.2,
member 4

TTGCCTCATACCTTGAATCCTAAAA
(SEQ ID NO: 5024)

BEXL1,

AAAGTTTTCGCTGAGGTTAATGTGA
(SEQ ID NO: 5025)

FLJ10097

GTGAACACTGCTTTACAAGCTTGTA
(SEQ ID NO: 5026)

GTGATTTACTTTTTCTGTAAGCCTT
(SEQ ID NO: 5027)

GTTTACACTTACCAGTTTCTAATGG
(SEQ ID NO: 5028)

GTCTCAGCCTAAAAGTTACGGTCAG
(SEQ ID NO: 5029)

TACGGTCAGCATGGCAATTCACCTA
(SEQ ID NO: 5030)

CTGGACTCAAAATCTCAGTTGTCTT
(SEQ ID NO: 5031)

TGTAGGACCTATCGTCCAGACTCAC
(SEQ ID NO: 5032)

CGTCCAGACTCACAGAGTGGGGCTC
(SEQ ID NO: 5033)

216220_s_—
ADORA1
RDC7
adenosine
134
GACCAGGTGTCTAGAGGCAACAGTG
(SEQ ID NO: 5034)

at

A1 receptor

TAGAGGCAACAGTGTTCTGAGCCCC
(SEQ ID NO: 5035)

GGCTGGGAGAAGGTGCTTGGGCTTC
(SEQ ID NO: 5036)

TGCTTGGGCTTCTGCGGTGAGGCAG
(SEQ ID NO: 5037)

GGGCTTCTGCGGTGAGGCAGGGGAG
(SEQ ID NO: 5038)

GAGGCAGGGGAGTCTGCTTGTCTTA
(SEQ ID NO: 5039)

GGGGAGTCTGCTTGTCTTAGATGTT
(SEQ ID NO: 5040)

GTCTTAGATGTTGGTGGTGCAGCCC
(SEQ ID NO: 5041)

CAGCCCCAGGACCAAGCTTAAGGAG
(SEQ ID NO: 5042)

GAGGAGAGCATCTGCTCTGAGACGG
(SEQ ID NO: 5043)

GGAAGGAGAGAGGTTGAGGATGCAC
(SEQ ID NO: 5044)

216682_s_—
FAM48A
RGD1307812
Family with
55578
CAGAAAAACTCATTGGTTACCATCA
(SEQ ID NO: 5045)

at

sequence

GTTACCATCAGAGTTTGCTAGGGCA
(SEQ ID NO: 5046)

similarity 48,

GGGCATCAGATTCTTACTCTGAAGA
(SEQ ID NO: 5047)

member A

AGAATATAATATTTATCCTGCCCTT
(SEQ ID NO: 5048)

TCCTGCCCTTCTTGTTATGAACTGT
(SEQ ID NO: 5049)

GGAAAATTTCCAGCTAATAGGTGCA
(SEQ ID NO: 5050)

GTAGTGAATCTAGACAGCAGTATTT
(SEQ ID NO: 5051)

TCTGATCAAACCCACTGATTGAAGA
(SEQ ID NO: 5052)

GACAGTCAATTATTGTGTACCTCCT
(SEQ ID NO: 5053)

GTGTACCTCCTGGTTTGATGCAAGA
(SEQ ID NO: 5054)

GATGCAAGAGACAGTACACAACAGT
(SEQ ID NO: 5055)

217731_s_—
ITM2B
RP11-
integral
9445
TTCCACCTTTATGTTTTAATATCCT
(SEQ ID NO: 5056)

at

196P14.1,
membrane

TGTTTTAATATCCTAGGCATCTGCT
(SEQ ID NO: 5057)

ABRI, BRI,
protein 2B

CCTAGGCATCTGCTGTAATAATATT
(SEQ ID NO: 5058)

BRI2,

ATAACTTGTGTTACTAATTTGTATA
(SEQ ID NO: 5059)

BRICD2B,

TAATTTGTATAACCCATATCTGTGC
(SEQ ID NO: 5060)

E25B, E3-16,

TGTATAACCCATATCTGTGCAATGG
(SEQ ID NO: 5061)

FBD

AAGTTGTTTAACTAGACTGCGTGTT
(SEQ ID NO: 5062)

ACTAGACTGCGTGTTGTTTTTCCCG
(SEQ ID NO: 5063)

GAATAGTTTGGTTCTTCAAATCTTA
(SEQ ID NO: 5064)

CAAATCTTAAGAGAATCCACATAAA
(SEQ ID NO: 5065)

AAAATTCACTTCTATATATACAATG
(SEQ ID NO: 5066)

217861_s_—
PREB
MGC3467,
prolactin
10113
GTCCACAGCTGAGGTTGCCTCTGAC
(SEQ ID NO: 5067)

at

SEC12
regulatory

AAAAGGCTTGGCTATGGCCCTGTGT
(SEQ ID NO: 5068)

element

CTTCGTCATCTGTGGATCCATCCAG
(SEQ ID NO: 5069)

binding

GAACAGCGGTATCTGAAGCCCAGGC
(SEQ ID NO: 5070)

AGAGGCTCCAGAGTTGAGCTTGTCC
(SEQ ID NO: 5071)

GATGCCCAAGAGCCTGGAGGCACTG
(SEQ ID NO: 5072)

CTGCAGAAACAGTTTCTCCTCCTCC
(SEQ ID NO: 5073)

ACATGAAGCCCCTGGCATTTGCTGG
(SEQ ID NO: 5074)

GATGGGTAGCACTAAGCCAGCTGGC
(SEQ ID NO: 5075)

AGCCAGCTGGCCTAAAGATGCAATA
(SEQ ID NO: 5076)

ATGAACCTCAGCCCATTAGGCAGGA
(SEQ ID NO: 5077)

217870_s_—
CMPK1
RP11-511i2.1,
cytidine
51727
GGAATGAGTTCTTATCTAGTGTTGC
(SEQ ID NO: 5078)

at

CMK, CMPK,
monophosphate

TCTTATCTAGTGTTGCAGGCCAGCA
(SEQ ID NO: 5079)

UMK, UMP-
(UMP-CMP)

GGTTTCGAGAGCATTCCTACTCACA
(SEQ ID NO: 5080)

CMPK, UMPK
kinase 1

GAGCATTCCTACTCACATAAGTGAA
(SEQ ID NO: 5081)

cytosolic

TGAGACTAGGTGCTTTGCTTCCTTT
(SEQ ID NO: 5082)

GCTTCCTTTCATCAGGTATCTTTCT
(SEQ ID NO: 5083)

AGGTATCTTTCTGTGGCATTTGAGA
(SEQ ID NO: 5084)

TTACTAAATTATGAGGCTTTGCTTT
(SEQ ID NO: 5085)

TAACTAGTTTTGTCATTCCATTTGT
(SEQ ID NO: 5086)

GATACAGTCACCAAGAATGTTTTGA
(SEQ ID NO: 5087)

AGACCCCAATTTAAGCCTTGCTTAT
(SEQ ID NO: 5088)

217933_s_—
LAP3
LAP, LAPEP,
leucine
51056
ATGTACAGCTGCAGCATTCCTGAAA
(SEQ ID NO: 5089)

at

PEPS
aminopeptidase

GTAACTCATCCTAAGTGGGCACATT
(SEQ ID NO: 5090)

3

TGGGCACATTTAGACATAGCAGGCG
(SEQ ID NO: 5091)

GCAGGCGTGATGACCAACAAAGATG
(SEQ ID NO: 5092)

GAAGTTCCCTATCTACGGAAAGGCA
(SEQ ID NO: 5093)

GAAAGGCATGACTGGGAGGCCCACA
(SEQ ID NO: 5094)

GGCCCACAAGGACTCTCATTGAGTT
(SEQ ID NO: 5095)

GAGTTCTTACTTCGTTTCAGTCAAG
(SEQ ID NO: 5096)

GACAATGCTTAGTTCAGATACTCAA
(SEQ ID NO: 5097)

AGAACTTCCTAATCACTTTTCAGAG
(SEQ ID NO: 5098)

GAAAATTACTATGCACTTGTCAGAA
(SEQ ID NO: 5099)

218126_at
FAM82C
RMD3;
family with
55177
CTTTTTTCCTTAGACCTTGCTGAGA
(SEQ ID NO: 5100)

FAM82A2;
sequence

ACCACACAAATCTGTCTCCTGGGTC
(SEQ ID NO: 5101)

FAM82C;
similarity 82,

TACCACTCCCCATTAGTTAATTTAT
(SEQ ID NO: 5102)

hRMD-3;
member C

GTTGTTCTCTCCCTTGAGTAATCTC
(SEQ ID NO: 5103)

ptpip51;

ACCTGCCCCAGGATTACACATGGGT
(SEQ ID NO: 5104)

FLJ10579

GGTAGAGCCTGCAAGACCTGAGACC
(SEQ ID NO: 5105)

GACCTGAGACCTTCCAATTGCTGGT
(SEQ ID NO: 5106)

CAGAGTGGCCCACAGACATTGCTTT
(SEQ ID NO: 5107)

GAATTCTACCTGTATTCCAGGGCTG
(SEQ ID NO: 5108)

AGGGCTGGACCACTTGATAACTTCC
(SEQ ID NO: 5109)

AACTTCCAGTGTCCTGGCAGCTTTT
(SEQ ID NO: 5110)

218434_s_—
AACS
ACSF1,
acetoacetyl-
65985
GGATCTCTTTATTGCACAGACTGAA
(SEQ ID NO: 5111)

at

FLJ12389,
CoA

TGTGAAGCAGTGGGTGTCCACCCGT
(SEQ ID NO: 5112)

FLJ41251,
synthetase

TGTGGTCACCGAGTGAGGACCCTCC
(SEQ ID NO: 5113)

SUR-5

CTGCCTCCACCTGAGAGTTGCTAGG
(SEQ ID NO: 5114)

GTTGCTAGGGGGTTCTTGTCGAGAT
(SEQ ID NO: 5115)

TGTCGAGATCATGTCATCAGCACCC
(SEQ ID NO: 5116)

CCTAAGTCAAGTCACGGGTTTCCAT
(SEQ ID NO: 5117)

GGGTTTCCATAGCCAGGCAGTTGGT
(SEQ ID NO: 5118)

TGGTATGTACAATTCAGTTCAGCGT
(SEQ ID NO: 5119)

TCAGCGTATGAACTTGTATCTCTAA
(SEQ ID NO: 5120)

GTATCTCTAATCTGATGTCCATTTT
(SEQ ID NO: 5121)

218551_at
RP5-
IIP45;
invasion
60672
CCACCGGCGAAAGAGCTTTGACGCC
(SEQ ID NO: 5122)

1077B9.4
FLJ12438;
inhibitory

CGAAAGAGCTTTGACGCCTCTGACA
(SEQ ID NO: 5123)

FLJ38609
protein 45

GTCTGAGAAAAGCTCAGCCCCCAGG
(SEQ ID NO: 5124)

TAGGTTGGGCAGGTGGGTGGACCCA
(SEQ ID NO: 5125)

AGGTGGGTGGACCCAAGCTTGTCTG
(SEQ ID NO: 5126)

TTGTCTGCTGCCTGAGTTCCAGAGA
(SEQ ID NO: 5127)

GTCTGCTGCCTGAGTTCCAGAGAGG
(SEQ ID NO: 5128)

GAGTTCCAGAGAGGGAGGACCCTGG
(SEQ ID NO: 5129)

CAGAGAGGGAGGACCCTGGGGTGGA
(SEQ ID NO: 5130)

GGGGTGGAGGGTGAGGGATTCTGTG
(SEQ ID NO: 5131)

GTGGAGGGTGAGGGATTCTGTGGAA
(SEQ ID NO: 5132)

218622_at
NUP37
FLJ22618,
mucleoporin
79023
CAATCCGGTTTTATGATCTTTTGGC
(SEQ ID NO: 5133)

MGC5585, p37
37 kDa

GGCCCAACAGGCTATTTTATCTCTT
(SEQ ID NO: 5134)

ACACCTTCAAAGTTGGAGCCGTTGC
(SEQ ID NO: 5135)

TATTACTCGGTCCAGTTATCCTCAA
(SEQ ID NO: 5136)

GAGACCTGTTCACATGGATCGAGCC
(SEQ ID NO: 5137)

GAGCCTGCTTATTCAGGTGGTCCAC
(SEQ ID NO: 5138)

TGCAACCACTGGTTATCCTGGCAAA
(SEQ ID NO: 5139)

TTCATCATTTAGGACACCCTCAGCC
(SEQ ID NO: 5140)

ACTCTCCCTCTGTGTGTAATTGGAG
(SEQ ID NO: 5141)

GAGACCACAAGCTGTTGTTTTGGGT
(SEQ ID NO: 5142)

AAGTGTTTTCTGTACCTTAGATTCA
(SEQ ID NO: 5143)

218686_s_—
RHBDF1
C16orf8,
rhomboid 5
64285
TGGATTGACAACTTTGCCCACATCT
(SEQ ID NO: 5144)

at

Dist1,
homolog 1

CACATCTCGGGGTTCATCAGTGGCC
(SEQ ID NO: 5145)

EGFR-RS,
(Drosophila)

AAACGCTGCCAGATCATCATCTTTC
(SEQ ID NO: 5146)

FLJ2235,

ATCTTTCAGGTGGTCTTCCTGGGCC
(SEQ ID NO: 5147)

FLJ22357,

ATCCCCTTCACTGACAAGTTCTGTG
(SEQ ID NO: 5148)

gene-89, gene-

GAAGTACGAACTGGACGCTCAGCTC
(SEQ ID NO: 5149)

90, hDist1

TACAGGAGTCACCTGCTCCATGTGG
(SEQ ID NO: 5150)

GGCCTGTTTCCTGAACACAGACCTC
(SEQ ID NO: 5151)

ACTGCCGGGCATTTATTATACTACT
(SEQ ID NO: 5152)

TACTTCCTGTCATAACCTTCTAACT
(SEQ ID NO: 5153)

CTTGACGACCACCTCATGTGGCCAA
(SEQ ID NO: 5154)

219148_at
PBK
SPK; TOPK;
PDZ binding
55872
AGCATACTATGCAGCGTTGGGAACT
(SEQ ID NO: 5155)

Nori-3;
kinase

CAGCGTTGGGAACTAGGCCACCTAT
(SEQ ID NO: 5156)

FLJ14385

TGAACTCTTCTCTGTATGCACTAAT
(SEQ ID NO: 5157)

AGACCCTAAAGATCGTCCTTCTGCT
(SEQ ID NO: 5158)

ATGTCTAGTGATCATCTCAGCTGAA
(SEQ ID NO: 5159)

GTGTGGCTTGCGTAAATAACTGTTT
(SEQ ID NO: 5160)

GAGGACCATAGTTTCTTGTTAACAT
(SEQ ID NO: 5161)

AAGCACTTGGAATTGTACTGGGTTT
(SEQ ID NO: 5162)

GTACTTTGATACTGCTCATGCTGAC
(SEQ ID NO: 5163)

TGCTCATGCTGACTTAAAACACTAG
(SEQ ID NO: 5164)

GGATCTACTGACATTAGCACTTTGT
(SEQ ID NO: 5165)

219258_at
TIPIN
FLJ20516
TIMELESS
54962
GAACATGATGTCACTTCTACTGAAT
(SEQ ID NO: 5166)

interacting

CTACTGAATTAGATCCCTTTCTGAC
(SEQ ID NO: 5167)

protein

GATCCCTTTCTGACAAACTTATCTG
(SEQ ID NO: 5168)

GTTAATGAATACACCCAGGGCACAC
(SEQ ID NO: 5169)

CCCAGGGCACACACGGTTGAAGAGG
(SEQ ID NO: 5170)

AACGAAGACATTCTGGACAATCCAT
(SEQ ID NO: 5171)

GAAACACTGCTGGACCAGTCTTTTA
(SEQ ID NO: 5172)

GCAACAGCAACTTGATGCTACATCC
(SEQ ID NO: 5173)

TGTATCTGTTAAGTCATCGTCCTGC
(SEQ ID NO: 5174)

TTAAGTCATCGTCCTGCAAGCTTGG
(SEQ ID NO: 5175)

GCAAGCTTGGCGTTACTATGTATTT
(SEQ ID NO: 5176)

219315_s_—
TMEM204
C16orf30,
transmembrane
79652
CTACGTGGAGTCACCATGCTGAGTC
(SEQ ID NO: 5177)

at

CLP24,
protein

CACACCTGCTATCGTGGAACAGCCT
(SEQ ID NO: 5178)

FLJ20898,
204

ACGGGATGAGTCTGGGTGACCTCTG
(SEQ ID NO: 5179)

MGc111564

GTGCGTTTACTGTTATGTCGGTCAT
(SEQ ID NO: 5180)

GTCGGTCATATGTCTGTACGTGTCG
(SEQ ID NO: 5181)

TCCAGCTTTCCTGGTTAGCGCAACG
(SEQ ID NO: 5182)

ACAGGTTAGGTGGCGCGAGGCTGCC
(SEQ ID NO: 5183)

CGCTCCGCTTTGCTTTGGGATTAAT
(SEQ ID NO: 5184)

TCTGCATCTGCTGAGAGGGGCACCC
(SEQ ID NO: 5185)

CCCCAGCCATATCTTACACTTTGGT
(SEQ ID NO: 5186)

GAATCGTGTTCGTGTCTGTTTTGCT
(SEQ ID NO: 5187)

219649_at
ALG6
0
asparagine-
29929
TTTAGTATGCTACCTCTTCTATTGA
(SEQ ID NO: 5188)

linked

AAGGATGAACTCCTAATGCCCTCTG
(SEQ ID NO: 5189)

glycosylation

CTAATGCCCTCTGTTGTGACAACAA
(SEQ ID NO: 5190)

6 homolog

TATAGCTTGTGTAACTTCCTTTTCA
(SEQ ID NO: 5191)

(S.

TTGTTTCTTATCTCAGTCATCACTA
(SEQ ID NO: 5192)

cerevisiae,

CACTATGGTGCTTCTGACGTTGATG
(SEQ ID NO: 5193)

alpha-1,3-

GACGTTGATGACTGTCACACTGGAT
(SEQ ID NO: 5194)

glucosyl-

TGGATCCTCCTCAGAAACTACCGGA
(SEQ ID NO: 5195)

transferase)

ATTGGTGTGTTTTGTATCTTGCTTG
(SEQ ID NO: 5196)

ATCTTGCTTGAACTTCCTGTTCTTC
(SEQ ID NO: 5197)

ACTTCCTGTTCTTCTTGGTATACTT
(SEQ ID NO: 5198)

219789_at
NPR3
ANPRC,
natriuretic
4883
TTATGATTAATCACCATCTGCCTCC
(SEQ ID NO: 5199)

GUCY2B,
peptide

CCAGGCCTTTCATCTCATGACAAAC
(SEQ ID NO: 5200)

NPRC
receptor

ATCGTGTCACTCTGTTAAATGTTCA
(SEQ ID NO: 5201)

C/guanylate

TGTTCATACTGTTTCAAGCCCATAT
(SEQ ID NO: 5202)

cyclase C

TGTTGTCTCCATATCTTGATGGCTT
(SEQ ID NO: 5203)

(atrionatri-

GGCTTTTGGGAGCATTTCACACAAG
(SEQ ID NO: 5204)

uretic peptide

CAGGTTTGTGGTTGAGGACTTCTCT
(SEQ ID NO: 5205)

receptor C)

GGACTTCTCTGTCCGATGTCTACAT
(SEQ ID NO: 5206)

GTCTACATTCAGGTTCTGACTTCAT
(SEQ ID NO: 5207)

TCCCTGTCTTTTTCAGTGTCTCATA
(SEQ ID NO: 5208)

GTCTCATAAACGCTACTCTGGATTG
(SEQ ID NO: 5209)

220232_at
SCD5
ACOD4,
stearoyl-CoA
79966
ACCTGTACACGTTGATTATTTTTGT
(SEQ ID NO: 5210)

FADS4,
desaturase 5

GAGTTTAAGCTATCATTTCCAGATG
(SEQ ID NO: 5211)

FLJ21032,

GGAGAGTTCCATAGATGTCTGTTAG
(SEQ ID NO: 5212)

HSCD5,

ATCCTTGTTAATTTTCTGTCTTGTT
(SEQ ID NO: 5213)

SCD2, SCD4

TAAAGTCTCCCACTATTATTATATG
(SEQ ID NO: 5214)

GTCTAAGTCTCCTTGTAGGTCTCTA
(SEQ ID NO: 5215)

GGGTGCTCCTGTATTAGGTGCATAC
(SEQ ID NO: 5216)

TTATATAATGCCCTTCTTTGTCTTT
(SEQ ID NO: 5217)

TAAATATTCCTGTATCCCTTTATTT
(SEQ ID NO: 5218)

GTCTTTGCACGTGAGGTGGGTCTCC
(SEQ ID NO: 5219)

CTGAATACAGCACACCGATGGGTTT
(SEQ ID NO: 5220)

220441_at
FLJ13236
FLJ13236, wus
hypothetical
79962
GTCAGCTGGCTTACCAGGTTTTGGG
(SEQ ID NO: 5221)

protein

TTACCAGGTTTTGGGCCTCTCAGAA
(SEQ ID NO: 5222)

FLJ13236

TACATCGGAGTTACCAGGAGCTAGT
(SEQ ID NO: 5223)

GGAGCTAGTGAAGGTCTGGCACCCA
(SEQ ID NO: 5224)

AGATCCAGGCTGCGTATGAAGTCCT
(SEQ ID NO: 5225)

GTCCTGAGTCAACCCAGGAAGCCCT
(SEQ ID NO: 5226)

CCTGAGGACTGACTCTTCCTAGCAG
(SEQ ID NO: 5227)

CTAGCAGAGCTGGGCAACTTGTCCC
(SEQ ID NO: 5228)

GGCAACTTGTCCCAAATCTAGCTTT
(SEQ ID NO: 5229)

CCAAATCTAGCTTTGCCCACGAATG
(SEQ ID NO: 5230)

TTGCCCACGAATGGCATCCCAACAG
(SEQ ID NO: 5231)

220596_at
GPATCH4
RP11-
G patch
54865
TCTTCTGCAAATTTCCCTTTAAACT
(SEQ ID NO: 5232)

284F21.4,
domain

TCCTCCTTTAATTAAATGGACTACA
(SEQ ID NO: 5233)

GPATC4
containing 4

GGACTACATGGGGGGGTAATCCAGG
(SEQ ID NO: 5234)

GCTTTCCCCTGGGCAGATGGTAGGC
(SEQ ID NO: 5235)

GGCAGATGGTAGGCAGGGAGCTGGG
(SEQ ID NO: 5236)

ATGGGGATCACCTTGAGTCCATCCA
(SEQ ID NO: 5237)

GAGGTGATATCATCCTTTTAAGAAG
(SEQ ID NO: 5238)

GTAGAAAGTGCCCAAACAGCCATCA
(SEQ ID NO: 5239)

CAAACAGCCATCAGTTCCATCCTGA
(SEQ ID NO: 5240)

TCAGTTCCATCCTGACTGCTTGTTA
(SEQ ID NO: 5241)

TGACTGCTTGTTAAGAATTCTCTGC
(SEQ ID NO: 5242)

220794_at
GREM2
PRDC;
gremlin 2,
64388
CGCCCCCTATTTGTGGACTAAAGAT
(SEQ ID NO: 5243)

DAND3;
cysteine knot

GATGAACTCTGGTGTGCATGCTATT
(SEQ ID NO: 5244)

CKTSF1B2
superfamily,

AAGGTCTCTATATTAACGCTGGTTT
(SEQ ID NO: 5245)

homolog

TCACATGTTTTGACTCTGGCTTGCA
(SEQ ID NO: 5246)

(Xenopus

TGGCTTGCAGCACCATTCGGAGTAA
(SEQ ID NO: 5247)

laevis)

GGAGTAAGGATGACAGCAGGCCCAG
(SEQ ID NO: 5248)

AGCAGGCCCAGAAGGTGTTTTACTC
(SEQ ID NO: 5249)

CAGCAATTCACTGTCATGCACCTAT
(SEQ ID NO: 5250)

TTCACTGACGTTACTAAGCATTGCA
(SEQ ID NO: 5251)

AAACCGTATACTACTTTCACTGCCA
(SEQ ID NO: 5252)

CTACTTTCACTGCCATGACACTAGG
(SEQ ID NO: 5253)

220960_x_—
RPL22
EAP, HBP15,
ribosomal
6146
AATTCTGATGTCGTACCTAAGGCTT
(SEQ ID NO: 5254)

at

HBP15/L22
protein L22

ACCTAAGGCTTGTCCATCTTTGTTG
(SEQ ID NO: 5255)

TTGTTGGAGGTGCCATGGCTCCTGT
(SEQ ID NO: 5256)

TGAAGTTCACTCTTGATTGCACCCA
(SEQ ID NO: 5257)

ATTGCACCCACCCTGTAGAAGATGG
(SEQ ID NO: 5258)

GGAGCAAGAGCAAGATCACCGTGAC
(SEQ ID NO: 5259)

ATCACCGTGACATCCGAGGTGCCTT
(SEQ ID NO: 5260)

GAATAATCTACGTGACTGGTTGCGC
(SEQ ID NO: 5261)

CTGGTTGCGCGTAGTTGCTAACAGC
(SEQ ID NO: 5262)

TACGAATTACGTTACTTCCAGATTA
(SEQ ID NO: 5263)

TTTATCCTTGTATCTCTGCAGTGTG
(SEQ ID NO: 5264)

221221_s_—
KLHL3
FLJ40871,
kelch-like 3
26249
GGATAATTACAGCCTCATAGCCCCT
(SEQ ID NO: 5265)

at

KIAA1129,
(Drosophila)

AGCCTTCGTCATGGGACTCAGTGAC
(SEQ ID NO: 5266)

MGC44594

GCACAGGACTGTGGCATTTGCAGCA
(SEQ ID NO: 5267)

AAATCACCCTAGTGCCATGTTTGGT
(SEQ ID NO: 5268)

TAGAGGACCCTTGTTGTACTTCTTG
(SEQ ID NO: 5269)

GTCCCTGTGGTTGTCATAGCCAGTC
(SEQ ID NO: 5270)

GTCAGACTTGATCACTGACACCCCG
(SEQ ID NO: 5271)

GACACCCCGTACAACATATTGCATA
(SEQ ID NO: 5272)

TAAGATCCTCGATCTGGTGTTCTCT
(SEQ ID NO: 5273)

GTTCTCTGCGTGGCTGTTAGGGACT
(SEQ ID NO: 5274)

GAACACTTGTCACATGCTTGATCAG
(SEQ ID NO: 5275)

221265_s_—
C15orf44
DKFZp564O1664
chromosome
81556
TCACCTCTAGAATAGCCACCCAAAG
(SEQ ID NO: 5276)

at

15 open

AGACCTTCCTGAGGCTGCCTCAGAA
(SEQ ID NO: 5277)

reading

CCTCAGAAGCACCACTTGCTGTTTT
(SEQ ID NO: 5278)

frame 44

GAAGATAGCTGCTGTTCCCATGATG
(SEQ ID NO: 5279)

TCCCATGATGGGCACATTTCCTGAG
(SEQ ID NO: 5280)

ACTGATGAGCATAGAGCACCCCTGC
(SEQ ID NO: 5281)

CAGGAAACCTGACCGGCAGGGGCTC
(SEQ ID NO: 5282)

CTCTGGCTTCCTGAAAGCTTCACCT
(SEQ ID NO: 5283)

TCTTCCCTCGTTTATATCTCAACTG
(SEQ ID NO: 5284)

GCAACTCAGACTGTCTGGAGCTTGC
(SEQ ID NO: 5285)

GTTTCAGAACTTTCCTTAGGACTTG
(SEQ ID NO: 5286)

221654_s_—
USP3
MGC129878,
ubiquitin
9960
TCTCACTTTGAGGCACATTTACATC
(SEQ ID NO: 5287)

at

MGC129879,
specific

TACATCAATGCTTTTGTTCCTCTCA
(SEQ ID NO: 5288)

SIH003, UBP
peptidase 3

AAGCAAGATGTGTTCCTTATTGTGA
(SEQ ID NO: 5289)

GTGAAGAGCGACACAACTGCCTGCT
(SEQ ID NO: 5290)

GCTGCCTTTCCACAGCTATAATGGA
(SEQ ID NO: 5291)

TGGACATCAGGTTGACTCTAAATCA
(SEQ ID NO: 5292)

GTGTGCACAATACTTGTGGCCCACA
(SEQ ID NO: 5293)

GACCAGGTAATTACTGCTTGTCTCT
(SEQ ID NO: 5294)

TTACTGCTTGTCTCTCAAGGCTGCT
(SEQ ID NO: 5295)

TCAAGGCTGCTGTCTTTATCAGCAC
(SEQ ID NO: 5296)

GGTTCAGTTGTACTTGTCCTGCAAA
(SEQ ID NO: 5297)

221747_at
TNS1
MSTP091,
tensin 1
7145
CCTCTGTCCTCAAATGTCCAAAATG
(SEQ ID NO: 5298)

DKFZp586K0617,

TTGGAGGACCTCTGTTCATATCCCA
(SEQ ID NO: 5299)

MGC88584,

GGCTCTTGCCAGCAGTGGAGTTACT
(SEQ ID NO: 5300)

MST091,

GAGTTACTGTAGAGGGATGTCCCAA
(SEQ ID NO: 5301)

MST122,

AGAGGGATGTCCCAAGCTTGTTTTC
(SEQ ID NO: 5302)

MST127,

TTTGAAACTCTCCTGTGTCTGTGTT
(SEQ ID NO: 5303)

MSTP122,

GTGTGTGAGAGCACATCAGTGTGTG
(SEQ ID NO: 5304)

MSTP127,

GCACATCAGTGTGTGCAGGCTGTGT
(SEQ ID NO: 5305)

MSRA6, TNS

TCCCTTCAGACCCATCATTGAGAAC
(SEQ ID NO: 5306)

CAGGCCCTCTGCGGGGGAAACAAGA
(SEQ ID NO: 5307)

GGGAAACAAGATCACCCAGCATCCT
(SEQ ID NO: 5308)

222357_at
ZBTB20
RP23-
zinc finger
26137
CGTCGACCTCCCTATGGATTGTTAA
(SEQ ID NO: 5309)

238M18.1,
and BTB

GGATTGTTAAGGGCCCTGTGCATAT
(SEQ ID NO: 5310)

1300017A20Rik,
domain

GGCCCTGTGCATATTTGCATGTAGC
(SEQ ID NO: 5311)

7330412A13Rik,
containing 20

TGCATGTAGCCAAAGATTCAGTCTC
(SEQ ID NO: 5312)

A930017C21Rik,

GATTCAGTCTCTTGCAGGAACTCTG
(SEQ ID NO: 5313)

D16Wsu73e,

GCAGGAACTCTGGTTGTCAACTGGT
(SEQ ID NO: 5314)

DPZF, HOF,

TCAACTGGTGATCTTGCCTTTGTCT
(SEQ ID NO: 5315)

ODA-8S,

AGGACAATTTTACCATTCTCTCCTG
(SEQ ID NO: 5316)

Oda8, Zfp288

TTTTAGTGCCGGTACATGAATTTGT
(SEQ ID NO: 5317)

TATTCTTTATAATTCCCTTTGAAGT
(SEQ ID NO: 5318)

GGGGAATCTAAAACCGACCAGATGT
(SEQ ID NO: 5319)

34408_at
RTN2
NSP2, NSPL1
reticulon 2
6253
TCCGAGCTAAAATCCCAGGGACCGG
(SEQ ID NO: 5320)

TTACCTGAGCGACCAGGACTACATT
(SEQ ID NO: 5321)

GCCTGCTGGGACTTGTAGTTGCCTA
(SEQ ID NO: 5322)

TGCTGGGACTTGTAGTTGCCTAGAC
(SEQ ID NO: 5323)

TGGGACTTGTAGTTGCCTAGACAGG
(SEQ ID NO: 5324)

TGTAGTTGCCTAGACAGGGCACCAC
(SEQ ID NO: 5325)

GTAGTTGCCTAGACAGGGCACCACC
(SEQ ID NO: 5326)

AGGCGTTGGTGTCTCCTGGATGCTA
(SEQ ID NO: 5327)

GGCGTTGGTGTCTCCTGGATGCTAC
(SEQ ID NO: 5328)

GCGTTGGTGTCTCCTGGATGCTACT
(SEQ ID NO: 5329)

CGTTGGTGTCTCCTGGATGCTACTA
(SEQ ID NO: 5330)

GGGAGGCCTGAGCTTGGATTTACAC
(SEQ ID NO: 5331)

GGAGGCCTGAGCTTGGATTTACACT
(SEQ ID NO: 5332)

GGCCTGAGCTTGGATTTACACTGTA
(SEQ ID NO: 5333)

CTGAGCTrGGATTTACACTGTAATA
(SEQ ID NO: 5334)

CTTGGATTTACACTGTAATAAAGAC
(SEQ ID NO: 5335)

58780_s_—
FLJ10357
SOLO
hypothetical
55701
CTGGAGTCCCTGGTGACTCCATTCT
(SEQ ID NO: 5336)

at

protein

GAGTCCCTGGTGACTCCATTCTGAG
(SEQ ID NO: 5337)

FLJ10357

GTCCCTGGTGACTCCATTCTGAGGT
(SEQ ID NO: 5338)

TCCCTGGTGACTCCATTCTGAGGTG
(SEQ ID NO: 5339)

CTGGTGACTCCATTCTGAGGTGTCA
(SEQ ID NO: 5340)

GGTGACTCCATTCTGAGGTGTCACA
(SEQ ID NO: 5341)

GACTCCATTCTGAGGTGTCACAAGC
(SEQ ID NO: 5342)

CTCCATTCTGAGGTGTCACAAGCAA
(SEQ ID NO: 5343)

TCCATTCTGAGGTGTCACAAGCAAT
(SEQ ID NO: 5344)

ATTCTGAGGTGTCACAAGCAATGAA
(SEQ ID NO: 5345)

TTCTGAGGTGTCACAAGCAATGAAG
(SEQ ID NO: 5346)

TCTGAGGTGTCACAAGCAATGAAGC
(SEQ ID NO: 5347)

TGAGGTGTCACAAGCAATGAAGCTA
(SEQ ID NO: 5348)

AGGTGTCACAAGCAATGAAGCTATG
(SEQ ID NO: 5349)

GTGTGACAGGGGAACCGTAGACTTT
(SEQ ID NO: 5350)

TGTGACAGGGGAACCGTAGACTTTA
(SEQ ID NO: 5351)

64408_s_—
CALML4
MGC4809,
calmodulin-
91860
GAAAGAAATTCTTCTAGCCATGTTG
(SEQ ID NO: 5352)

at

NY-BR-20
like 4

ATTCTTCTAGCCATGTTGATGGTGG
(SEQ ID NO: 5353)

CTTCTAGCCATGTTGATGGTGGACA
(SEQ ID NO: 5354)

CTAGCCATGTTGATGGTGGACAAGG
(SEQ ID NO: 5355)

CGGTCAAAACTCACGAGTCTGGGGG
(SEQ ID NO: 5356)

GGTCAAAACTCACGAGTCTGGGGGA
(SEQ ID NO: 5357)

GATCACCCTTCCTGGACGGGACTAT
(SEQ ID NO: 5358)

CACCCTTCCTGGACGGGACTATTGA
(SEQ ID NO: 5359)

TTCCTGGACGGGACTATTGAAGGAG
(SEQ ID NO: 5360)

CTCCCCTGGGCCTGAAAACTTGGAG
(SEQ ID NO: 5361)

CCTGGGCCTGAAAACTTGGAGCAAT
(SEQ ID NO: 5362)

CTGGGCCTGAAAACTTGGAGCAATT
(SEQ ID NO: 5363)

AACACAGTGGCAAGACAACATTACC
(SEQ ID NO: 5364)

AACATTACCCAACTATAGAAGAGAG
(SEQ ID NO: 5365)

TACCCAACTATAGAAGAGAGGCTAA
(SEQ ID NO: 5366)

ACCCAACTATAGAAGAGAGGCTAAC
(SEQ ID NO: 5367)

290132_s_—
COMMD4
FLJ20452
COMM

TCTGCAGCCTACGCATGAATAGGTT
(SEQ ID NO: 5368)

at

domain

GCAGCCTACGCATGAATAGGTTGGC
(SEQ ID NO: 5369)

containing 4

GCATGAATAGGTTGGCAGGTGTGGG
(SEQ ID NO: 5370)

AGCCTGCTGCAATCCGTGGAAGAGC
(SEQ ID NO: 5371)

GCTGCAATCCGTGGAAGAGCCCATG
(SEQ ID NO: 5372)

GCAATCCGTGGAAGAGCCCATGGTG
(SEQ ID NO: 5373)

TCCGTGGAAGAGCCCATGGTGCACC
(SEQ ID NO: 5374)

CCATGTCCCTCTCAGCAGACAAGTT
(SEQ ID NO: 5375)

ATGTCCCTCTCAGCAGACAAGTTCC
(SEQ ID NO: 5376)

TCCCTCTCAGCAGACAAGTTCCAGG
(SEQ ID NO: 5377)

CCTCTCAGCAGACAAGTTCCAGGTC
(SEQ ID NO: 5378)

All gene probe set identification numbers and Entrez Gene identification numbers of Table 2 are hereby incorporated by reference in their entirety

In accordance with this aspect of the present invention, a good disease prognosis expression profile consists of genes, from the collection of 101 genes informative of colon cancer disease outcome, having expression levels that are below that of an average tumor sample expression level that are selected from the group consisting of ACTN1, ADORA1, ARHGAP8, LOC553158, BEX4, C1orf95, C3orf63, CAMSAP1L1, CD59, CNPY2, DBN1, FAM48A, FLJ10357, GPATCH4, GRB10, GREM2, HDAC5, HOXA4, ITM2B, KLC1, KLF12, KLHL3, NPR3, PAM, PBX2, PDLIM4, PIR, RGL2, RHBDF1, RP5-1077B9.4, RTN2, SCD5, SHANK2, SVIL, TAPBP, TIPIN, TM4SF1, TMEM204, TNS1, TUSC3 and ZBTB20. A good disease expression profile further consists of genes having expression levels that are above the average tumor sample expression level that are selected from the group consisting of NARS, WDR1, WARS, CCT4, ATP5B, SORD, UBE2L6, PSME2, AIP, RRM2, LRRC41, CCT2, TAF9, CCNB2, RFC5, IDE, MAD2L1, PSMA4, NDUFC1, IVD, PPIH, NEO1, CXCL10, FXN, GABBR1, COMMD4, DFFB, GLMN, CASP7, ATP5G3, DDOST, CYB561, NR2F1, WDR68, CXCL2, CASP1, INDO, PFKM, CXCL11, MCAM, MAP2K5, MRPS11, NOLC1, EMP1, GMDS, RPLP0, RPLP0-like, PREB, CMPK1, LAP3, FAM82C, AACS, NUP37, PBK, ALG6, FLJ13236, RPL22, C15orf44, USP3 and CALML4.

Also in accordance with this aspect of the present invention, a bad disease prognosis expression profile consists of genes from the collection of 101 genes informative of colon cancer disease outcome, having expression levels below that of an average tumor sample expression level that are selected from the group consisting of NARS, WDR1, WARS, CCT4, ATP5B, SORD, UBE2L6, PSME2, AIP, RRM2, LRRC41, CCT2, TAF9, CCNB2, RFC5, IDE, MAD2L1, PSMA4, NDUFC1, IVD, PPIH, NEO1, CXCL10, FXN, GABBR1, COMMD4, DFFB, GLMN, CASP7, ATP5G3, DDOST, CYB561, NR2F1, WDR68, CXCL2, CASP1, INDO, PFKM, CXCL11, MCAM, MAP2K5, MRPS11, NOLC1, EMP1, GMDS, RPLP0, RPLP0-like, PREB, CMPK1, LAP3, FAM82C, AACS, NUP37, PBK, ALG6, FLJ13236, RPL22, C15orf44, USP3 and CALML4. A bad disease expression profile further consists of genes having expression levels that are above the average tumor sample expression level that are selected from the group consisting of ACTN1, ADORA1, ARHGAP8, LOC553158, BEX4, C1orf9S, C3orf63, CAMSAP1L1, CD59, CNPY2, DBN1, FAM48A, FLJ10357, GPATCH4, GRB10, GREM2, HDAC5, HOXA4, ITM2B, KLC1, KLF12, KLHL3, NPR3, PAM, PBX2, PDLIM4, PIR, RGL2, RHBDF1, RP5-1077B9.4, RTN2, SCD5, SHANK2, SVIL, TAPBP, TIPIN, TM4SF1, TMEM204, TNS1, TUSC3 and ZBTB20.

Determining the prognosis of a subject having colon cancer using the gene expression data of the present invention, involves calculating the percentage of genes analyzed having expression levels associated with a good disease prognosis expression profile and the percentage of genes analyzed having expression levels associated with a bad disease prognosis expression profile in the sample from the subject. A favorable prognosis for the subject exists when greater than 20%, more preferably, greater than 25%, and most preferably, greater than 30% of the genes analyzed have expression levels associated with a good disease prognosis expression profile and less than 30%, more preferably, less than 25%, and most preferably, less than 20% of the genes analyzed have expression levels associated with a bad disease prognosis expression profile. An unfavorable prognosis for the subject exists when greater than 20%, more preferably, greater than 25%, and most preferably, greater than 30% of the genes analyzed have expression levels associated with a bad disease prognosis expression profile and less than 30%, more preferably, less than 25%, and most preferably, less than 20% of the genes analyzed have expression levels associated with a good disease prognosis expression profile.

A biological sample obtained from the subject having colon cancer in accordance with the methods of the present invention can be any biological tissue, fluid, or cell sample. Typical biological samples include, but are not limited to, sputum, blood, blood cells (e.g., white cells), tissue or fine needle biopsy samples, urine, stool, peritoneal fluid, and pleural fluid, or cells therefrom. Biological samples may also include sections of tissues such as frozen sections taken for histological purposes. In a preferred embodiment of the present invention, the biological sample obtained from the subject having colon cancer is a population of primary colon cancer cells. The colon cancer cells can be derived from a stage I, II, III, or IV colon cancer tumor.

Methods of isolating RNA and protein from biological samples for use in the methods of the present invention are readily known in the art. Protein preparation can be carried out using any method that produces analyzable protein. For example, the sample cells or tissue can be lysed in a protein lysis buffer (e.g. 50 mM Tris-HCl (pH, 6.8), 100 mM DTT, 100 μg/ml PMSF, 2% SDS, 10% glycerol, 1 μg/ml each of pepstatin A, leupeptin, and aprotinin, and 1 mM sodium orthovanadate) and sheared with a 22-gauge needle. Other methods of protein isolation that are suitable for use in carrying out the methods of the present invention are fully described in DENNISON C., A GUIDE TO PROTEIN ISOLATION (Kluwer Academic Publishers 2003), which is hereby incorporated by reference in its entirety. The protein content of the samples can be estimated using the Lowry, Bradford, or bicinchoninic acid assays or any commercially available assay based on the aforementioned techniques.

Methods of isolation and purification of nucleic acids suitable for use in carrying out the methods of the present invention are described in detail in LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY: HYBRIDIZATION WITH NUCLEIC ACID PROBES, PART I. THEORY AND NUCLEIC ACID PREPARATION (P. Tijssen ed., Elsevier 1993) which is incorporated herein by reference. Total RNA can be isolated from a given sample using, for example, an acid guanidinium-phenol-chloroform extraction, a guanidinium isothiocyanate-ultracentrifugation method, or a lithium chloride-SDS-urea method. PolyA⁺ mRNA can be isolated using oligo(dT) column chromatography or (dT)n magnetic beads (See e.g., SAMBROOK AND RUSSELL, MOLECULAR CLONING: A LABORATORY MANUAL (Cold Springs Laboratory Press, 1989) or CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Fred M. Ausubel et al. eds., 1992) which are hereby incorporated by reference in their entirety). See also WO/2000024939 to Dong et al. which is hereby incorporated by reference in its entirety, for complexity management and other nucleic acid sample preparation techniques.

It may be desirable to amplify the nucleic acid sample prior to detecting gene expression. One of skill in the art will appreciate that a method which maintains or controls for the relative frequencies of the amplified nucleic acids to achieve quantitative amplification should be used.

Typically, methods for amplifying nucleic acids employ a polymerase chain reaction (PCR) (See e.g., PCR TECHNOLOGY: PRINCIPLES AND APPLICATIONS FOR DNA AMPLIFICATION (Henry Erlich ed., Freeman Press 1992); PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS (Michael Innis ed., Academic Press 1990); Mattila et al., “Fidelity of DNA Synthesis by the Thermococcus litoralis DNA Polymerase—An Extremely Heat Stable Enzyme with Proofreading Activity,” Nucleic Acids Res. 19:4967-73 (1991); Eckert et al., “DNA polymerase fidelity and the polymerase chain reaction,” PCR Methods and Applications 1:17-24 (1991); and U.S. Pat. Nos. 4,683,202, 4,683,195, 4,800,159 4,965,188, and 5,333,675, all to Mullis et al., which are hereby incorporated by reference in their entireties for all purposes. The sample can also be amplified on an array as described in U.S. Pat. No. 6,300,070 to Boles, which is incorporated herein by reference.

Other suitable amplification methods include the ligase chain reaction (LCR) (e.g., Wu et al., “The Ligation Amplification Reaction (LAR)—Amplification of Specific DNA Sequences Using Sequential Rounds of Template-Dependent Ligation,” Genomics 4:560-9 (1989), Landegren et al., “A Ligase-Mediated Gene Detection Technique,” Science 24-1:1077-80 (1988) and Barringer et al., “Blunt-End and Single-Strand Ligations by Escherichia coli Ligase: Influence on an In Vitro Amplification Scheme,” Gene 89:117-22 (1990), which are hereby incorporated by reference in their entirety); transcription amplification (Kwoh et al., “Transcription-Based Amplification System and Detection of Amplified Human Immunodeficiency Virus Type 1 with a Bead-Based Sandwich Hybridization Format,” Proc. Natl. Acad. Sci. USA 86:1173-7 (1989) and WO88/10315 to Gingeras, which are hereby incorporated by reference in their entirety); self-sustained sequence replication (Guatelli et al., “Isothermal, In Vitro Amplification of Nucleic Acids by a Multienzyme Reaction Modeled After Retroviral Replication,” Proc. Nat. Acad. Sci. USA 87:1874-8 (1990) and WO90/06995 to Gingeras, which are hereby incorporated by reference in their entirety); selective amplification of target polynucleotide sequences (U.S. Pat. No. 6,410,276 to Burg et al, which is hereby incorporated by reference in its entirety); consensus sequence primed polymerase chain reaction (CP-PCR) (U.S. Pat. No. 5,437,975 to McClelland, which is hereby incorporated by reference in its entirety); arbitrarily primed polymerase chain reaction (AP-PCR) (U.S. Pat. Nos. 5,413,909 to Bassam, and 5,861,245 to McClelland which are hereby incorporated by reference in their entirety); and nucleic acid based sequence amplification (NABSA) (See U.S. Pat. Nos. 5,409,818, 5,554,517, and 6,063,603 all to Davey, which are hereby incorporated by reference in their entirety). Other amplification methods that may be used are described in U.S. Pat. Nos. 5,242,794 to Whiteley; 5,494,810 to Barany; and 4,988,617 to Landegren, which are hereby incorporated by reference in their entirety.

As described herein, detecting the “expression level” of a gene can be achieved by measuring any suitable value that is representative of the gene expression level. The measurement of gene expression levels can be direct or indirect. A direct measurement involves measuring the level or quantity of RNA or protein. An indirect measurement may involve measuring the level or quantity of cDNA, amplified RNA, DNA, or protein; the activity level of RNA or protein; or the level or activity of other molecules (e.g., a metabolite) that are indicative of the foregoing. The measurement of expression can be a measurement of the absolute quantity of a gene product. The measurement can also be a value representative of the absolute quantity, a normalized value (e.g., a quantity of gene product normalized against the quantity of a reference gene product), an averaged value (e.g., average quantity obtained at different time points or from different tumor cell samples from a subject, or average quantity obtained using different probes, etc.), or a combination thereof.

When it is desirable to measure the expression level of a gene by measuring the level of protein expression, any protein hybridization or immunodetection based assay known in the art can be used. In a protein hybridization based assay, an antibody or other agent that selectively binds to a protein is used to detect the amount of that protein expressed in a sample. For example, the level of expression of a protein can be measured using methods that include, but are not limited to, western blot, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), fluorescent activated cell sorting (FACS), immunohistochemistry, immunocytochemistry, or any combination thereof. Also, antibodies, aptamers, or other ligands that specifically bind to a protein can be affixed to so-called “protein chips” (protein microarrays) and used to measure the level of expression of a protein in a sample. Alternatively, assessing the level of protein expression can involve analyzing one or more proteins by two-dimensional gel electrophoresis, mass spectroscopy (MS), matrix-assisted laser desorption/ionization-time of flight-MS (MALDI-TOF), surface-enhanced laser desorption ionization-time of flight (SELDI-TOF), high performance liquid chromatography (HPLC), fast protein liquid chromatography (FPLC), multidimensional liquid chromatography (LC) followed by tandem mass spectrometry (MS/MS), protein chip expression analysis, gene chip expression analysis, and laser densitometry, or any combinations of these techniques.

Measuring gene expression by quantifying mRNA expression can be achieved using any commonly used method known in the art including northern blotting and in situ hybridization (Parker et al., “mRNA: Detection by in Situ and Northern Hybridization,” Methods in Molecular Biology 106:247-283 (1999), which is hereby incorporated by reference in its entirety); RNAse protection assay (Hod et al., “A Simplified Ribonuclease Protection Assay,” Biotechniques 13:852-854 (1992), which is hereby incorporated by reference in its entirety); reverse transcription polymerase chain reaction (RT-PCR) (Weis et al., “Detection of Rare mRNAs via Quantitative RT-PCR,” Trends in Genetics 8:263-264 (1992), which is hereby incorporated by reference in its entirety); and serial analysis of gene expression (SAGE) (Velculescu et al., “Serial Analysis of Gene Expression,” Science 270:484-487 (1995); and Velculescu et al., “Characterization of the Yeast Transcriptome,” Cell 88:243-51 (1997), which is hereby incorporated by reference in its entirety). Alternatively, antibodies may be employed that recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes.

In a preferred embodiment of the present invention, mRNA expression is measured using a nucleic acid amplification assay that is a semi-quantitative or quantitative real-time polymerase chain reaction (RT-PCR) assay. Because RNA cannot serve as a template for PCR, the first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction. The two most commonly used reverse transcriptases are avilo myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukemia virus reverse transcriptase (MLV-RT), although others are also known and suitable for this purpose. The reverse transcription step is typically primed using specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling. For example, extracted RNA can be reverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, Calif., USA), following the manufacturer's instructions. The derived cDNA can then be used as a template in the subsequent PCR reaction.

Although the PCR step can use a variety of thermostable DNA-dependent DNA polymerases, it typically employs the Taq DNA polymerase, which has a 5′-3′ nuclease activity but lacks a 3′-5′ proofreading endonuclease activity. An exemplary PCR amplification system using Taq polymerase is TaqMan® PCR (Applied Biosystems, Foster City, Calif.). Taqman® PCR typically utilizes the 5′-nuclease activity of Taq or Tth polymerase to hydrolyze a hybridization probe bound to its target amplicon, but any enzyme with equivalent 5′ nuclease activity can be used. Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction. A third oligonucleotide, or probe, is designed to detect the nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.

TaqMan® RT-PCR can be performed using commercially available equipment, such as, for example, the ABI PRISM 7700® Sequence Detection System®(Perkin-Elmer-Applied Biosystems, Foster City, Calif., USA), or the Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany).

In addition to the TaqMan primer/probe system, other quantitative methods and reagents for real-time PCR detection that are known in the art (e.g. SYBR green, Molecular Beacons, Scorpion Probes, etc.) are suitable for use in the methods of the present invention.

To minimize errors and the effect of sample-to-sample variation, RT-PCR is usually performed using an internal standard. The ideal internal standard is expressed at a constant level among different tissues, and is unaffected by colon cancer. RNAs most frequently used to normalize patterns of gene expression are mRNAs for the housekeeping genes glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and β-actin.

Real time PCR is compatible both with quantitative competitive PCR, where internal competitor for each target sequence is used for normalization and quantitative comparative PCR using a normalization gene contained within the sample, or a housekeeping gene for RT-PCR. For further details see, e.g., Heid et al., “Real Time Quantitative PCR,” Genome Research 6:986-994 (1996), which is incorporated by reference in its entirety.

In a preferred embodiment of the present invention, the expression levels of genes informative of colon cancer prognosis are detected using an array-based technique. These arrays, also commonly referred to as “microarrays” or “chips” have been generally described in the art, see e.g., U.S. Pat. Nos. 5,143,854 to Pirrung et al.; 5,445,934 to Fodor et al.; 5,744,305 to Fodor et al.; 5,677,195 to Winkler et al.; 6,040,193 to Winkler et al.; 5,424,186 to Fodor et al., which are all hereby incorporated by reference in their entirety. A microarray comprises an assembly of distinct polynucleotide or oligonucleotide probes immobilized at defined positions on a substrate. Arrays are formed on substrates fabricated with materials such as paper, glass, plastic (e.g., polypropylene, nylon), polyacrylamide, nitrocellulose, silicon, optical fiber or any other suitable solid or semi-solid support, and configured in a planar (e.g., glass plates, silicon chips) or three-dimensional (e.g., pins, fibers, beads, particles, microtiter wells, capillaries) configuration. Probes forming the arrays may be attached to the substrate by any number of ways including (i) in situ synthesis (e.g., high-density oligonucleotide arrays) using photolithographic techniques (see Fodor et al., “Light-Directed, Spatially Addressable Parallel Chemical Synthesis,” Science 251:767-773 (1991); Pease et al., “Light-Generated Oligonucleotide Arrays for Rapid DNA Sequence Analysis,” Proc. Natl. Acad. Sci. U.S.A. 91:5022-5026 (1994); Lockhart et al., “Expression Monitoring by Hybridization to High-Density Oligonucleotide Arrays,” Nature Biotechnology 14:1675 (1996); and U.S. Pat. Nos. 5,578,832 to Trulson; 5,556,752 to Lockhart; and 5,510,270 to Fodor, which are hereby incorporated by reference in their entirety); (ii) spotting/printing at medium to low-density (e.g., cDNA probes) on glass, nylon or nitrocellulose (Schena et al., “Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray,” Science 270:467-470 (1995), DeRisi et al, “Use of a cDNA Microarray to Analyse Gene Expression Patterns in Human Cancer,” Nature Genetics 14:457-460 (1996); Shalon et al., “A DNA Microarray System for Analyzing Complex DNA Samples Using Two-Color Fluorescent Probe Hybridization,” Genome Res. 6:639-645 (1996); and Schena et al., “Proc. Natl. Acad. Sci. U.S.A. 93:10539-11286) (1995), which are hereby incorporated by reference in their entirety); (iii) masking (Maskos et al., “Oligonucleotide Hybridizations on Glass Supports: A Novel Linker for Oligonucleotide Synthesis and Hybridization Properties of Oligonucleotides Synthesised In Situ,” Nuc. Acids. Res. 20:1679-1684 (1992), which is hereby incorporated by reference in its entirety); and (iv) dot-blotting on a nylon or nitrocellulose hybridization membrane (see e.g., SAMBROOK AND RUSSELL, MOLECULAR CLONING: A LABORATORY MANUAL (Cold Springs Laboratory Press, 1989), which is hereby incorporated by reference in its entirety). Probes may also be noncovalently immobilized on the substrate by hybridization to anchors, by means of magnetic beads, or in a fluid phase such as in microtiter wells or capillaries. The probe molecules are generally nucleic acids such as DNA, RNA, PNA, and cDNA but may also include proteins, polypeptides, oligosaccharides, cells, tissues and any permutations thereof which can specifically bind the target molecules.

Fluorescently labeled cDNA for hybridization to the array may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from colon cancer tumor tissue of interest. Labeled cDNA applied to the array hybridizes with specificity to each nucleic acid probe spotted on the array. After stringent washing to remove non-specifically bound cDNA, the array is scanned by confocal laser microscopy or by another detection method, such as a CCD camera. Quantitation of hybridization of each arrayed element allows for assessment of corresponding mRNA abundance. With dual color fluorescence, separately labeled cDNA samples generated from two sources of RNA are hybridized pairwise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously. The miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes. Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al., “Parallel Human Genome Analysis: Microarray-Based Expression Monitoring of 1000 Genes,” “Proc. Natl. Acad. Sci. USA 93(20):10614-9 (1996), which is hereby incorporated by reference in its entirety).

When the use of microarray technology is desired, the expression levels of genes informative of colon cancer prognosis can be detected using commercially available arrays comprising nucleic acid probes, where at least five of the nucleic acid probes are complementary at least a portion of a nucleotide sequence (i.e., an RNA transcript or DNA nucleotide sequence) of a gene in the group of 176, 71, or 101 genes informative of colon cancer prognosis disclosed supra. As described herein, the expression levels of genes informative of colon cancer progression can be detected using the Affymetrix U133 gene expression arrays following the manufacturer's protocols. In a preferred embodiment of the present invention, however, the microarray comprises a plurality of nucleic acid probes, each nucleic acid probe having a nucleotide sequence that is complementary to at least a portion of a nucleotide sequence (RNA or DNA) of a gene selected from the group of 176 genes informative of colon cancer outcome disclosed supra. In another embodiment, the microarray comprises a plurality of nucleic acid probes, each nucleic acid probe having a nucleotide sequence that is complementary to at least a portion of a nucleotide sequence (RNA or DNA) of a gene selected from the group of 71 genes informative of colon cancer outcome described supra. In accordance with this aspect of the present invention, the nucleic acid probes of the present invention have a nucleotide sequence that is complementary to at least a portion of an RNA transcript or DNA nucleotide sequence encoded by a gene informative of colon cancer outcome. Exemplary nucleic acid probes having nucleotide sequences complementary to the RNA transcripts encoded by the 176 genes and the 71 genes informative of colon cancer outcome are provided in Table 1 by their Affymetrix identifier.

In another embodiment of the present invention, the microarray comprises a plurality of nucleic acid probes, each nucleic acid probe having a nucleotide sequence that is complementary to at least a portion of a nucleotide sequence (i.e., RNA transcript or DNA nucleotide sequence) of a gene selected from the group of 101 genes informative of colon cancer outcome disclosed supra. Exemplary nucleic acid probes having nucleotide sequences complementary to the RNA transcripts encoding the 101 genes informative of colon cancer outcome are provided in Table 2 by their Affymetrix identifier.

In another embodiment of the present invention, one or more supplementary analyses is performed to supplement or confirm the prognosis prediction achieved with the gene expression level analysis. In accordance with this embodiment of the present invention, the one or more additional analyses includes detecting microsatellite instability, measuring DNA promoter methylation, screening one or more mutations in one or more colon cancer oncogenes or tumor suppressor genes in the sample, or any combination of these analyses. The prognosis of a subject having colon cancer is then based on the detected expression levels of genes known to be informative of colon cancer in combination with one or more of these independent, additional analysis.

A deficient DNA mismatch repair (MMR) system is observed in about 10-15% of all colorectal carcinomas and in up to 90% of hereditary non-polyposis colorectal cancer (HNPCC) patients. Tumors with MMR defects acquire mutations in short repetitive DNA stretches, a phenomenon termed microsatellite instability. Therefore, the determination of microsatellite status is an ideal independent confirmatory prognostic analysis to perform in accordance with the methods of the present invention. Additionally, because the efficacy of adjuvant chemotherapy can be dependent on the microsatellite status of the tumor, determining the microsatellite status can be particular relevant to determining an effective individualized treatment plan for a subject having colorectal cancer.

In accordance with this aspect of the present invention, a favorable prognosis exists when a microsatellite instability-low status is detected, whereas an unfavorable prognosis exists when a microsatellite instability-high status is detected.

Methods and techniques for detecting microsatellite instability in a sample are well known in the art and are suitable for use in accordance with this aspect of the invention. In a preferred embodiment, microsatellite instability detection is performed using a PCR-based method to amplify tumor DNA and detect the five microsatellite markers established by the National Cancer Institute (Boland et al., “A National Cancer Institute Workshop of Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International Criteria for the Determination of Microsatellite Instability in Colorectal Cancer,” Cancer Res. 58(22):5248-57 (1998), which is hereby incorporated by reference in its entirety). These five microsatellite markers include two mononucleotide repeats (BAT26 and BAT25) and three dinucleotide repeats (D2S123, D5S346, and D17S250). The multiplex assay for rapid and accurate detection of the NCI 5-marker panel described by Nash et al., “Automated, Multiplex Assay for High-Frequency Microsatellite Instability in Colorectal Cancer,” J. Clin. Oncol. 21:3105-12 (2003), which is hereby incorporated by reference in its entirety, is particularly well suited for use in accordance with this aspect of the present invention. Alternatively, a PCR-based method for assessing the microsatellite instability status of a sample can be employed (e.g. detection of the 3′ UTR mononucleotide repeat, T25 (CAT25), of the CASP2 gene as described in U.S. Patent Application Publication No. 20080096197 to Findeisen et al., which is hereby incorporated by reference in its entirety).

Immunohistochemical approaches for detecting microsatellite instability are also suitable for use in accordance with this aspect of the present invention. Monoclonal antibodies specific for DNA mismatch repair genes, for example MLH1, MSH2, MSH6, and PMS2 have been described by Marcus et al. “Immunohistochemistry for hMLH1 and hMSH2: A Practical Test for DNA Mismatch Repair-Deficient Tumors,” Am J Surg Pathol. 23(10):1248-55 (1999); Lindor et al. “Immunohistochemistry Versus Microsatellite Instability Testing in Phenotyping Colorectal Tumors,” J Clin Oncol. 20(4):897-9 (2002); and Umar et al. “Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch syndrome) and Microsatellite Instability,” J Natl Cancer Inst. 96 (4):261-8 (2004), which are hereby incorporated by reference in their entirety.

A second analysis that is suitable to complement the detection of gene expression levels involves measuring the level of DNA promoter methylation. In higher order eukaryotic organisms, DNA methylation occurs at cytosines located 5′ to guanosine in a CpG dinucleotide. This modification has important regulatory effects on gene expression predominantly when it involves CpG rich areas known as CpG islands that are located in the promoter region of a gene sequence. Extensive methylation of CpG islands in tumor-suppressor genes has been associated with reduced expression of the tumor suppressor gene, resulting in unchecked cellular growth, tissue invasion, angiogenesis, and metastases. For example, the aberrant methylation of the Mut L homologue 1 gene (hMLH1) resulting in defective DNA mismatch repair has been associated with colorectal cancer. In accordance with this aspect of the invention, hMLH1 promoter methylation can be measured to compliment or confirm the gene expression detection analysis. Other genes known to be hypermethylated in colon cancer which are also suitable for promoter methylation analysis in accordance with this aspect of the invention include HPP1 (Sato et al., “Aberrent Methylation of the HPP1 Gene in Ulcerative Colitis-Associated Colorectal Carcinoma,” Cancer Research 62:6820-22 (2002), which is hereby incorporated by reference in its entirety); Reprimo (Takahashi et al., “Aberrent Methylation of Reprimo in Human Malignancies,” Int J Cancer 115(4):503-10 (2005), which is hereby incorporated by reference in its entirety); NEURL and FOXL2 (Schuebel et al., “Comparing the DNA Hypermethylome with Gene Mutations in Human Colorectal Cancer,” PLOS Genet. 3(9):e157-(2007), which is hereby incorporated by reference in its entirety); and ADAMTS1, CRABP1, and NR3C1 (Lind et al., “ADAMTS1, CRABP1, and NR3C1 identified as Epigenetically Deregulated Genes in Colorectal Tumorigenesis,” Cell Oncology 28(5-6):259-72 (2006), which is hereby incorporated by reference in its entirety).

In a preferred embodiment of the present invention the methylation level of the lecithin:retinol acyl transferase (LRAT) gene promoter nucleotide sequence, or region upstream thereof, is measured (See U.S. Patent Application Publication No. US20050227265 to Barany et al. and WO2008/077095 to Barany et al., which are hereby incorporated by reference in their entirety). In accordance with this aspect of the invention, a favorable prognosis exists when an increase in the methylation level of the lecithin:retinol acyl transferase gene promoter nucleotide sequence, or region upstream thereof, is measured.

DNA promoter methylation can be measured at a genome-wide or gene-specific level. For global methylation analysis, chromatographic methods, such as reverse-phase high pressure liquid chromatography and methyl accepting capacity assays are generally used. Alternatively, the restriction landmark genomic scanning for methylation (RLGS-M) assay as described by Hayashizaki et al., “Restriction Landmark Genomic Scanning Method and its Various Applications,” Electrophoresis 14(4):251-8 (1993) and CpG island microarry can also be used to measure genome-wide methylation. Various techniques available to measure gene-specific methylation, include DNA digestion with a methylation sensitive restriction enzyme followed by Southern blot detection of PCR amplification; methylation specific PCR; bisulfite genomic sequencing PCR; or in situ immunodetection using 5-methylcytosine specific antibody as described by Castilho et al., “5-Methylcytosine Distribution and Genome Organization in Triticale Before and After Treatment with 5-Azacytidine,” J Cell Sci 112:4397-404 (1999), which is hereby incorporated by reference in its entirety). Additional methods and techniques for measuring DNA methylation including the nearest neighbor analysis, chemical DNA sequencing, methylation sensitive restriction fingerprinting, combined bisulfite restriction analysis, and methyl-CpG binding column isolation are described in DNA Methylation Protocols (Mills and Ramsahoye, eds., Humana Press 2002), which is hereby incorporated by reference in its entirety. In a preferred embodiment, DNA promoter methylation analysis is carried out using the quantitative bisulfite-PCR/LDR/Universal Array platform described in U.S. Patent Application Publication No. US20050227265 to Barany et al.; WO2008/077095 to Barany et al.; and Chen et al., “Multiplexed Profiling of Candidate Genes for CpG Island Methylation Status using a Flexible PCR/LDR/Universal Array Assay,” Genome Research 16:282-9 (2006) which are incorporated by reference in their entirety.

In another embodiment of the present invention, the mutational status of one or more colon cancer oncogenes or tumor-suppressor genes is screened. The presence or absence of such mutations can contribute to the determination of a subject's prognosis. Mutations in several such genes, especially DNA mismatch repair genes, are well known in the art and can be screened in accordance with this aspect of the invention. In a preferred embodiment, the mutational status of K-ras, B-raf, APC, p53, PIK3CA, is screened. An unfavorable prognosis exists when mutations in one or more of these colon cancer oncogenes or tumor suppressor genes is identified.

Any art acceptable method for detecting the mutational status of a gene can be used in accordance with this aspect of the invention. Preferred methods include the endonuclease/ligase based mutation scanning method (Huang et al., “An Endonuclease/Ligase Based Mutation Scanning Method Especially Suited for Analysis of Neoplastic Tissue,” Oncogene 21:1909-21 (2002) and U.S. Pat. No. 7,198,894 to Barany et al., which are hereby incorporated by reference in their entirety); ligase detection reaction (LDR) (U.S. Pat. No. 6,312,892 to Barany et al., which is hereby incorporated by reference in their entirety); coupled LDR/PCR (U.S. Pat. Nos. 7,097,980, 6,797,470, 6,268,148, and 6,027,889 all to Barany et al., which are hereby incorporated by reference in their entirety); coupled PCR/restriction endonuclease digestion/LDR reaction (U.S. Pat. No. 7,014,994 to Barany et al., which is hereby incorporated by reference in its entirety); ligase detection reactions using addressable arrays (U.S. Pat. No. 7,083,917 to Barany and U.S. Patent Application Publication Nos. 20020150921, 20030022182, 20040259141, and 20040253625 all to Barany et al., which are hereby incorporated by reference in their entirety) and DNA microarray multiplex detection methods (Gerry et al., “Universal DNA Microarray Method for Multiplex Detection of Low Abundant DNA Mutations,” J Mol Biol 292:251-62 (1999), which is hereby incorporated by reference in its entirety). Other suitable methods for determining the mutational status of a gene include direct DNA sequencing techniques, (e.g. Sanger dideoxy or Maxam-Gilbert sequencing reactions) and massively parallel sequencing technology.

In a preferred embodiment of the present invention, the data generated from the detection of gene expression levels of the at least five genes selected from the group of 176, 71, or 101 genes informative of colon cancer prognosis is used to prepare a personalized genomic profile for a colon cancer patient. Information regarding microsatellite instability, DNA promoter methylation, and the mutational status of one or more oncogenes or tumor-suppressor genes can also be incorporated into an individual's personalized genomic profile. The genomic profile can be used to establish a personalized treatment plan for the colon cancer patient. Such treatment plan may consist of surgery, individual therapy, chemotherapy, radiation therapy or any combination thereof. In accordance with this aspect of the invention, the colon cancer patient is administered a cancer treatment based on the treatment plan.

FIG. 3 summarizes how a colon cancer patient's prognosis is determined using the 71, 101, or 176 gene predictor sets of the present invention. The left side of the figure outlines the steps involved in identifying genes predictive of colon cancer outcome generally, while the right side of the figure outlines the method of determining the prognosis of a subject having colon cancer of the present invention using three hypothetical patient samples where the expression of six genes is analyzed. First, the gene expression levels of at least five, but preferably all of the 71, 101, or 176 genes in a tumor sample obtained from the patient are determined and compared to average tumor sample expression levels. If gene expression for a particular gene is in the upper third of average tumor expression level in the patient sample and higher expression of that gene is associated with a bad disease expression profile, the patient is given a negative mark or negative score (see FIG. 3A). If, however, higher gene expression is associated with a good disease outcome, the patient is given a positive mark or score. As shown in the hypothetical example (FIG. 3B), the expression levels for genes A-F were assessed in samples 1-3. In sample 1, Genes A and C had expression values in the lower third of average tumor expression levels (see FIG. 3B, Table A, compare values in column 5 with values in column 2). Low expression of Genes A and C are associated with a good outcome (see FIG. 3B, Table A, column 4). Accordingly, sample 1 was given positive scores for these genes as indicated by the blue shading. Also in sample 1, Genes B and F had expression levels in the top third of average tumor expression levels. High expression of Gene B is associated with a bad outcome (sample 1 given negative score indicated by red shading), while high expression of Gene F is associated with a good outcome (blue shading). In total for sample 1, the expression levels of three genes was associated with a good disease outcome (i.e. Genes A, C, and F, FIG. 3B, Table B) resulting in a positive score of 3, while the expression level of one gene was associated with a bad disease outcome (i.e. Gene B) resulting in a negative score of 1 (genes E and F had neutral scores).

The negative and positive scores are converted to percentages based on the total number of genes analyzed. In the hypothetical example, sample 1 had 3 out of 6 genes, or 50%, with favorable or positive expression levels, and 1 out of 6 genes, or 17% with unfavorable or negative expression levels (FIG. 3B, Table C). The predicted outcome for the patient is determined by plotting the percentage of genes in the tumor sample that had expression values associated with a good disease outcome (y-axis) versus the percentage of genes in the tumor sample having expression levels associated with a bad disease outcome (x-axis) where the point of origin is set to 30%. In the hypothetical example, sample 1, with 50% of genes having expression levels associated with a good outcome and 17% of genes having expression levels associated with bad outcome falls into Group 2A, where the prognosis is generally favorable (FIG. 4B, scatterplot). Sample 2, with 17% of the genes having expression levels associated with a good outcome and 50% of the genes having expression levels associated with bad outcome falls into Group 4, where the prognosis is generally unfavorable. Sample 3, having 33% of the gene analyzed having expression levels associated a good outcome and 33% associated with a bad disease outcome binned to Group 3A, where the prognisis is generally inconclusive.

As indicated in FIG. 3A, supplementary analyses (i.e. LRAT methylation, MSI status, etc.) can be performed to provide additional prognostic information for patients that fall into intermediate groups (i.e. Groups 2 and 3) or to confirm the prognosis of those patients in Group 1.

As discussed supra, the predicted outcome for a patient, determined by gene expression levels as outlined above, can be used to guide treatment. For example, patients who bin to Group 1 have a favorable prognosis and may benefit from surgery only, whereas patients who bin to Group 4 have an unfavorable prognosis and may need to supplement surgery with chemotherapy or other more aggressive therapies. Treatment decisions should further take into consideration the stage of the tumor. For example, individuals with stage 2 tumors in Group 1 or 2A will most likely benefit from surgery without additional treatment. Individuals with stage 3 tumors in these groups are probably responsive to standard care. Individuals with stage 3 tumors in Groups 4 and 5 will most likely not be responsive to standard care, and thus would be candidates for enrolling into clinical trials of novel therapies.

The present invention is also directed to a method of identifying an agent that improves the prognosis of a subject having colon cancer. This method involves administering an agent (i.e., a candidate agent) to the subject having colon cancer and obtaining a first biological sample from the subject before said administering and a second biological sample from the subject after said administering. The method further involves detecting the expression level of at least five genes selected from the group of 176 genes informative of colon cancer prognosis disclosed supra. Determining increases or decreases in the expression levels of the at least five genes in the second sample compared to the first sample identifies an agent that improves the prognosis of a subject having colon cancer. In a preferred embodiment of this aspect of the present invention, the at least five genes is selected from the group of 71 genes informative of colon cancer prognosis disclosed supra.

In accordance with this aspect of the present invention, an agent that increases the expression levels of any one of the following genes: SERPINA1, RPLP0, RPLP0-like, CYB561, AKR1A1, AP3D1, ARL6IP4, OGFOD2, ASNA1, CFB, ERP29, SMG7, CASP1, CCNA2, LOC100131861, SAMM50, COX5A, CXCL11, DAZAP2, DDX23, FDFT1, COMMD4, GCHFR, GRHPR, GSR, ISG20, ITGAE, KIAA0746, SERINC2, FRYL, LRRC47, LAMP3, R3HCC1, MAPKAPK5, MCM5, MCRS1, TMEM106C, MMP3, MTUS1, LRRC41, NAT1, NDUFC1, YBX1, PEBP1, PIGR, PSMA5, SFPQ, SLC25A3, SLC39A8, SQRDL, SRP72, SSNA1, TAPBPL, TEGT, PBK, UCP2, UQCRH, XPO7, CCT2, CNOT7, DHX15, TMEM87A, ELP3, FAM82C, LL22NC03-5H6.5, DENND2D, WDR68, IL15RA, DENND2A, KIF13B, MFHAS1, SPATA5L1, MYRIP, PIGT, PSMD9, RPS27L, TNFRSF10B, UBE2L6, USP3, ATP5B, CALML4, C1orf144, TMEM33, C12orf52, GHITM, H2AFZ, LAP3, MRPL46, SORD, CNPY2, TNFSF10, U2AF2, CMPK1, UQCRFS1, WARS and WDR1 is an agent that improves the prognosis of a subject having colon cancer. An agent that causes a decrease in the expression levels of any one of the following genes: AK023058*, AIP, ARL2BP, C1GALT1, CDC42BPA, C8orf70, CLN5, COBL, CYB5B, MOSPD1, DOCK9, EGFR, FKBP14, DND1, DND1, GREM2, GPR177, GALNS, GRB10, GRP, GSTA1, RP3-377H14.5, HOXB7, ZNF117, TNIK, LANCL1, METRN, LEPREL1, NAB1, NISCH, OGT, OSBPL3, PDGFA, PRDM2, PRELP, PSPC1, RECQL, RYK, SMURF2, TLN1, UNC84A, USP12, ZMYM2, ZMYM5, AL359599*, ARL4A, N4BP2L2, GLS, C19orf36, TMCC1, METTL3, TMEM16A; RTN2, SCAMP1, SF3B1, SOX4, STK3, ZNF430, C6orf15, C7orf10, CHST12, ETV1, ACSL4, FLJ10357, C5orf23, AA058828*, CDR2L, KLC1, MAP4, NUMB, PAM, PGDS, PTHLH, ZC3H7B, SAV1, SGCD, SYNGR1, TES, IFT88, TRIM36 and VPS41 is an agent that improves the prognosis of a subject having colon cancer.

Another aspect of the present invention is directed to a collection of 71 genes having expression levels informative for predicting a prognosis of a patient having colon cancer. This collection of 71 genes includes the following genes of Table 1: SLC25A3, DAZAP2, TEGT, ERP29, PSMA5, DDX23, LOC100131861, SAMM50, SFPQ, NISCH, CYB5B, TMEM106C, EGFR, MCRS1, SERPINA1, CCNA2, NDUFC1, COX5A, GCHFR, ITGAE, PRDM2, PDGFA, GSR, GRP, COMMD4, XPO7, YBX1, SRP72, UCP2, SLC39A8, NAB1, WDR68, CXCL11, RECQL, CASP1, PTHLH, UNC84A, MTUS1, KIAA0746, SERINC2, DOCK9, FRYL, MAPKAPK5, LRRC47, RQCD1, TNIK, RPLP0, RPLP0-like, CLN5, NAT1, CDC42BPA, GSTA1, ZMYM5, RYK, PIGT, CMPK1, SQRDL, FAM82C, CNOT7, LL22NC03-5H6.5, PSPC1, TAPBPL, METRN, PBK, MRPL46, FKBP14, C1GALT1, GREM2, GPR177, DND1, and PRELP. The collection of 71 genes informative of predicting the prognosis of a patient having colon cancer can further include the following genes of Table 1: AA058828*, ACSL4, AIP, AK023058*, AKR1A1, AL359599*, AP3D1, ARL2BP, ARL4A, ARL61P4, OGFOD2, ASNA1, ATP5B, C12orf52, C19orf36, C1orf144, C5orf23, C6orf15, C7orf10, C8orf70, CALML4, CCT2, CDR2L, CFB, CHST12, CNPY2, COBL, CYB561, DENND2A, DENND2D, DHX15, DND1, ELP3, ETV1, FDFT1, FLJ10357, GALNS, GHITM, GLS, GRB10, GRHPR, H2AFZ, HOXB7, IFT88, IL15RA, ISG20, KIAA0746, SERINC2, KIF13B, KLC1, LAMP3, LANCL1, LAP3, LEPREL1, LRRC41, MAP4, MCM5, METTL3, MFHAS1, MMP3, MOSPD1, MYRIP, N4BP2L2, NUMB, OGT, OOSBPL3, PAM, PEBP1, PGDS, PIGR, PSMD9, R3HCC1, RP3-377H14.5, RPS27L, RTN2, SAV1, SCAMP1, SF3B1, SGCD, SLC39A8, SMG7, SMURF2, SORD, SOX4, SPATA5L1, SSNA1, STK3, SYNGR1, TEGT, TES, TLN1, TMCC1, TMEM16A, TMEM33, TMEM87A, TNFRSF10B, TNFSF10, TRIM36, U2AF2, UBE2L6, UCP2, UQCRFS1, UQCRH, USP12, USP3, VPS41, WARS, WDR1, ZC3H7B, ZMYM2, ZNF117, and ZNF430.

Also included in the present invention are arrays that are useful for practicing one or more of the above described methods. Such arrays consist of nucleic acid or peptide-based probes that are useful for detecting the expression of one or more genes, preferably at least five genes, from the collection of 71, 101, or 176 genes that are informative for predicting the prognosis of a subject having colon cancer, using any of the methods described supra for detecting gene expression. A variety of different array formats are known in the art with a wide variety of probe structures, substrate compositions, and attachment technologies (See e.g. U.S. Pat. Nos. 5,143,854 to Pirrung et al.; 5,288,644 to Beavis et al.; 5,324,633 to Fodor et al.; 5,432,049 to Fischer et al.; 5,470,710 to Weiss et al.; 5,492,806 to Drmanac et al.; 5,445,934 to Fodor et al.; 5,744,305 to Fodor et al.; 5,677,195 to Winkler et al.; 6,040,193 to Winkler et al.; and 5,424,186 to Fodor et al., which are all hereby incorporated by reference in their entirety). In a preferred embodiment, array(s) of the present invention consist of a plurality of nucleic acid probes, each nucleic acid probe having a nucleotide sequence that is complementary to at least a portion of a nucleotide sequence (e.g., RNA or DNA) of a gene selected from the collection of 71 genes, 101 genes, 176 genes, or any combination thereof. Exemplary nucleic acid probes having nucleotide sequences complementary to at least a portion of the nucleotide sequences (i.e., RNA transcript) encoded by the genes of the 71, 101, and 176 gene collections are provided in Tables 1 and 2, although variations of those probes, or other probes may also be suitable for use.

In a preferred embodiment of the present invention the arrays of the present invention are available together with suitable reagents as a kit. The kit can be used to determine gene expression levels in biological sample(s) from a subject having colon cancer and determine his or her prognosis. Additional reagents suitable for inclusion in such kits include, but are not limited to, gene specific primers for the collections of the 71, 101, and/or 176 genes, universal primers, dNTPs and/or rNTPS, fluorescent, biotinylated, or other post-synthesis labeling reagents, enzymes such as reverse transcriptase, DNA and/or RNA polymerases, and various wash and buffer mediums.

Another aspect of the present invention relates to a method for determining a subject's predisposition to having colon cancer. This method involves obtaining a biological sample from the subject and detecting the expression levels of at least five gene selected from the collection of 176 genes informative of colon cancer predisposition disclosed supra. The method further involves comparing the detected expression levels of the at least five genes from said sample with the expression levels of the corresponding five genes associated with a having a predisposition to colon cancer and determining the subject's predisposition to having colon cancer based on said comparing.

EXAMPLES
Example 1
Biological Sample Description and Collection

Expression array data was generated from 183 primary colon cancer (PCC) tumors, 46 large adenomas, 39 liver metastasis, 19 lung metastasis, 53 normal mucosa, 7 normal lung, and 12 normal liver tissues. In addition, SNP array data was collected from 89 colorectal (CRC) tissue samples (65 primary colon cancer, 9 liver metastasis, 10 lung metastasis, and 5 unclassified colon cancer), as well as 56 normal tissues (i.e., normal mucosa, liver, or kidney), 51 of which were matched to the CRC tissues. Tissue samples were obtained from CRC patients at Memorial Sloan Kettering Cancer Center (MSKCC), whose initial operations occurred between 1992 and 2004. Cancer samples included in SNP array analysis were characterized by pathologists (MSKCC) to have ≧70% pure tumor cells. Acquisition of tissues followed the strict protocols of the Institutional Review Boards of MSKCC and Cornell University Weill Medical College.

Example 2
RNA Preparation

Total RNA from microdissected tissue samples (both tumor and normal tissue samples) was prepared following the protocol recommended by Affymetrix (Santa Clara, Calif.). RNA was extracted from homogenized tissues using the Trizol protocol (Guanidinium thiocyanate-phenol-chloroform extraction) (Invitrogen Corp.) and purified using RNeasy columns (Qiagen).

Example 3
Genomic DNA Sample Extraction

Microdissected tissue samples (50-100 mg) were homogenized in liquid nitrogen and suspended in 400 ul proteinase K solution (50 ul 20 mg/ml proteinase K in proteinase K buffer). Phenol/chloroform (500 ul) was added and the mixture was shaken thoroughly in a phase lock gel tube. The upper aqueous layer containing genomic DNA was transferred to a separate tube and washed with isopropanol and 70% ethanol. The resulting pellet was resuspended in molecular biology-grade water.

Example 4
Expression Array

To generate the expression array data, the protocol recommended by Affymetrix, Inc. was strictly followed. Briefly, first strand cDNA was synthesized from 10 mg total RNA, using the One-Cycle cDNA Synthesis kit (which includes T7 (dT) primer, and SuperScript II Reverse Transcriptase). Additional reagents from the same kit (i.e., 2nd strand reaction mix, E. coli DNA ligase, and E. coli Polymerase I) were used to synthesize the 2nd strand cDNA. The cDNA product was transcribed in vitro to produce biotin-labeled cRNA, using MEGAscript T7 Kit (Ambion, Inc.). The labeled cRNA was fragmented and hybridized to GeneChip Human Genome U133A Array chip at 45° C. for 16 h. Afterwards, the arrays were washed and stained using SAPE (streptavidin-phycoerythrin) and biotinylated anti-streptavidin antibody. All of the washing and staining procedures were conducted using the Affymetrix Fluidic Station 450 (FS450). Following hybridization, the arrays were scanned using the GeneChip Scanner 3000. The Affymetrix GCOS software was used to generate image (DAT), cell intensity (CEL), and analysis (CHP) files for every sample. Standard thresholding, filtering operations, and normalizations were applied such that the average intensity value across all probesets for every sample was around 69.

Example 5
Kaplan-Meier Survival Analysis

The primary colorectal cancer samples were classified into two groups according to the level of gene expression as determined by the Affymetrix U133A expression array. Kaplan-Meier survival analysis was used to determine the disease-specific survival patterns on selected genes in areas of chromosomal aberrations. Follow-up (0-175 months; median 74 months) was censored at death from other causes for the Kaplan-Meier analysis. Statistical analysis and curves were generated using the JMP statistical software (version 5.1.2, SAS institute, Cary, N.C., USA).

Example 6
Identifying Genes That Predict Disease Outcome in Patients Having Colon Cancer

Primary colon tumor samples from 166 patients were used in the analysis to identify genes that are predictive of disease outcome. Of these samples, 56 were derived from patients that had died of disease (DOD), and 110 samples were derived from patient that either had no evidence of disease (NED) in long term follow up, were alive with disease (AWD), or died of other or unknown causes (DOC/DUC). Samples from the 110 patients who did not die of disease are collectively referred to as “non-DOD”.

FIG. 2 depicts the steps of identifying the 176 and 71 gene predictor sets of the present invention that are useful for predicting disease outcome in subjects having colon cancer. First, the expression levels of 22283 gene transcripts in the 166 primary colon cancer samples were analyzed and classified as having high, average, or low expression based on percentile ranks. An initial score was generated for gene expression in each sample wherein +1 was assigned for higher than average tumor expression and 0 for lower than average expression. A second score was also generated wherein +1 was assigned for expression levels in the top third of average tumor expression levels, 0 was assigned for expression levels in the middle third of average tumor expression levels, and −1 was assigned for expression levels in the bottom third of average tumor expression levels. Genes that had poor expression patterns as determined by the average expression level and the standard deviation, or genes that had expression patterns that did not differ significantly from normal samples were eliminated from the analysis (FIG. 2).

A computer analysis was performed to identify genes that had expression levels in the top third in samples from patients who died of disease (DOD) but in the bottom third in samples taken from patients who did not die of disease (non-DOD), and identify genes that had expression levels in the bottom third in samples from DOD patients, but in the top third in samples from non-DOD patients. This analysis identified genes that had different expression patterns in DOD and non-DOD samples and were candidates for further analysis.

A difference score for each of these candidate gene was then calculated by subtracting the total number of DOD tumor samples where gene expression was in the bottom third of tumor expression from the total number of DOD tumor samples where gene expression was in the top third of tumor expression. Genes having a difference score outside of 12 to 19 or -23 to −12 were eliminated from analysis while the remaining genes, 383 in total, were further analyzed using Kaplan-Meier survival curves (FIG. 2).

Kaplan-Maier curves were manually generated for all of the 383 genes using the JMP statistical analysis program (SAS Institute, Cary, N.C.). The chi-square values and p-values for all of these curves were then used to sort the genes by the greatest difference in survival based on expression. The 383 gene set that was identified based on difference scores was narrowed to 176 genes, where the 176 genes had KM curves with a p-value ≦0.02. The 176 gene set was further narrowed to 71 genes based on those genes having KM curves with a p-value of ≦0.0125 as shown in FIG. 2.

Table 3 below summarizes additional parameters calculated for each gene in the 176 gene set, which includes the 71 gene set. These parameters include (1) the average expression value for a particular gene across all tumor samples (“Ave Tumor”) and the standard deviation for expression for each gene probe used to detect expression (“Stdev Tumor”); (2) the difference score (“Diff”) which is the total number of DOD samples where the gene expression level was in the top third of tumor expression level minus the total number DOD samples where the gene expression level was in the bottom third of tumor expression level; (3) the percentage DOD samples having gene expression values in the top third of tumor expression (“D+1%”); (4) the percentage of DOD samples having gene expression values equal to the average, or the middle third of tumor expression (“D0%”); (5) the percentage of DOD samples having gene expression values in the bottom third of tumor expression (“D−1%”); (6) the percentage of difference between the two curves in the Kaplan-Meier analysis (“KM %”) calculated by dividing the number of DOD samples where the gene was expressed in the top third over the number of DOD and non-DOD samples where the gene was expressed in the top third; and 7) the chi-square and p-values of the KM survival curve analysis. The last two columns of Table 3 indicate whether increased (“up”) or decreased (“down”) expression of the particular gene predicts an unfavorable prognosis (“Bad Outcome Score”) or a favorable prognosis (“Good Outcome Score”).

TABLE 3

Gene Expression Data for the 176-Gene Predictor Set

D + 1 U1Bad
D − 1 Good

Accession
Avg
Stdev

KM

CHI

Outcome
Outcome

Gene Symbol
Number
Tumor
Tumor
Diff
%
D + 1%
D0%
D − 1%
Square
P value
Score
Score

CYB5-M
80777
155
75
19
35
53
31
18
12.1
0.0023
Up
down

PSPC1
55269
128
40
19
35
53
31
18
11.8
0.0027
Up
down

UNC84A
23353
404
130
19
35
51
35
16
11.7
0.0029
Up
down

CDC42BPA
8476
186
84
19
35
53
31
18
11.6
0.0030
Up
down

FLJ23091
79971
139
55
18
33
56
22
23
17.3
0.0002
Up
down

CIGALT1
56913
96
36
18
33
56
22
23
15.6
0.0004
Up
down

RYK
6259
101
32
18
33
51
33
18
12.1
0.0024
Up
down

MGC2601
79006
76
45
18
33
55
25
21
11.2
0.0037
Up
down

PRDM2
7799
127
30
18
33
51
33
18
9.9
0.0072
Up
down

KIAA0551
23043
108
48
18
33
47
40
14
9.4
0.0090
Up
down

FKBP14
55033
74
30
18
33
51
33
18
9.3
0.0091
Up
down

GSTA1
2938
89
22
18
33
49
37
16
8.9
0.0115
Up
down

FLJ21195
64388
29
22
17
31
53
27
21
15.6
0.0004
Up
down

EGFR
1956
135
55
17
31
55
24
23
15.2
0.0005
Up
down

NAB1
4664
276
96
17
31
51
31
20
12.7
0.0017
Up
down

ZNF237
9205
52
33
17
32
52
30
20
11.9
0.0026
Up
down

DOCK9
23348
185
418
17
32
48
38
16
11.1
0.0039
Up
down

PRELP
5549
127
68
17
32
51
31
19
9.9
0.0071
Up
down

FLJ20195
373863
96
32
17
32
50
34
18
8.8
0.0124
Up
down

FLJ20195
373863
121
31
17
32
48
38
16
7.9
0.0195
Up
down

PDGFA
5154
146
71
16
29
47
36
18
12.3
0.0021
Up
down

GRP
2922
60
59
16
29
49
33
20
12.1
0.0023
Up
down

PTHLH
5744
37
143
16
29
49
33
20
11.9
0.0026
Up

NISCH
11188
443
555
16
29
47
36
18
9.7
0.0078
Up
down

CLN5
1203
69
24
16
29
49
33
20
9.5
0.0086
Up
down

RECQL
5965
78
28
16
30
53
25
23
9.2
0.0101
Up
down

USP12
219333
163
62
16
29
49
33
20
8.6
0.0136
Up
down

DJ473B4
56180
177
68
16
29
49
33
20
8.5
0.0141
Up
down

OGT
8473
370
151
16
30
46
39
16
8.3
0.0157
Up
down

OSBPL3
26031
95
39
16
29
49
33
20
8.0
0.0180
Up
down

GALNS
2588
127
37
16
29
49
33
20
8.0
0.0184
Up
down

GLS
2744
209
96
16
29
45
40
16
10.4
0.0054

down

ZNF198
7750
282
94
15
28
47
35
20
14.1
0.0009
Up
down

HOXB7
3217
60
28
15
28
47
35
20
13.2
0.0014
Up
down

COBL
23242
172
73
15
28
47
35
20
11.8
0.0027
Up
down

GRB10
2887
228
115
15
28
49
31
21
11.6
0.0030
Up
down

PGDS
27306
41
24
15
30
53
26
23
11.0
0.0041
Up

TLN1
7094
134
39
15
28
49
31
21
10.7
0.0046
Up
down

AIP
9049
353
81
15
29
50
30
21
10.5
0.0054
Up
down

C7orf10
79783
21
24
15
28
47
35
20
10.3
0.0057
Up

MLAT4
55214
66
110
15
28
47
35
20
9.5
0.0088
Up
down

SGCD
6444
32
21
15
28
51
27
23
9.3
0.0094
Up

SMURF2
64750
196
82
15
28
47
35
20
9.2
0.0097
Up
down

H-plk
51351
108
44
15
28
49
31
21
9.1
0.0108
Up
down

HLA-F
285830
120
45
15
28
47
35
20
8.6
0.0134
Up
down

—

68
33
15
28
47
35
20
8.5
0.0139
Up
down

CGI-62
51101
132
58
15
29
50
30
21
8.2
0.0164
Up
down

LANCL1
10314
120
42
15
28
47
35
20
8.2
0.0165
Up
down

TRIM36
55521
36
24
15
28
47
35
20
7.8
0.0199
Up

RTN2
6253
90
45
15
28
45
38
18
10.4
0.0054

down

SOX4
6659
1055
392
15
28
44
42
16
9.5
0.0088

down

STK3
6788
136
70
15
28
45
38
18
8.6
0.0133

down

SCAMP1
9522
398
100
15
28
45
38
18
8.1
0.0177

down

KIAA0779
23023
125
45
15
28
45
38
18
8.0
0.0179

down

VPS41
27072
268
61
14
26
49
29
23
10.8
0.0044
Up

TES
26136
561
170
14
26
51
25
25
10.5
0.0051
Up

CHST12
55501
63
31
14
26
49
29
23
10.5
0.0053
Up

BART1
23568
49
133
14
30
47
38
18
10.4
0.0054
Up
down

PAM
5066
446
158
14
26
51
25
25
10.4
0.0056
Up

KNS2
3831
267
113
14
26
49
29
23
10.0
0.0067
Up

C6orf15
29113
45
88
14
26
49
30
23
9.4
0.0089
Up

HUMPPA
30850
64
86
14
26
49
29
23
9.0
0.0111
Up

FLJ14054
79614
63
50
14
26
51
26
25
8.6
0.0132
Up

RoXaN
23264
102
44
14
26
49
30
23
7.9
0.185
Up

ZNF430
80264
122
43
14
26
42
44
16
10.2
0.0060

down

—

70
27
14
26
42
44
16
8.8
0.0120

down

ARL4
10124
285
111
14
26
45
36
20
8.8
0.0121

down

OGT
8473
361
167
14
26
45
36
20
8.3
0.0158

down

SF3B1
23451
335
97
14
26
44
40
18
8.2
0.0163

down

SAV1
60485
80
43
13
24
51
24
27
12.1
0.0023
Up

FLJ10357
55701
115
50
13
24
51
24
27
10.6
0.0051
Up

ETV1
2115
37
32
13
24
51
24
27
10.0
0.0066
Up

FACL4
2182
58
31
13
24
49
27
25
9.4
0.0089
Up

FLT1

55
23
13
24
49
27
25
9.3
0.0092
Up

MAP4
4134
315
70
13
24
49
27
25
9.3
0.0094
Up

NUMB
8650
143
35
13
24
51
24
27
8.4
0.0149
Up

TG737
8100
207
89
13
25
49
28
25
8.2
0.0160
Up

CG005
10443
153
75
13
24
44
38
20
11.4
0.0033

down

SYNGR1
9145
55
26
12
22
49
25
27
9.9
0.0070
Up

ORAOV2
55107
88
94
12
23
42
41
19
10.2
0.0060

down

METTL3
56339
89
26
12
22
42
40
20
9.1
0.0107

down

IMAGE: 4215339
113177
24
32
12
23
42
41
19
8.9
0.0113

down

GHITM
227069
612
192
−13
−23
25
27
48
9.6
0.0081
down

WDR1
9948
754
179
−13
−23
25
27
48
8.8
0.0121
down

PBP
5037
509
173
−13
−23
27
24
50
8.2
0.0169
down

MGC5247
79029
132
57
−13
−23
18
42
41
11.0
0.0040

Up

FLJ22457
79961
159
49
−13
−23
19
41
41
8.9
0.0118

Up

USP3
9960
271
75
−13
−23
20
38
43
7.9
0.0191

Up

U2AF2
11338
111
47
−14
−25
24
29
48
11.3
0.0034
down

TNFSF10
8743
159
82
−14
−25
25
25
50
9.5
0.0084
down

DHX15
1665
1164
291
−14
−25
24
29
48
8.6
0.0132
down

UCP2
7351
379
261
−14
−25
25
25
50
8.5
0.0139
down

MFHAS1
9258
178
71
−14
−24
18
41
42
11.2
0.0036

Up

CCT2
10576
1156
310
−14
−25
20
36
45
11.0
0.0040

Up

TNFRSF10B
8795
74
40
−14
−25
20
36
45
10.1
0.0065

Up

IL15RA
3601
170
56
−14
−25
18
40
43
9.5
0.0086

Up

DHX15
1665
685
209
−14
−25
18
40
43
9.3
0.0097

Up

PSMD9
5715
292
83
−14
−25
20
36
45
8.6
0.0137

Up

ELP3
55140
78
24
−14
−25
20
36
45
8.2
0.0162

Up

TMEM4
10330
257
73
−15
−26
25
24
52
15.1
0.0005
down

ATP5B
506
2062
631
−15
−26
25
24
52
14.4
0.0007
down

LAP3
41056
593
288
−15
−26
25
24
52
14.2
0.0008
down

BF
629
246
142
−15
−26
22
31
48
12.3
0.0021
down
Up

SORD
6652
251
73
−15
−26
26
23
52
12.1
0.0023
down

WARS
7453
303
214
−15
−26
25
24
52
11.7
0.0029
down

PIGR
5284
473
567
−15
−26
22
31
48
11.3
0.0035
down
Up

CLN6
91860
192
98
−15
−26
25
24
52
10.4
0.0054
down

AKR1A1
10327
535
179
−15
−26
22
31
48
9.9
0.0068
down
Up

PBP
5037
1006
597
−15
−26
22
31
48
9.7
0.0076
down
Up

UQCRFS1
7386
1301
396
−15
−26
24
27
50
9.6
0.0080
down

MCM5
4174
95
221
−15
−26
22
31
48
9.4
0.0092
down
Up

DKFZp566C0424
26099
86
46
−15
−26
24
27
50
9.1
0.0107
down

UQCRH
7388
1537
506
−15
−26
22
31
48
8.9
0.0115
down
Up

MMP3
4314
311
321
−15
−26
22
31
48
8.9
0.0117
down
Up

ARL61P4

192
45
−15
−26
22
31
48
8.5
0.0142
down
Up

FLJ14827
84934
40
36
−15
−26
24
27
50
8.4
0.0153
down

FDFT1
2222
938
477
−15
−26
22
31
48
8.0
0.0181
down
Up

H2AFZ
3015
1025
472
−15
−26
24
27
50
7.9
0.0186
down

DKFZP564G2022
25963
576
318
−15
−26
18
38
45
13.0
0.0015

Up

RPS27L
51065
1489
480
−15
−26
20
35
46
12.2
0.0022

Up

KIAA1277
27147
49
31
−15
−26
20
35
46
11.1
0.0039

Up

UBE2L6
9246
435
200
−15
−26
18
38
45
10.4
0.0055

Up

KIF13B
23303
220
154
−15
−26
20
35
46
8.1
0.0167

Up

XPO7
23039
132
36
−16
−28
20
33
48
17.3
0.0002
down
Up

Clorf16
9887
56
33
−16
−27
22
29
49
13.6
0.0011
down
Up

TEGT
7009
1413
336
−16
−28
25
22
54
11.8
0.0027
down
Up

RQCD1

48
32
−16
−28
20
33
48
11.4
0.0033
down
Up

KIAA0826
285527
317
151
−16
−28
22
29
50
11.2
0.0036
down
Up

LAMP3
27074
72
46
−16
−28
22
29
50
11.1
0.0038
down
Up

SQRDL
58472
643
317
−16
−28
18
36
46
11.2
0.0038
down
Up

NAT1
9
165
81
−16
−28
20
33
48
10.7
0.0047
down
Up

NSEP1
4904
1957
735
−16
−28
20
33
48
10.5
0.0052
down
Up

KIAA0746

439
137
−16
−28
20
33
48
9.5
0.0085
down
Up

CCNA2
890
172
85
−16
−28
20
33
48
9.4
0.0087
down
Up

ISG20
3669
174
102
−16
−28
20
33
48
9.2
0.0099
down
Up

MTSG1
57509
283
121
−16
−28
18
36
46
9.0
0.0110
down
Up

AP3D1
8943
56
21
−16
−26
22
30
48
9.0
0.0113
down
Up

LOC203069
203069
108
35
−16
−28
22
29
50
8.9
0.0116
down
Up

SRP72
6731
574
143
−16
−28
20
33
48
8.8
0.0125
down
Up

—
1534
370
103
−16
−28
18
36
46
8.4
0.0147
down
Up

SSNA1
8636
183
47
−16
−28
20
33
48
8.0
0.0183
down
Up

FLJ10525
55161
206
67
−16
−28
22
29
50
7.8
0.0197
down

TEGT
7009
1252
328
−16
−28
15
44
43
23.1
0.0001

Up

FLJ10579
55177
228
52
−16
−28
16
40
45
13.6
0.0011

Up

FLJ20699
55020
114
72
−16
−28
16
40
45
9.2
0.0099

Up

MYRIP
25924
30
26
−16
−27
22
30
49
8.7
0.0131

Up

DAZAP2
9802
1313
275
−17
−30
20
31
50
15.5
0.0004
down
Up

UMP-CMPK
51727
800
256
−17
−30
24
24
54
14.9
0.0006
down

MRPL46
26589
147
43
−17
−30
24
24
54
14.3
0.0008
down

FLJ20452
54939
133
53
−17
−30
16
38
46
13.7
0.0011
down
Up

GCHFR
2644
122
54
−17
−30
20
31
50
13.1
0.0015
down
Up

ASNA1
439
214
51
−17
−30
20
31
50
11.7
0.0028
down
Up

TAPBP-R
55080
108
54
−17
−30
16
38
46
11.1
0.0039
down
Up

TOPK
55872
148
100
−17
−30
16
38
46
11.0
0.0041
down
Up

—
5265
990
1187
−17
−30
18
35
48
10.8
0.0046
down
Up

SERPINA1
5265
619
873
−17
−30
18
35
48
10.7
0.0047
down
Up

KIAA1185
57470
378
93
−17
−30
22
27
52
10.3
0.0057
down
Up

SLC39A8
64116
175
111
−17
−30
18
35
48
9.2
0.0100
down
Up

KIAA0746

765
256
−17
−30
18
35
48
8.5
0.0141
down
Up

MUF1
10489
156
48
−17
−30
20
31
50
7.8
0.0195
down
Up

HAN11
10238
83
28
−17
−30
15
42
45
14.2
0.0008

Up

CNOT7
29883
509
189
−17
−30
15
42
45
10.1
0.0065

Up

PIGT
51604
440
160
−17
−30
15
42
45
9.5
0.0084

Up

GSR
2936
132
92
−18
−32
18
33
50
15.5
0.0004
down
Up

ITGAE
3682
315
111
−18
−32
15
40
46
13.4
0.0012
down
Up

CASP1
834
92
74
−18
−32
18
33
50
12.1
0.0024
down
Up

UCP2
7351
271
102
−18
−32
18
33
50
11.5
0.0032
down
Up

DDX23
9416
171
76
−18
−32
18
33
50
11.2
0.0037
down
Up

CGI-51

146
208
−18
−32
18
33
50
9.8
0.0074
down
Up

COX5A
9377
1135
354
−19
−34
20
27
54
16.3
0.0003
down
Up

MAPKAPK5
8550
162
50
−19
−34
16
35
50
15.9
0.0004
down
Up

MCSR1
10445
202
63
−19
−34
20
27
54
13.9
0.0010
down
Up

—

2673
736
−19
−34
20
27
54
13.3
0.0012
down
Up

SLC25A3
5250
2389
573
−19
−34
16
35
50
13.4
0.0012
down
Up

PSMA5
5686
591
189
−19
−34
16
35
50
13.2
0.0013
down
Up

CXCL11
6373
116
210
−19
−34
20
27
54
12.5
0.0019
down
Up

GRHPR
9380
213
66
−19
−34
16
35
50
8.1
0.0169
down
Up

SFPQ
6421
716
188
−20
−34
22
22
56
16.6
0.0002
down
Up

NDUFC1
4717
744
298
−20
−35
18
29
54
14.4
0.0007
down
Up

C12orf8
10961
821
247
−21
−37
16
31
54
17.7
0.0001
down
Up

SLC39A8
64116
233
154
−21
−37
18
27
55
15.7
0.0004
down
Up

MGC5576
79022
577
215
−23
−41
20
20
61
30.6
0.0001
down
Up

Using the above-described methods, genes having expression levels above the average tumor expression level and genes having expression levels below the average tumor expression level in samples derived from patients who generally had poor outcome were discovered. The final list of validated genes was sorted by chromosomal location to identify consistent patterns of over or under expression that were chromosome location specific.

FIG. 4 is a scatterplot graphing the predicted survival outcome for the 166 stage I-IV primary colon cancers based on the 71 gene predictor set determined as outlined above. The x-axis of the plot depicts the percentage of genes for a given tumor sample that had expression values associated with a bad disease outcome. The y-axis of the plot depicted the percentage of genes for a given tumor sample that had expression values associated with a good disease outcome. Tumor samples from DOD patients (n=56) are represented by squares and all other samples (i.e., non-DOD) are represented by diamonds. Group 1 had good prognosis with only 6% being categorized as DOD. Group 4 had poor prognosis with 70% being categorized as DOD. Groups 2 and 3 had intermediate prognosis levels. Treatment, therefore, could be tailored to expected survival outcome as illustrated in the figure.

FIGS. 5A-E are scatterplots graphing the predicted outcomes for the 166 stage I-IV primary colon cancer tumor samples based on gene expression levels of the 71-genes in the 71-gene predictor set. The percentage of DOD patients increases steadily in each subgroup from Group 1 (0%) to Group 2A+2B (14%) to Group 3A+3B (42%) to Group 4 (69%) to Group 5+6 (83%). In FIGS. 5B, 5C, 5D and 5E, stage I, II, III and IV tumors are identified, respectively, and demonstrate binning is somewhat based on stage.

FIGS. 7 and 8 are scatterplots graphing the predicted outcome for the 166 stage I-IV primary colon cancer tumor samples based on gene expression levels of the 101 genes in the 101-gene predictor set ranked by the odds ratio analysis. The low risk category can be segregated from the intermediate and high risk categories by the lines indicated on the graph. The low risk category had 2% of patients who were in the DOD category. The high risk group by contrast had 87% of patients in the DOD category. The intermediate risk had 56% of patients in the DOD category. The predicted outcome for each patient can be used to tailor an individualized treatment plan for the patient as shown below each scatterplot.

FIGS. 9 and 10 are scatterplots graphing the predicted outcome for the 166 stage I-IV primary colon cancer tumor samples based on gene expression levels of the 71 genes in the 71-gene predictor set as shown in FIG. 4 with LRAT methylation status of various samples identified. Several DOD samples that had binned to group 1 based on gene expression levels had low to no LRAT methylation, which predicts poor prognosis. Removing these samples from group 1 based on LRAT methylation status improved the performance of the prognosis prediction in the low risk category. The low risk category in this analysis only had 3% of patients in the DOD category. The low risk groups had excellent prediction of good outcome. Group 1 does not contain patients with DOD status while Group 2A+2B only has 6% of patients with DOD status.

FIG. 11 is a scatterplot graphing the predicted outcome for the 166 stage I-IV primary colon cancer tumor samples based on gene expression levels of the 101 genes in the 101-gene predictor set ranked by difference score. Inclusion of LRAT methylation status was useful to reclassify some patient outcomes and improve the fidelity of prediction.

FIG. 16 shows the Kaplan Meier curves of genes found on the highly dysregulated chromosomal arm 8p. These genes, predictive of patient outcome, were identified from SNP and aberration studies from 89 tumor samples. In each case loss of expression of these genes was predictive of worse outcome, consistent with the common loss of the 8p chromosomal arm, where these genes are located.

Typically, Kaplan Meier curves revealed expression patterns with normal distribution (FIG. 19) or skewed distribution (FIG. 20), when expression levels were split into top, middle and bottom thirds.

Example 7
Validation of Genes That Predict Disease Outcome in Patients Having Colon Cancer

An additional 22 samples (FIG. 26), that were not included in the initial analysis, were used to validate the 71 gene list predictor set. None of the patient samples that binned to Group 1, where the prediction is for a good outcome, were derived from patients who DOD. Liver (FIG. 27) and lung (FIG. 28) metastases samples, largely binned to Group 4 when assessed for gene expression using the 71 gene predictor set. Large adenomas (FIG. 29), binned to group 1 in the majority of cases, unless there was the presence of synchronous metastases or tumor, consistent with early disease. Matched normal mucosa tissue (FIG. 30), adjacent to tumor, but no less than 10 cm from the tumor, when applied to the outcome predictor 71 gene set, binned to the various groups dependent upon outcome, possibly predicting a field effect or patient predisposition using expression profiling. FIG. 31 shows matched normal and tumor samples from the same patient, and the “direction” the expression profile of the outcome predictor 71 gene list, travels from normal to tumor samples, as indicated by the arrows. Typically, the normal tissue predicts a “better” outcome than the tumor tissue, again validating a role for this list of genes in tumor progression.

Example 8
Human Mapping (SNP) Array

SNP analysis was performed using the Affymetrix GeneChip Human Mapping 50K array Xba 240 array (or SNP array) following the protocol provided by Affymetrix (“GeneChip Mapping 100K Assay Manual”). Briefly, 0.25 μg of genomic DNA was digested with XbaI. The digests were ligated, PCR-amplified (such that the products were in the range of 250 to 2,000 bp), fragmented, biotin-labeled, and hybridized to the array. As in the expression array protocol, the SNP arrays also underwent staining and washing in Fluidics Station 450 (FS450) with the use of SAPE (streptavidin-phycoerythrin) and biotinylated anti-streptavidin antibody. The arrays were scanned in GeneChip Scanner 3000 to generate the image (DAT) and cell intensity (CEL) files. The CEL files were imported to GeneChip Genotyping Analysis Software (GTYPE) ver 4.1 software to generate the SNP calls.

Example 9
DNA Copy Number Analysis

The functionalities of Chromosomal Copy Number Analysis Tool (GNAT) software are embedded in GTYPE and the concepts and algorithms are initially described by Huang et al., “Whole Genome DNA Copy Number Changes Identified by High Density Oligonucleotide Arrays,” Hum. Genomics 1(4):287-99 (2004), which is hereby incorporated by reference in its entirety. GNAT uses the probe intensity data, as well as the GDAS-produced SNP calls to generate both the Single Point Analysis (SPA) and Genomic Smoothed Analysis (GSA) copy number (CN) estimates and the corresponding p-values. In addition, GNAT also generates the measures of loss of heterozygosity (LOH) based on the SNP calls. Once the SNP genotype calls and copy number estimates were obtained using GTYPE and GNAT, the data was further processed to refine the copy number data and to provide LOH calls that accommodate tissue and/or DNA aberration heterogeneity resulting in partially changed DNA (e.g. DNA with single gains at a given location in some of the strands and copy-neutral in other strands of the same chromosomal location). Regions of variation in copy number data are identified by applying segmentation and spatial filtering algorithms. The results are not constrained to integers. Sample-specific copy neutral, gain, and loss levels are obtained. For the LOH analysis, the SNPs that undergo an actual loss of heterozygosity from a normal control sample to the case sample are taken as input together with the SNPs that remain heterozygous. The majority of SNPs which are homozygous in the normal sample are ignored, as they are uninformative for regions of LOH. These two kind of SNPs are spatially averaged to allow for the effects of tissue heterogeneity. For those samples that lack a matched normal sample, the LOH values are inferred from the homozygosity data based on the relationship between these two quantities obtained from the matched tumor and normal samples.

Shown in FIGS. 17 and 18 are heat maps depicting the chromosomal aberrations (gain, loss, copy neutral LOH) for each colorectal cancer sample analyzed by SNP arrays. Also indicated are each patient's clinical status (AUN, alive unknown; AWD, alive with disease; DOC, dead of other causes; DOD, dead of disease; DUN, dead of unknown disease; NED, no evidence of disease). Each figure also indicates the status of microsatellite instability for each sample, which can be classified as MSS (microsatellite stable), MSI-H (high level of microsatellite instability), MSI-L (low level of microsateliite instability), according to the 5 marker-criteria set by Bolan et al., “A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International Criteria for the Determination of Microsatellite Instability in Colorectal Cancer” Cancer Research 58:5248-57 (1998), which is hereby incorporated by reference in its entirety. In addition, a sample may be categorized as MSI-H-P (high level of microsatellite instability), in accordance to the three marker-criteria suggested by Nash et al., “Automated, Multiplex Assay for High-Frequency Microsatellite Instability in Colorectal Cancer” J Clin Oncol 21:3105-12 (2003), which is hereby incorporated by reference in its entirety.

Example 10
Gene Expression Dysregulation in Regions of Chromosomal Aberrations

The simultaneous use of SNP and expression arrays allows one to analyze the patterns of gene expression in chromosomal regions usually characterized by aberrations (copy gains/losses involving either whole chromosomal arms, or regions of smaller size). Chromosomal arms 7p, 7q, 8q, 13q, 20p, and 20q, which usually gain additional copies in colorectal cancer, also have a high percentage of upregulated genes (see FIG. 13). On the other hand, the chromosomal arms 4q, 8p, 14q, 17p, 18p, and 18q, which are often lost in colorectal cancer, are marked by a high proportion of downregulated genes (FIG. 13). To determine if a gene is downregulated/upregulated, (z_ps)_Ti=(PS_Ti−AvePS_N)/(σPS)_Nwas calculated, where PS_Ti; is the normalized intensity level of a probeset (ps) (which represents a given gene) for the tumor sample Ti, AvePS_Nis the average intensity of a probeset (ps) among the normal mucosa samples, (σPS)_Nis the standard deviation of the intensity of ps among the normal mucosa samples. The percent upregulation of a given gene (100 (# tumor samples with z_ps≧3)/71) and the percent downregulation of a given gene (100 (# tumor samples with z_ps≦3)/71) was also calculated. “71” refers to the number of tumor samples represented in both SNP and expression array analyses. In FIG. 12, a red circle represents a gene whose percent upregulation is at least 10, while a green circle represents a gene whose percent downregulation is at least 10. As shown in FIG. 13, the highest upregulation rates occur in the 20q, 13q, 8q, 20p, 7p, and 7q chromosome arms, while downregulation of genes is most often seen in 18p, 18q, 17p, 14q, 15q, 4q and 8p chromosome arms. Therefore, the direction of changes in gene expression levels is often consistent with the types of aberrations occurring in the chromosomal arms where these genes are located. The effect of copy number to gene expression is also illustrated in FIG. 14. As demonstrated in this figure, the often lost 8p arm is populated by genes with reduced levels of expression, while the usually gained 8q arm contains a high percentage of upregulated genes. The expression levels of the top disregulated genes in those aneuploid chromosomes/chromosome arms are concordant with their prognostic effects. In other words, whether the lower expression of a gene considered downregulated, and higher expression of a gene considered upregulated, are indicative of poorer prognosis among the colon cancer patients was investigated. This was done by generating Kaplan-Meier (KM) plots based entirely on the levels of expression (182 colon cancer samples were divided into two: high expression and low expression groups) of the dysregulated genes indicated in FIG. 12. Table 4 is a list of 59 dysregulated genes which satisfied the following criteria: a) the p-value (log rank or Wilcoxon) for KM is less than or equal to 0.05, and b) lower expression levels of downregulated genes, or higher expression levels of upregulated genes correlating to worse clinical outcome.

TABLE 4

Chromosomal Aberrations Corresponding to Expression Changes and Outcome

Chromosomal
Class-
Accession

Probe
Gene

Location_—
ifica-
# (Entrez

Set ID
ID
AKA
Gene Title
MDB
tion
Gene ID)
Probe Sequence(s)

202678_at
GTF2A2
HsT18745,
general
chr15q22.2
Loss_—
2958
AAGCCATGGCATATCAG

TF2A2,
transcription

down

TTATACAG

TFIIA
factor IIA, 2,

(SEQ ID NO: 5379)

12 kDa

TGGGAAACAGTCTTCAG

GAGAGCCT

(SEQ ID NO: 5380)

TCATACAGTCTCAACAG

ATCACCCC

(SEQ ID NO: 5381)

TTGCCCTTCAAGTTCTA

CTTCAGTT

(SEQ ID NO: 5382)

TGCAGCACTGGCTCAGA

GGGTCAGG

(SEQ ID NO: 5383)

TCAGGGGCTCTCTAAAT

ACGTACAG

(SEQ ID NO: 5384)

GATTCTGCGATAATGTG

TGGACTTT

(SEQ ID NO: 5385)

AATACTGGCTCCAATAC

TACAGAAT

(SEQ ID NO: 5386)

CACCATCTTCTGTTATT

CATTGCTT

(SEQ ID NO: 5387)

GAAACTTGTAACTCTGT

AGCCTCTT

(SEQ ID NO: 5388)

CCTCTTACATCACCTTT

ATTATACA

(SEQ ID NO: 5389)

219060_at
C8orf
FLJ10204
chromosome 8
chr8q24.13
Gain_—
55093
AAGCTATCCTTTCATCG

32

open reading

up

AGGACAGC

frame 32

(SEQ ID NO: 5390)

ACATTATGGTACAGTTG

GCTTGGAA

(SEQ ID NO: 5391)

GGCTTGGAATTATGTCT

TTCTCTTT

(SEQ ID NO: 5392)

GTGCGTACTTGCTAAGAT

ATTCCTG

(SEQ ID NO: 5393)

GATATTCCTGTGGCTCA

TGCGTTAC

(SEQ ID NO: 5394)

GCGTTACAACACGAGGA

CTTAAGCC

(SEQ ID NO: 5395)

AAGCCAGTAATCGTTTT

TGTTCAGA

(SEQ ID NO: 5396)

AGAGGTGTGGAGGTAGA

GCCAGCCC

(SEQ ID NO: 5397)

TGTCTCTCCAGCTACAT

TGTAAGTT

(SEQ ID NO: 5398)

AAATGCCCATAAAAGGT

GCCCATAA

(SEQ ID NO: 5399)

AGCCCTCTCAGACTTGA

GCGTTAAT

201950_x_at
CAPZB
RP4-
capping protein
chr1p36.1
Loss_—
832
ACAAGTTGACCTCCACG

657E11.7,
(actin filament)

down

GTGATGCT

CAPB,
muscle Z-line,

(SEQ ID NO: 5401)

CAPPB,
beta

GATGCTGTGGCTGCAGA

CAPZ

CCAACAAA

MGC104401,

(SEQ ID NO: 5402)

MGC129749,

GACCAACAAATCTGGCT

MGC129750

CTGGCACC

(SEQ ID NO: 5403)

GGCACCATGAACCTCGG

AGGCAGCC

(SEQ ID NO: 5404)

TGAAACTGTGAGTGACT

GCTCCCCA

(SEQ ID NO: 5405)

TCCCCACACATAGCCAA

CATCGGGC

(SEQ ID NO: 5406)

ACATCGGGCGCCTGGTA

GAGGACAT

(SEQ ID NO: 5407)

CTGTTTCATGCTAACCA

GACACGCC

(SEQ ID NO: 5408)

TGCACTCGTTAGATTCC

TTTCTTAG

(SEQ ID NO: 5409)

AACAGCTGCATCATTGA

CCGCACAG

(SEQ ID NO: 5410)

AGAATAAAGCCGATAGC

CACCTCCT

(SEQ ID NO: 5411)

211595_s_at
MRPS11
HCC-2;
mitochondrial
chr15q25
Loss_—
64963
ACACAGATCCAGGTAGT

FLJ22512;
ribosomal

down

CTCTGCTA

FLJ23406
protein S11

(SEQID NO: 5412)

GTCTCTGCTAGTAATG

AGCCCCTTG

(SEQ ID NO: 5413)

AGCACAGACAGCAGGCA

TAGCCGCA

(SEQ ID NO: 5414)

AGCCGCAGCGGCGAGAG

CTAAACAA

(SEQ ID NO: 5415)

CAAAAGGGCGTGATCCA

CATCCGAG

(SEQ ID NO: 5416)

TTGTCTGCCATGCACGG

ACTGATCA

(SEQ ID NO: 5417)

GGACTGATCATGGGCGG

CCTGGAAG

(SEQ ID NO: 5418)

CTCAGCTCCAGTGGGAC

CTTGTAAA

(SEQ ID NO: 5419)

GGACCTTGTAAAATGCT

CCCTGTCA

(SEQ ID NO: 5420)

TCCCTGTCAGAGCTCTC

CAGAATAT

(SEQ ID NO: 5421)

GGTGTGCCCCAGAAGTA

AGCTTTGC

(SEQ ID NO: 5422)

212447_at
KBTBD2
BKLHD1
kelch repeat
chr7p14.3
Gain_—
25948
ACAGGTCTTCCAGTCAG

and BTB (POZ)

up

CTGGTCAT

domain

(SEQ ID NO: 5423)

containing 2

CAGTAAGAATTGCCAGC

CACTCATT

(SEQ ID NO: 5424)

CCACTCATTGTGCGGGT

CTGCGTGG

(SEQ ID NO: 5425)

AAGCCTCCACTTTCTGT

ATTATGTT

(SEQ ID NO: 5426)

GCTGATGTAGTTCTCCA

TCTTCAAG

(SEQ ID NO: 5427)

CAGGAATTCTCTGCACT

AGCTGTGC

(SEQ ID NO: 5428)

AACTAGCGCTGCTCTGG

CATTAATC

(SEQ ID NO: 5429)

AATCCCAGGAACCACTA

GCAGTAGT

(SEQ ID NO: 5430)

CGCCGCCAATCTAACAT

GAGCACAG

(SEQ ID NO: 5431)

AGCACAGGTGCTTCATG

ACAAACAT

(SEQ ID NO: 5432)

TCAACTGCACCATGTTC

TGGCACTG

(SEQ ID NO: 5433)

202675_at
SDHB
FLJ92337,
succinate
chr1p36.1-
Loss_—
6390
ACCCTCTTCCACACATG

IP, PGL4,
dehydrogenase
p35
down

TATGTGAT

SDH, SDH1,
complex,

(SEQ ID NO: 5434)

SDHIP
subunit B,

AAAGGATCTTGTTCCC

iron sulfur

GATTTGAGC

(Ip)

(SEQ ID NO: 5435)

GTTCCCGATTTGAGCAA

CTTCTATG

(SEQ ID NO: 5436)

TTTGAGCAACTTCTATG

CACAGTAC

(SEQ ID NO: 5437)

AGGATGAATCTCAGGAA

GGCAAGCA

(SEQ ID NO: 5438)

GCAGTCCATAGAAGAGC

GTGAGAAA

(SEQ ID NO: 5439)

AAGAGCGTGAGAAACTG

GACGGGCT

(SEQ ID NO: 5440)

GGAACGGAGACAAATAT

CTGGGGCC

(SEQ ID NO: 5441)

ATATCTGGGGCCTGCAG

TTCTTATG

(SEQ ID NO: 5442)

CTGCAGTTCTTATGCAG

GCCTATCG

(SEQ ID NO: 5443)

GATGACTTCACAGAGGA

GCGCCTGG

(SEQ ID NO: 5444)

202838_at
FUCA1
RP11-
fucosidase,
chr1p34
Loss_—
2517
AGAAAGAGGCGCTGCTC

45G17.1,
alpha-L-1,

down

ACTGTTTT

FUCA
tissue

(SEQ ID NO: 5445)

TAATCAACGAACTTCTC

TTCTCCAC

(SEQ ID NO: 5446)

CTCCACCCAGAGATGGC

TTTTCCAA

(SEQ ID NO: 5447)

ACAATGGAATCTTCCCT

CTGTTCTC

(SEQ ID NO: 5448)

CTCTGATAACCTACTTG

CTTACTCA

(SEQ ID NO: 5449)

CAATGCCTTTAAGCCAA

GTCACCCT

(SEQ ID NO: 5450)

CCAAGTCACCCTGTTGC

CTATGGGA

(SEQ ID NO: 5451)

GATTTGGCAAGCTCAAC

CACATGCT

(SEQ ID NO: 5452)

GTTGTCACCAACAGTCT

TTCTGCAA

(SEQ ID NO: 5453)

GGAAAAGGCTTACCAGG

CTGCTATG

(SEQ ID NO: 5454)

GGCTGCTATGGTCAACT

CTTCAGAA

(SEQ ID NO: 5455)

216510_x_at
EXOC7
2-5-3p,
immunoglobulin
chr17q25.1
Loss_—
28396///
AGTGGGTCTCAGCTATT

DKFZp686J
heavy constant

down
3493///
AGTGGGAG

04253,
alpha 1///

3495///
(SEQ ID NO: 5456)

EX070,
immunoglobulin

3500///
TCAGCTATTAGTGGGAG

EXO70,
heavy constant

3507///
TGCAGGTA

EXOC1,
delta///

3509
(SEQ ID NO: 5457)

Exo70p,
immunoglobulin

GGAGTGCAGGTACCACA

FLJ40965,
heavy constant

TACTACGC

FLJ46415,
gamma 1 (G1m

(SEQ ID NO: 5458)

YJL085W
marker)///

CAGGTACCACATACTAC

immunoglobulin

GCAGACTC

heavy constant

(SEQ ID NO: 5459)

mu///

TACGCAGACTCCGTGAA

immunoglobulin

GGGCCGGT

heavy variable

(SEQ ID NO: 5460)

group///

TTCACCACCTCCAGAGA

immunoglobulin

CAATTCCA

heavy variable

(SEQ ID NO: 5461)

4-31

GACAATTCCAAGAACAC

GCTGTATC

(SEQ ID NO: 5462)

CAAGAACACGCTGTATC

TGCAAATG

(SEQ ID NO: 5463)

CTGAGAGCCGAGGACAC

GGCCGTAT

(SEQ ID NO: 5464)

GACACGGCCGTATATTA

CTGTGCGA

(SEQ ID NO: 5465)

GCCGTATATTACTGTGC

GAAATCCC

(SEQ ID NO: 5466)

221774_x_at
FAM48A
C13;
family with
chr13q13.3
Gain_—
55578
ATACTTCAAGTCTCAGG

FP757;
sequence

up

CCCTTAAA

P38IP;
similarity 48,

(SEQ ID NO: 5467)

C13orf19;
member A

CTTAAATCTACTCCAG

bA421P11.4

CTTCCAGGT

(SEQ ID NO: 5468)

TATTTTTAACACTCTG

CAGCAGCAG

(SEQ ID NO: 5469)

GTAGTCCTCAACAGCCA

GGGGAGCA

(SEQ ID NO: 5470)

CAAGAACAGGCCTTATC

TGCTCAGC

(SEQ ID NO: 5471)

CAGTCACAGGCAGCTGC

AGTTGCGA

(SEQ ID NO: 5472)

GCAGTTGCGATTCTTGC

AGCATCAA

(SEQ ID NO: 5473)

GCAGCAGCAGCACAAAC

AGCTCAGC

(SEQ ID NO: 5474)

AGCTCAGCTACATCATC

ATCGGCAT

(SEQ ID NO: 5475)

TCATCGGCATACAGGCA

GCCAGTCA

(SEQ ID NO: 5476)

GTCTTGCATTACTTTTT

GTTCCTTT

(SEQ IDNO: 5477)

200027_at
NARS
ASNRS,
asparaginyl-
chr18q21.2-
Loss_—
4677
ATCTTTTCTAACTCTGC

NARS1
tRNA
q21.3
down

TTAGCTGC

synthetase

(SEQ ID NO: 5478)

AGCTGCTAATAATCCTG

AGGCATAG

(SEQ ID NO: 5479)

TAGTGATTCACAGTATC

CCTCTTAG

(SEQ ID NO: 5480)

AGTATCCCTCTTAGCAT

TAATTTAA

(SEQ ID NO: 5481)

GAGGCAGATTGATITTC

CCTCTTTC

(SEQ ID NO: 5482)

CCCACCATGTCCTTAGA

TCTAATCT

(SEQ ID NO: 5483)

TAGATCTAATCTGTGCT

ACCTTATT

(SEQ ID NO: 5484)

GCTACCTTATTAACTCA

CAGCAGGC

(SEQ ID NO: 5485)

ACAGCAGGCTTACTGAA

TGGCTTCA

(SEQ ID NO: 5486)

CAGATTTAGTTGATTTC

TCCACCAA

(SEQ ID NO: 5487)

GCATGTCATGTATTCTC

AATAGGCT

(SEQ ID NO: 5488)

208540_x_at
LOC
S100A11P
hypothetical
chr7q22.1
Gain_—
729659
ATGGCAAAAATCTCCAG

729659

LOC729659

up

CCCTACAG

(SEQ ID NO: 5489)

CTCCAGCCCTACAGAGA

CTGAGCGG

(SEQ ID NO: 5490)

GACTGAGCGGTGCATTG

AGTCCCTG

(SEQ ID NO: 5491)

AGTCCCTGATTGCTGTT

TTCCAGAA

(SEQ ID NO: 5492)

GGATGGTTACAACCGCA

ATCTCTCC

(SEQ ID NO: 5493)

CAACCGCAATCTCTCCA

AGACGGAG

(SEQ ID NO: 5494)

GACGGAGTTCCTAAGCT

TCATGAAT

(SEQ ID NO: 5495)

GAGCTGGCTGCCTTTAC

AAAGAACC

(SEQ ID NO: 5496)

CCGGTGTCCTTGACCAC

ATGAAGAA

(SEQ ID NO: 5497)

GATGTCAGCAGTGATGG

GCAGTTAG

(SEQ ID NO: 5498)

AATCTGATTGGTGGCCT

AGCTGTGG

(SEQ ID NO: 5499)

208813_at
GOT1
GIG18
glutamic-
chr10q24.1-
Loss_—
2805
ATGGCTGACCGGATTCT

oxaloacetic
q25.1
down

GACCATGA

transaminase 1,

(SEQ ID NO: 5500)

soluble

GGCACGACTAGAAGCCC

(aspartate

TCAAAACC

amino-

(SEQ ID NO: 5501)

transferase

AAATTGGCATGTTCAG

1)

CTTCACTGG

(SEQ ID NO: 5502)

GCTGCCAAGTGGTCGAA

TCAACGTG

(SEQ ID NO: 5503)

CTCCATCCATGAAGCAG

TCACCAAA

(SEQ ID NO: 5504)

TCCAGTGAAGAAACACC

ACCCGTCC

(SEQ ID NO: 5505)

GTCCAGTACCACCAAAG

TAGTTCTC

(SEQ ID NO: 5506)

CTGCCTGCACAAACCTA

CATGTACA

(SEQ ID NO: 5507)

GACTGAAAGGCTGCTCT

GGTGAGGC

(SEQ ID NO: 5508)

TAAACCGGCCCCACATG

AAGAGAAC

(SEQ ID NO: 5509)

GAGAACATCCCTTGAGA

CGAATTTG

(SEQ ID NO: 5510)

218371_s_at
PSPC1
RP11-
paraspeckle
chr13q12.11
Gain_—
55269
ATGTGGCTGAAGTTACC

523H24.2,
component 1

up

CGAAGTTC

DKFZp566B

(SEQ ID NO: 5511)

1447,

GTTACCCGAAGTTCAGC

FLJ10955,

TTGCAGTG

PSP1

(SEQ ID NO: 5512)

AGTTCAGCTTGCAGTGT

AATTCAGA

(SEQ ID NO: 5513)

GAATCATACTTCCTTTC

AGGTCAAA

(SEQ ID NO: 5514)

GTGGGAAATATCCTGTT

CGTGACCT

(SEQ ID NO: 5515)

TCCTGTTCGTGACCTAG

GAGAAACA

(SEQ ID NO: 5516)

TTCTTACTCCATACAAG

CAGTTTAT

(SEQ ID NO: 5517)

AAACATGCTACAGGGGC

ACATTTTC

(SEQ ID NO: 5518)

ACAGGGGCACATTTTCT

GTGGTTAA

(SEQ ID NO: 5519)

GCAGTTTTCCTTTGCAT

TGAGGGTT

(SEQ ID NO: 5520)

CTTTGCATTGAGGGTTT

TGGCTTTT

(SEQ ID NO: 5521)

202962_at
KIF13B
GAKIN,
kinesin family
chr8p21.1
Loss_—
23303
ATGTTTCTGGGCCTACC

KIAA0639
member 13B

down

AAGGTTCA

(SEQ ID NO: 5522)

CTGGGAATGTGACTGCT

GGAGCCTG

(SEQ ID NO: 5523)

TGAGAGTGTGTGTTGGT

GGCTGTGC

(SEQ ID NO: 5524)

ACAAGACGGGAGTCACC

CTGTGCTT

(SEQ ID NO: 5525)

CCAAGATACTGACCCAT

TGAACCCC

(SEQ ID NO: 5526)

TTCTCTCCACAAAGTCC

GTGGTGCC

(SEQ ID NO: 5527)

GGTGGGCTGCAGACACT

AATGGTGT

(SEQ ID NO: 5528)

GGTCTTGGAACAGCTTC

TCTATGTG

(SEQ ID NO: 5529)

GCTTCTCTATGTGTGGA

TTCGTGTA

(SEQ ID NO: 5530)

AACCACCTGTAATTTTG

TACCATAT

(SEQ ID NO: 5531)

GTACCATATGTGTCTTC

CATCAAA

(SEQ ID NO: 5532)

212166_at
XPO7
KIAA0745,
exportin 7
chr8p21
Loss_—
23039
ATTCCTGTTACTGTATT

RANBP16

down

AACCCTTG

(SEQ ID NO: 5533)

GGAACTCTAAGCCATGC

CAGAACAC

(SEQ ID NO: 5534)

CCCTAGCCCCTTGCAGT

GATAAATA

(SEQ ID NO: 5535)

GTGTTTGGTGTTCTTAT

CTCCACCC

(SEQ ID NO: 5536)

TCAGACAGATGCCTCTT

GCTTTTAA

(SEQ ID NO: 5537)

ACGTGTTGTAGGGTTCT

TGGTCTGT

(SEQ ID NO: 5538)

GAGAAGGAAGTGAGCCC

ACTGCTCT

(SEQ ID NO: 5539)

ATGTGGGTGAGTCCACC

AGAGGCCC

(SEQ ID NO: 5540)

CCAGCCCTCGAGGCAGT

GTGTGTGG

(SEQ ID NO: 5541)

ATATGTACCCTGCACTC

ATGAATGT

(SEQ ID NO: 5542)

GAAGTATTTAACATTCT

CCCATCCC

(SEQ ID NO: 5543)

217962_at
NOLA3
MGC70651,
nucleolar protein
chr15q14-
Loss_—
55505
ATTGACGAACACGTGAC

NOP10,
family A, member
q15
down

GCGGTCGG

NOP10P
3 (H/ACA small

(SEQ ID NO: 5544)

nucleolar RNPs)

CGGACCACTGCAGACTG

AGCGGTGG

(SEQ ID NO: 5545)

GATCATGTTCTCCAGTA

TTACCTC

(SEQ ID NO: 5546)

TGACCCGATGGGACAAC

AGACCTGC

(SEQ ID NO: 5547)

GGTTCTCCCCAGATGAC

AAATACTC

(SEQ ID NO: 5548)

TCTCGACACCGAATCAC

CATCAAGA

(SEQ ID NO: 5549)

GCTTCAAGGTGCTCATG

ACCCAGCA

(SEQ ID NO: 5550)

TGAGGGTCCCTTAAACT

GATGTCTT

(SEQ ID NO: 5551)

GAGACTCCGTAACCAAA

CTCTTCGG

(SEQ ID NO: 5552)

ACCAAACTCTTCGGACT

GTGAGCCC

(SEQ ID NO: 5553)

GCCATACTCTTTGGCAT

CCAGTCTC

(SEQ ID NO: 5554)

218273_s_at
PPM2C
FLJ32517,
protein
chr8q22.1
Gain_—
54704
ATTGACTTTGCAGCAGG

MGC119646,
phosphatase 2C,

up

GTGGCAGG

PDH, PDP,
magnesium-

(SEQ ID NO: 5555)

PDP1,
dependent,

GTCCTGCCTAGCTCAGA

PDPC
catalytic

TTTCATGG

subunit

(SEQ ID NO: 5556)

CAGATTTCATGGCACCT

GCACTTGA

(SEQ ID NO: 5557)

CACTTCTTTATCACAGG

TGTCTTGA

(SEQ ID NO: 5558)

TAGCTTCTTTTACCAAC

CTGAGAAA

(SEQ ID NO: 5559)

GTATCTTGCTGTGTGTA

GTCTCTTG

(SEQ ID NO: 5560)

TCACACCTTTCTTCACT

GAGATTCC

(SEQ ID NO: 5561)

TCCAGTTCTTCAAGCCA

TAAATGAC

(SEQ ID NO: 5562)

GATTATTTGACTGGAAT

GCTTCTTA

(SEQ ID NO: 5563)

GAATAACTATACTCCGT

TATCCACC

(SEQ ID NO: 5564)

TATCCACCCGATTTCCT

AATGTAAT

(SEQ ID NO: 5565)

200847_s_at
TMEM66
FLJ22274,
trans-
chr8p12
Loss_—
51669
ATTTCTAAAACCTGTGA

FOAP-7,
protein 66

down

TGCCCTAA

HSPC035,

(SEQ ID NO: 5566)

MGC8721,

AGGTGGTTGTAGCTGAT

XTP3

GAGTTATT

(SEQ ID NO: 5567)

TTATGCTAATTTGTGAG

TTCTGATC

(SEQ ID NO: 5568)

TCTGATCACTTTTGAGC

TCTGAAGC

(SEQ ID NO: 5569)

GAGCTCTGAAGCTTTGA

ATCATTCA

(SEQ ID NO: 5570)

TCAGTGGTGGAGATGGC

CTTCTGGT

(SEQ ID NO: 5571)

GGAGATGGCCTTCTGGT

AACTGAAT

(SEQ ID NO: 5572)

TAACTGAATATTACCTT

CTGTAGGA

(SEQ ID NO: 5573)

TGTGAATGACTCTGTGC

TGGCAAAA

(SEQ ID NO: 5574)

AAACCTCTATATTTCTT

TCGTTCAT

(SEQ ID NO: 5575)

TAACAAAAGCATGCAGT

TCTCTGTG

(SEQ ID NO: 5576)

209374_s_at
IGHM
DKFZp686I
immunoglobulin
chr14q32.33
Loss_—
3507
CACCATCACGTGCCTGG

15196,
heavy constant

down

TGACGGGC

DKFZp686I
mu

(SEQ ID NO: 5577)

15212,

GACGTCTTCGTGCAGTG

FLJ00385,

GATGCAGA

MGC104996,

(SEQ ID NO: 5578)

MGC52291,

GCAGTGGATGCAGAGGG

MU, VH

GGCAGCCC

(SEQ ID NO: 5579)

GATGCAGAGGGGGCAGC

CCTTGTCC

(SEQ ID NO: 5580)

GCCCTTGTCCCCGGAGA

AGTATGTG

(SEQ ID NO: 5581)

CCGGAGAAGTATGTGAC

CAGCGCCC

(SEQ ID NO: 5582)

CATCCTGACCGTGTCCG

AAGAGGAA

(SEQ ID NO: 5583)

GACCGTGTCCGAAGAGG

AATGGAAC

(SEQ ID NO: 5584)

TGCCCAACAGGGTCACC

GAGAGGAC

(SEQ ID NO: 5585)

GTCACCGAGAGGACCGT

GGACAAGT

(SEQ ID NO: 5586)

CGAGAGGACCGTGGACA

AGTCCACC

(SEQ ID NO: 5587)

54970_at
ZMIZ2
DKFZp761I
zinc finger,
chr7p13
Gain_—
83637
CAGCTTCAAGCAGAGG

2123,
MIZ-type

up

CCTCGGGGT

KIAA1886,
containing 2

(SEQ ID NO: 5588)

ZIMP7,

TGTAGAAACACTAACAG

hZIMP7

CTGGGAGA

(SEQ ID NO: 5589)

ATCAGGGAGGAACCTCC

AATGGGTG

(SEQ ID NO: 5590)

AGGAGGAAGCCACTGCA

TCTGTTGG

(SEQ ID NO: 5591)

GCATCTGTTGGCTCAGG

GCCCCAGC

(SEQ ID NO: 5592)

CGCCTGGGCTGTTGTGT

CTCCTGTC

(SEQ ID NO: 5593)

CTGTTGTGTCTCCTGTC

TGTGCCGA

(SEQ ID NO: 5594)

GTTGTGTCTCCTGTCTG

TGCCGATC

(SEQ ID NO: 5595)

TGTCTCCTGTCTGTGCC

GATCTCTA

(SEQ ID NO: 5596)

CTGTCTGTGCCGATCTC

TATTAAAG

(SEQ ID NO: 5597)

GTCTGTGCCGATCTCTA

TTAAAGGA

(SEQ ID NO: 5598)

CTGTGCCGATCTCTATT

AAAGGACT

(SEQ ID NO: 5599)

GTGCCGATCTCTATTAA

AGGACTCC

(SEQ ID NO: 5600)

GCCGATCTCTATTAAAG

GACTCCCT

(SEQ ID NO: 5601)

CTCTATTAAAGGACTCC

CTCTTGGT

(SEQ ID NO: 5602)

CTATTAAAGGACTCCCT

CTTGGTGG

(SEQ ID NO: 5603)

200611_s_at
WDR1
AIP1,
WD repeat
chr4p16.1
Loss_—
9948
CATGCAAAAATCGTCTG

NORI-1
domain 1

down

CCTGGCCT

(SEQ ID NO: 5604)

TGGCCTGGTCCCCAGAC

AATGAACA

(SEQ ID NO: 5605)

AGACAATGAACACTTTG

CCTCCGGT

(SEQ ID NO: 5606)

ACTTTGCCTCCGGTGGC

ATGGACAT

(SEQ ID NO: 5607)

GTGTATGTTTGGACCCT

GAGTGACC

(SEQ ID NO: 5608

AAGATCCAAGATGCAC

ACCGGCTGC

(SEQ ID NO: 5609)

ATGATGCCTCTGTCAAG

GAGTGGAC

(SEQ ID NO: 5610)

AGGAGTGGACAATCACC

TACTGAGG

(SEQ ID NO: 5611)

CCGCCTCTGGATGGACC

GAATCAGG

(SEQ ID NO: 5612)

AACTGCAGCGGAACATG

TCATTTCT

(SEQ ID NO: 5613)

TCGTCTCTGCAGGGTGT

CTGTACAC

(SEQ ID NO: 5614)

210154_at
ME2
0
malic enzyme 2,
chr6p25-
Loss_—
4200
CCAGGTGTGGCTTTAGC

NAD(+)-
p24|18q21
down

TGTTATTC

dependent,

(SEQ ID NO: 5615)

mitochondrial

GTGGCTTTAGCTGTTAT

TCTCTGTA

(SEQ ID NO: 5616)

TATTCTCTGTAACACCC

GGCATATT

(SEQ ID NO: 5617)

ACCCGGCATATTAGTGA

CAGTGTTT

(SEQ ID NO: 5618)

GACAGTGTTTTCCTAGA

AGCTGCAA

(SEQ ID NO: 5619)

AGCTGCAAAGGCCCTGA

CAAGCCAA

(SEQ ID NO: 5620)

AGGCCCTGACAAGCCAA

TTGACAGA

(SEQ ID NO: 5621)

AATTGACAGATGAAGAG

CTAGCCCA

(SEQ ID NO: 5622)

GCTAGCCCAAGGGAGAC

TTTACCCA

(SEQ ID NO: 5623)

TACCCACCGCTTGCTAA

TATTCAGG

(SEQ ID NO: 5624)

GGAAGTTTCTATTAACA

TTGCTATT

(SEQ ID NO: 5625)

217875_s_at
TMEPAI
PMEPA1,
prostate
chr20q13.
Gain_—
56937
CCCCAAACAGAACCATC

STAG1
trans-
31-q13.33
up

TTCGACAG

membrane

(SEQ ID NO: 5626)

protein,

ATCTTCGACAGTGACCT

androgen

GATGGATA

induced 1

(SEQ ID NO: 5627)

GATGGATAGTGCCAGGC

TGGGCGGC

(SEQ ID NO: 5628)

CGGCGGGCGCATGGAGG

GGCCGCCG

(SEQ ID NO: 5629)

CCTAGAGAGCGCAGCCA

TCTGGAGC

(SEQ ID NO: 5630)

AACAGAAAGGACACCCT

CTCTAGGG

(SEQ ID NO: 5631)

GGCTGGGGCTGCGTAGG

TGAAAAGG

(SEQ ID NO: 5632)

TGAAAAGGCAGAACACT

CCGCGCTT

(SEQ ID NO: 5633)

GTGAGAGGAAGGCGGGG

GGCGCAGC

(SEQ ID NO: 5634)

AAACCACGTTTCTTTGT

TGAGCTGT

(SEQ ID NO: 5635)

GTTGAGCTGTGTCTTGA

AGGCAAAA

(SEQ ID NO: 5636)

218435_at
DNAJC15
MCJ;
DnaJ (Hsp40)
chr13q14.1
Gain_—
29103
CCGACGTCGACCAGCAG

HSD18;
homolog,

up

GGACTGGT

DNAJD1
subfamily C,

(SEQ ID NO: 5637)

member 15

GATAGCTGTAGGACTGG

GTGTTGCA

(SEQ ID NO: 5638)

GGTGTTGCAGCTCTTGC

ATTTGCAG

(SEQ ID NO: 5639)

GCATTTGCAGGTCGCTA

CGCATTTC

(SEQ ID NO: 5640)

ACGCATTTCGGATCTGG

AAACCTCT

(SEQ ID NO: 5641)

GAAGATTTCAACTCCTA

GCTTTTCA

(SEQ ID NO: 5642)

TTTAGGTGTAAGCCCAT

CTGCTGGC

(SEQ ID NO: 5643)

TGGATCTCCTTACGTAG

CAGCCAAA

(SEQ ID NO: 5644)

ACATGGTCTTCTTAATT

TTCTATAT

(SEQ ID NO: 5645)

TGGATTGACCACAGTCT

TATCTTCC

(SEQ ID NO: 5646)

GTCTTATCTTCCACCAT

TAAGCTGT

(SEQ ID NO: 5647)

213738_s_at
ATP5A1
ATP5A,
ATP synthase,
chr18q12-
Loss_—
498
CGCCCTGCAATTAACGT

ATP5AL2,
H+
q21
down

TGGTCTGT

ATPM,
transporting,

(SEQ ID NO: 5648)

MOM2,
mitochondrial

TCCGCTGCCCAAACCAG

OMR, ORM,
F1 complex,

GGCTATGA

hATP1
alpha

(SEQ ID NO: 5649)

subunit 1,

GAAGCTGGAATTGGCT

cardiac muscle

CAGTATCGT

(SEQ ID NO: 5650)

GTATCGTGAGGTTGCTG

CTTTTGCC

(SEQ ID NO: 5651)

AACTTTTGAGTCGTGGC

GTGCGTCT

(SEQ ID NO: 5652)

GGCGTGCGTCTAACTGA

GTTGCTGA

(SEQ ID NO: 5653)

CAGTATTCTCCCATGGC

TATTGAAG

(SEQ ID NO: 5654)

AAGTGGCTGTTATCTAT

GCGGGTGT

(SEQ ID NO: 5655)

GCACCAAGCCTTGTTGG

GCACTATC

(SEQ ID NO: 5656)

AGCTTAAACTCCTGTGG

ATTCACAT

(SEQ ID NO: 5657)

GTTCAGTTTTGTCATTG

TTCTAGTA

(SEQ ID NO: 5658)

206134_at
ADAMDE
M12.219
ADAM-like,
chr8p21.2
Loss_—
27299
CTTTCTATATTGTTATC

C1

decysin 1

down

AGTCCAGG

(SEQ ID NO: 5659)

GACATTGGCTCTTTGTT

TAGGCCTA

(SEQ ID NO: 5660)

GAATTTGTGACTTAGTT

CTGCCCTT

(SEQ ID NO: 5661)

GAAAGCAGTCTTCCATC

AAATCACC

(SEQ ID NO: 5662)

AATGCACGGCTAAACTA

TTCAGAGT

(SEQ ID NO: 5663)

AAGTACTATGCTTTAAT

GCTTCTTT

(SEQ ID NO: 5664)

GCTTCTTTCATCTTACT

AGTATGGC

(SEQ ID NO: 5665)

TATGTTATTCCTCTGTG

TTCACTTC

(SEQ ID NO: 5666)

ACTTCGCCTTGCTCTTG

AAAGTGCA

(SEQ ID NO: 5667)

GTATATCCTATACACAC

ATCTCCTT

(SEQ ID NO: 5668)

TGAGAAGTCTACATTGC

TTACATTT

(SEQ ID NO: 5669)

204386_s_at
MRP63
MGC3243,
mitochondrial
chr13q12.11
Gain_—
78988
GAAATGGTCCTAATCCT

bMRP63
ribosomal

up

GAGTCGTC

protein 63

(SEQ ID NO: 5670)

TGAGTCGTCACCCTTGG

ATTTTATG

(SEQ ID NO: 5671)

ATGGATCACGGAGCTGA

CCATCTTT

(SEQ ID NO: 5672)

GACCATCTTTACCTGGT

CCTGGAAC

(SEQ ID NO: 5673)

GAAAATGAGCCTTTGGA

CCAGTCTT

(SEQ ID NO: 5674)

GAGCCTTTGGACCAGTC

TTTATTAA

(SEQ ID NO: 5675)

TGAGTAGTCTGCATATC

GAATATCT

(SEQ ID NO: 5676)

GAATATCTAGAGCTCTA

AACCCCCC

(SEQ ID NO: 5677)

GTCCTGTGGTTTCATTA

GTCTGATA

(SEQ ID NO: 5678)

AGGGATTTCCTCAGTCA

CAGATGAT

(SEQ ID NO: 5679)

GGAAAGCTGCAATAAAG

CCACAATG

(SEQ ID NO: 5680)

209368_at
EPHX2
CEH, SEH
epoxide
chr8p21-p12
Loss_—
2053
GAACAGAACCTGAGTCG

hydrolase 2,

down

TCGGACTT

cytoplasmic

(SEQ ID NO: 5681)

GGACTTTCAAAAGCCTC

TTCAGAGC

(SEQ ID NO: 5682)

GAGGAAATCCAGTTCT

ATGTGCAGC

(SEQ ID NO: 5683)

CAGAGGTCCTCTAAACT

GGTACCGA

(SEQ ID NO: 5684)

GGACGGAAGATCCTGAT

TCCGGCCC

(SEQ ID NO: 5685)

GCCCTGATGGTCACGGC

GGAGAAGG

(SEQ ID NO: 5686)

CGGAGAAGGACTTCGTG

CTCGTTCC

(SEQ ID NO: 5687)

GCACATGGAGGACTGGA

TTCCCCAC

(SEQ ID NO: 5688)

TGGCTGGATTCTGATGC

CCGGAACC

(SEQ ID NO: 5689)

GGAACCCACCGGTGGTC

TCAAAGAT

(SEQ ID NO: 5690)

GTAGAACGCAGCGTGTG

CCCACGCT

(SEQ ID NO: 5691)

206790_s_at
NDUFB1
CI-SGDH,
NADH
chr14q32.12
Loss_—
4707
GAACTTACTTCAGATTG

MNLL
dehydrogenase

down

TGCGGGAC

(ubiquinone) 1

(SEQ ID NO: 5692)

beta

CAGATTGTGCGGGACCA

subcomplex,

CTGGGTTC

1, 7 kDa

(SEQ ID NO: 5693)

GGACCACTGGGTTCATG

TTCTTGTC

(SEQ ID NO: 5694)

CTGGGTTCATGTTCTTG

TCCCTATG

(SEQ ID NO: 5695)

TGTCCCTATGGGATTTG

TCATTGGA

(SEQ ID NO: 5696)

GTGATGAACGGCTAACT

GCCTTCCG

(SEQ ID NO: 5697)

GCTAACTGCCTTCCGGA

ACAAGAGT

(SEQ ID NO: 5698)

ACTGCCTTCCGGAACAA

GAGTATGT

(SEQ ID NO: 5699)

AAAGGGAATTGCAACCC

AGTGAAGA

(SEQ ID NO: 5700)

GACTGGCTAGATTATCG

AATGTTCA

(SEQ ID NO: 5701)

GTTCACATTTTAAAGTT

CTGAGAGA

(SEQ ID NO: 5702)

204149_s_at
GSTM4
GSTM4-4,
glutathione
chr1p13.3
Loss_—
2948
GAGAACCAGGCTATGGA

GTM4,
S-transferase

down

CGTCTCCA

MGC131945,
M4

(SEQ ID NO: 5703)

MGC9247

CAGGCTATGGACGTCTC

CAATCAGC

(SEQ ID NO: 5704)

CTATGGACGTCTCCAAT

CAGCTGGC

(SEQ ID NO: 5705)

CTCCAATCAGCTGGCCA

GAGTCTGC

(SEQ ID NO: 5706)

TCTGCTACAGCCCTGAC

TTTGAGAA

(SEQ ID NO: 5707)

GCTACAGCCCTGACTTT

GAGAAACT

(SEQ ID NO: 5708)

ATACTTGGAGGAACTTC

CTACAATG

(SEQ ID NO: 5709)

GAGGAACTTCCTACAAT

GATGCAGC

(SEQ ID NO: 5710)

GGAACTTCCTACAATGA

TGCAGCAC

(SEQ ID NO: 5711)

ACTTCCTACAATGATGC

AGCACTTC

(SEQ ID NO: 5712)

GAAGAGGCCATGGTTTG

TTGGAGAC

(SEQ ID NO: 5713)

208909_at
UQCRFS1
RIP1,
ubiquinol-
chr19q12-
Loss_—
7386
GAGAGGCAAACCCCTGT

RIS1,
cytochrome c
q13.1
down

TTGTGCGT

RISP,
reductase,

(SEQ ID NO: 5714)

UQCR5
Rieske

CTGTTTGTGCGTCATAG

iron-sulfur

AACCCAGA

polypeptide 1

(SEQ ID NO: 5715)

GGACCCACAGCATGATC

TAGATCGA

(SEQ ID NO: 5716)

GATAGGTGTTTGCACTC

ATCTTGGC

(SEQ ID NO: 5717)

TCATCTTGGCTGTGTAC

CCATTGCA

(SEQ ID NO: 5718)

TTTTGGTGGTTATTACT

GCCCTTGC

(SEQ ID NO: 5719)

GGGTCACACTATGATGC

ATCTGGCA

(SEQ ID NO: 5720)

CAGGATCAGATTGGGTC

CTGCTCCT

(SEQ ID NO: 5721)

TGAAGTCCCCACGTATG

AGTTCACC

(SEQ ID NO: 5722)

GGACTCAAGTCATAGGC

TTCTTTCA

(SEQ ID NO: 5723)

GGCTTCTTTCAGTCTTT

ATGTCACC

(SEQ ID NO: 5724)

221432_s_at
SLC25A
MFRN2;
solute carrier
chr10q23-
Loss_—
81894
GCAGATGTACAACTCAC

28
MRS4L;
family 25,
q24
down

CATACCAC

MRS3/4;
member 28

(SEQ ID NO: 5725)

NPD016;

AATTCCTGCAGGAGCAC

DKFZp547C

TTTAACCC

109

(SEQ ID NO: 5726)

CCAGAGACGGTACAACC

CAAGCTCC

(SEQ ID NO: 5727)

TTGCGCAGGAGCTGTA

GCTGCCGCA

(SEQ ID NO: 5728)

CACAACCCCACTGGACG

TTTGCAAA

(SEQ ID NO: 5729)

TTGCAAAACACTGCTCA

ACACCCAG

(SEQ ID NO: 5730)

CACCCAGGAGTCCTTGG

CTTTGAAC

(SEQ ID NO: 5731)

GCATGGCTAGTGCCTTC

AGGACGGT

(SEQ ID NO: 5732)

CAAGTAGGTGGGGTGAC

CGCCTATT

(SEQ ID NO: 5733)

ATTTCCGAGGGGTGCAG

GCCAGAGT

(SEQ ID NO: 5734)

AGCCATCGCATGGTCTG

TGTATGAG

(SEQ ID NO: 5735)

211755_s_at
ATP5F1
MGC24431,
ATP synthase,
chr1p13.2
Loss_—
515
GCCTGGACTATCATATA

PIG47
H+ transporting,

down

TCTGTGCA

mitochondrial F0

(SEQ ID NO: 5736)

complex, subunit

ATCTGTGCAGAACATGA

B1

TGCGTCGA

(SEQ ID NO: 5737)

AAGCACGTGGTGCAAAG

CATCTCCA

(SEQ ID NO: 5738)

GACAATTGCCAAGTGCA

TTGCGGAC

(SEQ ID NO: 5739)

GCATTGCGGACCTAAAG

CTGCTGGC

(SEQ ID NO: 5740)

GAAGGCTCAAGCACAGC

CAGTTATG

(SEQ ID NO: 5741)

TGACAAAGTCTTTCTGT

GTTGGTGT

(SEQ ID NO: 5742)

GAACGAAATCTCTATCG

GCCAGTCA

(SEQ ID NO: 5743)

ATCGGCCAGTCAGATGT

TTCTCATC

(SEQ ID NO: 5744)

AAACTTGCTGCCTGACT

AAAGATTA

(SEQ ID NO: 5745)

AATTAATTCTACCATCT

TGCAATAA

(SEQ ID NO: 5746)

214937_x_at
PCM1
CXXC3,
pericentriolar
chr8p22-
Loss_—
5108
GGAAGTCCTGATACTGA

PCM1, RFT
material 1
p21.3
down

ATCTCCAG

(SEQ ID NO: 5747)

GAATCTCCAGTGTTAGT

GAATGACT

(SEQ ID NO: 5748)

GAAGATTTACCACTGAA

ACTGACAA

(SEQ ID NO: 5749)

GAACCTGAAACGGTGGG

AGCCCAGA

(SEQ ID NO: 5750)

GGGAGCCCAGAGTATAT

GAGATGTC

(SEQ ID NO: 5751)

ATGTCTTCAGAGGCTCA

TCTAACTC

(SEQ ID NO: 5752)

CATCTAACTCTGTCCTT

ACATACTC

(SEQ ID NO: 5753)

GTTTGACACTGCTTTTT

TGATAGGT

(SEQ ID NO: 5754)

TGATAGGTGTGGTCATT

TCTCCCCA

(SEQ ID NO: 5755)

GATTTAAGCCTTGACAC

ACTGTGTT

(SEQ ID NO: 5756)

ATTTTTTTCCCCATTGT

GATGTTTG

(SEQ ID NO: 5757)

206441_s_at
COMMD4
FLJ20452
COMM domain
chr15q24.2
Loss_—
54939
GGAGCTGCTGGGACAGG

containing 4

down

GGATTGAT

(SEQ ID NO: 5758)

AGCTCACGGCTGACGCC

AAGTTTGA

(SEQ ID NO: 5759)

TCCAGTGCGGCCAAGCA

CAGTGTCG

(SEQ ID NO: 5760)

AGTGTCGATGGCGAATC

CTTGTCCA

(SEQ ID NO: 5761)

TCCTTGTCCAGTGAACT

GCAGCAGC

(SEQ ID NO: 5762)

AGCTGGGGCTGCCCAAA

GAGCACGC

(SEQ ID NO: 5763)

CCAGCCTGTGCCGCTGT

TATGAGGA

(SEQ ID NO: 5764)

CAAAGCCCCTTGCAGAA

GCACTTGC

(SEQ ID NO: 5765)

TGAACTGCTCTTCGGGA

GGCAGCCC

(SEQ ID NO: 5766)

GCCCTGGTTCTAGGATG

CTGAGGCC

(SEQ ID NO: 5767)

GCCTCACTTCTCTCTTG

AGAACTTG

(SEQ ID NO: 5768)

219303_at
C13
RNF219;
ring finger
chr13q31.1
Gain_—
79596
GGCATGGAGCACTTGGG

orf7
FLJ13449;
protein 219

up

TTTAGAGG

FLJ25774;

(SEQ ID NO: 5769)

DKFZp686A

AAAACATCATAGCTTCA

01276;

TTGTTCCA

DKFZp686N

(SEQ ID NO: 5770)

15250;

GCTTCATTGTTCCAGAT

DKFZp686O

GTAACAGG

03173

(SEQ ID NO: 5771)

CATTCCAGGGGAGTTTT

CTTTTGAG

(SEQ ID NO: 5772)

TTTGCATGTTCCTGTTC

TTTGTGGA

(SEQ ID NO: 5773)

TCCTGTTCTTTGTGGAA

ACTATGCA

(SEQ ID NO: 5774)

TTTTGCTTGCTGTGTTT

TCCATACT

(SEQ ID NO: 5775)

ATGTAGGACAAAACTTTT

CTGTGAA

(SEQ ID NO: 5776)

CGTATTTGGTATGCCTA

TATAGGTC

(SEQ ID NO: 5777)

AATGGGTTTGTATGCTG

TTTAATGT

(SEQ ID NO: 5778)

GTATGCTGTTTAATGTG

CACTGAAC

(SEQ ID NO: 5779)

210107_at
CLCA1
CACC,
CLCA family
chr1p31-p22
Loss_—
1179
GGCCAAATCACCGACCT

CACC1,
member 1,

down

GAAGGCGG

CLCRG1,
chloride

(SEQ ID NO: 5780)

FLJ95147,
channel

TTCACGGGGGCAGTCT

GOB5
regulator

CATTAATCT

(SEQ ID NO: 5781)

GACTTGGACAGCTCCTG

GGGATGAT

(SEQ ID NO: 5782)

CAAGTGAATACTACTGC

TCTCATCC

(SEQ ID NO: 5783)

GGCACAGATCTTTTCA

TTGCTATTC

(SEQ ID NO: 5784)

ATCTTTGTTTATTCCTC

CACAGACT

(SEQ ID NO: 5785)

CGCCAGAGACACCTAGT

CCTGATGA

(SEQ ID NO: 5786)

TAGTCCTGATGAAACGT

CTGCTCCT

(SEQ ID NO: 5787)

TCTGCTCCTTGTCCTAA

TATTCATA

(SEQ ID NO: 5788)

TATCAACAGCACCATTC

CTGGCATT

(SEQ ID NO: 5789)

ACTGCAGCTGTCAATAG

CCTAGGGC

(SEQ ID NO: 5790)

218801_at
UGCGL2
RP11-
UDP-glucose
chr13q32.1
Gain_—
55757
GGCTCAGGAGCCAGTAT

31K22.2,
ceramide

up

CAAGCTCT

FLJ10873,
glucosyl-

(SEQ ID NO: 5791)

FLJ11485,
transferase-

AAGCTCTCAGTCAAGA

HUGT2,
like 2

TCCAAACAG

MGC117360,

(SEQ ID NO: 5792)

MGC150689,

GATCCAAACAGTCTTTC

MGC87276

AAACCTAG

(SEQ ID NO: 5793)

AGATCAGGATCTCCCCA

ATAATATG

(SEQ ID NO: 5794)

TACCAAGTCGCCATTAA

GTCTCTTC

(SEQ ID NO: 5795)

TCTTCCTCAAGACTGGC

TGTGGTGT

(SEQ ID NO: 5796)

GAATCCAAACTAAAAGC

TGCTGCCA

(SEQ ID NO: 5797)

CTGCCAGAATTGTCCCA

GAATGGGT

(SEQ ID NO: 5798)

GACACATGATGAACTCT

AGCACTGG

(SEQ ID NO: 5799)

TGCTGGGGAAGTCTGGA

GCCCCTGC

(SEQ ID NO: 5800)

AGCCCCTGCTGAGACGA

TTTGGAAG

(SEQ ID NO: 5801)

203478_at
NDUFC1
KFYI;
NADH
chr4q28.2-
Loss_—
4717
GGGGCCCAAGGAATTCG

MGC117464;
dehydrogenase
q31.1
down

CAAGATGG

MGC126847;
(ubiquinone) 1,

(SEQ ID NO: 5802)

MGC138266
subcomplex

AGGAATTCGCAAGATG

unknown, 1,

GCGCCGTCC

6 kDa

(SEQ ID NO: 5803)

GCCCTTCAGTGCGATCA

AAGTTCTA

(SEQ ID NO: 5804)

GTGCGATCAAAGTTCTA

CGTGCGAG

(SEQ ID NO: 5805)

TTCTACGTGCGAGAGCC

GCCGAATG

(SEQ ID NO: 5806)

CCGCCGAATGCCAAACC

TGACTGGC

(SEQ ID NO: 5807)

ACCTGACTGGCTGAAAG

TTGGGTTC

(SEQ ID NO: 5808)

TGAAAGTTGGGTTCACC

TTGGGCAC

(SEQ ID NO: 5809)

GTCTTCTTGTGGATCTA

TCTCATCA

(SEQ ID NO: 5810)

GGATCTATCTCATCAAA

CAACACAA

(SEQ ID NO: 5811)

CAAGCCAGCATTTGTAT

TTTGCATC

(SEQ ID NO: 5812)

218738_s_at
RNF138
HSD-4,
ring finger
chr18q12.1
Loss_—
51444
GGGGGTTGAAGTGTTTA

MGC8758,
protein 138

down

TCTGATTT

NARF,

(SEQ ID NO: 5813)

STRIN

AGTGCTAAGTTATCTAG

TTGGCTAC

(SEQ ID NO: 5814)

TAGTTGGCTACTATTAC

ACCTTAAA

(SEQ ID NO: 5815)

ACAATTACCTGTTTATA

TGGGCTC

(SEQ ID NO: 5816)

TATGGTGCTCATTTGTT

ATTCTCAA

(SEQ ID NO: 5817)

GAGAAAGATTCTACCAA

CCACTGTT

(SEQ ID NO: 5818)

TACCAACCACTGTTCAC

TACTTT

(SEQ ID NO: 5819)

GTAGAAGGCCCAAATCA

CAGAATAA

(SEQ ID NO: 5820)

GGATTTGCTGACATTCC

ATACTAAT

(SEQ ID NO: 5821)

GAATCTCAGAAGTAGTT

TGCTGCTA

(SEQ ID NO: 5822)

AACCCTTGTTGACTTTT

CTACACTG

(SEQ ID NO: 5823)

202956_at
ARFGEF
ARFGEP1,
ADP-ribosylation
chr8q13
Gain_—
10565
GGTAGGTGGTGATTTTG

1
BIG1,
factor guanine

up

AGGCTGTA

D730028O1
nucleotide-

(SEQ ID NO: 5824)

8Rik,
exchange factor

TGAGGCTGTAACATGCC

DKFZP434L
1(brefeldin A-

CAGAAGCT

057, P200
inhibited)

(SEQ ID NO: 5825)

GAAGCTGTTGTGGCCGA

CACTTCAA

(SEQ ID NO: 5826)

GTGGCCGACACTTCAAC

AATAGGGA

(SEQ ID NO: 5827)

ATATCCCTACTGACAGT

AACTACCT

(SEQ ID NO: 5828)

GTAACTACCTGTCACAT

ATTTCTCT

(SEQ ID NO: 5829)

CTTTTGGGTGGTGGGGC

TTGATGTA

(SEQ ID NO: 5830)

GGCATGGTTTGCGGAGG

TTAGATTT

(SEQ ID NO: 5831)

GTGAATTGTGCTCTGAT

GGTTAAAA

(SEQ ID NO: 5832)

AGATTGTCAAGCATTCC

GTATTAAC

(SEQ ID NO: 5833)

ATTGATTCCCATCTGGC

ATATTCTA

(SEQ ID NO: 5834)

208884_s_at
LOC
LOC730429
ubiquitin
chr8q22
Gain_—
51366
GGTAGTTGCAGAACAGC

730429

protein

up

CCTTACAT

ligase E3

(SEQ ID NO: 5835)

component

AGGTCTACTAGATGTGC

n-recognin 5

TTCCAAAA

(SEQ ID NO: 5836)

AAATGCTGATCAGTTTT

ACCTCTTT

(SEQ ID NO: 5837)

GCAGTTCAAGCGTTGGT

TCTGGTCA

(SEQ ID NO: 5838)

TTTTGGACATCAAGCCC

ATCACTGC

(SEQ ID NO: 5839)

GAAGAAGGATTCCAGCC

TATGCCCT

(SEQ ID NO: 5840)

GCCTATGCCCTCAATCA

CAATAAGA

(SEQ ID NO: 5841)

CCAACATCTTCCTACTG

CAAATACT

(SEQ ID NO: 5842)

ATACTTGCATTTCTCGA

CTTTACGT

(SEQ ID NO: 5843)

TCCCACTCTATTCCTCT

AAACAGAT

(SEQ ID NO: 5844)

AATTGTTACTCGCCATT

AAGACCAA

(SEQ ID NO: 5845)

203596_s_at
IFIT5
RI58;
interferon-
chr10q23.31
Loss_—
24138
GTACATAACTTCTATCA

FLJ53857;
induced

down

CTTGCCAC

FLJ92678
protein with

(SEQ ID NO: 5846)

tetratricopep-

AAATCAGGGCCTGTGTT

tide repeats 5

CATACACA

(SEQ ID NO: 5847)

GGCCTGAGATTTCTGCA

CTTTAAAC

(SEQ ID NO: 5848)

GTAAGGTCTACAGCATT

GTTCCTCA

(SEQ ID NO: 5849)

ATTGTTCCTCAAACTTG

GCTACGTA

(SEQ ID NO: 5850)

TTGGCTACGTATTGGAA

TCACCTAA

(SEQ ID NO: 5851)

CAAAACATGGATGTCTG

GGTCCCGC

(SEQ ID NO: 5852)

GTCCCGCCCCATAGAGA

ATGACTTA

(SEQ ID NO: 5853)

AATTGGCATGGGGTGCA

GTCCAGGC

(SEQ ID NO: 5854)

GTTTGCATTTGGGACTC

CTCATCAT

(SEQ ID NO: 5855)

GGACTCCTCATCATATA

CTTGGTAT

(SEQ ID NO: 5856)

212592_at
IGJ
IGCJ, JCH
immunoglobulin J
chr4q21
Loss_—
3512
GTATCAAAATCTTCCAA

polypeptide,

down

TTATCATG

linker protein

(SEQ ID NO: 5857)

for immuno-

ATCTTCCAATTATCAT

globulin

GCTCACCTG

alpha and mu

(SEQ ID NO: 5858)

polypeptides

TCCAATTATCATGCTCA

CCTGAAAG

(SEQ ID NO: 5859)

GCTCACCTGAAAGAGGT

ATGCTCTC

(SEQ ID NO: 5860)

GAGGTATGCTCTCTTAG

GAATACAG

(SEQ ID NO: 5861)

TAGGAATACAGTTTCTA

GCATTAAA

(SEQ ID NO: 5862)

TAATAAAATGTTCCTCG

CATTCCCC

(SEQ ID NO: 5863)

AGTTTCACTGTGTAGAG

AACATATA

(SEQ ID NO: 5864)

ATAGGTCAATTATATGT

CTCCATTA

(SEQ ID NO: 5865)

AAACATGTTCTAGAACT

AGTTACAA

(SEQ ID NO: 5866)

AAATATATTTGGACATA

ACAGACTT

(SEQ ID NO: 5867)

212692_s_at
LRBA
BGL,
LPS-responsive
chr4q31.3
Loss_—
987
GTCTGTCTATCAATATT

CDC4L,
vesicle

down

GTTCTTCA

DKFZp686A
trafficking,

(SEQ ID NO: 5868)

09128,
beach and

TTTCCTGATCTGTCATC

DKFZp686K
anchor

TTCATAGC

03100,
containing

(SEQ ID NO: 5869)

DKFZp686P

AATGCTCTTGAGCTCA

2258,

CAACATTTG

FLJ16600,

(SEQ ID NO: 5870)

FLJ25686,

ACCAAAGCTCACTACTG

LAB300,

CGGTTTGC

LBA,

(SEQ ID NO: 5871)

MGC72098

GTTTGCCTGTGCCTGGA

CAATGAGG

(SEQ ID NO: 5872)

GGACAATGAGGCGGAGC

CACTGTTG

(SEQ ID NO: 5873)

TCCCCGGGTTTGCAAAT

AGAGGCTA

(SEQ ID NO: 5874)

TAGAGGCTACCGGGTGC

TGTATTCA

(SEQ ID NO: 5875)

GTTATTAAACTATCATC

TCCACCTT

(SEQ ID NO: 5876)

CTCCACCTTCCTTTTGA

TTAGCAAT

(SEQ ID NO: 5877)

GGTGGTGTATAATTCTA

CTTTTCTA

(SEQ ID NO: 5878)

202548_s_at
ARHGEF
RP11-
Rho guanine
chr13q34
Gain_—
8874
GTTACGGCATTGCCTTT

7
494P5.1,
nucleotide

up

TCTTTCTG

BETA-PIX,
exchange

(SEQ ID NO: 5879)

COOL1,
factor

TTCTGTGGATCCAGTAT

DKFZp686C
(GEF) 7

CTTCCTCG

12170,

(SEQ ID NO: 5880)

DKFZp761K

ATCTTCCTCGGCTTTTT

1021,

AGGGAGCA

KIAA0142,

(SEQ ID NO: 5881)

KIAA0412,

AAACCTGCCCTGTTG

Nbla10314,

TATATAACTG

P50,

(SEQ ID NO: 5882)

P50BP,

AACTGTGTCTGTTTCA

P85,

CCGTGTGAC

P85COOL1,

(SEQ ID NO: 5883)

P85SPR,

GCCACGATTTGCCCGAG

PAK3, PIXB

GGTTACTC

(SEQ ID NO: 5884)

CCTTTGCTCTCACCTT

GTATGGATG

(SEQ ID NO: 5885)

GATGAAGCCATTTCTTA

TCCTGTAG

(SEQ ID NO: 5886)

GTAGCATCAGAAGCTC

GTTCCTTCA

(SEQ ID NO: 5887)

CACACTCAGTGGCGTCT

GTGCTTGT

(SEQ ID NO: 5888)

CACCCAGGGCGCCTGTT

GACAAGTG

(SEQ ID NO: 5889)

209627_s_at
OSBPL3
DKFZp667P
oxysterol
chr7p15
Gain_—
26031
GTTATGCCTTCTGGCTA

1518,
binding

up

CTACAGAA

KIAA0704,
protein-like 3

(SEQ ID NO: 5890)

MGC21526,

ACAGAATCTCCGCAGAC

ORP-3,

CTTTTAGT

ORP3,

(SEQ ID NO: 5891)

OSBP3

GAAGGTGTCCTTATGGT

CTTAGGAA

(SEQ ID NO: 5892)

ATAGCTATTTTCATTT

GCTCTATTT

(SEQ ID NO: 5893)

TGCTCTATTTTCCTCTG

CATTGTAC

(SEQ ID NO: 5894)

GCATTGTACTAATCTGT

TACTCAGT

(SEQ ID NO: 5895)

GTTACTCAGTGTTAGTC

TTCATTTT

(SEQ ID NO: 5896)

GTGTTGGAAACCTGCGT

CATGTAAA

(SEQ ID NO: 5897)

AATCTTCCACTTAACCA

CTGAAAAT

(SEQ ID NO: 5898)

AGCTCCTATTAATTTGC

TTATCCCC

(SEQ ID NO: 5899)

TATCCCCCTCATGTAGC

TAGTTGAA

(SEQ ID NO: 5900)

212448_at
NEDD4L
FLJ33870,
neural precursor
chr18q21
Loss_—
23327
GTTGTGCCTCTTGTGTG

KIAA0439,
cell expressed,

down

CTAGATTA

NEDD4-2,
developmentally

(SEQ ID NO: 5901)

RSP5,
down-regulated

ACTTGACTTGATCCTCT

hNedd4-2
4-like

GAGCTCAA

(SEQ ID NO: 5902)

GGCAGAGGACTGAGGGT

ACCTGCAC

(SEQ ID NO: 5903)

TGCACAGTTTGATTCTT

TTCCACGT

(SEQ ID NO: 5904)

TTTTCCACGTGTAAGTC

TCCATTGC

(SEQ ID NO: 5905)

GTCTCCATTGCAGAATT

GTCGTGCT

(SEQ ID NO: 5906)

GTGTGGGAGTTGAACGA

CCCTGCTG

(SEQ ID NO: 5907)

GACCCTGTCGGGGCAGT

CAGGGGAC

(SEQ ID NO: 5908)

GAGATTTGATCTCATGC

GAGTCATC

(SEQ ID NO: 5909)

CCTGCCCTGGCTGGCAT

GTGAGAAG

(SEQ ID NO: 5910)

GCTGAGTGTTGGTTCCT

TTTTCTTA

(SEQ ID NO: 5911)

205770_at
GSR
MGC78522
glutathione
chr8p21.1
Loss_—
2936
TACCAACGTCAAAGGCA

reductase

down

TCTATGCA

(SEQ ID NO: 5912)

GCAATAGCTGCTGGCCG

AAAACTTG

(SEQ ID NO: 5913)

AACTTGCCCATCGACTT

TTTGAATA

(SEQ ID NO: 5914)

CAACATCCCAACTGTGG

TCTTCAGC

(SEQ ID NO: 5915)

TATTCAACGAGCTTTAC

CCCGATGT

(SEQ ID NO: 5916)

TTACCCCGATGTATCAC

GCAGTTAC

(SEQ ID NO: 5917)

AAATGCTGCAGGGTTTT

GCTGTTGC

(SEQ ID NO: 5918)

TTTGACAACACAGTCGC

CATTCACC

(SEQ ID NO: 5919)

TTCACCCTACCTCTTCA

GAAGAGCT

(SEQ ID NO: 5920)

AAGAGCTGGTCACACTT

CGTTGAGA

(SEQ ID NO: 5921)

GAACCAGGAGACACGTG

TGGCGGGC

(SEQ ID NO: 5922)

209234_at
KIF1 B
CMT2,
kinesin family
chr1p36.2
Loss_—
23095
TAGCCAAACGGCTGTGC

CMT2A,
member 1B

down

TCAGATGG

CMT2A1,

(SEQ ID NO: 5923)

FLJ23699,

TGAGCTGAGGTTGGTCT

HMSNII,

CTTGCCAA

KIAA0591,

(SEQ ID NO: 5924)

KIAA1448,

GTTGTTCTTCATGTCTT

KLP,

CGAGTTCA

MGC134844

(SEQ ID NO: 5925)

TTTTTTTCATTCTGCCT

ATTCTGGC

(SEQ ID NO: 5926)

ATCAGCTCACTTGAGG

AGTCCCTCA

(SEQ ID NO: 5927)

GGCATCGTCTTAGACTT

TGTGGCTC

(SEQ ID NO: 5928)

TGTGGCTCTAAAGTAC

CTGTCTGTT

(SEQ ID NO: 5929)

ATTTCAAGTCTCTTGTC

ACCATCCT

(SEQ ID NO: 5930)

AAGACTTTGCAAACTGA

TCTCTCCC

(SEQ ID NO: 5931)

GATCTCTCCCCCGTGAA

GGAGTTGA

(SEQ ID NO: 5932)

AACCTTGCGTCACGGAG

CTGTTAGT

(SEQ ID NO: 5933)

202594_at
LEPROT
HSPC112,
leptin
chr8p21.2-
Loss_—
23484
TATTGCCTAACTTAAGC

L1
Vps55,
receptor
p21.1
down

CATGACTT

my047
overlapping

(SEQ ID NO: 5934)

transcript-

AATATCGGCGTGTGGCT

like 1

GGAGCCTT

(SEQ ID NO: 5935)

AGTTGGGAACTCTTTGT

GCTTGTGA

(SEQ ID NO: 5936)

GTGCTTGTGATCTACTG

GACTTTTT

(SEQ ID NO: 5937)

CAGGAAGTGCATTCTCT

GGTCCTTC

(SEQ ID NO: 5938)

TCCCTATTTTCTGTTCT

GGATGTCA

(SEQ ID NO: 5939)

AGTGCACTGCTACTGTT

TTATCCAC

(SEQ ID NO: 5940)

GTTTTATCCACTTGGCC

ACAGACTT

(SEQ ID NO: 5941)

AGACTTTTTCTAACAGC

TGCGTATT

(SEQ ID NO: 5942)

GCATTGGCAGCATTGTG

TCTTTGAC

(SEQ ID NO: 5943)

GTGTCTTTGACCTTGTA

TACTAGCT

(SEQ ID NO: 5944)

220183_s_at
NUDT6
gfg; bFGF;
nudix
chr4q26
Loss_—
11162
TATTGGAGACACAGCGG

FGF-2; gfg-
(nucleoside

down

TTCGAGAA

1; ASFGF2;
diphosphate

(SEQ ID NO: 5945)

FGF-AS;
linked moiety

GAGACACAGCGGTTCGA

FGF2AS
X)-type

GAAGTTTT

motif 6

(SEQ ID NO: 5946)

ACAGCGGTTCGAGAAGT

TTTTGAAG

(SEQ ID NO: 5947)

ATCAGAATTCAGGTCCG

TCCTGAGT

(SEQ ID NO: 5948)

AGGTCCGTCCTGAGTAT

TCGGCAAC

(SEQ ID NO: 5949)

TCCGTCCTGAGTATTCG

GCAACAGC

(SEQ ID NO: 5950)

GTCCTGAGTATTCGGCA

ACAGCACA

(SEQ ID NO: 5951)

GTATTCGGCAACAGCAC

ACAAATCC

(SEQ ID NO: 5952)

TCGGCAACAGCACACAA

ATCCTIGGA

(SEQ ID NO: 5953)

ACAGCACACAAATCCTG

GAGCTTTT

(SEQ ID NO: 5954)

ACACAAATCCTGGAGCT

TTTGGGAA

(SEQ ID NO: 5955)

217022_s_at
IGH@
IGH;
immunoglobulin
chr14q32.33
Loss_—
1001265
TCAAGTGGGAAGAGCGC

IGH.1@;
heavy locus///

down
83///
TGTTCAAG

IGHDY1;
immunoglobulin

28303///
(SEQ ID NO: 5956)

MGC72071;
heavy constant

3492///
GTGGGAAGAGCGCTGT

MGC88774
alpha 1///

3493///
TCAAGGACC

immunoglobulin

3494
(SEQ ID NO: 5957)

heavy constant

ATCCGGAAACACATTCC

alpha 2 (A2m

GGCCCGAG

marker)///

(SEQ ID NO: 5958)

immunoglobulin

CCCTGAACGAGCTGGTG

heavy variable

ACGCTGAC

3/OR16-13///

(SEQ ID NO: 5959)

hypothetical

GAACGAGCTGGTGACGC

LOC100126583

TGACGTGC

(SEQ ID NO: 5960)

CCCCGCGAGAAGTACCT

GACTTGGG

(SEQ ID NO: 5961)

GAGAAGTACCTGACTTG

GGCATCCC

(SEQ ID NO: 5962)

CACCTTCGCTGTGACC

AGCATACTG

(SEQ ID NO: 5963)

TCGCTGTGACCAGCATA

CTGCGCGT

(SEQ ID NO: 5964)

TGACCAGCATACTGCG

CGTGGCAGC

(SEQ ID NO: 5965)

TCAATGTGTCTGTTGTC

ATGGCGGA

(SEQ ID NO: 5966)

212112_s_at
STX12
RP3-
syntaxin 12
chr1p35-
Loss_—
23673
TCACTTGTGGTTCTACA

426I6.4,

p34.1
down

TTCCTGGT

MGC51957,

(SEQ ID NO: 5967)

STX13,

TGAATGTTGCTGTCAAA

STX14

GGGCTGCC

(SEQ ID NO: 5968)

TGCCCCCTACCTTATAA

GGGTTGCT

(SEQ ID NO: 5969)

ATATAAATGTTGTCCAC

TTCCCTTT

(SEQ ID NO: 5970)

CCTTTTCCACAGGCCTA

GAACAGTT

(SEQ ID NO: 5971)

CATAATTTGTTTAGGCT

CCCACATA

(SEQ ID NO: 5972)

GGCCAACAACTTTGGTT

CATCCTTT

(SEQ ID NO: 5973)

GAGGATTTGGCTACCCT

GAGTATAT

(SEQ ID NO: 5974)

TTATATTCATTTCTTCT

GTTCTCCT

(SEQ ID NO: 5975)

AGGGCCCAAATGCATAA

GTTTCTTT

(SEQ ID NO: 5976)

AAGTTTCTTTGCACTGT

TGCACTTA

(SEQ ID NO: 5977)

202033_s_at
RB1CC1
CC1,
RB1-inducible
chr8q11
Gain_—
9821
TGATTTGTCCTGCAGTG

DRAGOU14,
coiled-coil 1

up

CTCATTCA

FIP200

(SEQ ID NO: 5978)

AACAGCAGGCCATCTTT

TTATGCAA

(SEQ ID NO: 5979)

ACTTCACTGGTGTACAT

CGTTTACT

(SEQ ID NO: 5980)

TCGTTTACTTTTTAACT

GGCTTCAT

(SEQ ID NO: 5981)

AGAAATGCGGACCAAAC

TACTTCAT

(SEQ ID NO: 5982)

ACTACTTCATTTTCTCA

AAGGGCAT

(SEQ ID NO: 5983)

GCATACCTTGTGCATTG

TGGCTTAT

(SEQ ID NO: 5984)

GATGAGCCATATTAATT

GCCTGTTA

(SEQ ID NO: 5985)

GTTATTATTACCAGCATT

TGTCCTT

(SEQ ID NO: 5986)

ATACTTGCACTCTTTAA

CACATTCT

(SEQ ID NO: 5987)

AGAGGAGTGTTATTGCA

TGCTGATA

(SEQ ID NO: 5988)

212096_s_at
MTUS1
ATIP,
mitochondrial
chr8p22
Loss_—
57509
TGGGTCATTTACATGTA

DKFZp586D
tumor

down

CACTACAT

1519,
suppressor 1

(SEQ ID NO: 5989)

DKFZp686F

GATACTCATGTTGCATG

20243,

TTCTTTTA

FLJ14295,

(SEQ ID NO: 5990)

KIAA1288,

TAGTGATTTTGTGTCTT

MP44,

AAGTCTTT

MTSG1

(SEQ ID NO: 5991)

TAAGTCTTTAACTTCCA

ATACTTCA

(SEQ ID NO: 5992)

GTATGTAACCTTCCATG

TTTGCTTC

(SEQ ID NO: 5993)

GGAAATGTAGGTTCACT

GCCACTTC

(SEQ ID NO: 5994)

GGTTCACTGCCACTTCA

TGAGATAT

(SEQ ID NO: 5995)

CATGAGATATCTCTGCT

CACGCTTC

(SEQ ID NO: 5996)

CAAAGTTGGGTTTGCC

ATTCATCCC

(SEQ ID NO: 5997)

ATGGTAAATCTTGTGTT

GTTCCCTG

(SEQ ID NO: 5998)

TGTCCTCCGTATTACGT

GACCGGCA

(SEQ ID NO: 5999)

212295_s_at
SLC7A1
ERR;
solute carrier
chr13q12-
Gain_—
6541
TTCCTGCTTAAGTTGTG

ATRC1;
family 7
q14
up

CCTTTCAG

CAT-1;
(cationic

(SEQ ID NO: 6000)

HCAT1;
amino acid

AAGTTGTGCCTTTCAGC

REC1L
transporter,

TTCAATGA

y+ system),

(SEQ ID NO: 6001)

member 1

GAATAGCTGTGGTTTCT

CCAGTAAA

(SEQ ID NO: 6002)

TCTTCTACTGAACATGG

AGCCATTA

(SEQ ID NO: 6003)

AAATCAGGTTGGTCTCT

GCTGGGTC

(SEQ ID NO: 6004)

GACAAGTGTAGTTGTCG

TCCACCAC

(SEQ ID NO: 6005)

TCGTCCACCACCTTTCA

AAAAATGT

(SEQ ID NO: 6006)

CCTTTTTGCTGACAACA

CTGTGTAC

(SEQ ID NO: 6007)

ACACTGTGTACATTGAC

CACTTCCT

(SEQ ID NO: 6008)

ACCACTTCCTACCATAC

TTTATGTT

(SEQ ID NO: 6009)

GGTACATTATCTCATGC

TTCTGCAA

(SEQ ID NO: 6010)

219822_at
MTRF1
RF1; MRF1;
mitochondrial
chr13q14.1-
Gain_—
9617
TTGGACCCCAAGGATTT

MTTRF1;
translational
q14.3
up

GCGAATAG

MGC47721
release

(SEQ ID NO: 6011)

factor 1

GATACATTTCGAGCCAA

AGGAGCAG

(SEQ ID NO: 6012)

TGATAGTGCCGTCAGAC

TTGTCCAC

(SEQ ID NO: 6013)

CCACATCCCCACAGGGC

TAGTAGTA

(SEQ ID NO: 6014)

GCCTTTCGTGTGTTGAG

AGCTAGAC

(SEQ ID NO: 6015)

GAGCTAGACTCTACCAG

CAGATTAT

(SEQ ID NO: 6016)

AGAGCCCAGTCAGAGCG

AATTCGGA

(SEQ ID NO: 6017)

TCGGACATATAATTTCA

CCCAGGAT

(SEQ ID NO: 6018)

GTCAGTGACCACAGGAT

AGCATATG

(SEQ ID NO: 6019)

GGGAAGGGCCTGGATCA

GCTAATTC

(SEQ ID NO: 6020)

GCTGAACTTTTGGATGA

ACACCTTA

(SEQ ID NO: 6021)

209384_at
PROSC
FLJ11861
proline
chr8p11.2
Loss_—
11212
TTTTTCCTCTGGGACCT

synthetase

down

ACAGTGAT

cotranscribed

(SEQ ID NO: 6022)

homolog

CTCCTCCACTATAATCC

(bacterial)

TCTTTAGG

(SEQ ID NO: 6023)

AACCCAGTGAATCTCAT

TACTCCTA

(SEQ ID NO: 6024)

GCCTTTTCAGGCACATG

GTTTCAAC

(SEQ ID NO: 6025)

GACATTCCTTGTCCTGA

GGAGCACT

(SEQ ID NO: 6026)

TTCCAGGCATAGTTACA

GCTTCCCC

(SEQ ID NO: 6027)

GCTTCCCCACTGTATTT

ACAAGCCA

(SEQ ID NO: 6028)

TGTGCAACTCTTCTGGA

TCATTAAT

(SEQ ID NO: 6029)

AAATGGCTTCAGTATGG

CTTGTTTT

(SEQ ID NO: 6030)

TCCAGATGGCTTTTTCT

CTTATTTT

(SEQ ID NO: 6031)

GAAGCCCCAGTCTTTGA

TTTTACAG

(SEQ ID NO: 6032)

All gene probe set identification numbers and Entrez Gene identification numbers of Table 4 are hereby incorporated by reference in their entirety

The concordance between dysregulation and prognostic effect is highly evident in the 8p arm (FIG. 15). The KM plots for the 10 dysregulated genes in the 8p arm (Table 4) are illustrated in FIG. 16. Interestingly, the 20q arm, which is the most highly dysregulated chromosome arm (FIG. 13), has only one gene (TMEPAI) considered a good prognostic indicator. Among the 8p genes in the list is MTUS1, a putative tumor suppressor (Seibold et al., “Identification of a New Tumor Suppressor Gene Located at Chromosome 8p21.3-22” Faseb J 17:1180-1182 (2003), which is hereby incorporated by reference in its entirety) previously shown to be downregulated in colorectal cancer (Lee et al., “Differential Expression in Normal-Adenoma-Carcinoma Sequence Suggests Complex Molecular Carcinogenesis in Colon” Oncol Rep 16:747-754 (2006), which is hereby incorporated by reference in its entirety). The downregulation of PCM1 has been detected in both ovarian cancer (Pils et al., “Five Genes from Chromosomal Band 8p22 are Significantly Down-Regulated in Ovarian Carcinoma: N33 and EFA6R Have a Potential Impact on Overall Survival” Cancer 104:2417-2429 (2005), which is hereby incorporated by reference in its entirety) and breast cancer (Armes et al., “Candidate Tumor-Suppressor Genes on Chromosome Arm 8p in Early-Onset and High-Grade Breast Cancers” Oncogene 23:5697-5702 (2004), which is hereby incorporated by reference in its entirety). Recent studies suggest that the downregulation of ADAMDEC1 and EPHX2 may be directly associated with metastasis in colon cancer (Macartney-Coxson et al., “Metastatic Susceptibility Locus, an 8p Hot-Spot for Tumor Progression Disrupted in Colorectal Liver Metastases: 13 Candidate Genes Examined at the DNA, mRNA and Protein Level” BMC Cancer 8:18 (2008), which is hereby incorporated by reference in its entirety), and in breast cancer (Thomassen et al., “Gene Expression Meta-Analysis Identifies Chromosomal Regions and Candidate Genes Involved in Breast Cancer Metastasis” Breast Cancer Res Treat 113(2):239-49 (2008), which is hereby incorporated by reference in its entirety) respectively.

Example 11
Lecithin:Retinol Acyl Transferase Gene Promoter Methylation Analysis

Sodium bisulfite has been widely used to distinguish 5-methylcytosine from cytosine. Bisulfite converts cytosine into uracil via a deamination reaction while leaving 5-methylcytosine unchanged. Genomic DNAs extracted from colon tumor samples were used in this study. Typically, 1˜0.5 μg genomic DNA in a volume of 40 μl was incubated with 0.2N NaOH at 37° C. for 10 minutes. Next, 30 μl of 10 mM hydroquinone and 520 μl of 3M sodium bisulfite were added to the reaction. Sodium bisulfite (3M) was made with 1.88 g sodium bisulfite (Sigma Chemicals, ACS grade) dissolved in a final total of 5 ml deionized water at pH 5.0. The bisulfite/DNA mixture was incubated for 16 hours in a DNA thermal cycler (Perkin Elmer Cetus), cycling between 50° C. for 20 minutes and 85° C. for 15 seconds. The bisulfite treated DNA was desalted using MICROCON centrifugal filter devices (Millipore, Bedford, Mass.) or, alternatively, was cleaned with Wizard DNA clean-up kit (Promega, Madison, Wis.). The eluted DNA was incubated with one-tenth volume of 3N NaOH at room temperature for 5 minutes before ethanol precipitation. The DNA pellet was then resuspended in 20 μl deionized H₂O and stored at 4° C. until PCR amplification.

Example 12
Multiplex PCR Amplification

Two promoter regions of the LRAT gene were simultaneously amplified in a multiplex fashion. The multiplex PCR has two stages, namely a gene-specific amplification (stage one) and a universal amplification (stage two). The PCR primers are shown in Table 5.

TABLE 5

Primer Sequences for LRAT Analysis

CONC.

PRIMERS

SEQUENCE (5′ to 3′)
in PCR

LRAT
SEQ ID
CGCTGCCAACTACCGCACATCTTAT
1.25 pmol

RP1
NO: 6033
TTTTTATTGTGGTTTGGTTGAGTC

LRAT
SEQ ID
CGCTGCCAACTACCGCACATCACCT
1.25 pmol

FP1
NO: 6034
CCAACATAAAATTCTTCATCCTAC

LRAT
SEQ ID
CGCTGCCAACTACCGCACATCATAAT
2.5 pmol

RP3
NO: 6035
CGTGTTGTTTATATGATGTTCGATA

LRAT
SEQ ID
CGCTGCCAACTACCGCACATCCACAA
2.5 pmol

FP3
NO: 6036
CAAACTATAAAAAATAAAACCCAAC

UniB2
SEQ ID
CGCTGCCAACTACCGCACATC
12.5 pmol

NO: 6037

The gene-specific PCR primers were designed such that the 3′ sequence contains a gene-specific region and the 5′ region contains an universal sequence. The gene specific primers design allows hybridization to promoter regions containing as few CpG sites as possible. For primers that inevitably include one or more CpG dinucleotides, the nucleotide analogs, K and P, which can hybridize to either C or T nucleotides or G or A nucleotides, respectively, can be included in the primer design. To reduce the cost of primer synthesis, PCR primers were designed without nucleotide analogs and using nucleotides G to replace K (purine derivative) and T to replace P (pyrimidine derivative), respectively. This type of primer design favors pairing to DNA that was initially methylated, although it also allows the mismatch pairing of G/T when the original DNA was unmethylated at that site. The ethidium bromide staining intensity of PCR amplicons separated by the agarose gel electrophoresis, demonstrated that this primer design was as robust as using analogs-containing primers.

In the first stage, the multiplex PCR reaction mixture (12.40 consisted of 0.5 μl bisulfite modified DNA, 400 μM of each dNTP, 1× AmpliTaq Gold PCR buffer, 4 mM MgCl2, and 1.25 U AmpliTaq Gold polymerase. The gene-specific PCR primer concentrations are listed in the Table 5. Mineral oil was added to each reaction before thermal cycling. The PCR procedure included a pre-denaturation step at 95° C. for 10 minutes, 15 cycles of three-step amplification with each cycle consisting of denaturation at 94° C. for 30 second, annealing at 60° C. for 1 minute, and extension at 72° C. for 1 minute. A final extension step was at 72° C. for 5 minutes.

The second stage of multiplex PCR amplification was primed from the universal sequences (UniB) located at the extreme 5′ end of the gene-specific primers. The second stage PCR reaction mixture (12.50 consisted of 400 μM of each dNTP, 1× AmpliTaq Gold PCR buffer, 4 mM MgCl2, 12.5 μmol universal primer B (UniB) and 1.25 U AmpliTaq Gold polymerase. The UniB PCR primer sequence is listed in the Table 5. The 12.5 μl reaction mixtures were added through the mineral oil to the finished first stage PCR reactions. The PCR procedure included a pre-denaturation step at 95° C. for 10 minutes, 30 cycles of three-step amplification with each cycle consisting of denaturation at 94° C. for 30 second, annealing at 55° C. for 1 minute, and extension at 72° C. for 1 minute. A final extension step was at 72° C. for 5 minutes.

After the two-stage PCR reaction, 1.25 μl Qiagen Proteinase K (approximately 20 mg/ml) was added to the total 25 μl reaction. The Proteinase K digestion condition consisted of 70° C. for 10 minutes and 90° C. for 15 minutes.

Example 13
Ligase Detection Reaction and Hybridization to Universal Array

Ligation detection reactions were carried out in a 20 μl volume containing 20 mM Tris-HCl pH 7.6, 10 mM MgCl2, 100 mM KCl, 20 mM DTT, 1 mM NAD, 50 fmol wild-type Tth ligase, 500 fmol each of LDR probes, 5-10 ng each of the PCR amplicons. The Tth ligase can be diluted in a buffer containing 15 mM Tris-HCl pH 7.6, 7.5 mM MgCl2, 0.15 mg/ml BSA. To ensure the scoring accuracy of a LRAT promoter methylation status, 30 LDR probes were designed to interrogate the methylation levels of ten CpG dinucleotide sites within the PCR amplified regions. Two discriminating LDR probes and one common LDR probe were designed for each of the CpG sites. The LDR probe mix contains 60 discriminating probes (30 probes for each channel) and 10 common probes (Table 6). The reaction mixtures were pre-heated for 3 minutes at 95° C., and then cycled for 20 rounds of 95° C. for 30 seconds and 60° C. for four minutes.

The ligation detection reaction (20 μl) was diluted with equal volume of 2× hybridization buffer (8×SSC and 0.2% SDS), and denatured at 95° C. for 3 minutes then plunged on ice. The Universal Arrays (Amersham Biosciences, Piscataway, N.J.) were assembled with ProPlate slide modules (Grace Bio-Labs, Bend, Oreg.) and filled with the 40 μl denatured LDR mixes. The assembled arrays were incubated in a rotating hybridization oven for 60 minutes at 65° C. After hybridization, the arrays were rinsed briefly in 4×SSC and washed in 2×SSC, 0.1% SDS for 5-10 minutes at 63.5° C. The fluorescent signals were measured using a ProScanArray scanner (Perkin Elmer, Boston, Mass.).

TABLE 6

Probe Sequences for Ligase Detection Reaction

PRIMERS
SEQUENCE (5′ to 3′)

LRAT 53T
(Cy5) TGTTATTT TT TAT TGT GGT TTG GTT GAG TTG GTT
(SEQ ID NO: 6038)

LRAT 172Tb
(Cy5) TTGTTTTTTTTTTTT TTT AGT GGT TGT ATT TTG TGT T
(SEQ ID NO: 6039)

LRAT 218T
(Cy5) TTTTGTC GGA GTG GTA TTG GTA TTT TTT TAA GAT
(SEQ ID NO: 6040)

LRAT 222T
(Cy5) GGTTTGTAGG TGA GTA GTA GTG TAG TAT TTT TGT TTG GT
(SEQ ID NO: 6041)

LRAT 242Tb
(Cy5) GTGTAGTATTTTTGT TTG GTG AGT TTA ATT TGT TTA GTT T
(SEQ ID NO: 6042)

LRAT 263T
(Cy5) TTAATTTGTT TAG TTT GGT TTT TGT TGG AGT GGT ATT
(SEQ ID NO: 6043)

LRAT2nd 40T
(Cy5) TTTATATGA TGT TTG ATA TTT TGT TGG TTT TGA TAG AT
(SEQ ID NO: 6044)

LRAT2nd 91T
(Cy5) GTAGAAGGTGG TTT TTA ATA AGT GTT TTA TTT TGG GT
(SEQ ID NO: 6045)

LRAT2nd 145T
(Cy5) GTATTCGCG TGG ATA TAG TGG AGG ATT TTG TTT AT
(SEQ ID NO: 6046

LRAT2nd 218T
(Cy5) TAGAAAAAGGTATTG TTT AAT GAG GAG GTG GTG T
(SEQ ID NO: 6047)

LRAT 53C
(Cy3) ATTTTTTATTGTGGTTTGGTTGAGTCGGTC
(SEQ ID NO: 6048)

LRAT 172C
(Cy3) TTTTTTTTTAGCGGTCGTATTTTGCGTC
(SEQ ID NO: 6049)

LRAT 218C
(Cy3) TGTCGGAGTGGTATCGGTATTTTTTTAAGAC
(SEQ ID NO: 6050)

LRAT 222C
(Cy3) GTAGGTGAGTAGTAGCGTAGTATTTTTGTTCGGC
(SEQ ID NO: 6051)

LRAT 242C
(Cy3) TTTTGTTCGGCGAGTTTAATTTGTTTAGTTC
(SEQ ID NO: 6052)

LRAT 263C
(Cy3) TGTTTAGTTCGGTTTTTGTCGGAGTGGTATC
(SEQ ID NO: 6053)

LRAT2nd 40C
(Cy3) ATATGATGTTCGATATTTTGTTGGTTTTGATAGAC
(SEQ ID NO: 6054)

LRAT2nd 91C
(Cy3) GGTGGTTTTTAATAAGCGTTTTATTTTGGGC
(SEQ ID NO: 6055)

LRAT2nd 145C
(Cy3) TCGCGTGGATATAGTGGAGGATTTCGTTTAC
(SEQ ID NO: 6056)

LRAT2nd 218C
(Cy3) GGTATTGTTTAACGAGGAGGTGGCGC
(SEQ ID NO: 6057)

LRAT 53C (Z18)
pGTTAGGTTTCGTTGTTTTTTTTTGTTTTTTTTTTTTTTTAGGGAGGCTGCTGTC
(SEQ ID NO: 6058)

CTTTCGATCA

2LRAT 172C
pGTATTTTATTTGGTTTGTAGGTGAGTAGTAGCGTAGTATTTTTG
(SEQ ID NO: 6059)

(Z19)
ACAGCGTGTTCGTTGCTTGCATCA

3LRAT 222Cc
pGAG TTT AAT TTG TTT AGT TCG GTT TTT GTT
(SEQ ID NO: 6060)

(Z31)
GGATTGCGGGAACTCACGAGGTCGTAT

4LRAT 242Cb
pGGTTTTTGTCGGAGTGGTATTGGTATTTTTTTAATGGCGATGGTCCACTCGCAA
(SEQ ID NO: 6061)

(Z20)
TCA

5LRAT 263Cb
pGGT ATT TTT TTA AGA CGT TTT TTT TTT TGT AGG
(SEQ ID NO: 6062)

(Z32)
ATGGCACGGCTCGATAGGTCAAGCTTT

6LRAT 218C
pGTTTTTTTTTTTGTAGGATGAAGAATTTTATGTTGGAGGCATCGCACTTCGCTT
(SEQ ID NO: 6063)

(Z30)
TGGCTGATT

7LRAT2nd 40C
pGAT ATG GGG TGT ACG TAG AAG GTG GTT
(SEQ ID NO: 6064)

(Z10)
TTTACAAGGCACGTCCCAGACGCATCAA

8LRAT2nd 91C
pGTT ATT GTT AAA GTG GTT AGT ATT TGC GTG GAT ATA
(SEQ ID NO: 6065)

(Z11)
GTGGCACGGGAGCTGACGACGTGTCAA

9LRAT2nd 145C
pGGAGTTAATATTTTGGTTAATTATTTGGACGAGTTTTTTTAGACGCACCGCAAC
(SEQ ID NO: 6066)

(Z12)
AGGCTGTCAA

10LRAT2nd 218C
pGGAGGGTTGAAAAGTTGTTGGGTTTTATTTTTCATCGCTGCAAGTACCGCACTC
(SEQ ID NO: 6067)

(Z13)
AA

Example 14
Determination of Cytosine Methylation Levels at CpG Dinucleotide Sites

LDR is a single tube multiplex reaction with three probes interrogating each of the selected CpG sites. LDR products are captured on a Universal microarray using the ProPlate system (Grace BioLabs) where 64 hybridizations (four slides with 16 sub-arrays each) are carried out simultaneously. Each slide is scanned using a Perkin Elmer ProScanArray (Perkin Elmer, Boston, Mass.) under the same laser power and PMT within the linear dynamic range. The Cy3 and Cy5 dye bias were determined by measuring the fluorescence intensity of an equal quantity of Cy3 and Cy5 labeled LDR probes manually deposited on a slide surface. The fluorescence intensity ratio (W=ICy3/ICy5) was used to normalize the label bias when calculating the methylation ratio Cy3/(Cy3+Cy5). The methylation standard curves for each interrogated CpG dinucleotide were established using various combinations of in vitro methylated and unmethylated normal human lymphocyte genomic DNAs. The methylation levels of six CpG dinucleotides in the 5′-UTR regions were averaged and used to determine the overall promoter methylation status of LRAT gene.

Example 15
Quantitative Aspect of Bisulfite/PCR-PCR/LDR/Universal Array

Because PCR primer and LDR probe design does not bias amplification or detection of methylation status, independent of methylation status of neighboring CpG dinucleotides (i.e. by using nucleotide analogues or degenerate bases within the primer designs), it is possible to quantify methylation status of given CpG sites in the genome.

To demonstrate that the assay is quantitative, genomic DNA in vitro methylated with SssI methylase was mixed with normal human lymphocytes DNA (carrying unmethylated alleles), such that the test samples contained 0%, 20%, 40%, 60%, 80%, and 100% of methylated alleles and these mixtures were subjected to Bisulfite-PCR/LDR/Universal Array analysis. The fluorescence intensity is presented by Cy3 (methylated alleles) or Cy5, (unmethylated alleles) on each double spotted zipcode addresses. The average fluorescence intensity of two duplicated spots was used to calculate the methylation ratio of each analyzed cytosine using the formula Cy3average/(Cy3 average+Cy5 average).

The measured methylation ratios of each interrogate cytosine was plotted against the methylation levels of mixed genomic DNAs. The R²values (correlation coefficient) of these experiments are between 0.97 and 0.89, which demonstrates the linearity of the described assay. Such standard curves can be used as reference points for further measurements done in clinical samples. Similar standard curves were also established for genes such as p16INK4a, p14ARF, TIMP3, APC, RASSF1, ECAD, MGMT, DAPK, GSTP1 and RARβ (Cheng et al., “Multiplexed Profiling of Candidate Genes for CpG Island Methylation Status Using a Flexible PCR/LDR/Universal Array Assay,” Genome Res. 16(2):282-289 (2006), which is hereby incorporated by reference in its entirety). In “100%” in vitro methylated DNA sample, the Cy3average/(Cy3 average+Cy5 average) ratios of the investigated CpG sites were between 0.6 and 0.9. This observation suggested that in vitro methylation is not fully efficient due to sequence context variation of each CpG site. This analysis also confirmed the different percentage of methylation at each CpG dinucleotide and suggested that methylation level is not 100% at each CpG site in cell line DNA (Cheng et al., “Multiplexed Profiling of Candidate Genes for CpG Island Methylation Status Using a Flexible PCR/LDR/Universal Array Assay,” Genome Res. 16(2):282-289 (2006), which is hereby incorporated by reference in its entirety). By comparing the ratio of (methylated):(methylated+unmethylated) DNA in different cell lines, one can extrapolate the CpG methylation level at a given position. Overall, the data demonstrate that the bisulfite-PCR/LDR/Universal Array approach is a quantitative method for the measurement of DNA methylation.

Example 16
Tumor Specific LRAT Promoter Hypermethylation

Since aberrant DNA methylation may also result from aging, it is necessary to identify a promoter region where its methylation is disease specific. To demonstrate LRAT promoter region methylation is tumor specific, CRC tumor samples (n=133) and the adjacent normal tissues (n=69) were analyzed using bisulfite/PCR-PCR/LDR/Universal Array approach. For each clinical sample, the methylation levels of ten CpG dinucleotide sites residing in the 5′-UTR (CpG sites 1-6) and exon-1 (CpG sites 7-10) regions of LRAT promoter were interrogated. Since the tumor (disease) specific aberrant methylation was identified in the 5′-UTR, the methylation levels of CpG sites 1-6 were averaged (the mean value) to determine the overall promoter methylation status. A promoter with a mean value of methylation signal intensity greater than 0.2 was scored as hypermethylated (methylation score 1), while a mean value equal to or less than 0.2 was scored as unmethylated (methylation score 0). This approach allowed a simple scoring system to use quantitative methylation data from multiple representative CpG sites across a larger DNA sequence region. Such quantitative reports give non-ambiguous and repeatable results of study DNA methylation.

A series of 133 CRC patient samples from Memorial-Sloan Kettering Cancer Center tumor bank were subject to bisulfite/PCR-PCR/LDR/Universal Array analysis. The methylation levels of ten CpG dinucleotide sites in the LRAT promoter region were determined for each CRC sample. The average methylation level of CpG sites 1-6 was used to score the overall LRAT promoter methylation status. A hypermethylated promoter was defined as having an average methylation level greater than 0.2.

LRAT promoter hypermethylation in CRCs was initially studied in microsatellite instability (MSI) tumors that often show multiple hypermethylated genes. LRAT hypermethylation was found in 36 of 40 MSI samples (90%) and was confirmed using methylation specific PCR (FIG. 22A). Since the MSI patients typically have a better clinical outcome and MSI accounts for only 10-15% of sporadic CRCs, the frequency of aberrant LRAT hypermethylation in the majority of CRC instances was examined in 81 microsatellite stable (non-MSI) colorectal samples (FIG. 22B).

LRAT promoter methylation is significantly associated with increased survival for all sporadic, non-MSI CRC patients. When all four CRC stages were considered, patients with LRAT promoter hypermethylation had a better disease-specific survival rate than patients with unmethylated promoter (FIG. 23). Only 12 of 39 (30.8%) individuals with LRAT promoter hypermethylation had died within the study period, whereas 23 of 42 (54.8%) individuals with unmethylated LRAT promoter had died. Log rank test was used to compare the two survival curves produced from methylated and unmethylated LRAT groups (p=0.0296).

In a validation study, Kaplan-Meier survival analysis was carried out on an additional 44 non-MSI colorectal samples (total n=125) (FIG. 24) and a similar survival curve (p=0.02) was observed. In a subset of 60 colorectal tumor samples, analysis of methylation status of LRAT and retinoic acid receptor β(RARβ) revealed that promoter hypermethylation at both genes correlates with better prognosis (p=0.007, FIG. 25). This observation suggests that the association between LRAT methylation silencing and better prognosis may represent a RARβ independent pathway to the inhibition of tumorigenesis

Since the MSI patients typically have a better survival and clinical outcome, Kaplan-Meier survival analysis was performed on patients with non-MSI genotype. Survival was measured from the date of resection of colorectal cancer to the date of death, the completion of 5 years of follow-up, or the last clinical review before April 2006. Only cancer-related deaths were analyzed as events. A p-value of less than 0.05 was considered as statistical significance.

Although preferred embodiments have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various modifications, additions, substitutions, and the like can be made without departing from the spirit of the invention and these are therefore considered to be within the scope of the invention as defined in the claims which follow.

METHODS FOR IDENTIFYING GENES WHICH PREDICT DISEASE OUTCOME FOR PATIENTS WITH COLON CANCER

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Parent Case Info

Government Interests

PCT Information

Provisional Applications (1)